Compositions and methods related to tumor activated antibodies
A polypeptide complex with a T-cell engager, peptide mask, and half-life extending molecule improves half-life and reduces toxicity, enhancing therapeutic efficacy in cancer treatment.
Patent Information
- Application Number
- PCT/US2026/026598
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-04
- Publication Date
- 2026-11-12
AI Technical Summary
T-cell engagers face challenges such as off-target toxicity and slow clearance, which can limit their therapeutic efficacy in cancer treatment.
A polypeptide complex comprising a T-cell engager with an antigen binding domain, a peptide mask that impairs antigen binding, and a half-life extending molecule, such as a variant Fc domain, is developed to enhance half-life and reduce toxicity, featuring a cleavable linker for controlled release within the tumor microenvironment.
The modified T-cell engager exhibits improved half-life, reduced toxicity, enhanced therapeutic activity, and increased specificity, addressing the limitations of existing T-cell engagers.
Smart Images

Figure US2026026598_12112026_PF_FP_ABST
Abstract
Description
[0001] WSGR Docket No. 52426-781.601
[0002] COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES
[0003] CROSS REFERENCE
[0004]
[0001] The present application claims the benefit of U. S. Provisional Application No. 63 / 800,959 filed on May 06, 2025, which is incorporated herein by reference in its entirety.
[0005] SUMMARY
[0006]
[0002] In an aspect, provided herein is, inter alia, a polypeptide or polypeptide complex comprising: a T cell engager comprising an antigen binding domain;
[0007] a peptide mask that binds to the antigen binding domain and impairs binding of the antigen binding domain to an antigen; and
[0008] a half-life extending molecule that is in tandem with the peptide mask, wherein the half-life extending molecule comprises a fragment crystallizable (Fc) domain, wherein the Fc domain comprises a single chain Fc (scFc) or one or more mutations.
[0009]
[0003] In some embodiments, the half-life extending molecule is operatively linked to the peptide mask within a single contiguous polypeptide chain.
[0010]
[0004] In some embodiments, the one or more mutations comprise a M428G, aN434A, and / or H435R according to EU numbering.
[0011]
[0005] In some embodiments, the one or more mutations are selected from the group consisting of L234A, L235A, N297G, P329G, Y349C, S354C, T366S, T366W, L368A, Y407V, M428G, N434A, H435R, and Y436F mutation according to EU numbering relative to SEQ ID NO: 2335.
[0012]
[0006] In some embodiments, the Fc domain comprises a first polypeptide and a second polypeptide.
[0013]
[0007] In some embodiments, the first polypeptide comprises one or more mutations selected from the group consisting of L234A, L235A, N297G, P329G, Y349C, T366S, L368A, Y407V, M428G, N434A, H435R, and Y436F, according to EU numbering, and / or the second polypeptide comprises one or more mutations selected from the group consisting of L234A, L235A, N297G, P329G, S354C, and T366W, according to EU numbering.
[0014]
[0008] In some embodiments, the one or more mutations comprise one or more knob-in-hole (KIH) mutations.
[0015]
[0009] In some embodiments, the Fc domain comprises a first polypeptide and a second polypeptide, wherein the first polypeptide of the Fc domain comprises a hole mutation and the second polypeptide of the Fc domain comprises a knob mutation.
[0016]
[0010] In some embodiments, the first polypeptide of the Fc domain comprises T366S, L368A, and Y407V mutations according to EU numbering, and the second polypeptide of the Fc domain comprises a T366W mutation according to EU numbering.
[0017] [OH] In some embodiments, the Fc domain comprises Fc effector function silencing mutations comprising L234A, L235A, and P329G mutations according to EU numbering.
[0018]
[0012] In some embodiments, the Fc domain comprises an engineered disulfide.WSGR Docket No. 52426-781.601
[0019]
[0013] In some embodiments, the Fc domain comprises a Y349C mutation and a S354C mutation according to EU numbering, and wherein the engineered disulfide is formed between two cysteines at the positions of the Y349C mutation and the S354C mutation.
[0020]
[0014] In some embodiments, the Fc domain comprises aN297G mutation according to EU numbering.
[0021]
[0015] In some embodiments, the one or more mutations comprise a ProA or ProG mutation.
[0022]
[0016] In some embodiments, the Fc domain comprises aH435R and / or a Y436F mutations according to EU numbering.
[0023]
[0017] In some embodiments, the Fc domain comprises a M428G and / or aN434A mutations according to EU numbering.
[0024]
[0018] In some embodiments, the Fc domain lacks a C-terminal glycine and a C-terminal lysine.
[0025]
[0019] In some embodiments, the Fc domain lacks C-terminal G446 and K447 residues according to EU numbering.
[0026]
[0020] In some embodiments,
[0027] (i) the Fc domain comprises a scFc comprising an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2337;
[0028] (ii) the Fc domain comprises a scFc comprising an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2338; or
[0029] (iii) the Fc domain comprises a scFc comprising an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2339.
[0030]
[0021] In some embodiments, half-life extending molecule further comprises a polymer.
[0031]
[0022] In some embodiments, the polymer is polyethylene glycol (PEG).
[0032]
[0023] In some embodiments, the antigen binding domain comprises a CD3 binding domain.
[0033]
[0024] In some embodiments, the CD3 binding domain comprises an anti-CD3 heavy chain variable domain that comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 comprise amino acid sequences of HC-CDR1: SEQ ID NO: 2340, HC-CDR2: SEQ ID NO: 2341, and HC-CDR3: SEQ ID NO: 2342 and the second antigen recognizing molecule comprises an anti-CD3 light chain variable domain that comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, and wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 comprise amino acid sequences of LC-CDR1: SEQ ID NO: 2343, LC-CDR2: SEQ ID NO: 2344, and LC-CDR3: SEQ ID NO: 2344.
[0034]
[0025] In some embodiments, the CD3 binding domain comprises a single chain variable fragment (scFv).
[0035]
[0026] In some embodiments, the scFv comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2346.WSGR Docket No. 52426-781.601
[0036]
[0027] In some embodiments, the peptide mask is bound to the antigen binding domain through ionic interactions, electrostatic interactions, hydrophobic interactions, Pi -stacking interactions, or H-bonding interactions, or a combination thereof.
[0037]
[0028] In some embodiments, the peptide mask has less than 70% sequence homology to CD3.
[0038]
[0029] In some embodiments, the peptide mask comprises an amino acid sequence according to U1 -U2-C-U4-P-U6-U7-U8-U9-U10-U11- U12-C-U14 and U1 is selected from D, Y, F, I, N, V, H, L, A, T, S, and P; U2 is selected from D, Y, L, F, I, N, A, V, H, T, and S; U4 is selected from G and W; U6 is selected from E, D, V, and P; U7 is selected from W, L, F, V, G, M, I, and Y; U8 is selected from E, D, P, and Q; U9 is selected from E, D, Y, V, F, W, P, L, and Q; U10 is selected from S, D, Y, T, I, F, V, N, A, P, L, and H; Ull is selected from I, Y, F, V, L, T, N, S, D, A, and H; U12 is selected from F, D, Y, L, I, V, A, N, T, P, S, G, and H; and U14 is selected from D, Y, N, F, I, P, V, A, T, H, L, M, and S.
[0039]
[0030] In some embodiments, U1 is selected fromD, Y, F, I, V, and N; U2 is selected from D, Y, L, F, I, and N; U4 is selected from G and W; U6 is selected from E and D; U7 is selected from W, L, F, G, and V; U8 is selected from E and D; U9 is selected from E, D, Y, and V; U10 is selected from S, D, Y, T, and I; Ull is selected from I, Y, F, V, L, and T; U12 is selected from F, D, Y, L, I, V, A, G, and N; and U14 is selected from D, Y, N, F, I, M, and P.
[0040]
[0031] In some embodiments, U1 is selected from D, Y, V, and F; U2 is selected from D, Y, L, and F; U4 is selected from G and W; U6 is selected from E and D; U7 is selected from W, L, G, and F; U8 is selected from E and D; U9 is selected from E and D; U10 is selected from S, D, T, and Y; U11 is selected from I, Y, V, L, and F; U12 is selected from F, D, Y, G, A, and L; U14 is selected from D, Y, M, and N.
[0041]
[0032] In some embodiments, the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 1-904, and 2364.
[0042]
[0033] In some embodiments, the peptide mask comprises the amino acid sequence of SEQ ID NO: 4 or a peptide sequence that has 1, 2, or 3 amino acid substitutions, additions, or deletions relative to the amino acid sequence of SEQ ID NO: 4.
[0043]
[0034] In some embodiments, the antigen binding domain comprises a CD28 binding domain.
[0044]
[0035] In some embodiments, the antigen binding domain comprises an anti-CD28 heavy chain variable domain that comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 comprise amino acid sequences of HC-CDR1: SEQ ID NO: 2347, HC-CDR2: SEQ ID NO: 2348, and HC-CDR3: SEQ ID NO: 2349 and the anti-CD28 antibody comprises an anti-CD28 light chain variable domain that comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, and wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 comprise amino acid sequences of LC-CDR1: SEQ ID NO: 2350, LC-CDR2: (KAS), and LC-CDR3: SEQ ID NO: 2351.
[0045]
[0036] In some embodiments, the anti-CD28 heavy chain variable domain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2352,WSGR Docket No. 52426-781.601
[0046] and wherein the anti-CD28 light chain variable domain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2353.
[0047]
[0037] In some embodiments, the antigen binding domain comprises a single chain variable fragment (scFv), a single domain antibody, a Fab, a Fab’, or a CrossFab.
[0048]
[0038] In some embodiments, the antigen binding domain comprises the scFv, and the scFv comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2354, SEQ ID NO: 2355, SEQ ID NO: 2356, or SEQ ID NO: 2357.
[0049]
[0039] In some embodiments, the antigen binding domain comprises the Fab, and the Fab comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2358 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2359.
[0050]
[0040] In some embodiments, the antigen binding domain comprises the CrossFab, and wherein:
[0051] (i) the CrossFab comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2360 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2361; or
[0052] (ii) the CrossFab comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2362 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2363.
[0053]
[0041] In some embodiments, the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 904-1058.
[0054]
[0042] In some embodiments, the peptide mask comprises the amino acid sequence of SEQ ID NO: 944 or the amino acid sequence of SEQ ID NO: 973.
[0055]
[0043] In some embodiments, the peptide mask comprises an amino acid sequence according to X1-X2-X3-C-X4-X5-X6-X7-X8-X9-Xio-C-Xn-Xi2whereinXi is selected from M, I, L, and V; X2 is selected from D, H, N, A, F, S, T, Y, and V; X3 is selected from W, L, and F; X4 is selected from P, A, and L; X5 is selected from R, T, I, M, S, K, L, V, W, F, A, P, and D; X6is selected from E, D, Y, H, S, F, A, N, T, I, P, and V; X7is selected from L, M, R, S, Q, and H; Xs is selected from W and Q; X9 is selected from H, N, D, A, S, Y, T, F, V, L, and I; X10 is selected from E, V, L, D, Y, R, Q, H, F, K, A, M, andN; Xu is selected from F, Y, L, W, and V; and X12 is selected from N, A, F, S, Y, H, D, T, and L.
[0056]
[0044] In some embodiments, Xi is selected from M, I, and L; X2 is selected from D, H, N, and A; X3 is W; X4 is P; X5 is selected from R, T, I, M, S, and K; Xe is selected from E, D, Y, H, S, and F; X7 is selected from L, M, and R; Xs is W; X9 is selected from H, N, D, A, S, and V; X10 is selected from E, V, L, D, and H; Xn is selected from F, Y, and L; and X12 is selected from N, A, F, S, and Y.
[0057]
[0045] In some embodiments, the peptide mask comprisesan amino acid sequence according to SEQ ID NO: 912.
[0058]
[0046] In some embodiments, the peptide mask comprises an amino acid sequence according to: J1-J2-W-C-J3-J4-J5-J6-J7-J8-J9-C-J10-J11, wherein:WSGR Docket No. 52426-781.601
[0059] Ji is selected from A, R, N, D, Q, E, G, H, I, L, K, F, P, S, T, W, Y, and V;
[0060] J2 is selected from D, P, and Y;
[0061] J3 is selected from P and Q;
[0062] J4 is selected from R, L, and I;
[0063] Js is selected from D, H, Y, and I;
[0064] Je is selected from L, S, and R;
[0065] J7 is selected from W and G;
[0066] J8is selected from V, A, D, H, L, and N;
[0067] J9 is selected from H, L, E, and D;
[0068] J10 is selected from F, Y, and L; and
[0069] J11 is selected from A, N, H, and T.
[0070]
[0047] In some embodiments, Ji is selected from A, R, N, D, Q, E, G, H, K, F, P, S, T, W, and Y.
[0071]
[0048] In some embodiments, Ji is selected from R, Q, E, H, I, L, K, F, T, W, Y, and V;
[0072] J2 is D;
[0073] J3 is P;
[0074] J4 is R;
[0075] Js is D;
[0076] Je is L;
[0077] J7is W;
[0078] J8is V;
[0079] J9 is H;
[0080] J10 is F; and
[0081] J11 is A.
[0082]
[0049] In some embodiments, the peptide mask comprises an amino acid sequence according to: Z1-C-Z2-Z3 -Z4 -Z5 -Ze -Z7 -Z8-Z9-Z10 -Zi 1 -C-Zi 2 , wherein :
[0083] Zi is selected from Y, H, and A;
[0084] Z2is selected from D, E, A, Q, S, V, M, H, L, F, T, W, and N;
[0085] Z3 is selected from G, E, S, and A;
[0086] Z4 is selected from H, L, W, and A;
[0087] Z5is selected from L, S, A, T, I, V, M, R, E, D, F, H, K, Q, N, Y, W, and G;
[0088] Z6is selected from P, A, E, Q, S, L, W, G, V, D, K, I, M, R, T, F, H, N, and Y;
[0089] Z7is selected from E, Q, I, M, V, A, L, R, W, P, D, T, K, S, G, H, and N;
[0090] Z8is selected from Y, H, F, W, N, Q, and A;
[0091] Z9 is selected from M, I, L, R, V, K, F, Q, Y, W, and A;
[0092] Z10 is selected from A, Q, S, W, E, L, G, D, T, M, N, V, H, R, Y, K, P, F, and I;
[0093] Zn is selected from K, Q, N, H, E, P, and A; and
[0094] Z12 is selected from L, M, I , F, V, Y, Q, D, T, and A.WSGR Docket No. 52426-781.601
[0095]
[0050] In some embodiments, Zi is selected from Y and H;
[0096] Z2is selected from D, E, A, Q, S, V, M, H, L, F, T, W, and N;
[0097] Z3 is selected from G, E, and S;
[0098] Z4 is selected from H, L, and W;
[0099] Z5is selected from L, S, A, T, I, V, M, R, E, D, F, H, K, Q, N, Y, W, and G;
[0100] Z6is selected from P, A, E, Q, S, L, W, G, V, D, K, I, M, R, T, F, H, N, and Y;
[0101] Z7is selected from E, Q, I, M, V, A, L, R, W, P, D, T, K, S, G, H, and N;
[0102] Z8is selected from Y, H, F, W, N, and Q;
[0103] Z9 is selected from M, I, L, R, V, K, F, Q, Y, and W;
[0104] Z10 is selected from A, Q, S, W, E, L, G, D, T, M, N, V, H, R, Y, K, P, F, and I;
[0105] Zn is selected from K, Q, N, H, E, and P; and
[0106] Z12 is selected from L, M, I , F, V, Y, Q, D, and T.
[0107]
[0051] In some embodiments, the peptide mask comprises the amino acid sequence of SEQ ID NO: 1029, the amino acid sequence of SEQ ID NO: 989, or the amino acid sequence of SEQ ID NO: 898.
[0108]
[0052] In some embodiments, the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 1019-1038.
[0109]
[0053] In some embodiments, the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 1009-1018.
[0110]
[0054] In some embodiments, the peptide mask comprises an amino acid sequence according to: U1-C-U2-U3-U4-U5-U6-U7-U8-U9-U10-U11-C-U12, wherein:
[0111] Ui is selected from T, S, L, M, W, Q, P, R, G, N, I, Y, D, E, V, H, and A;
[0112] U2 is selected from A, S, T, K, E, R, G, N, W, and D;
[0113] U3 is selected from A, E, P, D, G, W, Q, V, and F;
[0114] U4 is selected from G, V, F, D, E, R, and A;
[0115] U5 is selected from A, F, V, S, L, P, and M;
[0116] U6is selected from T, S, H, M, A, N, P, G, Q, D, Y, V, L, I, E, K, F, and R;
[0117] U7 is selected from Y, W, F, L, N, T, Q, I, and A;
[0118] U8is selected from P, S, T, A, E, K, Q, N, V, G, H, L, D, Y, I, M, and R;
[0119] U9 is selected from W, L, and A;
[0120] U10 is selected from P, S, R, L, E, and A;
[0121] Un is selected from L, A, T, M, V, W, Y, E, Q, I, F, S, P, K, R, D, H, N, and G; and
[0122] U12 is selected from L, F, V, M, I, Y, E, W, and A.
[0123]
[0055] In some embodiments, Ui is selected from T, S, L, M, W, Q, P, R, G, N, I, Y, D, E, V, and H;
[0124] U2 is selected from A, S, T, K, E, R, G, N, W, and D;
[0125] U3 is selected from A, E, P, D, G, W, Q, V, and F;
[0126] U4 is selected from G, V, F, D, E, and R;
[0127] U5 is selected from A, F, V, S, L, P, and M;WSGR Docket No. 52426-781.601
[0128] U6is selected from T, S, H, M, A, N, P, G, Q, D, Y, V, L, I, E, K, F, and R;
[0129] U7 is selected from Y, W, F, L, N, T, Q, and I;
[0130] U8is selected from P, S, T, A, E, K, Q, N, V, G, H, L, D, Y, I, M, and R;
[0131] U9 is selected from W, L, and A;
[0132] U10 is selected from P, S, R, L, and E;
[0133] Un is selected from L, A, T, M, V, W, Y, E, Q, I, F, S, P, K, R, D, H, N, and G; and
[0134] U12 is selected from L, F, V, M, I, Y, E, and W.
[0135]
[0056] In some embodiments, the peptide mask comprises the amino acid sequence of SEQ ID NO: 994.
[0136]
[0057] In some embodiments, the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 1001-1008.
[0137]
[0058] In some embodiments, the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 1039-1058.
[0138]
[0059] In some embodiments, the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 977-2324.
[0139]
[0060] In some embodiments, the peptide mask comprises a peptide sequence of at least 10 amino acids in length.
[0140]
[0061] In some embodiments, the peptide mask comprises a peptide sequence of at least 10 amino acids in length and no more than 20 amino acids in length.
[0141]
[0062] In some embodiments, the peptide mask comprises a peptide sequence of at least 16 amino acids in length acids.
[0142]
[0063] In some embodiments, the peptide mask comprises a peptide sequence of no more than 40 amino in length.
[0143]
[0064] In some embodiments, the peptide mask comprises at least two cysteine amino acid residues.
[0144]
[0065] In some embodiments, the peptide mask comprises a cyclic peptide or a linear peptide.
[0145]
[0066] In some embodiments, the half-life extending molecule is linked to a T cell engager via a linker.
[0146]
[0067] In some embodiments, the linker is a peptide sequence having at least 5 to no more than 50 amino acids.
[0147]
[0068] In some embodiments, the linker is a peptide sequence having at least 10 to no more than 30 amino acids.
[0148]
[0069] In some embodiments, the linker is a peptide sequence having at least 10 amino acids.
[0149]
[0070] In some embodiments, the linker is a peptide sequence having at least 18 amino acids.
[0150]
[0071] In some embodiments, the linker is a peptide sequence having at least 26 amino acids.
[0151]
[0072] In some embodiments, the linker has a formula comprising (G2S)n, wherein n is an integer from 1 to 3.
[0152]
[0073] In some embodiments, the linker has a formula selected from the group consisting of (G2S)n, (GS)n, (GSGGS)n, (GGGS)n, (GGGGS)n, and (GSSGGS)n, wherein n is an integer of at least 1.WSGR Docket No. 52426-781.601
[0153]
[0074] In some embodiments, the linker comprises an amino acid sequence according to any one of SEQ ID NOs: 2371-2402.
[0154]
[0075] In some embodiments, the linker comprises an amino acid sequence of Linker 25 (ISSGLLSGRSDAG) (SEQ ID NO: 2397), Linker 26 (AAGLLAPPGGLSGRSDAG) (SEQ ID NO: 2398), Linker 27 (SPLGLSGRSDAG) (SEQ ID NO: 2399), or Linker 28 (LSGRSDAGSPLGLAG) (SEQ ID NO: 2400), or an amino acid sequence that has 1, 2, or 3 amino acid substitutions, additions, or deletions relative to the amino acid sequence of Linker 25, Linker 26, Linker 27, or Linker 28.
[0155]
[0076] In some embodiments, the polypeptide or polypeptide complex comprises a modified amino acid, a non-natural amino acid, a modified non-natural amino acid, or a combination thereof.
[0156]
[0077] In some embodiments, the modified amino acid or modified non-natural amino acid comprises a post-translational modification.
[0157]
[0078] In some embodiments, a linker is bound to N-terminus of the antigen binding domain and / or C-terminus of the antigen binding domain.
[0158]
[0079] In another aspect, provided herein is a method of extending half-life of a T-cell engager comprising tethering a peptide mask that is in tandem to a half-life extending molecule to the T-cell engager via a linker to generate a modified T-cell engager, wherein the half-life extending molecule comprises a fragment crystaHizable (Fc) domain, wherein the Fc domain comprises a single chain Fc (scFc) or one or more mutations,
[0159] wherein the linker is cleaved when inside a tumor microenvironment and the peptide mask that is in tandem to the half-life extending molecule is released from the modified T-cell engager to generate a cleaved T-cell engager, and
[0160] wherein the modified T-cell engager has a longer half-life in a subject as compared to the unmodified T-cell engager.
[0161]
[0080] In some embodiments, the peptide mask is operatively linked to the half-life extending molecule within a single contiguous polypeptide chain.
[0162]
[0081] In some embodiments, the modified T-cell engager has a half-life of at least or about 12 hours, 24 hours 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, 96 hours, 100 hours, 108 hours, 120 hours, 140 hours, 160 hours, 180 hours, 200 hours, or more than 200 hours.
[0163]
[0082] In some embodiments, the modified T-cell engager has a half-life of at least or about 1 hour, 5 hours, 10 hours, 15 hours, 20 hours, 25 hours, 30 hours, 35 hours, 40 hours, 50 hours or more than the unmodified T-cell engager.
[0164]
[0083] In some embodiments, the one or more mutations comprise a M428G, aN434A, and / or H435R according to EU numbering.
[0165]
[0084] In some embodiments, the one or more mutations are selected from the group consisting of L234A, L235A, N297G, P329G, Y349C, S354C, T366S, T366W, L368A, Y407V, M428G, N434A, H435R, and Y436F mutation according to EU numbering relative to SEQ ID NO: 2335.WSGR Docket No. 52426-781.601
[0166]
[0085] In some embodiments, the one or more mutations comprise one or more knob-in-hole (KIH) mutations.
[0167]
[0086] In some embodiments, the Fc domain comprises a first polypeptide and a second polypeptide, wherein the first polypeptide of the Fc domain comprises a hole mutation and the second polypeptide of the Fc domain comprises a knob mutation.
[0168]
[0087] In some embodiments, the Fc domain comprises a first polypeptide and a second polypeptide, wherein the first polypeptide of the Fc domain comprises T366S, L368A, and Y407V mutations according to EU numbering, and the second polypeptide of the Fc domain comprises a T366W mutation according to EU numbering.
[0169]
[0088] In some embodiments, the Fc domain comprises Fc effector function silencing mutations comprising L234A, L235A, and P329G mutations according to EU numbering.
[0170]
[0089] In some embodiments, the Fc domain comprises an engineered disulfide.
[0171]
[0090] In some embodiments, the Fc domain comprises a Y349C mutation and a S354C mutation according to EU numbering, and wherein the engineered disulfide is formed between two cysteines at the positions of the Y349C mutation and the S354C mutation.
[0172]
[0091] In some embodiments, the Fc domain comprises aN297G mutation according to EU numbering.
[0173]
[0092] In some embodiments, the one or more mutations comprise a ProA or ProG mutation.
[0174]
[0093] In some embodiments, the Fc domain comprises a H435R and / or a Y436F according to EU numbering.
[0175]
[0094] In some embodiments, the Fc domain comprises a M428G and / or a N434A according to EU numbering.
[0176]
[0095] In some embodiments, the Fc domain lacks a C-terminal glycine and a C-terminal lysine.
[0177]
[0096] In some embodiments, the Fc domain lacks C-terminal G446 and K447 residues according to EU numbering.
[0178]
[0097] In some embodiments,:
[0179] (i) the Fc domain comprises a scFc comprising an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2337;
[0180] (ii) the Fc domain comprises a scFc comprising an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2338; or
[0181] (iii) the Fc domain comprises a scFc comprising an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2339.
[0182]
[0098] In some embodiments, half-life extending molecule further comprises a polymer.
[0183]
[0099] In some embodiments, the polymer is polyethylene glycol (PEG).WSGR Docket No. 52426-781.601
[0184] BRIEF DESCRIPTION OF THE DRAWINGS
[0185]
[0100] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0186]
[0101] FIG. 1 illustrates a cartoon configuration of an illustrative multispecific antibody construct that comprises a T cell engager comprising an antigen binding domain (e.g., CD3 binding domain, CD28 binding domain), a peptide mask that binds to the antigen binding domain and impairs binding of the antigen binding domain to an antigen; and an illustrative half-life extending molecule comprising a variant Fc domain, that is in tandem with the peptide mask.
[0187]
[0102] FIG. 2 illustrates the core sequence motif of peptide- 87 sequences generated using WebLogo 3.7.12.
[0188]
[0103] FIG. 3 illustrates the core sequence motif of anti-CD28 Fab peptide-92 sequences generated using WebLogo 3.7.12.
[0189]
[0104] FIG. 4 illustrates the core sequence motif of optimized anti-CD28 scFv Peptide-9 sequences generated using WebLogo 3.7.4.
[0190] DETAILED DESCRIPTION
[0191]
[0105] Multispecific antibodies combine the benefits of different binding specificities derived from two or more antibodies into a single composition. Multispecific antibodies, such as T-cell engagers (TCEs) for redirecting T cells to cancers have shown promise in both pre-clinical and clinical studies. This approach relies on binding of one antigen interacting portion of the antibody to a tumor-associated antigen or marker, while a second antigen interacting portion can bind to an effector cell antigen on a T cell, such as cluster of differentiation 3 (CD3), which then triggers cytotoxic activity. While TCEs have displayed potent anti -tumor activity in some cancers, TCE therapeutics may face challenges such as off-target toxicity in healthy tissue and slow clearance.
[0192]
[0106] Activation of T cells is a highly regulated process that typically requires two signaling events for full functionality: the first signal (signal 1) is initiated upon binding of the major histocompatibility complex (MHC)-antigen complex, which helps distinguish “self’ from “non-self ’ to the T cell receptor (TCR), and the second costimulatory signal (signal 2) occurs through activation of a costimulatory receptor, such as CD28. While the first signal activates a T cell and triggers T cell mediated toxicity of the recognized cell, if the T cell does not receive a second costimulatory signal it can lead to T cell tolerance whereby the T cells continue to recognize the tumor antigen but do not mount an immune response against the tumor cell. The second costimulatory signal prevents T cell tolerance, and further activates the T cell to enhance T cell cytotoxicity towards the targeted cell. CD3-targeted T cell engagers (TCE) create signal 1 through TCE signaling without the need for a TCR / MHC interaction.
[0193]
[0107] Disclosed herein is a polypeptide or polypeptide complex comprising a T-cell engager comprising an antigen binding domain (e.g., CD3 binding domain, CD28 binding domain), a peptide mask that binds toWSGR Docket No. 52426-781.601
[0194] the antigen binding domain and impairs binding of the antigen binding domain to an antigen; and a half-life extending molecule that is in tandem with the peptide mask. The half-life extending molecule can comprise a fragment crystaHizable (Fc) domain such as a variant Fc domain comprising one or more mutations or a single chain Fc (scFc). The half-life extending molecule can be attached to the polypeptide or polypeptide complex via the cleavable linker such that cleavage of the cleavable linker by tumor-specific proteases releases the half-life extending molecule to promote rapid clearance. By using a T-cell engager comprising a half-life extending molecule comprising a Fc domain such as a variant Fc domain (i.e., comprising one or more mutations) or a scFc, the T-cell engager can exhibit improved technical effects, for example, improved pharmacokinetics, improved pharmacodynamics, enhanced or prolonged half-life, improved solubility, improved or enhanced stability, ease of production, enhanced therapeutic activity, reduced immunogenicity, reduced toxicity, improved potency, improved production, improved expression yields from, for example, cell lines, and / or improved specificity.
[0195] Certain Definitions
[0196]
[0108] The terminology used herein is for the purpose of describing particular cases only and is not intended to be limiting. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms “including”, “includes”, “having”, “has”, “with”, or variants thereof are used in either the detailed description and / or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising.”
[0197]
[0109] The term “antibody” is used in the broadest sense and covers fully assembled antibodies, antibody fragments that can bind antigen, for example, Fab, F(ab’)2, Fv, single chain antibodies (scFv), diabodies, antibody chimeras, hybrid antibodies, bispecific antibodies, and the like.
[0198] [HO] The term “complementarity determining region” or “CDR” is a segment of the variable region of an antibody that is complementary in structure to the epitope to which the antibody binds and is more variable than the rest of the variable region. Accordingly, a CDR is sometimes referred to as hypervariable region. A variable region comprises three CDRs. CDR peptides can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick et al., Methods: A Companion to Methods in Enzymology 2: 106 (1991); Courtenay-Luck, “Genetic Manipulation of Monoclonal Antibodies,” in Monoclonal Antibodies: Production, Engineering and Clinical Application, Ritter et al. (eds.), pages 166-179 (Cambridge University Press 1995); and Ward et al., “Genetic Manipulation and Expression of Antibodies,” m Monoclonal Antibodies: Principles and Applications, Birch et al., (eds.), pages 137-185 (Wiley-Liss, Inc. 1995).
[0199] [Hl] The term “Fab” refers to a protein that contains the constant domain of the light chain and the first constant domain (CHI) of the heavy chain. Fab fragments differ from Fab' fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHI domain including one or more cysteines from the antibody hinge region. Fab’-SH is the designation herein for Fab' in which the cysteine residue(s) of theWSGR Docket No. 52426-781.601
[0200] constant domains bear a free thiol group. Fab' fragments are produced by reducing the F(ab’)2 fragment’s heavy chain disulfide bridge. Other chemical couplings of antibody fragments are also known.
[0201]
[0112] A “CrossFab configuration” as used herein is a Fab molecule wherein the variable domains or the constant domains of the Fab heavy and light chain are exchanged (replaced by each other) (see, e.g., W02009 / 080252A1 and WO2017 / 055388A2). For example, a Fab molecule in a CrossFab configuration may comprise a peptide chain composed of the variable light chain domain and the heavy chain constant domain (VL-CH1 in an N- to C-terminal direction), and a peptide chain composed of the variable heavy chain domain and the light chain constant domain (VH-CL in an N- to C-terminal direction).
[0202]
[0113] A “single-chain variable fragment (scFv)” is a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of an antibody, connected with a short linker peptide of ten to about 25 amino acids. The linker is usually rich in glycine for flexibility, as well as serine or threonine for solubility, and can either connect the N-terminus of the VH with the C-terminus of the VL, or vice versa. This protein retains the specificity of the original antibody, despite removal of the constant regions and the introduction of the linker. scFv antibodies are, e.g. described in Houston, J. S., Methods in Enzymol. 203 (1991) 46-96). In addition, antibody fragments comprise single chain polypeptides having the characteristics of a VH domain, namely being able to assemble together with a VL domain, or of a VL domain, namely being able to assemble together with a VH domain to a functional antigen binding site and thereby providing the antigen binding property of full length antibodies.
[0203]
[0114] As used herein, the term “percent (%) amino acid sequence identity” with respect to a sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as EMBOSS MATCHER, EMBOSS WATER, EMBOSS STRETCHER, EMBOSS NEEDLE, EMBOSS LALIGN, BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
[0204]
[0115] In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X / Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequenceWSGR Docket No. 52426-781.601
[0205] identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.
[0206]
[0116] The terms “complementarity determining region,” and “CDR,” which are synonymous with “hypervariable region” or “HVR,” are known in the art to refer to non- contiguous sequences of amino acids within antibody variable regions, which confer antigen specificity and / or binding affinity. In general, there are three CDRs in each heavy chain variable region (CDR-H1, CDR-H2, CDR-H3) and three CDRs in each light chain variable region (CDR-L1, CDR-L2, CDR-L3). “Framework regions” and “FR” are known in the art to refer to the non-CDR portions of the variable regions of the heavy and light chains. In general, there are four FRs in each full-length heavy chain variable region (FR-H1, FR-H2, FR-H3, and FR-H4), and four FRs in each full-length light chain variable region (FR-L1, FR-L2, FR-L3, and FR-L4). The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of a number of well-known schemes, including those described by Kabatet al. (1991), “Sequences ofProteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (“Kabaf ’ numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 (“Chothia” numbering scheme); MacCallum et al., J. Mol. Biol.
[0207] 262:732-745 (1996), “Antibody-antigen interactions: Contact analysis and binding site topography,” J. Mol. Biol. 262, 732-745.” (“Contact” numbering scheme); Lefranc MP et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol, 2003 Jan;27(l):55-77 (“IMGT’ numbering scheme); Honegger A and Pluckthun A, “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool,” J Mol Biol, 2001 Jun 8;309(3):657-70, (“Aho” numbering scheme); and Whitelegg NR and Rees AR, “WAM: an improved algorithm for modelling antibodies on the WEB,” Protein Eng. 2000 Dec;13(12):819-24 (“AbM’ numbering scheme. In certain embodiments the CDRs of the antibodies described herein can be defined by a method selected from Kabat, Chothia, IMGT, Aho, AbM, or combinations thereof.
[0208]
[0117] The boundaries of a given CDR or FR may vary depending on the scheme used for identification. For example, the Kabat scheme is based on structural alignments, while the Chothia scheme is based on structural information. Numbering for both the Kabat and Chothia schemes is based upon the most common antibody region sequence lengths, with insertions accommodated by insertion letters, for example, “30a,” and deletions appearing in some antibodies. The two schemes place certain insertions and deletions (“indels”) at different positions, resulting in differential numbering. The Contact scheme is based on analysis of complex crystal structures and is similar in many respects to the Chothia numbering scheme.
[0209] Polypeptide or Polypeptide Complexes
[0210] Disclosed herein is a polypeptide or polypeptide complex comprising a T cell engager, a peptide mask and a half-life extending molecule that is in tandem with the peptide mask (FIG. 1). In some embodiments, the T cell engager comprises a T-cell binding domain.
[0211] Half-Life Extending Molecule
[0212]
[0118] In some embodiments, the half-life extending molecule comprises a fragment crystallizable (Fc) domain. In some embodiments, the half-life extending molecule comprises a variant Fc domain. A variant FcWSGR Docket No. 52426-781.601
[0213] domain can comprise one or more mutations compared with a reference Fc domain. A variant Fc domain can comprise one or more mutations selected from the group consisting of L234A, L235A, N297G, P329G, Y349C, S354C, T366S, T366W, L368A, Y407V, M428G, N434A, H435R, and Y436F, according to EU numbering, relative to wildtype human IgGl Fc, e.g., SEQ ID NO: 2335.
[0214]
[0119] In some embodiments, the Fc domain comprises a single chain Fc (scFc) domain. In some embodiments, the single chain Fc domain comprises a first polypeptide and a second polypeptide, wherein the first polypeptide and the second polypeptide are linked together. In some embodiments, the first polypeptide comprises one or more mutations selected from the group consisting of L234A, L235A, N297G, P329G, Y349C, T366S, L368A, Y407V, M428G, N434A, H435R, and Y436F, according to EU numbering. In some embodiments, the second polypeptide comprises one or more mutations selected from the group consisting of L234A, L235A, N297G, P329G, S354C, and T366W, according to EU numbering.
[0215]
[0120] In some embodiments, the Fc domain comprises one or more mutations. For example, the mutations can be one or more of L234A, L235A, N297G, P329G, Y349C, S354C, T366S, T366W, L368A, Y407V, M428G, N434A, H435R, and Y436F mutation, according to EU numbering, relative to SEQ ID NO: 2335.
[0216]
[0121] In some embodiments, the Fc domain comprises one or more knob-in-hole (KIH) mutations. In some embodiments, the Fc domain comprises a first polypeptide and a second polypeptide, wherein the first polypeptide of the Fc domain comprises a hole mutation and the second polypeptide of the Fc domain comprises a knob mutation. In some embodiments, the first polypeptide of the Fc domain comprises T366S, L368A, and Y407V mutations according to EU numbering, and the second polypeptide of the Fc domain comprises a T366W mutation according to EU numbering. In some embodiments, the Fc domain comprises Fc effector function silencing mutations L234A, L235A, and P329G according to EU numbering. In some embodiments, the Fc domain comprises an engineered disulfide. In some embodiments, the Fc domain comprises a Y349C mutation and a S354C mutation according to EU numbering, and the engineered disulfide is formed between two cysteines at the positions of the Y349C mutation and the S354C mutation. In some embodiments, the Fc domain comprises aN297G mutation according to EU numbering. In some embodiments, the Fc domain lacks a C-terminal glycine and a C-terminal lysine to reduce heterogeneity. In some embodiments, the Fc domain lacks C-terminal G446 and K447 residues according to EU numbering to reduce heterogeneity.
[0217]
[0122] In some embodiments, the Fc domain comprises two polypeptides. In some embodiments, the Fc domain has a knobs-into-holes format, wherein the first polypeptide of the Fc domain comprises a hole mutation, and wherein second polypeptide of the Fc domain comprises a knob mutation. In some embodiments, the first polypeptide of the Fc domain comprises mutations T366S, L368A and Y407V according to EU numbering, and wherein the second polypeptide of the Fc domain comprises a mutation T366W according to EU numbering. In some embodiments, the first polypeptide of the Fc domain comprising the hole mutation further comprises a mutation Y349C according to EU numbering, wherein the second polypeptide of the Fc domain comprising the knob mutation further comprises a mutation S354C according to EU numbering, and wherein the Fc domain comprises an engineered disulfide bond formedWSGR Docket No. 52426-781.601
[0218] between these two cysteines. In some embodiments, one or both of the polypeptides of the Fc domain comprise mutations L234A, L235A, and P329G according to EU numbering. In some embodiments, one or both of the polypeptides of the Fc domain comprise the mutation N297G according to EU numbering.
[0219]
[0123] In some embodiments, the Fc domain comprises one or more ProA or ProG mutations. Protein A (Pro A) and / or Protein G (ProG) can bind to Fc domain of antibodies and can be used for antibody purification and / or immunoprecipitation. The ProA mutations and / or ProG mutations of the Fc domain can modulate Protein A and / or Protein G binding and purification to help separate heterodimer from homodimers. In some embodiments, the term “ProA mutations” of the Fc domain, as used herein, refers to the mutations that modulate Protein A binding. In some embodiments, the term “ProG mutations” of the Fc domain, as used herein, refers to the mutations that modulate Protein G binding. In some embodiments, ProA mutations can include H435R and Y436F according to EU numbering. In some embodiments, ProG mutations can include M428G and N434A according to EU numbering. In some embodiments, the first polypeptide of the Fc domain comprises mutations H435R and Y436F (e.g., ProA mutations) according to EU numbering. In some embodiments, the first polypeptide of the Fc domain comprises mutations M428G and N434A (e.g., ProG mutations) according to EU numbering. In some embodiments, the second polypeptide of the Fc domain comprises mutations H435R and Y436F (e.g., ProA mutations) according to EU numbering. In some embodiments, the second polypeptide of the Fc domain comprises mutations M428G and N434A (e.g., ProG mutations) according to EU numbering.
[0220]
[0124] In some embodiments, the Fc domain comprises one or more of KIH mutations, ProA, and / or ProG mutations. In some embodiments, the first polypeptide of the Fc domain comprises the hole mutation and further comprises mutations H435R and Y436F (e.g., ProA mutations) according to EU numbering. In some embodiments, the first polypeptide of the Fc domain comprising the hole mutation further comprises mutations M428G and N434A (e.g., ProG mutations) according to EU numbering.
[0221]
[0125] In some embodiments, the Fc domain lacks one or more effector functions and / or lacks glycosylation. In some embodiments, the effector function is selected from the group consisting of antibodydependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complementdependent cytotoxicity (CDC), binding to a Fey receptor (FcyR), or any combination thereof. In some embodiments, the Fc domain lacks the C-terminal G446 and K447 residues by EU numbering to reduce heterogeneity.
[0222]
[0126] In some embodiments, the half-life extending molecule comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to any one of the sequences in Table 1. In some embodiments, the half-life extending molecule comprises of any one of the amino acid sequences in Table 1
[0223]
[0127] In some embodiments, the Fc domain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2337. In some embodiments, the Fc domain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and anWSGR Docket No. 52426-781.601
[0224] amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2338. In some embodiments, the Fc domain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2339.
[0225]
[0128] In some embodiments, the half-life extending molecule comprises a polymer. In some embodiment^ the polymer is polyethylene glycol (PEG). In some embodiments, half-life extending molecule comprises albumin.
[0226]
[0129] In some embodiments, the albumin is serum albumin. In some embodiments, the albumin is human serum albumin. In some embodiments, half-life extending molecule comprises a polypeptide, a ligand, or a small molecule. In some embodiments, the polypeptide, the ligand or the small molecule binds serum protan or a fragment thereof, a circulating immunoglobulin or a fragment thereof, or CD35 / CR1. In some embodiments, the serum protein comprises a thyroxine- binding protein, a transthyretin, a 1-acid glycoprotein, a transferrin, transferrin receptor or a transferrin-binding portion thereof, a fibrinogen, or an albumin. In some embodiments, the circulating immunoglobulin molecule comprises IgGl, IgG2, IgG3, IgG4, slgA, IgM or IgD. In some embodiments, the serum protein is albumin. In some embodiments, the polypeptide is an antibody. In some embodiments, the antibody comprises a single domain antibody, a single chain variable fragment, or a Fab. In some embodiments, the single domain antibody comprises a single domain antibody that binds to albumin. In some embodiments, the single domain antibody is a human or humanized antibody. In some embodiments, the single domain antibody is 645gHlgLl. In some embodiments, the single domain antibody is 645dsgH5gL4. In some embodiments, the single domain antibody is 23-13-A01 -sc02. In some embodiments, the single domain antibody is A10m3 or a fragment thereof. In some embodiments, the single domain antibody is DOM7r-31. In some embodiments, the single domain antibody is DOM7h-ll-15. In some embodiments, the single domain antibody is Alb-1, Alb-8, or Alb-23. In some embodiments, the single domain antibody is 10E. In some embodiments, the single domain antibody comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the single domain antibody comprise: HC-CDR1: SEQ ID NO: 2324, HC-CDR2: SEQ ID NO: 2325, and HC-CDR3: SEQ ID NO: 2326. In some embodiments, the single domain antibody comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, andHC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the single domain antibody comprise: HC-CDR1: SEQ ID NO: 2328, HC-CDR2: SEQ ID NO: 2329, and HC-CDR3: SEQ ID NO: 2330. In some embodiments, the single domain antibody comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 195. In some embodiments, the single domain antibody comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2331. In some embodiments, the single domain antibody comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2332. In some embodiments, the single domain antibody comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2333. In some embodiments, the single domain antibodyWSGR Docket No. 52426-781.601
[0227] comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2334. In some embodiments, the single domain antibody is SA21.
[0228]
[0130] In some embodiments, the polypeptide or polypeptide complex comprises a modified amino acid, a non-natural amino acid, a modified non-natural amino acid, or a combination thereof. In some embodiment^ the modified amino acid or modified non-natural amino acid comprises a post-translational modification.
[0229] Table 1. Half-Life Extending Molecule Sequences
[0230] Construct Description Amino Acid Sequence SEQ ID NO:
[0231] (N to C)
[0232] Anti-Albumin: CDR-H1 GSTFYTAV
[0233] 2324 Anti-Albumin: CDR-H2 IRWTALTT
[0234] 2325 Anti-Albumin: CDR-H3 AARGTLGLFTTADSYDY
[0235] 2326 Anti-albumin (HE-1) EVQLVESGGGLVQPGGSLRLSCAASGSTF YTAVMGWVRQAPGKGLEWVAAIRWTA LTTSYADSVKGRFTISRDGAKTTLYLQM NSLRPEDTAVYYCAARGTLGLFTTADSY DYWGQGTLVTVSS 2327 10G Anti- Albumin: CDR-H1 GFTFSKFG
[0236] 2328 10G Anti- Albumin: CDR-H2 ISGSGRDT
[0237] 2329 10G Anti- Albumin: CDR-H3 TIGGSLSV
[0238] 2330 10G Anti-albumin (HE-2) EVQLVESGGGLVQPGNSLRLSCAASGFT FSKFGMSWVRQAPGKGLEWVSSISGSGR DTLYADSVKGRFnSRDNAKITLYLQMN
[0239] S LRPEDTAVYYCTIGGSLSVS S QGTLVTV SS 2331 Anti-Albumin (HE-3) EVQLVESGGGLVQPGGSLRLSCAASGSTF 2332
[0240] YTAVMGWVRQAPGKGLEWVAAIRWTA LTTSYADSVKGRFTISRDNAKTTLYLQMN SLRPEDTAVYYCAARGTLGLFTTADAYD YWGQGTLVTVSS
[0241] Anti -Albumin (HE -4) EVQLVESGGGLVQPGNSLRLSCAASGFTF 2333
[0242] SSFGMSWVRQAPGKGLEWVSSISGSGSD TLYADSVKGRFTISRDNAKTTLYLQMNSL RPEDTAVYYCTIGGSLSRS S QGTLVTVS S
[0243] scFc DKTHTCPPCPAPELLGGPSVFLFPPKPKDT 2334
[0244] LMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPCEEQYGSTYRCVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEK TISI<AI<GQPREPQVYTLPPSREEMTI<NQV SLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGGG GSGGGGSGGGGSGGGGSGGGGSGGGGS DKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPCEEQYGSTYRCVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEK TISI<AI<GQPREPQVYTLPPSREEMTI<NQV
[0245]
[0246] SLTCLVKGFYPSDIAVEWESNGQPENNYKWSGR Docket No. 52426-781.601
[0247] TTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHE ALHNHYTQKSLSLSP
[0248] Wildtype human IgGl Fc DKTHTCPPCPAPELLGGPSVFLFPPKPKDT 2335
[0249] LMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHE ALHNHYTQKSLSLSPGK
[0250] Knob in hole Fc DKTHTCPPCPAPEAAGGPSVFLFPPKPKD 2336
[0251] TLMISRTPEVTCVVVDVSHEDPEVKFNW
[0252] “Knob” Fc
[0253] YVDGVEVHNAKTKPREEQYGSTYRVVSV
[0254] (LALAPG; -GK) LTVLHQDWLNGKEYKCKVSNKALGAPIE KTTSKAKGQPREPQVYTLPPCRDELTKNQ VSLWCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVF S CS VMHE ALHNHYTQKSLSLSP
[0255] Knob in hole Fc DKTHTCPPCPAPEAAGGPSVFLFPPKPKD 2337
[0256] TLMISRTPEVTCVVVDVSHEDPEVKFNW
[0257] “Hole” Fc
[0258] YVDGVEVHNAKTKPREEQYGSTYRVVSV
[0259] (LALAPG; -GK) LTVLHQDWLNGKEYKCKVSNKALGAPIE KTISKAKGQPREPQVCTLPPSRDELTKNQ VSLSCAVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLVSKLTVDKSRWQ QGNVF S CS VMHE ALHNHYTQKSLSLSP
[0260] Knob in hole Fc DKTHTCPPCPAPEAAGGPSVFLFPPKPKD 2336
[0261] TLMISRTPEVTCVVVDVSHEDPEVKFNW
[0262] “Knob” Fc (ProA mutations)
[0263] YVDGVEVHNAKTKPREEQYGSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALGAPIE KTTSKAKGQPREPQVYTLPPCRDELTKNQ VSLWCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVF S CS VMHE ALHNHYTQKSLSLSP
[0264] Knob in hole Fc DKTHTCPPCPAPEAAGGPSVFLFPPKPKD 2338
[0265] TLMISRTPEVTCVVVDVSHEDPEVKFNW
[0266] “Hole” Fc (ProA mutations)
[0267] YVDGVEVHNAKTKPREEQYGSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALGAPIE KTISKAKGQPREPQVCTLPPSRDELTKNQ VSLSCAVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLVSKLTVDKSRWQ QGNVF S CS VMHE ALHNRFTQKSLSLSP
[0268] Knob in hole Fc DKTHTCPPCPAPEAAGGPSVFLFPPKPKD 2336
[0269] TLMISRTPEVTCVVVDVSHEDPEVKFNW
[0270] “Knob” Fc (ProG mutations)
[0271] YVDGVEVHNAKTKPREEQYGSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALGAPIE KTTSKAKGQPREPQVYTLPPCRDELTKNQ VSLWCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVF S CS VMHE ALHNHYTQKSLSLSP
[0272] Knob in hole Fc DKTHTCPPCPAPEAAGGPSVFLFPPKPKD 2339
[0273] TLMISRTPEVTCVVVDVSHEDPEVKFNW
[0274] “Hole” Fc (ProG mutations)
[0275] YVDGVEVHNAKTKPREEQYGSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALGAPIE
[0276]
[0277] KTISKAKGQPREPQVCTLPPSRDELTKNQWSGR Docket No. 52426-781.601
[0278] VSLSCAVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLVSKLTVDKSRWQ
[0279]
[0280] QGNVFSCSVGHEALHAHYTQKSLSLSP
[0281] CD3 Binding Domain
[0282]
[0131] In some embodiments, the antigen binding domain comprises a cluster of differentiation 3 (CD3) binding domain. In some embodiments, the antigen binding domain comprises an anti-CD3 antibody. In some embodiments, the antigen binding domain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to any one of the sequences in Table 2. In some embodiments, the antigen binding domain comprises any one of the amino acid sequences in Table 2.
[0283]
[0132] In some embodiments, the antigen binding domain (e.g., anti-CD3 antibody) comprises an anti-CD3 heavy chain variable domain that comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 comprise amino acid sequences ofHC-CDRl: SEQ ID NO: 2340, HC-CDR2: SEQ ID NO: 2341, and HC-CDR3: SEQ ID NO: 2342, and the antigen binding domain (e.g., anti-CD3 antibody) comprises an anti-CD3 light chain variable domain that comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, and wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 comprise amino acid sequences of LC-CDR1: SEQ ID NO: 2343, LC-CDR2: SEQ ID NO: 2344, and LC-CDR3: SEQ ID NO: 2345. In some embodiments, the antigen binding domain (e.g., anti-CD3 antibody) that binds to CD3 comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2346. In some embodiments, the antigen binding domain (e.g., anti-CD3 antibody) comprises a single chain variable fragment (scFv) or a Fab or Fab’ fragment.
[0284] Table 2. anti-CD3 amino acid sequences (CDRs as determined by IMGT numbering system)
[0285] Construct Description Amino Acid Sequence SEQ ID (Nto C) NO:
[0286] SP34.185 CD3: HC: CDR1 GFTFNKYA 2340 SP34.185 CD3: HC: CDR2 IRSKYNNYAT 2341 SP34.185 CD3: HC: CDR3 VRHGNFGNSYI SYWAY 2342 SP34.185 CD3: LC: CDR1 TGAVTSGNY 2343 SP34.185 CD3: LC: CDR2 GT 2344 SP34.185 CD3: LC: CDR3 VLWYSNRWV 2345 SP34.185 scFv EVQLVESGGGLVQPGGSLKLSCA 2346
[0287] (VH - linker 1 - VL) ASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSV KDRFTI SRDDSKNT AYLQMNNLK TEDTAVYYCVRHGNFGNSYISY WAYWGOGTLVTVSSGGGGSGGG GSGGGGSQTWTQEPSLTVSPGG TVTT .TCGSSTGAVTSGNYPNWV
[0288] QQKPGQAPRGLI GGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPED EAEYYCVLWYSNRWVFGGGTKL
[0289]
[0290] TVLWSGR Docket No. 52426-781.601
[0291] CD 3 Masks
[0292]
[0133] In some embodiments, the peptide mask is a peptide that impairs binding of an anti-CD3 antibody to CD3. In some embodiments, the peptide mask is bound to the T-cell binding domain through ionic interactions, electrostatic interactions, hydrophobic interactions, Pi-stacking interactions, or H-bonding interactions, or a combination thereof. In some embodiments, the peptide mask has less than 70% sequence homology to CD3. In some embodiments, the peptide mask comprises a peptide sequence of at least 10 amino acids in length. In some embodiments, the peptide mask comprises a peptide sequence of at least 10 amino acids in length and no more than 20 amino acids in length. In some embodiments, the peptide mask comprises a peptide sequence of at least 16 amino acids in length. In some embodiments, the peptide mask comprises a peptide sequence of no more than 40 amino in length. In some embodiments, the peptide mask comprises at least two cysteine amino acid residues. In some embodiments, the peptide mask comprises a cyclic peptide or a linear peptide. In some embodiments, the peptide mask comprises a cyclic peptide. In some embodiments, the peptide mask comprises a linear peptide. In some embodiments, Pi comprises at least two cysteine amino acid residues.
[0293]
[0134] In some embodiments, the peptide mask comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to any one of the sequences in Table 3-6. In some embodiments, the peptide mask comprises any one of the amino acid sequences in Table 3-6.
[0294]
[0135] In some embodiments, the peptide mask comprises an amino acid sequence according to U1-U2-C-U4-P-U6-U7-U8-U9-Uio-Un-Ui2-C-Ui4and Ui is selected from D, Y, F, I, N, V, H, L, A, T, S, and P; U2is selected from D, Y, L, F, I, N, A, V, H, T, and S; U4 is selected from G and W; Ue is selected from E, D, V, and P; U7 is selected from W, L, F, V, G, M, I, and Y; U8is selected from E, D, P, and Q; U9 is selected from E, D, Y, V, F, W, P, L, and Q; U10 is selected from S, D, Y, T, I, F, V, N, A, P,_L, and H; Un is selected from I, Y, F, V, L, T, N, S, D, A, and H; Unis selected from F, D, Y, L, I, V, A, N, T, P, S, G, and H; and U14 is selected from D, Y, N, F, I, P, V, A, T, H, L, M, and S. In some embodiments, Ui is selected from D, Y, F, I, V, and N; U2 is selected from D, Y, L, F, I, and N; U4 is selected from G and W; Ue is selected from E and D; U7 is selected from W, L, F, G, and V; U8is selected from E and D; U9 is selected from E, D, Y, and V; U10 is selected from S, D, Y, T, and I; Un is selected from I, Y, F, V, L, and T; U12 is selected from F, D, Y, L, I, V, A, G, and N; and U14 is selected from D, Y, N, F, I, M, and P. In some embodiments, Ui is selected from D, Y, V, and F; U2 is selected from D, Y, L, and F; U4 is selected from G and W; Ue is selected from E and D; U7 is selected from W, L, G, and F; U8is selected from E and D; U9 is selected from E and D; U10 is selected from S, D, T, and Y; Un is selected from I, Y, V, L, and F; U is selected from F, D, Y, G, A, and L; U14 is selected from D, Y, M, and N.
[0295]
[0136] In some embodiments, the peptide mask comprises the amino acid sequences according to any one of SEQ ID NOs: 1-904, and 2364. In some embodiments, the peptide mask comprises the amino acid sequences according to any one of SEQ ID NOs: 1-31, 2364, and 893-904. In some embodiments, the peptide mask comprises the amino acid sequence according to SEQ ID NO: 3. In some embodiments, the peptide mask comprises the amino acid sequence according to SEQ ID NO: 4.WSGR Docket No. 52426-781.601
[0296] Table 3. CD3 Mask Sequences
[0297] Construct Description Amino Acid Sequence SEQ ID (N to C) NO:
[0298] SP34.185 scFv mask GGGSQCLGPEWEVCPY 1 SP34.185 scFv mask GGVYCGPEFDESVGCM 2 SP34.185 scFv mask Peptide- A GS QCLGPEWEVCPY 3 SP34.185 scFv mask Peptide-B VYCGPEFDESVGCM 4 SP34.194 scFv mask Peptide- AM YLWGCEWNCAGITT 5
[0299]
[0300] Table 4. CD3 Mask Ala Scan Sequences - Peptide A and Peptide-B
[0301] Peptide-ID anti-CD3
[0302] Sequence SEQ ID NO:
[0303] Panned target
[0304] Peptide-A SP34.185 GS QCLGPEWEVCPY 2364
[0305] Peptide-C SP34.185 AS QCLGPEWEVCPY 6
[0306] Peptide-D SP34.185 GAQCLGPEWEVCPY 7
[0307] Peptide-E SP34.185 GSACLGPEWEVCPY 8
[0308] Peptide-F SP34.185 GSQCAGPEWEVCPY 9
[0309] Peptide-G SP34.185 GS QCLAPEWEVCPY 10
[0310] Peptide-H SP34.185 GSQCLGAEWEVCPY 11
[0311] Peptide-I SP34.185 GSQCLGPAWEVCPY 12
[0312] Peptide-J SP34.185 GSQCLGPEAEVCPY 13
[0313] Peptide-K SP34.185 GSQCLGPEWAVCPY 14
[0314] Peptide-L SP34.185 GSQCLGPEWEACPY 15
[0315] Peptide-M SP34.185 GSQCLGPEWEVCAY 16
[0316] Peptide-N SP34.185 GSQCLGPEWEVCPA 17
[0317] Peptide-A SP34.185 GS QCLGPEWEVCPY 18
[0318] Peptide-B SP34.185 VYCGPEFDESVGCM 4
[0319] Peptide-0 SP34.185 AYCGPEFDESVGCM 20
[0320] Peptide-P SP34.185 VACGPEFDESVGCM 21
[0321] Peptide-Q SP34.185 VYCAPEFDESVGCM 22
[0322] Peptide-R SP34.185 VYCGAEFDESVGCM 23
[0323] Peptide- S SP34.185 VYCGPAFDESVGCM 24
[0324] Peptide-T SP34.185 VYCGPEADESVGCM 25
[0325] Peptide-U SP34.185 VYCGPEFAESVGCM 26
[0326] Peptide-V SP34.185 VYCGPEFDASVGCM 27
[0327] Peptide-W SP34.185 VYCGPEFDEAVGCM 28
[0328] Peptide-X SP34.185 VYCGPEFDESAGCM 29
[0329] Peptide-Y SP34.185 VYCGPEFDESVACM 30
[0330]
[0331] Peptide-Z SP34.185 VYCGPEFDESVGCA 31WSGR Docket No. 52426-781.601
[0332] Table 5. Clonal Phage Peptide Sequences from the Peptide-B Optimization Library Panning (-) indicates same amino acid as in CD3 scFv Peptide-B corresponding position (e.g. Phage-1 position).
[0333] Amino add position sequence Phage binding ELISA
[0334] Phage SP34.185 SEQ ID ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Backgroud SP34.185 scFv signal NO:
[0335] signal scFv in presence signal of CD3 Phage- 1 / Peptid 0.06 2.79 0.09 4 e B V Y c G p E F D E S V G C M
[0336] Phage-2 D D W D W E F D F A A 0.08 2.75 0.09 32 Phage-3 Y I L D P D F L Y D 0.08 2.88 0.10 33 Phage-4 F D - w - D w E - Y F V - D 0.08 2.79 0.09 34 Phage-5 Y I w D w E Y F D D 0.08 2.74 0.09 35 Phage-6 N I - w - D w E D D Y F - F 0.09 2.54 0.09 36 Phage-7 N F - w - D w E Y I Y P - I 0.07 2.77 0.09 37 Phage-8 D w D w E D F L I 0.08 2.54 0.08 38 Phage-9 H A - w - D w E - Y F P - N 0.08 2.85 0.09 39 Phage- 0.09 2.63 0.10
[0337] 10 Y D D V Y V V 40 Phage- 0.09 2.73 0.08
[0338] 11 I D w D w E D D T F Y 41 Phage- 0.08 2.66 0.15
[0339] 12 Y L D G T L A Y 42 Phage- 0.11 2.13 0.08
[0340] 13 D D G I L Y 43 Phage- 0.07 2.44 0.09
[0341] 14 F I w D w E D Y F A 44 Phage- 0.07 2.71 0.07
[0342] 15 G D w D w E w D F Y D 45 Phage- 0.12 2.67 0.08
[0343] 16 Y L w D w E Y I D L D 46 Phage- 17 S F - w - D w E - Y F D - D 0.10 2.60 0.07 47 Phage- 0.09 2.57 0.07
[0344] 18 D D w D w E Y A S D 48 Phage- 0.09 2.52 0.09
[0345] 19 N L w D w E Y P F F D 49 Phage- 0.08 2.34 0.09
[0346] 20 F D - w - D w E - - F V - D 50 Phage- 0.13 2.30 0.10
[0347] 21 D I D G T I I D 51 Phage- 0.09 2.28 0.09
[0348] 22 D D - w - D w E Y Y A V - D 52 Phage- - w - - - 0.10 2.17 0.08
[0349] 23 Y D D w E Y S N D 53 Phage- 0.07 2.16 0.07
[0350] 24 I N w D w E D Y F F D 54 Phage- 0.06 2.87 0.07
[0351] 25 N I w D w E D D T F F 55 Phage- 0.09 2.87 0.08
[0352] 26 N I w D w E P N S F F 56 Phage- 0.09 2.39 0.08
[0353] 27 Y D M I D F 57 Phage- 0.11 2.73 0.12
[0354] 28 D F w D w E F p F I H 58 Phage- 0.07 2.36 0.08
[0355] 29 D F M I T I 59 Phage- 0.10 2.32 0.08
[0356] 30 Y D T V I 60 Phage- 0.07 2.26 0.08
[0357] 31 H D w D w E w D I F I 61 Phage- 0.11 2.71 0.11
[0358] 32 H A w D w E Y N P N 62 Phage- 0.08 2.65 0.08
[0359] 33 D V w D w E w D F F N 63 Phage- 0.10 2.57 0.08
[0360]
[0361] 34 N w D w E Y Y I P N 64WSGR Docket No. 52426-781.601
[0362] Phage- 35 I I w D W E F I D Y N 0.08 2.10 0.07 65 Phage- 0.07 2.53 0.08
[0363] 36 s L - w - D W E Y D I A - P 66 Phage- 0.08 2.49 0.09
[0364] 37 D L L I F P 67 Phage- 38 T N - w - D W E w V L P - P 0.14 2.47 0.10 68 Phage- 0.13 2.29 0.09
[0365] 39 I E w D W E p N Y F P 69 Phage- 0.07 2.28 0.07
[0366] 40 I F w D w E D Y D P 70 Phage- 0.07 2.26 0.08
[0367] 41 I D - w - D w E Y D F F - P 71 Phage- 0.18 2.11 0.13
[0368] 42 L F w D w E D F F P 72 Phage- 0.11 2.20 0.10
[0369] 43 D w D w E D Y A D T 73 Phage- 0.11 2.34 0.09
[0370] 44 I w D w E Q Y F P V 74 Phage- 0.09 2.85 0.09
[0371] 45 I E w D w E P I Y P Y 75 Phage- 0.07 2.55 0.08
[0372] 46 I T w D w E V Y F P Y 76 Phage- 0.06 2.51 0.09
[0373] 47 I D w D w E Y I H P Y 77 Phage- 0.12 2.50 0.12
[0374] 48 I D w D w E Y I N P Y 78 Phage- 0.09 2.44 0.09
[0375] 49 A D w D w E A F P Y 79 Phage- 0.09 2.31 0.07
[0376] 50 I D w D w E Y I Y P Y 80 Phage- 0.09 2.08 0.09
[0377] 51 N I w D w E D D N F F 81 Phage- 0.09 2.06 0.09
[0378] 52 Y D w D w E Y V D A Y 82 Phage- 0.09 2.03 0.11
[0379] 53 F D G Y V D 83 Phage- 54 D I - w - D w E Y I N I - S 0.11 2.02 0.11 84 Phage- 0.07 2.01 0.08
[0380] 55 F V w D w E D F N F D 85 Phage- 0.07 2.01 0.09
[0381] 56 F A w D w E D Y A D 86 Phage- 0.08 1.99 0.09
[0382] 57 D N - w - D w E Y D F F - V 87 Phage- 0.09 1.96 0.11
[0383] 58 Y D w D w E Y N D A 88 Phage- 0.07 1.91 0.09
[0384] 59 D D - - - D G - - T I I - V 89 Phage- - - - - 0.10 1.89 0.10
[0385] 60 F P w D w E Y A I D 90 Phage- 0.12 1.86 0.07
[0386] 61 P D D G L F T 91 Phage- 0.07 1.83 0.07
[0387] 62 D N w D W E Y D Y F V 92 Phage- 0.12 1.82 0.08
[0388] 63 I F w D w E F Y D Y 93 Phage- 0.08 1.82 0.08
[0389] 64 A D w D w E Y F P N 94 Phage- 0.12 1.81 0.10
[0390] 65 H T w D w E D D I F N 95 Phage- 0.09 1.80 0.09
[0391] 66 F A w D w E A F L L 96 Phage- 0.08 1.77 0.08
[0392] 67 Y D L I A D 97 Phage- 0.08 1.77 0.10
[0393] 68 N S w D W E Y D I I D 98 Phage- 0.07 1.75 0.07
[0394] 69 F A w D w E V A P Y 99 Phage- 0.10 1.75 0.12
[0395] 70 L D D G T L T Y 100 Phage- 0.07 1.74 0.09
[0396]
[0397] 71 L w D w E F Y D P 101WSGR Docket No. 52426-781.601
[0398] Phage- 72 H A w V w E Y F P N 0.07 1.72 0.08 102 Phage- 0.08 1.71 0.07
[0399] 73 N E - w - N G E p T F P - T 103 Phage- 0.08 1.70 0.07
[0400] 74 L T D G T L Y D 104 Phage- 75 Y D - - - - Y - - - - P - I 0.13 1.67 0.09 105 Phage- 0.09 1.66 0.08
[0401] 76 I E w D W E p N s F D 106 Phage- 0.12 1.66 0.09
[0402] 77 Y D L I H Y 107 Phage- 0.08 1.63 0.08
[0403] 78 I - T I - N 108 Phage- 0.09 1.62 0.10
[0404] 79 I V E A Y L Y 109 Phage- 0.09 1.61 0.08
[0405] 80 F D D G T Y D 110 Phage- 0.08 1.57 0.11
[0406] 81 I D D G T I S Y 111 Phage- 0.10 1.55 0.11
[0407] 82 N s T L 112 Phage- 0.08 1.53 0.08
[0408] 83 Y D D G Y F D 113 Phage- 0.09 1.53 0.09
[0409] 84 N F w D W E Y F N D N 114 Phage- 0.07 1.47 0.07
[0410] 85 L w D W E A F F D D 115 Phage- 0.16 1.47 0.10
[0411] 86 I w E W P A N 116 Phage- 0.08 1.46 0.10
[0412] 87 F w D w E D N F F N 117 Phage- 0.08 1.46 0.08
[0413] 88 V w D w E T F F P D 118 Phage- 0.10 1.45 0.09
[0414] 89 D N D G T Y I N 119 Phage- 0.07 1.45 0.08
[0415] 90 D N w D w E Y N F F V 120 Phage- 91 F - - - - - V E - D Y L - I 0.10 1.43 0.10 121 Phage- 0.07 1.43 0.07
[0416] 92 D N w D w E Y D I F V 122 Phage- 0.08 1.42 0.08
[0417] 93 I D I A P 123 Phage- 0.10 1.42 0.10
[0418] 94 Y F - - - - V E - Y T L - F 124 Phage- 0.06 1.37 0.08
[0419] 95 F A P N 125 Phage- 0.11 1.36 0.08
[0420] 96 F D - - - - V E - Y F Y - A 126 Phage- - - - 0.18 1.35 0.12
[0421] 97 D F w D w E D F F F A 127 Phage- 0.08 1.35 0.09
[0422] 98 F F D G T L S N 128 Phage- 0.14 1.35 0.09
[0423] 99 F I A L 129 Phage- 0.09 1.32 0.10
[0424] 100 Y D A I Y 130 Phage- 0.10 1.32 0.15
[0425] 101 Y I w D w E Y L Y P 131 Phage- 0.08 1.31 0.08
[0426] 102 F D w D w E P T T H 132 Phage- 0.14 1.31 0.10
[0427] 103 Y D w D w E D F P I D 133 Phage- 0.08 1.30 0.07
[0428] 104 V w D w E Y I D D S 134 Phage- 0.12 1.30 0.08
[0429] 105 I N w D w E V I S F D 135 Phage- 0.10 1.29 0.10
[0430] 106 L S w D w E V T P L 136 Phage- 0.09 1.28 0.08
[0431] 107 F A w D w E V D I Y 137 Phage- 0.10 1.25 0.08
[0432]
[0433] 108 Y D M I V D 138WSGR Docket No. 52426-781.601
[0434] Phage- 109 Y D w D W E V F I V D 0.06 1.25 0.07 139 Phage- 0.10 1.25 0.08
[0435] 110 D N - w - D W E H N F F - V 140 Phage- 0.07 1.23 0.08
[0436] 111 Y D D G I Y P 141 Phage- 112 Y D - - - - - E F p Y Y - F 0.12 1.23 0.12 142 Phage- 0.11 1.22 0.09
[0437] 113 A D Y P V 143 Phage- 0.08 1.22 0.10
[0438] 114 F L V E V H Y s 144 Phage- 0.08 1.22 0.08
[0439] 115 T D - w - D w E Y I T S - s 145 Phage- 0.09 1.21 0.09
[0440] 116 A F L I T D 146 Phage- 0.09 1.19 0.09
[0441] 117 N D w D W E Y F S Y 147 Phage- 0.08 1.19 0.09
[0442] 118 F D w E I V T D Y 148 Phage- 0.13 1.19 0.11
[0443] 119 N L M I I P 149 Phage- 0.10 1.19 0.14
[0444] 120 D L M I Y D 150 Phage- 0.09 1.18 0.09
[0445] 121 F D D G V D Y I D 151 Phage- 0.11 1.18 0.08
[0446] 122 Y A w D W E D F A Y 152 Phage- 0.10 1.17 0.10
[0447] 123 H D M I V V 153 Phage- 0.07 1.17 0.08
[0448] 124 F E F I F L A 154 Phage- 0.08 1.16 0.09
[0449] 125 Y D L I L D 155 Phage- 0.11 1.16 0.10
[0450] 126 S V w D W E F Y S D 156 Phage- 0.13 1.16 0.10
[0451] 127 P D G T A I T 157 Phage- 128 D D - - - - L E w Y Y P - Y 0.09 1.16 0.08 158 Phage- 0.08 1.14 0.09
[0452] 129 F I L P N 159 Phage- 0.11 1.14 0.33
[0453] 130 I D L P D 160 Phage- 0.08 1.13 0.08
[0454] 131 F L - - - - - E - D A P - Y 161 Phage- 0.10 1.13 0.07
[0455] 132 I F D G T H I H 162 Phage- 0.10 1.11 0.21
[0456] 133 - F - w - D W E Y I D F - N 163 Phage- - - 0.12 1.11 0.11
[0457] 134 I F - - Y - - - L H - I 164 Phage- 0.08 1.11 0.10
[0458] 135 H L w D W E w Y D P 165 Phage- 0.08 1.11 0.09
[0459] 136 F I M I A N 166 Phage- 0.09 1.10 0.08
[0460] 137 I F V E M I F L N 167 Phage- 0.11 1.09 0.11
[0461] 138 Y D w E F p D I 168 Phage- 0.10 1.09 0.08
[0462] 139 N L L I T F 169 Phage- 0.08 1.09 0.08
[0463] 140 F V E D F Y F Y 170 Phage- 0.11 1.07 0.11
[0464] 141 D L I N 171 Phage- 0.08 1.07 0.08
[0465] 142 D L P D 172 Phage- 0.09 1.07 0.09
[0466] 143 A I L I A P 173 Phage- 0.08 1.07 0.09
[0467] 144 I V E D Y N L Y 174 Phage- 0.10 1.06 0.09
[0468]
[0469] 145 H T w D w E D Y T V P 175WSGR Docket No. 52426-781.601
[0470] Phage- 146 s D w D W E Y F Y D N 0.10 1.06 0.08 176 Phage- 0.09 1.05 0.08
[0471] 147 - F - - - D G - - T - H - D 177 Phage- 0.09 1.05 0.08
[0472] 148 D Y H I 178 Phage- 149 A D - - - D G - - - I I - H 0.07 1.05 0.08 179 Phage- 0.10 1.05 0.08
[0473] 150 F L L T V 180 Phage- 0.11 1.04 0.09
[0474] 151 I L V E D Y Y Y 181 Phage- 0.09 1.04 0.09
[0475] 152 H L - w - D w E - Y H S - D 182 Phage- 0.08 1.04 0.11
[0476] 153 I F w D w E D Y N F T 183 Phage- 0.12 1.04 0.11
[0477] 154 I V D G T L I H 184 Phage- 0.12 1.03 0.11
[0478] 155 A D w D w E w D Y T D 185 Phage- 0.20 1.02 0.21
[0479] 156 I T T T N 186 Phage- 0.20 1.02 0.09
[0480] 157 Y H w D w E Y T S D 187 Phage- 0.11 1.01 0.10
[0481] 158 N V E Y A L T 188 Phage- 0.15 1.00 0.19
[0482] 159 F I M I H D 189 Phage- 0.14 1.00 0.10
[0483] 160 D N w D w E F A V P 190 Phage- 0.10 1.00 0.09
[0484] 161 Y D L T V D 191 Phage- 0.08 0.99 0.08
[0485] 162 Y D I A Y 192 Phage- 0.07 0.97 0.09
[0486] 163 I D w D w E Y T H D 193 Phage- 0.09 0.96 0.09
[0487] 164 D D L I I I 194 Phage- 165 - - - - - - Y - - - s F - F 0.09 0.91 0.08 195 Phage- 0.09 0.86 0.07
[0488] 166 F N w D W E D p Y F V 196 Phage- 0.08 0.82 0.07
[0489] 167 Y D Y S Y s 197 Phage- 0.13 0.79 0.09
[0490] 168 - A - w - D W E Y T D S - F 198 Phage- 0.10 0.77 0.09
[0491] 169 T D A Y 199 Phage- 0.07 0.75 0.08
[0492] 170 T D - w - D w E F Y A D - D 200 Phage- - - 0.09 0.69 0.09
[0493] 171 Y D - - L - - - - I - H 201 Phage- 0.07 0.69 0.07
[0494] 172 S D D G I I T 202 Phage- 0.08 0.67 0.09
[0495] 173 Y I D D 203 Phage- 0.08 0.62 0.09
[0496] 174 F F I I A V 204 Phage- 0.16 0.60 0.10
[0497] 175 D T F D 205 Phage- 0.10 0.59 0.10
[0498] 176 Y D W E w p I D V 206 Phage- 0.13 0.59 0.11
[0499] 177 F I E L F S F Y 207 Phage- 0.15 0.42 0.11
[0500] 178 Y V I T P 208 Phage- 0.09 0.37 0.25
[0501] 179 I L I N N 209 Phage- 0.08 0.09 0.08
[0502] 180 V A M G Q H Y L D 210 Phage- 0.08 0.08 0.08
[0503] 181 V T K M G H Y L S 211 Phage- 0.08 0.98 0.08
[0504]
[0505] 182 Y D w D W E Y V Y A Y 212WSGR Docket No. 52426-781.601
[0506] Phage- 183 D L L N D 0.09 0.98 0.08 213 Phage- 0.14 0.97 0.16
[0507] 184 Y - T V - Y 214 Phage- 0.08 0.96 0.09
[0508] 185 L D w D W E w p Y S N 215 Phage- 186 F I - w - D W E D D F F - Y 0.08 0.96 0.09 216 Phage- 0.11 0.95 0.10
[0509] 187 D L V E W Y F F N 217 Phage- 0.07 0.94 0.08
[0510] 188 Y D L I V F 218 Phage- 0.09 0.92 0.09
[0511] 189 L N - w - V W E D D - F - Y 219 Phage- 0.09 0.91 0.09
[0512] 190 F N w D w E D P N F V 220 Phage- 0.10 0.91 0.13
[0513] 191 I w D w E D D Y F P 221 Phage- 0.10 0.91 0.08
[0514] 192 F L S V Y 222 Phage- 0.10 0.91 0.09
[0515] 193 Y D L I F Y 223 Phage- 0.11 0.90 0.10
[0516] 194 H L D G F T F 224 Phage- 0.08 0.90 0.08
[0517] 195 Y F M L Y I 225 Phage- 0.07 0.90 0.07
[0518] 196 Y V E Y A N Y 226 Phage- 0.16 0.90 0.58
[0519] 197 N T T A Y 227 Phage- 0.09 0.90 0.08
[0520] 198 I D w D w E A F N Y 228 Phage- 0.09 0.89 0.08
[0521] 199 A L E F F L T 229 Phage- 0.08 0.89 0.08
[0522] 200 I V E V H H Y 230 Phage- 0.10 0.89 0.11
[0523] 201 F F A D 231 Phage- 202 Y D - - - - L - - T I I - A 0.08 0.89 0.08 232 Phage- 0.09 0.89 0.10
[0524] 203 I L W E Y P L D S 233 Phage- 0.09 0.88 0.10
[0525] 204 F I T T N 234 Phage- 0.17 0.88 0.15
[0526] 205 F - - - - - L - - - - S - D 235 Phage- 0.10 0.87 0.10
[0527] 206 H L L T F 236 Phage- 0.09 0.87 0.09
[0528] 207 L I - - - - V E D Y s L - H 237 Phage- - - 0.08 0.87 0.08
[0529] 208 Y F - - M - - - - Y - D 238 Phage- 0.13 0.87 0.09
[0530] 209 H M I Y I 239 Phage- 0.08 0.87 0.09
[0531] 210 F D L I N D 240 Phage- 0.07 0.87 0.08
[0532] 211 Y V E Y I Y T 241 Phage- 0.08 0.85 0.07
[0533] 212 L A w V R E I N A I 242 Phage- 0.08 0.85 0.08
[0534] 213 I D w D W E D I T F D 243 Phage- 0.11 0.85 0.15
[0535] 214 I V L I T P 244 Phage- 0.08 0.85 0.09
[0536] 215 F E L p A D D 245 Phage- 0.10 0.85 0.09
[0537] 216 F D N P F 246 Phage- 0.10 0.83 0.10
[0538] 217 D A w D w E Y S S D 247 Phage- 0.08 0.83 0.09
[0539] 218 D H w D w E p N Y F V 248 Phage- 0.09 0.83 0.10
[0540]
[0541] 219 D w D w E I N Y I F 249WSGR Docket No. 52426-781.601
[0542] Phage- 220 I w D w E Y V Y A N 0.10 0.82 0.09 250 Phage- 0.07 0.82 0.08
[0543] 221 D F - - - - V E - D Y L - D 251 Phage- 0.11 0.82 0.09
[0544] 222 H D D G R D Y D A 252 Phage- 223 L A - w - D w E D D Y F - V 0.08 0.82 0.09 253 Phage- 0.10 0.82 0.10
[0545] 224 D I w D w E D Y L P V 254 Phage- 0.08 0.81 0.10
[0546] 225 I L I E V Y A L P 255 Phage- 0.10 0.81 0.11
[0547] 226 I F - - - - w E F - - L - N 256 Phage- 0.07 0.80 0.08
[0548] 227 T V E D F s L V 257 Phage- 0.11 0.80 0.09
[0549] 228 F I w E F V D A F 258 Phage- 0.06 0.80 0.07
[0550] 229 F A w D w E D S P D 259 Phage- 0.12 0.80 0.08
[0551] 230 I L V E L I F P 260 Phage- 0.08 0.80 0.08
[0552] 231 F V E Y I Y Y 261 Phage- 0.10 0.79 0.09
[0553] 232 D s L I I D 262 Phage- 0.11 0.79 0.08
[0554] 233 F L D G T s V D 263 Phage- 0.11 0.79 0.08
[0555] 234 F N w N G E p T Y F V 264 Phage- 0.09 0.78 0.09
[0556] 235 L A w V W E Y P T I 265 Phage- 0.09 0.78 0.09
[0557] 236 D V E D Y Y 266 Phage- 0.08 0.77 0.07
[0558] 237 I T w D w E Y A N T 267 Phage- 0.15 0.77 0.13
[0559] 238 F F D G T Y S I 268 Phage- 239 T D - w - D w E Y A T S - D 0.09 0.76 0.09 269 Phage- 0.10 0.76 0.11
[0560] 240 F N D G Y D Y L D 270 Phage- 0.11 0.76 0.08
[0561] 241 Y D w D W E V D F H P 271 Phage- 0.08 0.76 0.08
[0562] 242 N I - w - D w E D D S F - F 272 Phage- 0.13 0.75 0.09
[0563] 243 A T I S 273 Phage- 0.10 0.74 0.09
[0564] 244 S - T F - D 274 Phage- - - - - - - - - 0.08 0.74 0.08
[0565] 245 P I Y D V A 275 Phage- 0.11 0.74 0.11
[0566] 246 Y D G Y N s I 276 Phage- 0.11 0.74 0.10
[0567] 247 D w D W E V F I A D 277 Phage- 0.12 0.74 0.10
[0568] 248 D L V E V N L L 278 Phage- 0.09 0.74 0.09
[0569] 249 F D M T T F 279 Phage- 0.13 0.74 0.14
[0570] 250 N F w D W E p I Y F T 280 Phage- 0.08 0.73 0.08
[0571] 251 D D G F F L 281 Phage- 0.10 0.73 0.09
[0572] 252 D D G T A F I 282 Phage- 0.10 0.73 0.09
[0573] 253 N I M L V I 283 Phage- 0.08 0.73 0.09
[0574] 254 I I F F F 284 Phage- 0.10 0.73 0.38
[0575] 255 N F Y I S I 285 Phage- 0.11 0.73 0.51
[0576]
[0577] 256 H L I E A D I N 286WSGR Docket No. 52426-781.601
[0578] Phage- 257 D V E D Y L D 0.08 0.72 0.09 287 Phage- 0.11 0.72 0.10
[0579] 258 D - - - - - L - - - I N - D 288 Phage- 0.09 0.72 0.08
[0580] 259 F L L F V 289 Phage- 260 P D - - - - W E F Y - T - N 0.12 0.72 0.08 290 Phage- 0.09 0.72 0.08
[0581] 261 F D E Y I Y A T 291 Phage- 0.12 0.72 0.11
[0582] 262 D S I N 292 Phage- 0.08 0.72 0.07
[0583] 263 D F - - - - V E - Y I F - F 293 Phage- 0.08 0.71 0.08
[0584] 264 P V w D w E Y V S S D 294 Phage- 0.09 0.71 0.09
[0585] 265 Y I R N L L 295 Phage- 0.11 0.71 0.11
[0586] 266 Y D L I V D 296 Phage- 0.09 0.71 0.08
[0587] 267 H D w D W E D F Y F V 297 Phage- 0.12 0.71 0.10
[0588] 268 H Y I D Y 298 Phage- 0.08 0.71 0.08
[0589] 269 L F M p D I F N 299 Phage- 0.10 0.71 0.12
[0590] 270 H D L E F H Y A Y 300 Phage- 0.08 0.70 0.08
[0591] 271 D F L I N F 301 Phage- 0.10 0.70 0.10
[0592] 272 Y F L I A N 302 Phage- 0.10 0.70 0.08
[0593] 273 T D w D W E D D I I D 303 Phage- 0.09 0.70 0.08
[0594] 274 Y D L I Y F 304 Phage- 0.10 0.70 0.11
[0595] 275 Y w D W w Y T D 305 Phage- 276 P I - - - - L E - - Y L - N 0.13 0.69 0.52 306 Phage- 0.12 0.69 0.11
[0596] 277 F D I V Y 307 Phage- 0.09 0.68 0.07
[0597] 278 L D G I F F D P 308 Phage- 0.07 0.68 0.07
[0598] 279 A - - - - - Y - - - L T - V 309 Phage- 0.14 0.68 0.14
[0599] 280 D F L I I A 310 Phage- 0.08 0.68 0.08
[0600] 281 Y D - L D - N 311 Phage- - - 0.14 0.67 0.08
[0601] 282 A I A D 312 Phage- 0.10 0.67 0.10
[0602] 283 L L D G V D F F D 313 Phage- 0.12 0.66 0.13
[0603] 284 N F L p D I F F 314 Phage- 0.08 0.66 0.08
[0604] 285 F V E V S L N 315 Phage- 0.12 0.66 0.10
[0605] 286 Y D D G Y A F Y H 316 Phage- 0.08 0.65 0.08
[0606] 287 N F I E F D Y L D 317 Phage- 0.06 0.65 0.08
[0607] 288 D D G V D F I N 318 Phage- 0.08 0.65 0.07
[0608] 289 T D w D W E Y I Y S S 319 Phage- 0.14 0.65 0.11
[0609] 290 F E I T N I 320 Phage- 0.07 0.64 0.08
[0610] 291 F D w D w E F F H 321 Phage- 0.08 0.63 0.08
[0611] 292 D F D G F P 322 Phage- 0.13 0.63 0.09
[0612]
[0613] 293 H N L L V D 323WSGR Docket No. 52426-781.601
[0614] Phage- 294 I D G A D Y T D 0.07 0.63 0.07 324 Phage- 0.08 0.62 0.08
[0615] 295 F D - - - - - E F P - I - F 325 Phage- 0.09 0.62 0.08
[0616] 296 Y N L T D 326 Phage- 297 F D - - - - L - - - I H - A 0.07 0.62 0.08 327 Phage- 0.15 0.61 0.10
[0617] 298 D I V E Y F L F 328 Phage- 0.10 0.61 0.09
[0618] 299 F D V L T F 329 Phage- 0.08 0.61 0.08
[0619] 300 F D - - - - I E - F H L - F 330 Phage- 0.12 0.61 0.10
[0620] 301 A L I I D 331 Phage- 0.09 0.61 0.10
[0621] 302 Y N L I T N 332 Phage- 0.08 0.61 0.07
[0622] 303 F D w D W E p D L 333 Phage- 0.08 0.60 0.08
[0623] 304 D V L L P 334 Phage- 0.09 0.60 0.08
[0624] 305 N L L P P 335 Phage- 0.08 0.60 0.10
[0625] 306 Y w D W E Y D I F S 336 Phage- 0.08 0.60 0.09
[0626] 307 D D T Y N 337 Phage- 0.09 0.60 0.09
[0627] 308 F E V F H Y 338 Phage- 0.07 0.60 0.09
[0628] 309 T D w D w E Y F L D 339 Phage- 0.09 0.60 0.09
[0629] 310 w E Y L P 340 Phage- 0.06 0.59 0.08
[0630] 311 D D N G Y A T F I Y 341 Phage- 0.16 0.59 0.38
[0631] 312 F L I E D D T H Y 342 Phage- 313 F A - w - D w E - T I P - H 0.08 0.59 0.08 343 Phage- 0.10 0.58 0.08
[0632] 314 L Y N Y 344 Phage- 0.09 0.58 0.09
[0633] 315 Y D I S I 345 Phage- 0.12 0.57 0.10
[0634] 316 Y D - N - Y 346 Phage- 0.10 0.57 0.09
[0635] 317 A I w D w E F D Y 347 Phage- 0.07 0.57 0.08
[0636] 318 L T - w - V R E - I F A - D 348 Phage- 0.09 0.57 0.09
[0637] 319 - L - Y Y - N 349 Phage- 0.07 0.56 0.08
[0638] 320 N V Y A P N 350 Phage- 0.11 0.55 0.09
[0639] 321 H D I S V 351 Phage- 0.12 0.55 0.41
[0640] 322 F D L T D N 352 Phage- 0.09 0.55 0.08
[0641] 323 Y F V E H F Y Y 353 Phage- 0.09 0.54 0.09
[0642] 324 D L I I H 354 Phage- 0.11 0.54 0.08
[0643] 325 D D V p D I T Y 355 Phage- 0.10 0.54 0.08
[0644] 326 D N L V D 356 Phage- 0.10 0.54 0.08
[0645] 327 H w D W E p N Y V D 357 Phage- 0.09 0.53 0.09
[0646] 328 D L L F L 358 Phage- 0.08 0.53 0.11
[0647] 329 D D L V A 359 Phage- 0.13 0.53 0.09
[0648]
[0649] 330 A A L I V D 360WSGR Docket No. 52426-781.601
[0650] Phage- 331 D F E I N N F 0.14 0.52 0.48 361 Phage- 0.08 0.52 0.07
[0651] 332 Y - N A - Y 362 Phage- 0.10 0.52 0.11
[0652] 333 L N S Y 363 Phage- 334 Y D - I D - D 0.09 0.52 0.09 364 Phage- 0.11 0.52 0.14
[0653] 335 D S E F Y Y V F 365 Phage- 0.10 0.52 0.08
[0654] 336 Y I L L I H 366 Phage- 0.11 0.52 0.10
[0655] 337 F D - - - - V E - D Y F - Y 367 Phage- 0.08 0.52 0.07
[0656] 338 F D Y L Y F 368 Phage- 0.10 0.51 0.10
[0657] 339 L D G Y S F H 369 Phage- 0.12 0.51 0.09
[0658] 340 I P M V N 370 Phage- 0.12 0.51 0.09
[0659] 341 I I D G Y D F T D 371 Phage- 0.11 0.51 0.08
[0660] 342 I F L I I Y 372 Phage- 0.18 0.51 0.18
[0661] 343 D Y D Y 373 Phage- 0.12 0.51 0.08
[0662] 344 L S M L Y D 374 Phage- 0.08 0.51 0.09
[0663] 345 Y D w D W E Y N I D T 375 Phage- 0.09 0.51 0.08
[0664] 346 N H D G T I V F 376 Phage- 0.11 0.50 0.12
[0665] 347 N F L I P H 377 Phage- 0.08 0.50 0.09
[0666] 348 F H I E Y A L D 378 Phage- 0.07 0.50 0.08
[0667] 349 V E D Y N L Y 379 Phage- 350 - - - - - D G - - L A N - Y 0.09 0.50 0.08 380 Phage- 0.17 0.50 0.26
[0668] 351 L I V I A D L P N 381 Phage- 0.10 0.50 0.08
[0669] 352 D I I P D S D 383 Phage- 0.11 0.50 0.45
[0670] 353 I - - - - - W E - A D Y - D 384 Phage- 0.10 0.50 0.10
[0671] 354 I D w D W E D D S I Y 385 Phage- 0.09 0.50 0.11
[0672] 355 - L - - - - V E D F T L - D 386 Phage- 0.09 0.49 0.09
[0673] 356 L - - - - V I E - I Y Y - Y 387 Phage- 0.14 0.49 0.38
[0674] 357 F F E V H S D N 388 Phage- 0.10 0.49 0.08
[0675] 358 N D V E L V S D N 389 Phage- 0.09 0.49 0.08
[0676] 359 D L L T V D 390 Phage- 0.08 0.49 0.08
[0677] 360 I P V E D Y N L N 391 Phage- 0.10 0.49 0.10
[0678] 361 Y L E W P V N 392 Phage- 0.08 0.49 0.10
[0679] 362 Y D L I N 393 Phage- 0.08 0.49 0.08
[0680] 363 D G F D A 394 Phage- 0.08 0.49 0.10
[0681] 364 N D W E D T Y F L 395 Phage- 0.13 0.48 0.16
[0682] 365 P M E L S N S 396 Phage- 0.15 0.48 0.10
[0683] 366 D D E V I S D Y 397 Phage- 0.08 0.48 0.08
[0684]
[0685] 367 D L P D P D 398WSGR Docket No. 52426-781.601
[0686] Phage- 368 I F V Y 0.11 0.48 0.10 399 Phage- 0.10 0.48 0.11
[0687] 369 A - - - - - Y E V F A D - N 400 Phage- 0.09 0.48 0.09
[0688] 370 I D Y D L 401 Phage- 371 H I - w - D W E - F H D - N 0.07 0.48 0.08 402 Phage- 0.08 0.48 0.08
[0689] 372 Y D L T I T L 403 Phage- 0.09 0.48 0.08
[0690] 373 Y L L T I L N 404 Phage- 0.10 0.48 0.14
[0691] 374 F F - - - - - E - A F L - F 405 Phage- 0.07 0.47 0.08
[0692] 375 I L L F T A 406 Phage- 0.09 0.47 0.08
[0693] 376 F H V E L Y T D N 407 Phage- 0.08 0.47 0.08
[0694] 377 N L V E Y N F Y 408 Phage- 0.21 0.47 0.09
[0695] 378 F D V E T Y Y F 409 Phage- 0.12 0.47 0.37
[0696] 379 F E D H Y Y 410 Phage- 0.11 0.47 0.11
[0697] 380 A I w E V V A D N 411 Phage- 0.12 0.47 0.25
[0698] 381 F I w D w E D N Y N 412 Phage- 0.08 0.47 0.10
[0699] 382 I F I D 413 Phage- 0.12 0.47 0.43
[0700] 383 N L V E D V Y D H 414 Phage- 0.09 0.47 0.09
[0701] 384 H V E Y H N N 415 Phage- 0.09 0.47 0.09
[0702] 385 D I Y Y S T 416 Phage- 0.13 0.46 0.10
[0703] 386 D L T L I A 417 Phage- 387 I A - - - - 0.12 0.46 0.09
[0704] M p - D I D - Y 418 Phage- 0.10 0.46 0.10
[0705] 388 I D L I F D 419 Phage- 0.11 0.46 0.11
[0706] 389 Y F D V E D F A D 420 Phage- 0.12 0.46 0.34
[0707] 390 Y N - - - - w E Y A I L - D 421 Phage- 0.14 0.46 0.22
[0708] 391 I V E D Y I V N 422 Phage- 0.07 0.46 0.07
[0709] 392 Y D - - - - I - - - T P - A 423 Phage- - - 0.09 0.46 0.09
[0710] 393 D T w D w E H I Y A - D 424 Phage- 0.13 0.45 0.12
[0711] 394 D I M T N 425 Phage- 0.10 0.45 0.09
[0712] 395 Y D w D w E R Y F P I 426 Phage- 0.13 0.45 0.11
[0713] 396 H L L A S 427 Phage- 0.09 0.45 0.09
[0714] 397 Y D D G T T I A 428 Phage- 0.07 0.45 0.08
[0715] 398 Y Y E D V L D F 429 Phage- 0.14 0.45 0.10
[0716] 399 D F M T I S D 430 Phage- 0.08 0.44 0.07
[0717] 400 I L L L V D 431 Phage- 0.12 0.44 0.40
[0718] 401 L I W E V I T N D 432 Phage- 0.09 0.44 0.09
[0719] 402 Y D Y F P 433 Phage- 0.08 0.44 0.08
[0720] 403 A L V E V Y D V V 434 Phage- 0.10 0.44 0.09
[0721]
[0722] 404 Y H w D w E D V N F Y 435WSGR Docket No. 52426-781.601
[0723] Phage- 405 F L 0.09 0.44 0.08
[0724] M G G L T F Y Y 436 Phage- - - - - - - 0.09 0.43 0.19
[0725] 406 I I - Y - - - F 437 Phage- 0.11 0.43 0.09
[0726] 407 F F H F 438 M
[0727] Phage- 0.09 0.43 0.09 - - 408 A F L F A 439 Phage- 0.08 0.43 0.08
[0728] 409 N D G T N I D 440 Phage- 0.13 0.43 0.09
[0729] 410 Y L W E w V H N L 441 Phage- 0.08 0.43 0.09 - - - - - - - 411 A T D G H I A 442 Phage- 0.07 0.42 0.08
[0730] 412 V E V L D Y D 443 Phage- 0.08 0.42 0.08
[0731] 413 I H w E F Y T D D 444 Phage- 0.13 0.42 0.32
[0732] 414 D D L T A D 445 Phage- 0.11 0.42 0.17
[0733] 415 Y L I D N 446 Phage- 0.09 0.42 0.09
[0734] 416 L L V E D V F A Y 447 Phage- 0.08 0.42 0.08
[0735] 417 Y D L L T D 448 Phage- 0.09 0.41 0.09
[0736] 418 F D L T N Y 449 Phage- 0.08 0.41 0.09
[0737] 419 F A w D W E I N D H 450 Phage- 0.09 0.41 0.09
[0738] 420 Y Y E D I Y N 451 Phage- 0.09 0.40 0.08
[0739] 421 N V V E D Y T F Y 452 Phage- 0.12 0.40 0.08
[0740] 422 A L E Y D F T 453 Phage- 0.08 0.40 0.09
[0741] 423 F D I T I T 454 Phage- 0.10 0.40 0.09 - - - - - - - 424 N L L T L V A 455 Phage- 0.08 0.40 0.08
[0742] 425 Y S w D W E Y L A N 456 Phage- 0.09 0.40 0.10
[0743] 426 G I V E D Y N Y D 457 Phage- 0.07 0.40 0.07 - - - - - - - - - 427 F F L N H 458 Phage- 0.11 0.40 0.09
[0744] 428 Y Y E D F Y F 459 Phage- 0.11 0.40 0.10 - - - - - - - - - 429 L Y T D Y 460 Phage- 0.10 0.40 0.08 - - - - - - - 430 D V E D F L Y 461 Phage- 0.08 0.40 0.09
[0745] 431 T L V E L Y I F D 462 Phage- 0.11 0.40 0.09
[0746] 432 F E I A D Y 463 Q
[0747] Phage- 0.11 0.40 0.18
[0748] 433 D D V E Y H L D 464 Phage- 0.13 0.39 0.09
[0749] 434 D L E D V T L H 465 Phage- 0.09 0.39 0.08
[0750] 435 L V E D V N L Y 466 Phage- 0.09 0.39 0.09
[0751] 436 D I L T I D Y 467 Phage- 0.08 0.39 0.08
[0752] 437 T V E D I N Y 468 Phage- 0.08 0.39 0.08
[0753] 438 I V w D w E Y P N D 469 Phage- 0.11 0.39 0.10
[0754] 439 S D L I I T 470 Phage- 0.15 0.39 0.10
[0755] 440 Y D L p D Y D N 471 Phage- 0.12 0.39 0.17
[0756] 441 N L w D W E Y Y A D 472
[0757]
[0758] WSGR Docket No. 52426-781.601
[0759] Phage- 442 D D L L P H 0.10 0.39 0.08 473 Phage- 0.08 0.39 0.08
[0760] 443 S L - - - D G Q - D Y T - F 474 Phage- 0.13 0.39 0.11
[0761] 444 L I w D W E Y N F T 475 Phage- 445 F H - - - D G - - T - P - I 0.08 0.39 0.08 476 Phage- 0.08 0.38 0.08
[0762] 446 F D W E w I Y D F 477 Phage- 0.08 0.38 0.09
[0763] 447 I W L D D 478 Phage- 0.10 0.38 0.11
[0764] 448 L I - - - - I - - - A S - N 479 Phage- 0.11 0.38 0.34
[0765] 449 T s w V D w E F S D I 480 Phage- 0.10 0.38 0.08
[0766] 450 Y V E D Y V D 481 Phage- 0.09 0.38 0.08
[0767] 451 D D Q E F I Y A I 482 Phage- 0.11 0.38 0.10
[0768] 452 A D w D w E Y A D Y 483 Phage- 0.08 0.38 0.07
[0769] 453 Y I H I 484 Phage- 0.08 0.37 0.09
[0770] 454 S E w D w E p F F D N 485 Phage- 0.07 0.37 0.07
[0771] 455 Y H M L I T 486 Phage- 0.09 0.37 0.07
[0772] 456 S D w D w E D A Y F I 487 Phage- 0.08 0.37 0.08
[0773] 457 D V E Y Y H D 488 Phage- 0.10 0.37 0.10
[0774] 458 D N Y I A N 489 Phage- 0.08 0.37 0.10
[0775] 459 L V E F Y D Y Y 490 Phage- 0.09 0.37 0.08
[0776] 460 Y T M T I 491 Phage- 461 N F - w - D W E V N s F - D 0.09 0.37 0.08 492 Phage- 0.12 0.36 0.09
[0777] 462 N A w D W E Y I D F N 493 Phage- 0.09 0.36 0.07
[0778] 463 Y N M I F S 494 Phage- - 0.08 0.36 0.09
[0779] 464 L D - - - L - - - I T - Y 495 Phage- 0.11 0.36 0.08
[0780] 465 H I N D 496 Phage- 0.08 0.36 0.08
[0781] 466 I I - - - - L p - D Y V - T 497 Phage- - - 0.08 0.36 0.08
[0782] 467 D I I D S 498 Phage- 0.10 0.36 0.09
[0783] 468 P L F 499 Phage- 0.07 0.36 0.08
[0784] 469 F D Y 500 Phage- 0.08 0.36 0.08
[0785] 470 Y D w D w E A L P A 501 Phage- 0.10 0.36 0.10
[0786] 471 D D w D w E D Y F F 502 Phage- 0.11 0.36 0.11
[0787] 472 H F w E L F s D Y 503 Phage- 0.07 0.35 0.07
[0788] 473 I T w D w E V N F P Y 504 Phage- 0.20 0.35 0.16
[0789] 474 P D L I T N 505 Phage- 0.08 0.35 0.07
[0790] 475 N L w D W E A F F P Y 506 Phage- 0.08 0.35 0.07
[0791] 476 F E Y I R D Y 507 Phage- 0.09 0.35 0.10
[0792] 477 F F I I D 508 Phage- 0.08 0.35 0.10
[0793]
[0794] 478 L K G G P T Y N S 509WSGR Docket No. 52426-781.601
[0795] Phage- 479 L A w V w E p G H D 0.11 0.35 0.10 510 Phage- 0.07 0.35 0.08
[0796] 480 D - - - - - V E D V N D - Y 511 Phage- 0.08 0.35 0.07
[0797] 481 D E A H Y N 512 Phage- 482 - L - - - - L - - T L T - I 0.08 0.35 0.07 513 Phage- 0.10 0.34 0.09
[0798] 483 Y I E D Y N L N 514 Phage- 0.13 0.34 0.14
[0799] 484 Y I V E Y Y N F 515 Phage- 0.08 0.34 0.09
[0800] 485 D I - - - - L - - - I F - F 516 Phage- 0.07 0.34 0.08
[0801] 486 D I V E D Y L Y 517 Phage- 0.10 0.34 0.08
[0802] 487 T L E D A P I 518 Phage- 0.14 0.34 0.09
[0803] 488 N w D w E Y I N S V 519 Phage- 0.07 0.34 0.09
[0804] 489 N D V E Y Y Y T 520 Phage- 0.08 0.34 0.08
[0805] 490 I T M I D N 521 Phage- 0.10 0.34 0.29
[0806] 491 Y M A D L I D 522 Phage- 0.11 0.33 0.09
[0807] 492 I D L I V T 523 Phage- 0.08 0.33 0.07
[0808] 493 H T w D W E w D Y D 524 Phage- 0.08 0.33 0.10
[0809] 494 I H W E L I D D L 525 Phage- 0.08 0.33 0.08
[0810] 495 Y T L I T T 526 Phage- 0.11 0.33 0.09
[0811] 496 F H V E T Y F 527 Phage- 0.07 0.33 0.08
[0812] 497 D L L I N 528 Phage- 498 I - D Y - I 0.08 0.33 0.10 529 Phage- 0.09 0.33 0.09
[0813] 499 D L I E D L V T 530 Phage- 0.09 0.33 0.09
[0814] 500 N I L Q D I V P 531 Phage- - 0.08 0.33 0.08
[0815] 501 N N - - - M - - I T - Y 532 Phage- 0.08 0.33 0.08
[0816] 502 H T L I V V 533 Phage- 0.12 0.33 0.23
[0817] 503 Y - - - - - I E D I L V - T 534 Phage- - - 0.07 0.33 0.11
[0818] 504 N T - - - E F V H L - P 535 Phage- 0.10 0.33 0.09
[0819] 505 D I M T V D 536 Phage- 0.09 0.32 0.07
[0820] 506 A I V E I V N Y Y 537 Phage- 0.10 0.32 0.28
[0821] 507 H L V E D p T A V 538 Phage- 0.10 0.32 0.09
[0822] 508 A D L I S T 539 Phage- 0.07 0.32 0.09
[0823] 509 F D L I D 540 Phage- 0.10 0.32 0.08
[0824] 510 D V I D N 541 Phage- 0.08 0.32 0.07
[0825] 511 Y L V E I s I F 542 Phage- 0.10 0.31 0.30
[0826] 512 S A L H V 543 Phage- 0.08 0.31 0.08
[0827] 513 H L w D w E D S A N 544 Phage- 0.10 0.31 0.08
[0828] 514 H T w D w E Y D Y D F 545 Phage- 0.10 0.31 0.10
[0829]
[0830] 515 Y D w E V A L N 546WSGR Docket No. 52426-781.601
[0831] Phage- 516 T L I E Y I V Y 0.09 0.31 0.23 547 Phage- 0.09 0.31 0.09
[0832] 517 S - I F - T 548 Phage- 0.08 0.31 0.08
[0833] 518 D I L H Y 549 Phage- 519 L F - - - - - E - A Y L - I 0.08 0.31 0.08 550 Phage- 0.10 0.31 0.10
[0834] 520 I F I E D F V T 551 Phage- 0.08 0.31 0.08
[0835] 521 D D w E Y Y A V 552 Phage- 0.10 0.31 0.09
[0836] 522 D D - - - - L - - T T I - Y 553 Phage- 0.10 0.31 0.09
[0837] 523 A S L I A D 554 Phage- 0.08 0.31 0.09
[0838] 524 Y L V E D Y D Y Y 555 Phage- 0.12 0.30 0.09
[0839] 525 D L w E T I F A 556 Phage- 0.12 0.30 0.11
[0840] 526 D F D G E F Y I P 557 Phage- 0.15 0.30 0.17
[0841] 527 V E N I L H 558 Phage- 0.12 0.30 0.21
[0842] 528 D V E N Y F F 559 Phage- 0.10 0.30 0.10
[0843] 529 N D w D w Y F L S D 560 Phage- 0.08 0.30 0.09
[0844] 530 R D w D w E V P Y F D 561 Phage- 0.10 0.30 0.13
[0845] 531 N L V E A Y Y 562 Phage- 0.23 0.30 0.08
[0846] 532 F D w D G E L N Y L T 563 Phage- 0.18 0.30 0.10
[0847] 533 Y V E D V N L I 564 Phage- 0.11 0.29 0.09
[0848] 534 D N Y I T L 565 Phage- 535 L N - w - D W E - D Y S - N 0.09 0.29 0.09 566 Phage- 0.12 0.29 0.26
[0849] 536 P T V E L L S N 567 Phage- 0.11 0.29 0.08
[0850] 537 D H V E L I F Y H 568 Phage- 0.08 0.29 0.08
[0851] 538 F H - - - - L - - - I F - Y 569 Phage- 0.16 0.29 0.16
[0852] 539 F D L E T V P 570 Phage- 0.08 0.29 0.08
[0853] 540 D F - - - - L - - - L P - A 571 Phage- - - 0.09 0.29 0.09
[0854] 541 D S - - L - - - I Y - D 572 Phage- 0.12 0.29 0.10
[0855] 542 A D w D W E F L L F 573 Phage- 0.10 0.28 0.08
[0856] 543 I L V E L D F N 574 Phage- 0.09 0.28 0.07
[0857] 544 F F E I F L Y 575 Phage- 0.07 0.28 0.07
[0858] 545 Y N D G Y D H 576 Phage- 0.11 0.28 0.11
[0859] 546 D N L T I T F 577 Phage- 0.09 0.28 0.23
[0860] 547 H N D G A F I N 578 Phage- 0.10 0.28 0.23
[0861] 548 D V E D L V P 579 Phage- 0.08 0.28 0.07
[0862] 549 D L L N F 580 Phage- 0.11 0.28 0.27
[0863] 550 D Q D F H H 581 Phage- 0.10 0.28 0.18
[0864] 551 Y D w E F T D D I 582 Phage- 0.14 0.28 0.19
[0865]
[0866] 552 D I Y E D I I Y 583WSGR Docket No. 52426-781.601
[0867] Phage- 553 F D L T P p 0.11 0.28 0.08 584 Phage- 0.09 0.28 0.26
[0868] 554 N - - - - - L - - T s V - D 585 Phage- 0.17 0.28 0.11
[0869] 555 Y W E F F D D 586 Phage- 556 Y A - - - - L - - - - T - D 0.09 0.28 0.08 587 Phage- 0.08 0.28 0.10
[0870] 557 F L V E Q D Y F V 588 Phage- 0.09 0.27 0.26
[0871] 558 D N R D 589 Phage- 0.10 0.27 0.24
[0872] 559 N D - - - D G I - T - D - Y 590 Phage- 0.08 0.27 0.09
[0873] 560 Y F V E D Y N D F 591 Phage- 0.10 0.27 0.07
[0874] 561 N L I F Y 592 Phage- 0.10 0.27 0.08
[0875] 562 I D w D w E Y I P T 593 Phage- 0.07 0.27 0.08
[0876] 563 I D G F I A 594 Phage- 0.08 0.27 0.07
[0877] 564 D V Y 595 Phage- 0.13 0.27 0.09
[0878] 565 F w E D I T D D 596 Phage- 0.08 0.26 0.08
[0879] 566 L D V T F T H 597 Phage- 0.13 0.26 0.10
[0880] 567 D D Y F A H 598 Phage- 0.12 0.26 0.11
[0881] 568 I Y Q D L P N 599 Phage- 0.09 0.26 0.08
[0882] 569 L D V E Y N Y V 600 Phage- 0.14 0.26 0.08
[0883] 570 Y V S A N 601 Phage- 0.10 0.26 0.10
[0884] 571 T P L E A I Y 602 Phage- 572 Y F - A D - N 0.08 0.26 0.08 603 Phage- 0.12 0.26 0.25
[0885] 573 D D E D I I D 604 Phage- 0.08 0.26 0.09
[0886] 574 L V V E L N H N 605 Phage- 0.09 0.26 0.27
[0887] 575 - I - - - D G E - L I A - A 606 Phage- 0.09 0.25 0.08
[0888] 576 F A w D W Q T Y V N 607 Phage- 0.08 0.25 0.08
[0889] 577 Y I - - - - V E F L F F - N 608 Phage- 0.12 0.25 0.12
[0890] 578 T Q - - - K G E P T Y H - Y 609 Phage- 0.10 0.25 0.17
[0891] 579 N V E Y H N D 610 Phage- 0.08 0.25 0.07
[0892] 580 w E F F S D A 611 Phage- 0.10 0.25 0.22
[0893] 581 F L E F F Y 612 Phage- 0.13 0.25 0.09
[0894] 582 D I E N F Y Y 613 Phage- 0.08 0.25 0.09
[0895] 583 Y A V E Y Y A 614 Phage- 0.08 0.25 0.07
[0896] 584 D L I I D 615 Phage- 0.07 0.25 0.07
[0897] 585 N D M I A Y 616 Phage- 0.09 0.25 0.21
[0898] 586 Y L A A 617 Phage- 0.08 0.25 0.09
[0899] 587 I A N D 618 Phage- 0.07 0.24 0.07
[0900] 588 L T w D w E D F F N 619 Phage- 0.10 0.24 0.23
[0901]
[0902] 589 F _2_ E I N Y Y 620WSGR Docket No. 52426-781.601
[0903] Phage- 590 T L E F F L Y 0.13 0.24 0.08 621 Phage- 0.12 0.24 0.09
[0904] 591 P D - - - - L - - - - A - H 622 Phage- 0.09 0.24 0.24
[0905] 592 N D E I I F V 623 Phage- 593 Y I - F Y - N 0.25 0.24 0.08 624 Phage- 0.20 0.24 0.07
[0906] 594 H A L L L N 625 Phage- 0.09 0.24 0.21
[0907] 595 Y W E A L A 626 Phage- 0.10 0.24 0.16
[0908] 596 A F - - - - V E - Y D L - N 627 Phage- 0.15 0.23 0.09
[0909] 597 Y N A S 628 Phage- 0.08 0.23 0.09
[0910] 598 Y L V E D D T L A 629 Phage- 0.08 0.23 0.08
[0911] 599 A V N D 630 Phage- 0.13 0.23 0.08
[0912] 600 N w E V Y S L P 631 Phage- 0.07 0.23 0.07
[0913] 601 D F V E D T Y H 632 Phage- 0.08 0.23 0.10
[0914] 602 I S Y E w D Y A N 633 Phage- 0.08 0.23 0.08
[0915] 603 N L I I Y 634 Phage- 0.07 0.23 0.08
[0916] 604 Y D T A P Y 635 Phage- 0.09 0.23 0.22
[0917] 605 Y L E N F L T 636 Phage- 0.08 0.22 0.09
[0918] 606 F D V D A 637 Phage- 0.09 0.22 0.09
[0919] 607 Y D Q E I s F N 638 Phage- 0.09 0.22 0.09
[0920] 608 I D I E L Y D D F 639 Phage- 609 T F - - - - L - - - - Y - Y 0.08 0.22 0.07 640 Phage- 0.09 0.22 0.07
[0921] 610 F F I N A V 641 Phage- 0.12 0.22 0.10
[0922] 611 Y H w D W E p I Y I I 642 Phage- 0.08 0.22 0.08
[0923] 612 A I - - - - Y E - D H Y - Y 643 Phage- 0.12 0.22 0.08
[0924] 613 P L D G F N Y N F 644 Phage- 0.09 0.22 0.09
[0925] 614 F P - w - D W E w D N N - H 645 Phage- - - 0.10 0.22 0.11 615 D - - D G - - L A A - H 646 Phage- 0.08 0.22 0.07
[0926] 616 D w D W E Y Y S D 647 Phage- 0.07 0.21 0.10
[0927] 617 Y Y D T 648 Phage- 0.08 0.21 0.08
[0928] 618 N L W E N F A D F 649 Phage- 0.12 0.21 0.10
[0929] 619 Y L L E V F F V D 650 Phage- 0.09 0.21 0.08
[0930] 620 I F L E D Y S I F 651 Phage- 0.09 0.21 0.08
[0931] 621 D L E Q Y D L F 652 Phage- 0.11 0.21 0.13
[0932] 622 L L V N E D P L D Y 653 Phage- 0.08 0.21 0.08
[0933] 623 I D F Y 654 Phage- 0.08 0.21 0.08
[0934] 624 I I V E I D I S 655 Phage- 0.08 0.21 0.11
[0935] 625 I A w D w E D Y S S P 656 Phage- 0.09 0.21 0.07
[0936]
[0937] 626 Y V E D I N D I 657WSGR Docket No. 52426-781.601
[0938] Phage- 627 N I M I D I 0.08 0.21 0.07 658 Phage- - - - - - 0.07 0.21 0.08
[0939] 628 F D w D W E L S Y 659 Phage- 0.09 0.21 0.19
[0940] 629 Y F W E D H F F D 660 Phage- 630 T - - - - - - E - D S Y - D 0.12 0.20 0.09 661 Phage- 0.11 0.20 0.09
[0941] 631 N L V E L I D I S 662 Phage- 0.08 0.20 0.08
[0942] 632 D N w E V Y L N 663 Phage- 0.08 0.20 0.09
[0943] 633 F L - D L - F 664 Phage- 0.09 0.20 0.19
[0944] 634 H I Q I T 665 Phage- 0.10 0.20 0.09
[0945] 635 F D w D w E D N S Y D 666 Phage- 0.08 0.20 0.07
[0946] 636 T A w E F D F N D 667 Phage- 0.10 0.20 0.11
[0947] 637 H H w D w E D Y S T P 668 Phage- 0.07 0.20 0.08
[0948] 638 Y N F 669 Phage- 0.08 0.20 0.09
[0949] 639 L H w D w E I D I D 670 Phage- 0.08 0.20 0.09
[0950] 640 D I D G Q D F V S 671 Phage- 0.09 0.20 0.07
[0951] 641 D V w D W E V N Y F D 672 Phage- 0.12 0.20 0.10
[0952] 642 N M I D A 673 Phage- 0.11 0.19 0.19
[0953] 643 D N A T V N 674 Phage- 0.08 0.19 0.08
[0954] 644 D L E V H N N 675 Phage- 0.13 0.19 0.09
[0955] 645 N S Y F 676 Phage- 646 N I - w - D w E - D N F - S 0.08 0.19 0.08 677 Phage- 0.08 0.19 0.08
[0956] 647 F V w E V Y D D D 678 Phage- 0.10 0.19 0.17
[0957] 648 A L E V V H L V 679 Phage- 0.07 0.19 0.09
[0958] 649 P F - - - - M - - T I D - Y 680 Phage- 0.08 0.19 0.08
[0959] 650 L L V M E D V F A Y 681 Phage- - 0.07 0.19 0.08
[0960] 651 D L T N - Y 682 Phage- - - - - - - 0.10 0.18 0.10
[0961] 652 H D M E Y Y L P 683 Phage- 0.08 0.18 0.09
[0962] 653 T D Y I I P 684 Phage- 0.09 0.18 0.08
[0963] 654 L w D W E D Y A D N 685 Phage- 0.07 0.18 0.09
[0964] 655 N D L L T D 686 Phage- 0.11 0.18 0.08
[0965] 656 I L I A Y 687 Phage- 0.11 0.18 0.14
[0966] 657 N V E F N F H 688 Phage- 0.08 0.18 0.09
[0967] 658 D V I E Y S F I 689 Phage- 0.10 0.18 0.12
[0968] 659 D L V E I T D A 690 Phage- 0.12 0.18 0.12
[0969] 660 H D F I 691 Phage- 0.10 0.18 0.13
[0970] 661 P L V L E D I Y Y 692 Phage- 0.10 0.18 0.11
[0971] 662 D L E D I I D N 693 Phage- 0.10 0.18 0.18
[0972]
[0973] 663 D V E V P S N N 694WSGR Docket No. 52426-781.601
[0974] Phage- 664 I I L T A D 0.10 0.18 0.09 695 Phage- 0.10 0.18 0.14
[0975] 665 D H - N - D 696 Phage- 0.07 0.18 0.07
[0976] 666 F D L Y S 697 Phage- 667 F A - w - D w E - V Y I - Y 0.08 0.18 0.08 698 Phage- 0.08 0.18 0.09
[0977] 668 L L D S 699 Phage- 0.09 0.18 0.08
[0978] 669 D L L E A F L A 700 Phage- 0.10 0.18 0.08
[0979] 670 F A - - - - L - - T L T - L 701 Phage- 0.17 0.18 0.10
[0980] 671 F D V E I S N D 702 Phage- 0.09 0.17 0.16
[0981] 672 H L E Y P F D N 703 Phage- 0.10 0.17 0.15
[0982] 673 A E H T T N 704 Phage- 0.08 0.17 0.08
[0983] 674 L V s E Q F T F I 705 Phage- 0.10 0.17 0.09
[0984] 675 D L Y D N 706 Phage- 0.13 0.17 0.15
[0985] 676 F W E F D V I 707 Phage- 0.08 0.17 0.09
[0986] 677 F T V E Y D H I 708 Phage- 0.12 0.17 0.11
[0987] 678 Y N T F 709 Phage- 0.08 0.17 0.08
[0988] 679 A V N N S A 710 Phage- 0.10 0.17 0.09
[0989] 680 I w D W E V p N D A 711 Phage- 0.12 0.17 0.12
[0990] 681 Y F E F F H Y 712 Phage- 0.12 0.17 0.12
[0991] 682 Y V D G S F D 713 Phage- 683 I s - - - - V E - F F Y - Y 0.10 0.17 0.08 714 Phage- 0.17 0.17 0.15
[0992] 684 L I V E D Y D 715 Phage- 0.14 0.17 0.16
[0993] 685 V E D H N Y A 716 Phage- 0.08 0.17 0.10
[0994] 686 L D - - - - - E F V Y I - A 717 Phage- 0.17 0.17 0.11
[0995] 687 Y D E D L P I 718 Phage- 0.10 0.17 0.14
[0996] 688 D V - - - - V E - D Y Y - D 719 Phage- 0.08 0.17 0.10
[0997] 689 N D - w - D w E Y D N V - V 720 Phage- 0.10 0.16 0.16
[0998] 690 D L E V A N D N 721 Phage- 0.09 0.16 0.07
[0999] 691 H D L I S N 722 Phage- 0.08 0.16 0.08
[1000] 692 L D w D W E T T H D 723 Phage- 0.09 0.16 0.09
[1001] 693 I I V E D D Y L 724 Phage- 0.09 0.16 0.09
[1002] 694 Y w D w E V I I D 725 Phage- 0.12 0.16 0.09
[1003] 695 F D I Y T N N 726 Phage- 0.08 0.16 0.11
[1004] 696 I T L T I N D 727 Phage- 0.07 0.16 0.08
[1005] 697 D S V E D I Y I 728 Phage- 0.07 0.16 0.08
[1006] 698 Y L G N H 729 Phage- 0.08 0.16 0.10
[1007] 699 D N L P D Y F D 730 Phage- 0.11 0.16 0.08
[1008]
[1009] 700 L E V S N N 731WSGR Docket No. 52426-781.601
[1010] Phage- 701 D w D W E D I V D 0.10 0.16 0.09 732 Phage- 0.07 0.16 0.07
[1011] 702 - - - w - D W E D N F P - Y 733 Phage- 0.08 0.16 0.08
[1012] 703 D V E H F N H 734 Phage- 704 A D - - - - I E - D A Y - Y 0.12 0.16 0.09 735 Phage- 0.09 0.16 0.07
[1013] 705 I L w D w E D A T F Y 736 Phage- 0.09 0.16 0.08
[1014] 706 I H w D w E D F N I P 737 Phage- 0.07 0.16 0.07
[1015] 707 T I - - - - V E D Y N D - I 738 Phage- 0.08 0.16 0.08
[1016] 708 D D L A I 739 Phage- 0.13 0.16 0.08
[1017] 709 D D w D W E D H I F F 740 Phage- 0.12 0.15 0.12
[1018] 710 N V E I I F D 741 Phage- 0.08 0.15 0.09
[1019] 711 I F w D w E D D T V I 742 Phage- 0.12 0.15 0.15
[1020] 712 I I E I S D L 743 Phage- 0.11 0.15 0.09
[1021] 713 F D V E Y N D D 744 Phage- 0.08 0.15 0.10
[1022] 714 N D L T L Y I 745 Phage- 0.12 0.15 0.17
[1023] 715 A I L E D I S N 746 Phage- 0.07 0.15 0.07
[1024] 716 H L T N Y 747 Phage- 0.10 0.15 0.11
[1025] 717 S L A I 748 Phage- 0.08 0.15 0.08
[1026] 718 L E L A D T 749 Q
[1027] Phage- 0.07 0.15 0.08
[1028] 719 I D L I A N 750 Phage- 720 F D - - - D G 0.10 0.15 0.08
[1029] Q - D L V - N 751 Phage- 0.09 0.15 0.15
[1030] 721 N L E F F D Y 752 Phage- 0.09 0.14 0.14
[1031] 722 S I L D I V P 753 Q
[1032] Phage- 0.08 0.14 0.08 - - - - - - - 723 N P Y A H D 754 Phage- 0.12 0.14 0.11
[1033] 724 Y D L Y Y N N 755 Phage- 0.07 0.14 0.08 - - - - - - - - 725 D L T I F D 756 Phage- 0.09 0.14 0.10 - - - - - - - - - 726 D N L T T 757 Phage- 0.10 0.14 0.13
[1034] 727 D L s Y D 758 Phage- 0.07 0.14 0.07
[1035] 728 Y E F I D F F 759 Phage- 0.08 0.14 0.09
[1036] 729 Y D w D w E V I T Y N 760 Phage- 0.06 0.14 0.07
[1037] 730 F D I E D F F V 761 Phage- 0.10 0.14 0.14
[1038] 731 I F w D w D I N F D 762 Phage- 0.37 0.14 0.09
[1039] 732 N F L p D I T Y 763 Phage- 0.09 0.14 0.07
[1040] 733 S L E Y Y H L 764 Phage- 0.12 0.14 0.13
[1041] 734 A S L L D L 765 Phage- 0.09 0.14 0.08
[1042] 735 S F R E w D L A Y 766 Phage- 0.08 0.14 0.12
[1043] 736 H L E D V L D I 767 Phage- 0.20 0.14 0.09
[1044] 737 L D D G F Y Y L 768
[1045]
[1046] WSGR Docket No. 52426-781.601
[1047] Phage- 738 D N w D W E D I A T 0.16 0.14 0.11 769 Phage- 0.09 0.14 0.08
[1048] 739 S D - - - - L - - T I H - I 770 Phage- 0.08 0.14 0.08
[1049] 740 N S D G D L 771 Phage- 741 D L - - - - L - - - T L - I 0.07 0.14 0.08 772 Phage- 0.09 0.14 0.11
[1050] 742 F D S F N Y 773 Phage- 0.12 0.14 0.13
[1051] 743 D L E D D I Y 774 Phage- 0.10 0.14 0.14
[1052] 744 H A - - - - - E - D T Y - F 775 Phage- 0.11 0.14 0.08
[1053] 745 S D L A I 776 Phage- 0.09 0.13 0.11
[1054] 746 I V L p D Y N Y 777 Phage- 0.09 0.13 0.08
[1055] 747 D L F I F 778 Phage- 0.13 0.13 0.08
[1056] 748 Y D T L T N 779 Phage- 0.11 0.13 0.12
[1057] 749 Y D V E I N D 780 Phage- 0.07 0.13 0.07
[1058] 750 F I E D D H V I 781 Phage- 0.12 0.13 0.12
[1059] 751 F I w E D D Y A S 782 Phage- 0.10 0.13 0.09
[1060] 752 N F N 783 Phage- 0.07 0.13 0.07
[1061] 753 N L V E I L I D 784 Phage- 0.11 0.13 0.08
[1062] 754 D S V E Y D L N 785 Phage- 0.09 0.13 0.08
[1063] 755 T L E I T D N 786 Phage- 0.09 0.13 0.09
[1064] 756 T V K M E M N S T D 787 Phage- 757 - H - w - D W E D A - S - N 0.10 0.12 0.11 788 Phage- 0.08 0.12 0.08
[1065] 758 D L D G N L D F F 789 Phage- 0.09 0.12 0.07
[1066] 759 D L D G E H Y Y D 790 Phage- 0.11 0.12 0.12
[1067] 760 F N - - - - V E - I L L - T 791 Phage- 0.09 0.12 0.07
[1068] 761 H V E N I N D I 792 Phage- 0.09 0.12 0.08
[1069] 762 I D - - - - L - - - - I - D 793 Phage- - - 0.08 0.12 0.09
[1070] 763 I F - - I E Q p A L - Y 794 Phage- 0.10 0.12 0.08
[1071] 764 Y D Q D L V P 795 Phage- 0.13 0.12 0.09
[1072] 765 H A w D w E P N Y D 796 Phage- 0.11 0.12 0.10
[1073] 766 N V w D w E D Y N Y 797 Phage- 0.09 0.12 0.12
[1074] 767 S F Q L G D N Y D I 798 Phage- 0.08 0.12 0.09
[1075] 768 D D L T T V Y 799 Phage- 0.09 0.12 0.14
[1076] 769 N F W E V A T L L 800 Phage- 0.09 0.11 0.07
[1077] 770 D L V E D T Y N 801 Phage- 0.08 0.11 0.08
[1078] 771 A L V E Q V D L T 802 Phage- 0.08 0.11 0.08
[1079] 772 D D L N N 803 Phage- 0.09 0.11 0.11
[1080] 773 I F E Q I I Y D 804 Phage- 0.09 0.11 0.10
[1081]
[1082] 774 S D w D w E V Y Y S 805WSGR Docket No. 52426-781.601
[1083] Phage- 775 F F D G V A I D 0.09 0.11 0.07 806 Phage- 0.11 0.11 0.07
[1084] 776 D D - w - D W E D D - Y - Y 807 Phage- 0.08 0.11 0.08
[1085] 777 Y D T V P 808 Phage- 778 S - - - - - L - - - - N - V 0.10 0.11 0.08 809 Phage- 0.09 0.11 0.10
[1086] 779 A F V s F Q Q s L p H D 810 Phage- 0.09 0.11 0.09
[1087] 780 N V E Y F V F 811 Phage- 0.07 0.11 0.08
[1088] 781 T N - w - D w E - D F A - V 812 Phage- 0.08 0.10 0.08
[1089] 782 D D E I I L F 813 Phage- 0.08 0.10 0.10
[1090] 783 N S L E D Y H L P 814 Phage- 0.09 0.10 0.08
[1091] 784 I H D S G F D F D 815 Phage- 0.08 0.10 0.08
[1092] 785 F D L E D H L F 816 Phage- 0.10 0.10 0.08
[1093] 786 T V w D E Y A D D 817 Phage- 0.09 0.10 0.09
[1094] 787 Y F w D w E A A D L 818 Phage- 0.08 0.10 0.07
[1095] 788 S D I 819 Phage- 0.08 0.10 0.08
[1096] 789 A V L P D I V Y 820 Phage- 0.08 0.10 0.30
[1097] 790 L V E Y H L A 821 Phage- 0.12 0.10 0.11
[1098] 791 s L w D w E V D N F 822 Phage- 0.07 0.10 0.07
[1099] 792 T I D G D Y N H 823 Q
[1100] Phage- 0.12 0.10 0.09
[1101] 793 F L G E p T Y L T 824 Phage- 794 D D - w L - 0.10 0.10 0.08
[1102] Q H D I Y V - A 825 Phage- 0.07 0.10 0.08
[1103] 795 I F V E V A F F 826 Phage- 0.09 0.10 0.09
[1104] 796 A L V E D D Y D L 827 Phage- 0.08 0.10 0.08 - - - - - 797 D D I E L Y L T A 828 Phage- 0.07 0.10 0.07
[1105] 798 T D w D w E D D S I D 829 Phage- 0.08 0.10 0.08 - - - - - - 799 S I L E I F L N 830 Phage- 0.07 0.10 0.09 - - - - - - 800 N D L E D I L F 831 Phage- 0.09 0.09 0.08
[1106] 801 D D L T Y S Y 832 Phage- 0.10 0.09 0.09
[1107] 802 F V W E I D L I 833 Phage- 0.07 0.09 0.07
[1108] 803 Y D L L S P 834 Phage- 0.08 0.09 0.08
[1109] 804 N L L I I P 835 Phage- 0.08 0.09 0.09
[1110] 805 I D w D W E F N N F 836 Phage- 0.08 0.09 0.09
[1111] 806 A L E H D Y Y 837 Phage- 0.14 0.09 0.09
[1112] 807 D D s I D L D 838 Q Q
[1113] Phage- 0.08 0.09 0.07
[1114] 808 S s I Y Y 839 Phage- 0.07 0.09 0.07
[1115] 809 S L D A P N 840 Q
[1116] Phage- 0.09 0.09 0.08
[1117] 810 D A L T T H D 841 Phage- 0.07 0.09 0.08
[1118] 811 N D V E V A D F 842
[1119]
[1120] WSGR Docket No. 52426-781.601
[1121] Phage- 812 Y I E Q D Y F F 0.08 0.09 0.08 843 Phage- - - - - - - 0.11 0.09 0.08
[1122] 813 T D D G T N Y F 844 Phage- 0.08 0.09 0.08
[1123] 814 Y D V L P 845 Phage- 815 I D - A Y - T 0.08 0.09 0.08 846 Phage- 0.09 0.09 0.09
[1124] 816 F D E F F H Y 847 Phage- 0.09 0.09 0.08
[1125] 817 F P I E Y D Y V 848 Phage- 0.09 0.09 0.07
[1126] 818 A D - - - I - E s I D I - V 849 Phage- 0.10 0.09 0.10
[1127] 819 I S D L W p T D I T 850 Phage- 0.09 0.09 0.07
[1128] 820 D D D G V H T N 851 Phage- 0.09 0.09 0.08
[1129] 821 I D w D W E G F A N 852 Phage- 0.08 0.08 0.07
[1130] 822 L N D G T F Y D 853 Phage- 0.08 0.08 0.09
[1131] 823 I H L G A Y I S S 854 Phage- 0.08 0.08 0.08
[1132] 824 T I w D W E D Y F Y 855 Phage- 0.07 0.08 0.07
[1133] 825 H S L A Q Q D L V I 856 Phage- 0.07 0.08 0.08
[1134] 826 N N A S D L s D N s I 857 Phage- 0.09 0.08 0.07
[1135] 827 N W D W E D A N 858 Phage- 0.08 0.08 0.07
[1136] 828 L F Y F 859 Phage- 0.07 0.08 0.07
[1137] 829 L F T V L F F D D 860 Phage- 0.08 0.08 0.07
[1138] 830 F D L S A 861 Phage- 831 Y - - - - - V E - N - Y - I 0.07 0.08 0.08 862 Phage- 0.12 0.08 0.10
[1139] 832 D L D T I H 863 Phage- 0.09 0.08 0.07
[1140] 833 F Q W A A N A F 864 Phage- - 0.09 0.08 0.09
[1141] 834 F T - - Y - - - I T - P 865 Phage- 0.07 0.08 0.08
[1142] 835 L N V N S V I 866 Phage- 0.07 0.08 0.07
[1143] 836 A I - w - D W E - F S D - H 867 Phage- 837 Y - - - 0.10 0.08 0.09
[1144] V D L G A N - Y - Y 868 Phage- 0.07 0.08 0.07
[1145] 838 H V E D Y H D 869 Phage- 0.08 0.08 0.07
[1146] 839 N D s L Q Y D I P T V 870 Phage- 0.15 0.08 0.07
[1147] 840 Y V R Q L V Y H Y N 871 Phage- 0.08 0.08 0.07
[1148] 841 H D D G I I S 872 Phage- 0.08 0.08 0.08
[1149] 842 F D L T I I P 873 Phage- 0.07 0.08 0.07
[1150] 843 D s D R G N A A H 874 Phage- 0.07 0.08 0.08
[1151] 844 N I L A Q N D P T N 875 Phage- 0.10 0.08 0.09
[1152] 845 T N S K s Q V D H I 876 Phage- 0.09 0.07 0.07
[1153] 846 N H H Q w L T N N 877 Phage- 0.09 0.07 0.08
[1154] 847 L L H Q G L Y H L H 878 Phage- 0.09 0.07 0.07
[1155]
[1156] 848 T N D s K L E G D D N F 879WSGR Docket No. 52426-781.601
[1157] Phage- 849 N D M L L D 0.08 0.07 0.07 880 Phage- 0.07 0.0
[1158] 850 F H - - - - V - - - - 7 0.07
[1159] I N N 881 Phage- 0.07 0.07 0.08
[1160] 851 D F D G T Y V s 882 Phage- 852 - s - - - 0.07 0.07 0.08
[1161] Q - - - N N T - N 883 Phage- 0.08 0.07 0.08
[1162] 853 H L s E F D I I 884 Q
[1163] Phage- 0.08 0.07 0.08
[1164] 854 D D w E F V F F D 885 Phage- 0.07 0.07 0.07 - - - - 855 Y N E D P s I 886 Q Q Q
[1165] Phage- 0.08 0.07 0.08
[1166] 856 N T T H F N L 887 Q
[1167] Phage- 0.08 0.07 0.08
[1168] 857 H P G E V D Y V 888 Q
[1169] Phage- 0.07 0.07 0.07
[1170] 858 A s R L G D A Y N 889 Q
[1171] Phage- 0.07 0.07 0.07
[1172] 859 D I A E V H V Y T P 890 Q
[1173] Phage- 0.08 0.07 0.08
[1174] 860 F F E G N L A Y L L L 891 Phage- 0.07 0.07 0.07 - - - - - - 861 Y D G E N I V D 892
[1175]
[1176] Table 6. CD3 scFv Mask Peptide-B Optimization
[1177] SEQ ID
[1178] Peptide- ID Sequence
[1179] NO:
[1180] 893 DDCWPDWEFDFACA Peptide- AA
[1181] 894 YICGLDFPDFLYCD Peptide- AB
[1182] 895 FDCWPDWEEYFVCD Peptide-AC
[1183] 896 YICWPDWEEYFDCD Peptide- AD
[1184] 897 NICWPDWEDDYFCF Peptide- AE
[1185] 898 NFCWPDWEYIYPCI Peptide- AF
[1186] 899 VDCWPDWEEDFLCI Peptide-AG
[1187] 900 HACWPDWEEYFPCN Peptide- AH
[1188] 901 YDCGPDVDESYVCV Peptide- Al
[1189] 902 IDCWPDWEDDTFCY Peptide- AJ
[1190] 903 YLCGPDGDETLACY Peptide- AK
[1191] 904 VDCGPDGDESILCY Peptide- AL
[1192]
[1193] CD28 Binding Domain
[1194]
[0137] In some embodiments, the antigen binding domain comprises a CD28 binding domain. In some embodiments, the antigen binding domain that binds to CD28 comprises an anti-CD28 antibody or fragment thereof.
[1195]
[0138] In some embodiments, the antigen binding domain (e.g., anti-CD28 antibody) comprises an anti- CD28 heavy chain variable domain that comprises complementarity determining regions (CDRs): HC- CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 comprise amino acid sequences of HC-CDR1: SEQ ID NO: 2347, HC-CDR2: SEQ ID NO: 2348, and HC-CDR3: SEQ ID NO: 2349 and the antigen binding domain (e.g. , anti-CD28 antibody) comprises an anti-CD28 light chain variable domain that comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2,WSGR Docket No. 52426-781.601
[1196] and LC-CDR3, and wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 comprise amino acid sequences ofLC-CDRl: SEQIDNO: 2350, LC-CDR2: (KAS), andLC-CDR3: SEQIDNO: 2351. In some embodiments, the anti-CD28 heavy chain variable domain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2352, and the anti-CD28 light chain variable domain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2354. In some embodiments, the anti-CD28 heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 2353, and the anti-CD28 light chain variable domain comprises the amino acid sequence of SEQ ID NO: 2354.
[1197] Table 7. anti-CD28 sequences. CDR sequences are underlined and were determined using IMGT definition.
[1198] Construct Description Amino Acid Sequence SEQ ID NO:
[1199] anti-CD28: HC: CDR1 GYTFTSYY 2347 anti-CD28: HC: CDR2 IYPGNVNT 2348 anti-CD28: HC: CDR3 TRSHYGLDWNFDV 2349 anti-CD28: LC: CDR1 QNIYVW 2350 anti-CD28: LC: CDR2 KAS
[1200] anti-CD28: LC: CDR3 QQGQTYPYT 2351 anti-CD28: HC OVOLVQSGAEVKKPGASVKVSCKASGYTFTSYYI 2352
[1201] HWVRQAPGQGLEWIGSIYPGNVNTNYNEKFKDR ATLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYG LDWNFDVWGQGTTVTVSS
[1202] anti-CD28: LC DIQMTOSPSSLSASVGDRVHTCHASONIYVWLN 2353
[1203] WYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSG TDFTLTISSLOPEDFATYYCOOGOTYPYTFGGGTK VEIK
[1204] Anti-CD28 scFv OVOLVQSGAEVKKPGASVKVSCKASGYTFTSYYI 2354 (VH - linker 1 - VL) HWVRQAPGQGLEWIGSIYPGNVNTNYNEKFKDR ATLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYG LDWNFDVWGQGTTVTVSSGGGGSGGGGSGGGGS DIQMTOSPSSLSASVGDRVHTCHASONIYVWLN WYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSG TDFTLTISSLOPEDFATYYCOOGOTYPYTFGGGTK VEIK
[1205] Anti-CD28 scFv OVOLVQSGAEVKKPGASVKVSCKASGYTFTSYYI 2355 (VH - linker 1 - VL) HWVRQAPGQCLEWIGSIYPGNVNTNYNEKFKDR
[1206] Disulfide mutation: ATLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYG
[1207] G44C, G235C LDWNFDVWGQGTTVTVSSGGGGSGGGGSGGGGS DIQMTOSPSSLSASVGDRVHTCHASONIYVWLN WYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSG TDFTLTISSLOPEDFATYYCQQGQTYPYTFGCGTK VEIK
[1208] Anti-CD28 scFv DIQMTOSPSSLSASVGDRVHTCHASONIYVWLN 2356 (VL - linker 1 - VH) WYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSG TDFTLTISSLOPEDFATYYCOOGOTYPYTFGGGTK VEIKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPG ASVKVSCKASGYTFTSYYIHWVRQAPGOGLEWIG
[1209]
[1210] SIYPGNVNTNYNEKFKDRATLTVDTSISTAYMELSWSGR Docket No. 52426-781.601
[1211] RLRSDDTAVYFCTRSHYGLDWNFDVWGQGTTVT
[1212] vss
[1213] Anti-CD28 scFv DIQMTQSPSSLSASVGDRVHTCHASQNIYVWLN 2357 (VL - linker 1 - VH) WYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSG Disulfide mutation: TDFTLTISSLQPEDFATYYCQQGQTYPYTFGCGTK G100C, G166C VEIKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPG ASVKVSCKASGYTFTSYYIHWVRQAPGQCLEWIG SIYPGNVNTNYNEKFKDRATLTVDTSISTAYMELS RLRSDDTAVYFCTRSHYGLDWNFDVWGQGTTVT VSS
[1214] Anti-CD28 Fab LC DIQMTQSP S SLS AS VGDRVHTCHAS QNIYVWLNW 2358
[1215] YQQKPGKAPKLLIYKASNLHTGVP SRFS GS GS GTD FTLTI S SLQPEDF ATYYCQQGQTYPYTFGGGTKVEI KRTV AAP S VFIFPP SDEQLKS GTAS VVCLLNNFYPR EAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNR GEC
[1216] Anti-CD28 Fab HC QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYI 2359
[1217] HWVRQAPGQGLEWIGSIYPGNVNTNYNEKFKDRA TLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYGL DWNFDVWGQGTTVTVSSASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSC
[1218] Anti-CD28 CrossFab LC DIQMTQSP S SLS AS VGDRVHTCHAS QNIYVWLNW 2360 LC mutations: YQQKPGKAPKLLIYKASNLHTGVP SRFS GS GS GTD
[1219] SS added FTLTI S SLQPEDF ATYYCQQGQTYPYTFGGGTKVEI
[1220] KS S AS TKGP S VFP L AP S S KS TS GGTAALGCLVKDY FPEPVTVS WNS GALTS GVHTFP AVLQS S GLYSLS S VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS C
[1221] Anti-CD28 CrossFab HC QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYI 2361 HC mutations: HWVRQAPGQGLEWIGSIYPGNVNTNYNEKFKDRA
[1222] AS replaced RT TLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYGL DWNFDVWGQGTTVTVSSASVAAPSVFIFPPSDEQL KSGTASVVCLLNNFYPREAKVQWKVDNALQSGN SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA CEVTHQGLS SPVTKSFNRGEC
[1223] Anti-CD28 CrossFab DIQMTQSP S SLS AS VGDRVHTCHAS QNIYVWLNW 2362 EE / RK LC YQQKPGKAPKLLIYKASNLHTGVP SRFS GS GS GTD
[1224] LC mutations: FTLTI S SLQPEDF ATYYCQQGQTYPYTFGGGTKVEI
[1225] SS added; K139E; K205E KS S AS TKGP S VFPLAP S S KSTS GGTAALGCLVEDYF
[1226] PEP VTVS WNS GALTS GVHTFP AVLQS S GLYSLS SV VTVPSSSLGTQTYICNVNHKPSNTKVDEKVEPKSC
[1227] Anti-CD28 CrossFab QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYI 2363 EE / RK HC HWVRQAPGQGLEWIGSIYPGNVNTNYNEKFKDRA
[1228] HC mutations: TLTVDTSISTAYMELSRLRSDDTAVYFCTRSHYGL
[1229] AS replaced RT; E136R; DWNFDVWGQGTTVTVSSASVAAPSVFIFPPSDRKL Q137K KSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
[1230] SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
[1231]
[1232] CEVTHQGLS SPVTKSFNRGECWSGR Docket No. 52426-781.601
[1233]
[0139] In some embodiments, the antigen binding domain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to any one of the sequences in Table 7. In some embodiments, the antigen binding domain comprises any one of the amino acid sequences in Table 7.
[1234]
[0140] In some embodiments, the antigen binding domain (e.g., anti-CD28 antibody) comprises a single chain variable fragment (scFv), a single domain antibody, a Fab, a Fab’, or a CrossFab. In some embodiments, the antigen binding domain (e.g., anti-CD28 antibody) comprises the scFv. In some embodiments, the antigen binding domain (e.g., anti-CD28 antibody) comprises a single chain variable fragment (scFv) with an engineered disulfide. In some embodiments, the antigen binding domain (e.g., anti-CD28 antibody) comprises the scFv, and the scFv comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2354. In some embodiments, the antigen binding domain (e.g., anti-CD28 antibody) comprises the scFv, and the scFv comprises the amino acid sequence of SEQ ID NO: 2354. In some embodiments, the antigen binding domain (e.g., anti-CD28 antibody) comprises the scFv, and the scFv comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2355. In some embodiments, the antigen binding domain comprises the scFv, and the scFv comprises the amino acid sequence of SEQ ID NO: 2355. In some embodiments, the antigen binding domain (e.g., anti-CD28 antibody) comprises the scFv, and the scFv comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2356. In some embodiments, the antigen binding domain comprises the scFv, and the scFv comprises the amino acid sequence of SEQ ID NO: 2356. In some embodiments, the antigen binding domain (e.g., anti-CD28 antibody) comprises the scFv, and the scFv comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2357.
[1235]
[0141] In some embodiments, the antigen binding domain (e.g., anti-CD28 antibody) comprises the scFv, and the scFv comprises the amino acid sequence of SEQ ID NO: 2357.
[1236]
[0142] In some embodiments, the antigen binding domain (e.g., anti-CD28 antibody) comprises the Fab. In some embodiments, the Fab comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2358 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2359. In some embodiments, the antigen binding domain (e.g., anti-CD28 antibody) comprises the CrossFab. In some embodiments, the CrossFab comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2360 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2361. In some embodiments, the CrossFab comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2362 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2363.
[1237] CD28 Masks
[1238]
[0143] In some embodiments, the peptide mask is a peptide that impairs binding of an antigen binding domain (e.g., anti-CD28 antibody) to CD28. In some embodiments, the peptide mask is bound to the T-cellWSGR Docket No. 52426-781.601
[1239] binding domain through ionic interactions, electrostatic interactions, hydrophobic interactions, Pi-stacking interactions, or H-bonding interactions, or a combination thereof. In some embodiments, the peptide mask has less than 70% sequence homology to CD28. In some embodiments, the peptide mask comprises a peptide sequence of at least 10 amino acids in length. In some embodiments, the peptide mask comprises a peptide sequence of at least 10 amino acids in length and no more than 20 amino acids in length. In some embodiments, the peptide mask comprises a peptide sequence of at least 16 amino acids in length. In some embodiments, the peptide mask comprises a peptide sequence of no more than 40 amino in length. In some embodiments, the peptide mask comprises at least two cysteine amino acid residues. In some embodiments, the peptide mask comprises a cyclic peptide or a linear peptide. In some embodiments, the peptide mask comprises a cyclic peptide. In some embodiments, the peptide mask comprises a linear peptide. In some embodiments, the peptide mask comprises at least two cysteine amino acid residues.
[1240]
[0144] In some embodiments, the peptide mask comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to any one of the sequences in Table 8-11. In some embodiments, the peptide mask comprises any one of the amino acid sequences in Table 8-11.
[1241]
[0145] A consensus sequence was calculated from all the sequences of Table 10 using WebLogo 3.7.12, and the consensus sequence is shown in FIG. 2. A consensus sequence was calculated from all the sequences of Table 11 using WebLogo 3.7.12, and the consensus sequence is shown in FIG. 3. FIG. 4 further shows the core sequence motif of optimized anti-CD28 scFv Peptide-9 sequences generated using WebLogo 3.7.4.
[1242]
[0146] In some embodiments, the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 904-1058.
[1243] Table 8. CD28 Peptide Mask Sequences
[1244] Construct Amino Acid Sequence SEQ ID NO:
[1245] Description (N to C)
[1246] Peptide- 1 YWYCSPSIVRCVLV 904
[1247] Peptide-2 LICKSGSILILCAQ 905
[1248] Peptide- 3 SPCGLFQWMEICEF 906
[1249] Peptide-4 SFCGLFLDLWICEF 907
[1250] Peptide- 5 DNCYVIWGFEWQCR 908
[1251] Peptide- 6 VNCMRVHRTLTWCV 909
[1252] Peptide- 7 FCTPREWSFLNFVC 910
[1253] Peptide- 8 CFAYLWIDSWIRVC 911
[1254] Peptide-9 MDWCPRERWVDCFF 912
[1255] Peptide- 10 GQHCATSMWRYCMF 913
[1256] Peptide- 11 WICDKSGSIMLCRA 914
[1257] Peptide- 12 GYCHYWGDMVMWCG 915
[1258] Peptide- 13 DNCHYIWGFEWQCG 916
[1259] Peptide- 14 IDCIMVHMVKPWCF 917
[1260] Peptide- 15 NCQPWYWNMFAFGC 918
[1261] Peptide- 16 NCQPWYWNMIAFGC 919
[1262]
[1263] Peptide- 17 GCFTWSQRTFPFTC 920WSGR Docket No. 52426-781.601
[1264] Peptide- 18 CFYAEYYDQVYSFC 921 Peptide- 19 ADWCPRERWVDCFF 922 Peptide-20 MAWCPRERWVDCFF 923 Peptide-21 MDACPRERWVDCFF 924 Peptide- 22 MDWCARERWVDCFF 925 Peptide-23 MDWCPAERWVDCFF 926 Peptide- 24 MDWCPRARWVDCFF 927 Peptide-25 MDWCPREAWVDCFF 928 Peptide-26 MDWCPRERAVDCFF 929 Peptide-27 MDWCPRERWADCFF 930 Peptide-28 MDWCPRERWVACFF 931 Peptide-29 MDWCPRERWVDCAF 932 Peptide- 30 MDWCPRERWVDCFA 933 Peptide- 31 MDWCPIDLWNECFF 934 Peptide-32 MDWCPIHLWHVCFN 935 Peptide- 33 MDWCPIYLWSECFN 936 Peptide-34 MNWCPKDIWYLCFN 937 Peptide- 35 MDWCPLHMWHECF S 938 Peptide- 36 MDWCPLYLWNECFN 939 Peptide- 37 MDWCPRDLWDLCFA 940 Peptide- 38 MDWCPRDLWHECFA 941 Peptide- 39 MDWCPRDLWHLCFS 942 Peptide-40 MDWCPRDLWSECFF 943 Peptide-41 MDWCPRDLWVHCFA 944 Peptide-42 MDWCPRDMWDECFA 945 Peptide-43 MDWCPRDMWSECFA 946 Peptide-44 MDWCPRDMWS VCF S 947 Peptide-45 MDWCPRFMWDECFN 948 Peptide-46 MDWCPRHMWNYCFA 949 Peptide-47 MDWCPRSLWHECFA 950 Peptide-48 MDWCPRYLWHVCFA 951 Peptide-49 MHWCPVDLWYLCYN 952 Peptide- 50 MDWCPVHLWSVCFA 953 Peptide-52 ADWCPRDLWVHCFA 954 Peptide- 53 RDWCPRDLWVHCFA 955 Peptide-54 NDWCPRDLWVHCFA 956 Peptide- 55 DDWCPRDLWVHCFA 957 Peptide- 56 QDWCPRDLWVHCFA 958 Peptide- 57 EDWCPRDLWVHCFA 959 Peptide- 58 GDWCPRDLWVHCFA 960 Peptide- 59 HDWCPRDLWVHCFA 961 Peptide- 60 IDWCPRDLWVHCFA 962 Peptide- 61 EDWCPRDLWVHCFA 963 Peptide- 62 KDWCPRDLWVHCFA 964
[1265]
[1266] Peptide- 63 EDWCPRDLWVHCFA 965WSGR Docket No. 52426-781.601
[1267] Peptide- 64 PDWCPRDLWVHCFA 966 Peptide- 65 SDWCPRDLWVHCFA 967 Peptide- 66 TDWCPRDLWVHCFA 968 Peptide- 67 WDWCPRDLWVHCFA 969 Peptide-68 YDWCPRDLWVHCFA 970 Peptide- 69 VDWCPRDLWVHCFA 971 Peptide- 70 LDWCPRHLWALCFN 972 Peptide- 71 IDWCPRYLWDECYN 973 Peptide- 72 IDWCPLHLWHECYH 974 Peptide- 73 VPWCQIISGLECLT 975 Peptide- 74 IYWCPIDRWNDCYN 976 Peptide- 75 YWSCFQIPFTCFYF 977 Peptide- 76 WECLKYTEANACTY 978 Peptide- 77 FMCLPQNPHPLCFK 979 Peptide- 78 PDCQTILFKPWCVR 980 Peptide- 79 ACDTYFAGMINECF 981 Peptide-80 GCQYPWAFDAMSCP 982 Peptide- 81 WCWDYKLWVPTQCP 983 Peptide- 82 WCWDYREWVPMTCP 984 Peptide-83 ECHWSMWAVGHACF 985 Peptide- 84 YCAGHSPINIGKCL 986 Peptide-85 WCWDYKLWVPMTCP 987 Peptide-86 DCWWMFESYPGRCI 988 Peptide-87 YCAGHAWQYINKCL 989 Peptide- 88 WCWYYREWVPMTCP 990 Peptide-89 YWYCSPSIVRCVLV 991 Peptide- 90 PDCHTILFKPWCVR 992 Peptide- 91 WICDKSGSIMLCRA 993 Peptide- 92 S C AAGAS YAWPYCL 994 Peptide- 93 DCPWLSGFSRPLLC 995 Peptide- 94 YCAGMSTIQLWLKC 996 Peptide- 95 YCAGHMPQYEVKCL 997 Peptide- 96 YCAGHTEEHYVKCM 998 Peptide- 97 YCMGHSHEHIWKCL 999 Peptide-98 YCAGHSHEYLAKCE 1000 Peptide- 99 AC AAGAS YAWPYCL 1001 Peptide- 100 S CAAAAS YAWPYCL 1002 Peptide- 101 S C AAGAAY AWP YCL 1003 Peptide- 102 SCAAGASAAWPYCL 1004 Peptide- 103 SC AAGAS YAAP YCL 1005 Peptide- 104 S C AAGAS YAWAYCL 1006 Peptide- 105 S C AAGAS YAWP ACL 1007 Peptide- 106 S C AAGAS YAWPYC A 1008 Peptide- 107 ACAGHAWQYINKCL 1009 Peptide- 108 YCAAHAWQYINKCL 1010 Peptide- 109 YCAGAAWQYINKCL 1011 Peptide-110 YCAGHAAQYINKCL 1012 Peptide-Ill YCAGHAWAYINKCL 1013 Peptide- 112 YCAGHAWQAINKCL 1014 Peptide-113 YCAGHAWQYANKCL 1015 Peptide- 114 YCAGHAWQYIAKCL 1016
[1268]
[1269] Peptide-115 YCAGHAWQYINACL 1017WSGR Docket No. 52426-781.601
[1270] Peptide-116 YCAGHAWQYINKCA 1018
[1271] Peptide-117 YCEGHSPEYILKCL 1019
[1272] Peptide-118 YCEGHRPEYILKCL 1020
[1273] Peptide-119 YCEGHEGIYFWKCL 1021
[1274] Peptide- 120 YCEGHLPEYIEKCL 1022
[1275] Peptide- 121 YCEGHAPEYIAKCL 1023
[1276] Peptide- 122 YCEGHAPEYIRKCL 1024
[1277] Peptide- 123 YCEGHAPEYIWKCL 1025
[1278] Peptide- 124 YCEGHS QENI WKCL 1026
[1279] Peptide- 125 YCEGHLPEYLGKCL 1027
[1280] Peptide- 126 YCEGHLPEYREKCL 1028
[1281] Peptide- 127 YCEGHLPEYLAKCL 1029
[1282] Peptide- 128 YCEGHS QEYLWKCL 1030
[1283] Peptide- 129 YCEGHS SEYIQKCL 1031
[1284] Peptide- 130 HCS GHHWLQVWKCF 1032
[1285] Peptide- 131 YCWSHSPPFIKKCY 1033
[1286] Peptide- 132 YCEGHLPEYRNKCL 1034
[1287] Peptide- 133 YCEGHLPEYLEKCV 1035
[1288] Peptide- 134 YCEGHLPEYIQKCL 1036
[1289] Peptide- 135 YCEGHLPEYIWKCL 1037
[1290] Peptide- 136 YCEGHAPEYIGKCL 1038
[1291] Peptide- 137 TCSAGATWPWPICL 1039
[1292] Peptide- 138 LCAAGASWPWPVCL 1040
[1293] Peptide- 139 TCSAGASYPWPLCL 1041
[1294] Peptide- 140 TCAAGAAWPWPQCL 1042
[1295] Peptide- 141 TCSAGATYTWPKCF 1043
[1296] Peptide- 142 TCAAGATWSWPACF 1044
[1297] Peptide- 143 TCAAGAAWGWPLCF 1045
[1298] Peptide- 144 LCAAGATYPWPLCL 1046
[1299] Peptide- 145 TCSAGAAYPWPLCL 1047
[1300] Peptide- 146 TCSAGAAYSWPACF 1048
[1301] Peptide- 147 LCAAGATYPWPTCL 1049
[1302] Peptide- 148 SCSAGAHYPWPQCF 1050
[1303] Peptide- 149 TCSAGATYEWPRCL 1051
[1304] Peptide- 150 TCSAGAHYPWPICL 1052
[1305] Peptide- 151 SCSAGAAYYWPWCL 1053
[1306] Peptide- 152 TCSAGATWAWPLCF 1054
[1307] Peptide- 153 TCAAGATYLWPTCL 1055
[1308] Peptide- 154 TCAAGAHYPWPACL 1056
[1309] Peptide- 155 LCAAGFTYPWPLCL 1057
[1310] Peptide- 156 LCKPGVPYKWPTCL 1058
[1311] Peptide-288 Met(O)-DWCPRDLWVHCFA 1059
[1312] Peptide-289 Met(O)2-DWCPRDLWVHCFA 1060
[1313]
[1314] Peptide-290 MDWCPRERWVDCFF 1061
[1315] 1Met(O) is methionine sulfoxide; Met(O)2 is methionine sulfone.
[1316]
[0147] In some embodiments, the peptide mask comprises the amino acid sequence of SEQ ID NO: 73 or a peptide sequence that has 1, 2, or 3 amino acid substitutions, additions, or deletions relative to the amino acid sequence of SEQ ID NO: 944. In some embodiments, the peptide mask comprises the amino acid sequence of SEQ ID NO: 944. In some embodiments, the peptide mask comprises the amino acid sequence of SEQ ID NO: 973 or a peptide sequence that has 1 , 2, or 3 amino acid substitutions, additions, or deletionsWSGR Docket No. 52426-781.601
[1317] relative to the amino acid sequence of SEQ ID NO: 973. In some embodiments, the peptide mask comprises the amino acid sequence of SEQ ID NO: 973.
[1318]
[0148] In some embodiments, the peptide mask comprises an amino acid sequence according to X1-X2-X3-C-X4-X5-X6-X7-X8-X9-Xio-C-Xn-Xi2whereinXi is selected from M, I, L, and V; X2 is selected from D, H, N, A, F, S, T, Y, and V; X3 is selected from W, L, and F; X4 is selected from P, A, and L; X5 is selected from R, T, I, M, S, K, L, V, W, F, A, P, and D; X6is selected from E, D, Y, H, S, F, A, N, T, I, P, and V; X7is selected from L, M, R, S, Q, and H; Xs is selected from W and Q; X9 is selected from H, N, D, A, S, Y, T, F, V, L, and I; X10 is selected from E, V, L, D, Y, R, Q, H, F, K, A, M, and N; Xu is selected from F, Y, L, W, and V; and X12 is selected fromN, A, F, S, Y, H, D, T, and L. In some embodiments, Xi is selected from M, I, and L; X2 is selected from D, H, N, and A; X3 is W; X4 is P; X5 is selected from R, T, I, M, S, and K; Xe is selected from E, D, Y, H, S, and F; X7 is selected from L, M, and R; Xs is W; X9 is selected from H, N, D, A, S, and V; X10 is selected from E, V, L, D, and H; Xu is selected from F, Y, and L; and X12 is selected from N, A, F, S, and Y. In some embodiments, Xi is M; X2 is selected from D and H; X3 is W; X4 is P; X5 is selected from R, T, and I; Xe is selected from E, D, and Y; X7 is selected from L, M, and R; Xs is W; X9 is selected from H, N, D, and V; X10 is selected from E, V, L, D, and H; Xu is F; and X12 is selected from N, A, and F.
[1319]
[0149] In some embodiments, the peptide mask comprisesan amino acid sequence according to SEQ ID NO: 912 or an amino acid sequence that has 1, 2, or 3 amino acid mutations, substitutions, or deletions relative to SEQ ID NO: 912. In some embodiments, the peptide mask comprisesan amino acid sequence according to SEQ ID NO: 912. In some embodiments, the peptide mask comprises an amino acid sequence selected from any one of SEQ ID NOs: 912, 944, 973, and 1062-1488.
[1320] Table 9. Phage panning results of Anti-CD28 scFv Peptide-9 library sequences. (-) indicates same amino acid as in anti-CD28 scFv Peptide-9 corresponding position.
[1321] Amino add position sequence Phage binding ELISA
[1322] Cloncal CD28
[1323] SEQ
[1324] phage CD28 scFv
[1325] ID 1 1 1 1 1 Backgroud ID peptide 1 2 3 4 5 6 7 8 9 scFv signal in
[1326] 0 1 2 3 4 signal NO: sequence signal presence
[1327] of CD28
[1328] Phage- MDWCPRE
[1329] 0.084 2.042 0.489 912 9 RWVDCFF M D w c p R E R W v D C F F
[1330] Phage- MDWCPID
[1331] 0.066 2.515 0.187 1062 19 LWNECFF - - - - - I D L - N E - - - Phage- MDWCPIH
[1332] 0.082 2.526 0.167
[1333] 20 LWHVCFN - - - - - I H L - H V - - N 1063 Phage- MDWCPIY
[1334] 0.075 2.635 0.513
[1335] 21 LWSECFN - - - - - I Y L - s E - - N 1064 Phage- MNWCPKD
[1336] 0.073 2.625 0.168
[1337] 22 IWYLCFN - N - - - K D I - Y L - - N 1065 Phage- MDWCPLH
[1338] 0.086 2.511 0.151
[1339] 23 MWHECFS - - - - - L H M - H E - - s 1066
[1340]
[1341] WSGR Docket No. 52426-781.601
[1342] Phage- MDWCPLY
[1343] 0.065 2.612 0.247 24 LWNECFN - - - - - L Y L - N E - - N 1067 Phage- MDWCPRD
[1344] 0.078 2.696 0.219 25 LWDLCFA - - - - - - D L - D L - - A 1068 Phage- MDWCPRD
[1345] 0.063 2.710 0.277 26 LWHECFA - - - - - - D L - H E - - A 1069 Phage- MDWCPRD
[1346] 0.059 2.592 0.290 27 LWHLCFS - - - - - - D L - H L - - S 1070 Phage- MDWCPRD
[1347] 0.068 2.574 0.218 28 LWSECFF - - - - - - D L - S E - - - 1071 Phage- MDWCPRD
[1348] 0.062 2.554 0.179 29 LWVHCFA - - - - - - D L - - H - - A 1072 Phage- MDWCPRD
[1349] 0.116 2.593 0.250 30 MWDECFA - - - - - - D M - D E - - A 1073 Phage- MDWCPRD
[1350] 0.069 2.701 0.293 31 MWSECFA - - - - - - D M - S E - - A 1074 Phage- MDWCPRD
[1351] 0.062 2.619 0.207 32 MWSVCFS - - - - - - D M - S V - - S 1075 Phage- MDWCPRF
[1352] 0.079 2.680 0.256 33 MWDECFN - - - - - - F M - D E - - N 1076 Phage- MDWCPRH
[1353] 0.089 2.712 0.242 34 MWNYCFA - - - - - - H M - N Y - - A 1077 Phage- MDWCPRS
[1354] 0.064 2.544 0.255 35 LWHECFA - - - - - - S L - H E - - A 1078 Phage- MDWCPRY
[1355] 0.072 2.475 0.226 36 LWHVCFA - - - - - - Y L - H V - - A 1079 Phage- MHWCPVD
[1356] 0.079 2.659 0.417 37 LWYLCYN - H - - - V D L - Y L - Y N 1080 Phage- MDWCPVH
[1357] 0.072 2.650 0.302 38 LWSVCFA - - - - - V H L - S V - - A 1081 Phage- MDWCPMH
[1358] 0.073 2.555 0.299 39 LWHQCFN - - - - - M H L - H Q - - N 1082 Phage- MDWCPID
[1359] 0.061 2.661 0.297 40 MWDQCFN - - - - - I D M - D Q - - N 1083 Phage- MAWCPRD
[1360] 0.062 0.853 0.147 41 KWSECFS - A - - - - D K - S E - - S 1084 Phage- MDWCPRH
[1361] 0.071 2.505 0.254 42 LWVHCFN - - - - - - H L - - H - - N 1085 Phage- MDWCPRA
[1362] 0.115 2.499 0.252 43 LWHECFY - - - - - - A L - H E - - Y 1086 Phage- MDWCPIA
[1363] 0.111 2.458 0.224 44 LWAECFN - - - - - I A L - A E - - N 1087 Phage- MDWCPRP
[1364] 0.078 2.346 0.121 45 LWHECFS - - - - - - P L - H E - - S 1088 Phage- MHWCPID
[1365] 0.082 2.278 0.225 46 LWAECYA - H - - - I D L - A E - Y A 1089 Phage- MAWCPVY
[1366] 0.094 2.273 0.351 47 LWHECFN - A - - - V Y L - H E - - N 1090 Phage- IDWCPRYL
[1367] 0.061 2.243 0.153 48 WDECYN I - - - - - Y L - D E - Y N 1091
[1368]
[1369] WSGR Docket No. 52426-781.601
[1370] Phage- MSWCPIHL
[1371] 0.083 2.057 0.284 49 WNECFN - s - - - I H L - N E - - N 1092 Phage- MDWCPPY
[1372] 0.063 1.639 0.100 50 LWNVCFS - - - - - p Y L - N V - - S 1093 Phage- MDWCPMD
[1373] 0.071 1.635 0.107 51 LWDYCFN - - - - - M D L - D Y - - N 1094 Phage- MDWCPIN
[1374] 0.062 1.498 0.096 52 LWDECFS - - - - - I N L - D E - - S 1095 Phage- MDWCPMH
[1375] 0.071 1.043 0.122 53 LWNKCFN - - - - - M H L - N K - - N 1096 Phage- MNWCPRD
[1376] 0.068 1.948 0.177 54 MWYQCFN - N - - - - D M - Y Q - - N 1097 Phage- QDWCPRH
[1377] 0.138 0.074 0.081 55 MWSFCFH Q - - - - - H M - S F - - H 1098 Phage- MHWCPMD
[1378] 0.062 0.515 0.084 56 QWSNCFN - H - - - M D Q - S N - - N 1099 Phage- MDWCPRH
[1379] 0.073 0.478 0.110 57 RWVDCFY - - - - - - H - - - - - - Y 1100 Phage- MHWCPID
[1380] 0.074 0.287 0.077 58 RWADCFN - H - - - I D - - A - - - N 1101 Phage- MDWCPRD
[1381] 0.073 2.446 0.147 59 SWHLCFA - - - - - - D s - H L - - A 1102 Phage- MDWCPRT
[1382] 0.508 2.593 1.198 60 LWYLCFN - - - - - - T L - Y L - - N 1103 Phage- MVSCPTT
[1383] 0.079 1.329 0.072 61 MWNRCFN - V s - - T T M - N R - - N 1104 Phage- MDWCPSY
[1384] 0.065 1.995 0.133 62 LWNECFF - - - - - S Y L - N E - - - 1105 Phage- MDWCPRA
[1385] 0.068 2.676 0.339 64 LWAECFN - - - - - - A L - A E - - N 1106 Phage- MDWCPMY
[1386] 0.064 2.609 0.471 65 LWNECFN - - - - - M Y L - N E - - N 1107 Phage- MDWCPRY
[1387] 0.079 2.537 0.358 66 LWNECFY - - - - - - Y L - N E - - Y 1108 Phage- MNWCPTA
[1388] 0.067 1.644 0.169 67 LWHVCFN - N - - - T A L - H V - - N 1109 Phage- MDWCPMY
[1389] 0.080 2.479 0.358 68 MWYECFA - - - - - M Y M - Y E - - A 1110 Phage- MDWCPIH
[1390] 0.065 2.457 0.143 69 MWADCFA - - - - - I H M - A - - - A 1111 Phage- ITWCPSSM
[1391] 0.065 0.379 0.110 70 WNRCFI I T - - - S S M - N R - - I 1112 Phage- MDWCPRY
[1392] 0.071 2.628 0.429 71 LWHECFA - - - - - - Y L - H E - - A 1113 Phage- MFWCPTT
[1393] 0.111 0.662 0.338 72 MWNRCFT - F - - - T T M - N R - - T 1114 Phage- MDWCPRA
[1394] 0.071 2.686 0.401 73 LWHECFN - - - - - - A L - H E - - N 1115 Phage- MDWCPRD
[1395] 0.097 2.707 1.023 74 MWLFCYN - - - - - - D M - L F - Y N 1116
[1396]
[1397] WSGR Docket No. 52426-781.601
[1398] Phage- MDWCPRS
[1399] 0.072 1.951 0.281 75 HWHVCYN - - - - - - s H - H V - Y N 1117 Phage- MDWCPRY
[1400] 0.084 2.727 1.530 76 LWSDCFA - - - - - - Y L - S - - - A 1118 Phage- MDWCPFY
[1401] 0.092 2.672 0.291 77 LWDECFN - - - - - F Y L - D E - - N 1119 Phage- MDWCPRH
[1402] 0.070 2.654 0.704 78 LWHECFN - - - - - - H L - H E - - N 1120 Phage- MDWCPRD
[1403] 0.066 2.649 0.382 79 LWHECFS - - - - - - D L - H E - - S 1121 Phage- MDWCPMY
[1404] 0.071 2.641 0.411 80 LWNECFS - - - - - M Y L - N E - - S 1122 Phage- MDWCPRF
[1405] 0.515 2.637 1.151 81 LWSVCFN - - - - - - F L - S V - - N 1123 Phage- MDWCPRD
[1406] 0.060 2.634 0.151 82 LWTECFA - - - - - - D L - T E - - A 1124 Phage- MDWCPRF
[1407] 0.065 2.629 0.483 83 LWDECFN - - - - - - F L - D E - - N 1125 Phage- MDWCPKY
[1408] 0.184 2.622 0.826 84 LWSVCFF - - - - - K Y L - S V - - - 1126 Phage- MDWCPMD
[1409] 0.063 2.617 0.187 85 LWYQCFN - - - - - M D L - Y Q - - N 1127 Phage- MDWCPRH
[1410] 0.066 2.611 0.292 86 LWAECFF - - - - - - H L - A E - - - 1128 Phage- MDWCPKD
[1411] 0.200 2.608 0.213 87 LWYLCFA - - - - - K D L - Y L - - A 1129 Phage- MDWCPIH
[1412] 0.078 2.602 0.453 88 LWHYCFN - - - - - I H L - H Y - - N 1130 Phage- MDWCPRA
[1413] 0.065 2.598 0.472 89 LWNVCFN - - - - - - A L - N V - - N 1131 Phage- MDWCPID
[1414] 0.062 2.590 0.488 90 LWHLCFY - - - - - I D L - H L - - Y 1132 Phage- MDWCPRD
[1415] 0.060 2.587 0.424 91 LWFLCYN - - - - - - D L - F L - Y N 1133 Phage- MDWCPRH
[1416] 0.364 2.583 0.373 92 LWHECFF - - - - - - H L - H E - - - 1134 Phage- MDWCPRY
[1417] 0.115 2.582 0.372 93 LWTVCFS - - - - - - Y L - T V - - s 1135 Phage- MDWCPRD
[1418] 0.065 2.573 0.246 94 LWSLCFY - - - - - - D L - S L - - Y 1136 Phage- MDWCPRF
[1419] 0.062 2.571 0.227 95 LWSECFN - - - - - - F L - S E - - N 1137 Phage- MDWCPRT
[1420] 0.070 2.571 0.584 96 LWAYCFN - - - - - - T L - A Y - - N 1138 Phage- MDWCPKD
[1421] 0.078 2.568 0.165 97 LWDYCFA - - - - - K D L - D Y - - A 1139 Phage- MDWCPKY
[1422] 0.096 2.566 0.422 98 LWDVCFN - - - - - K Y L - D V - - N 1140 Phage- MDWCPRY
[1423] 0.114 2.564 0.404 99 LWNMCFH - - - - - - Y L - N M - - H 1141
[1424]
[1425] WSGR Docket No. 52426-781.601
[1426] Phage- MDWCPRY
[1427] 0.062 2.560 0.549 100 LWTECFN - - - - - - Y L - T E - - N 1142 Phage- MDWCPRS
[1428] 0.140 2.552 0.338 101 LWHYCFA - - - - - - S L - H Y - - A 1143 Phage- MDWCPRY
[1429] 0.063 2.552 0.354 102 LWAECFY - - - - - - Y L - A E - - Y 1144 Phage- MDWCPRD
[1430] 0.074 2.552 0.218 103 LWHECFN - - - - - - D L - H E - - N 1145 Phage- MDWCPRD
[1431] 0.076 2.549 0.156 104 LWDLCFF - - - - - - D L - D L - - - 1146 Phage- MDWCPRY
[1432] 0.087 2.546 0.570 105 LWNVCFN - - - - - - Y L - N V - - N 1147 Phage- MDWCPIY
[1433] 0.061 2.546 0.215 106 LWDECFN - - - - - I Y L - D E - - N 1148 Phage- MDWCPRD
[1434] 0.061 2.537 0.207 107 LWAECFN - - - - - - D L - A E - - N 1149 Phage- MDWCPRA
[1435] 0.075 2.536 0.191 108 LWHECFT - - - - - - A L - H E - - T 1150 Phage- MDWCPKN
[1436] 0.081 2.530 0.248 109 LWHVCFN - - - - - K N L - H V - - N 1151 Phage- MDWCPRY
[1437] 0.069 2.529 0.283 110 LWDECFN - - - - - - Y L - D E - - N 1152 Phage- MDWCPFY
[1438] 0.099 2.528 0.594 111 LWNECFY - - - - - F Y L - N E - - Y 1153 Phage- MHWCPRA
[1439] 0.077 2.528 0.240 112 LWDVCYN - H - - - - A L - D V - Y N 1154 Phage- MDWCPRD
[1440] 0.164 2.520 0.137 113 LWNVCFF - - - - - - D L - N V - - - 1155 Phage- MDWCPRY
[1441] 0.066 2.504 0.210 114 LWFECFA - - - - - - Y L - F E - - A 1156 Phage- MDWCPRY
[1442] 0.105 2.490 0.421 115 LWHECFN - - - - - - Y L - H E - - N 1157 Phage- MDWCPRD
[1443] 0.072 2.474 0.242 116 LWYACFA - - - - - - D L - Y A - - A 1158 Phage- MDWCPRY
[1444] 0.079 2.462 0.235 117 LWFECFS - - - - - - Y L - F E - - S 1159 Phage- MDWCPRH
[1445] 0.074 2.459 0.663 118 LWDECFF - - - - - - H L - D E - - - 1160 Phage- MDWCPRY
[1446] 0.129 2.419 1.166 119 LWHMCYS - - - - - - Y L - H M - Y s 1161 Phage- MDWCPRD
[1447] 0.074 2.414 0.173 120 LWHACFS - - - - - - D L - H A - - s 1162 Phage- MDWCPRD
[1448] 0.068 2.412 0.268 121 LWHVCFF - - - - - - D L - H V - - - 1163 Phage- MDWCPRD
[1449] 0.059 2.406 0.201 122 LWDQCYA - - - - - - D L - D Q - Y A 1164 Phage- MDWCPIH
[1450] 0.104 2.405 0.203 123 LWNECFA - - - - - I H L - N E - - A 1165 Phage- MDWCPRP
[1451] 0.063 2.403 0.138 124 LWDMCFF - - - - - - P L - D M - - - 1166
[1452]
[1453] WSGR Docket No. 52426-781.601
[1454] Phage- MDWCPVS
[1455] 0.107 2.401 0.409 125 LWHVCFY - - - - - V s L - H V - - Y 1167 Phage- MDWCPRF
[1456] 0.072 2.400 0.503 126 LWNECFN - - - - - - F L - N E - - N 1168 Phage- MDWCPRA
[1457] 0.080 2.385 0.375 127 LWNECFA - - - - - - A L - N E - - A 1169 Phage- MDWCPRD
[1458] 0.084 2.372 0.137 128 LWIECFF - - - - - - D L - I E - - - 1170 Phage- MDWCPSY
[1459] 0.062 2.340 0.096 129 LWTVCFA - - - - - s Y L - T V - - A 1171 Phage- MDWCPRY
[1460] 0.066 2.337 0.168 130 LWDACFF - - - - - - Y L - D A - - - 1172 Phage- MDWCPRS
[1461] 0.113 2.336 0.401 131 LWIYCFN - - - - - - S L - I Y - - N 1173 Phage- MDWCPTY
[1462] 0.205 2.329 0.224 132 LWFECFN - - - - - T Y L - F E - - N 1174 Phage- MDWCPRF
[1463] 0.064 2.284 0.246 133 LWDECFF - - - - - - F L - D E - - - 1175 Phage- MDWCPSY
[1464] 0.096 2.284 0.198 134 LWHECFA - - - - - s Y L - H E - - A 1176 Phage- MDWCPKF
[1465] 0.065 2.279 0.142 135 LWHECFS - - - - - K F L - H E - - S 1177 Phage- MHWCPIY
[1466] 0.071 2.234 0.193 136 LWDECFN - H - - - I Y L - D E - - N 1178 Phage- MDWCPRY
[1467] 0.101 2.193 0.308 137 LWHECFH - - - - - - Y L - H E - - H 1179 Phage- MDWCPTN
[1468] 0.061 2.163 0.096 138 LWHECFA - - - - - T N L - H E - - A 1180 Phage- MDWCPRD
[1469] 0.096 2.158 0.280 139 LWDVCFA - - - - - - D L - D V - - A 1181 Phage- MDWCPMD
[1470] 0.090 2.149 0.263 140 LWDVCFN - - - - - M D L - D V - - N 1182 Phage- MDWCPRS
[1471] 0.106 2.131 0.356 141 LWNVCFF - - - - - - S L - N V - - - 1183 Phage- MDWCPVI
[1472] 0.066 2.030 0.173 142 LWDFCFN - - - - - V I L - D F - - N 1184 Phage- LDWCPLN
[1473] 0.062 2.028 0.095 143 LWDLCYF L - - - - L N L - D L - Y - 1185 Phage- MDWCPRH
[1474] 0.061 2.012 0.159 144 LWYACFN - - - - - - H L - Y A - - N 1186 Phage- MDWCPKH
[1475] 0.065 1.977 0.132 145 LWIECFA - - - - - K H L - I E - - A 1187 Phage- MDWCPRH
[1476] 0.136 1.918 0.199 146 LWSECFY - - - - - - H L - S E - - Y 1188 Phage- MHWCPRD
[1477] 0.070 1.834 0.112 147 LWVVCFN - H - - - - D L - - V - - N 1189 Phage- MHWCPEY
[1478] 0.074 1.687 0.092 148 LWNECFA - H - - - E Y L - N E - - A 1190 Phage- MDWCPRD
[1479] 0.070 1.669 0.089 149 LWAVCFA - - - - - - D L - A V - - A 1191
[1480]
[1481] WSGR Docket No. 52426-781.601
[1482] Phage- MDWCPRH
[1483] 0.058 1.613 0.176 150 LWNVCFS - - - - - - H L - N V - - s 1192 Phage- MDFCPISL
[1484] 0.081 1.585 0.129 151 WHECFF - - F - - I S L - H E - - - 1193 Phage- MDWCPKY
[1485] 0.073 1.540 0.109 152 LWDKCFH - - - - - K Y L - D K - - H 1194 Phage- MDWCPRH
[1486] 0.093 1.395 0.182 153 LWDLCFF - - - - - - H L - D L - - - 1195 Phage- MDWCPRD
[1487] 0.114 1.382 0.145 154 LWNVCFA - - - - - - D L - N V - - A 1196 Phage- MHWCPLH
[1488] 0.063 1.370 0.113 155 LWNECYH - H - - - L H L - N E - Y H 1197 Phage- MDWCPKH
[1489] 0.058 1.351 0.108 156 LWHQCFH - - - - - K H L - H Q - - H 1198 Phage- MDWCPRS
[1490] 0.066 1.335 0.152 157 LWSYCFH - - - - - - S L - S Y - - H 1199 Phage- MDWCPRY
[1491] 0.110 1.265 0.244 158 LWTECFF - - - - - - Y L - T E - - - 1200 Phage- MAWCPMN
[1492] 0.070 1.202 0.145 159 LWDQCFF - A - - - M N L - D Q - - - 1201 Phage- MHWCPRA
[1493] 0.070 1.178 0.144 160 LWHECFN - H - - - - A L - H E - - N 1202 Phage- MDWCPRH
[1494] 0.150 1.122 0.144 161 LWDQCFA - - - - - - H L - D Q - - A 1203 Phage- MNWCPTD
[1495] 0.087 1.093 0.095 162 LWHECFN - N - - - T D L - H E - - N 1204 Phage- MFWCPRY
[1496] 0.086 1.078 0.175 163 LWHECFN - F - - - - Y L - H E - - N 1205 Phage- MDWCPKF
[1497] 0.100 1.075 0.139 164 LWDLCFA - - - - - K F L - D L - - A 1206 Phage- MDWCPFY
[1498] 0.070 1.024 0.141 165 LWDECFL - - - - - F Y L - D E - - L 1207 Phage- MDWCPRH
[1499] 0.061 0.925 0.096 166 LWDLCFA - - - - - - H L - D L - - A 1208 Phage- MSWCPQD
[1500] 0.095 0.860 0.112 167 LWHVCFN - s - - - Q D L - H V - - N 1209 Phage- MDWCPKD
[1501] 0.073 0.762 0.100 168 LWHECFN - - - - - K D L - H E - - N 1210 Phage- MDWCPRD
[1502] 0.100 0.740 0.108 169 LWNVCFN - - - - - - D L - N V - - N 1211 Phage- MNWCPSD
[1503] 0.071 0.739 0.131 170 LWHLCFN - N - - - s D L - H L - - N 1212 Phage- MNWCPSH
[1504] 0.195 0.702 0.192 171 LWHMCYF - N - - - s H L - H M - Y - 1213 Phage- MDWCPPY
[1505] 0.068 0.692 0.094 172 LWYECFA - - - - - p Y L - Y E - - A 1214 Phage- MDWCPMN
[1506] 0.168 0.670 0.124 173 LWSECFN - - - - - M N L - S E - - N 1215 Phage- MDWCPKH
[1507] 0.063 0.663 0.105 174 LWNECFN - - - - - K H L - N E - - N 1216
[1508]
[1509] WSGR Docket No. 52426-781.601
[1510] Phage- MDWCPAY
[1511] 0.082 0.640 0.120 175 LWAECFS - - - - - A Y L - A E - - s 1217 Phage- MDWCPSD
[1512] 0.075 0.629 0.164 176 LWHECFH - - - - - S D L - H E - - H 1218 Phage- MDWCPVS
[1513] 0.075 0.616 0.100 177 LWDHCFN - - - - - V S L - D H - - N 1219 Phage- LDWCPRD
[1514] 0.176 0.610 0.105 178 LWHVCFF L - - - - - D L - H V - - - 1220 Phage- MDWCPWI
[1515] 0.141 0.581 0.137 179 LWNECFN - - - - - w I L - N E - - N 1221 Phage- MHWCPRY
[1516] 0.132 0.550 0.127 180 LWDECFN - H - - - - Y L - D E - - N 1222 Phage- MYWCPRD
[1517] 0.145 0.512 0.102 181 LWDVCFN - Y - - - - D L - D V - - N 1223 Phage- MHWCPRS
[1518] 0.168 0.456 0.115 182 LWNECYF - H - - - - S L - N E - Y - 1224 Phage- IDWCPRDL
[1519] 0.127 0.370 0.129 183 WALCFN I - - - - - D L - A L - - N 1225 Phage- MHWCPIN
[1520] 0.081 0.316 0.098 184 LWNECFS - H - - - I N L - N E - - S 1226 Phage- MERCPRFL
[1521] 0.132 0.216 0.093 185 WNECFN - E R - - - F L - N E - - N 1227 Phage- QDWCPTY
[1522] 0.101 0.123 0.122 186 LWHHCFN Q - - - - T Y L - H H - - N 1228 Phage- IGKLTLCL
[1523] 0.274 0.116 0.100 187 NADLVI I G K L T L C L N A - L V I 1229 Phage- MDWCPSY
[1524] 0.100 0.083 0.079 188 LWDQCFF - - - - - S Y L - D Q - - - 1230 Phage- VDWCPRY
[1525] 0.064 0.065 0.061 189 LWHVCYN V - - - - - Y L - H V - Y N 1231 Phage- MDWCPRD
[1526] 0.099 2.687 2.259 190 MWAECFF - - - - - - D M - A E - - - 1232 Phage- MDWCPRD
[1527] 0.099 2.564 0.235 191 MWYECFN - - - - - - D M - Y E - - N 1233 Phage- DVWCPKY
[1528] 0.101 2.529 0.418 192 MWSLCFN D V - - - K Y M - S L - - N 1234 Phage- MDWCPMD
[1529] 0.059 2.516 0.277 193 MWVNCFN - - - - - M D M - - N - - N 1235 Phage- MDWCPSD
[1530] 0.062 2.474 0.200 194 MWHECYA - - - - - S D M - H E - Y A 1236 Phage- MDWCPKH
[1531] 0.101 2.395 0.372 195 MWFMCFN - - - - - K H M - F M - - N 1237 Phage- MDWCPRY
[1532] 0.079 2.364 0.357 196 MWYQCFS - - - - - - Y M - Y Q - - S 1238 Phage- MDWCPRH
[1533] 0.129 2.342 0.298 197 MWYECFF - - - - - - H M - Y E - - - 1239 Phage- MDWCPRA
[1534] 0.321 2.326 0.426 198 MWNHCFN - - - - - - A M - N H - - N 1240 Phage- MDWCPRN
[1535] 0.102 2.315 0.209 199 MWAQCFA - - - - - - N M - A Q - - A 1241
[1536]
[1537] WSGR Docket No. 52426-781.601
[1538] Phage- MFWCPFD
[1539] 0.150 2.292 0.469 200 MWHFCFN - F - - - F D M - H F - - N 1242 Phage- MDWCPRD
[1540] 0.072 2.292 0.119 201 MWDQCFD - - - - - - D M - D Q - - D 1243 Phage- MFWCPMD
[1541] 0.091 2.260 0.207 202 MWDQCFN - F - - - M D M - D Q - - N 1244 Phage- MSWCPRD
[1542] 0.065 2.248 0.174 203 MWFYCYA - S - - - - D M - F Y - Y A 1245 Phage- MDWCPRH
[1543] 0.067 2.245 0.130 204 MWNVCFS - - - - - - H M - N V - - S 1246 Phage- MDWCPTD
[1544] 0.061 2.201 0.126 205 MWHHCFL - - - - - T D M - H H - - L 1247 Phage- IHWCPINM
[1545] 0.060 2.080 0.203 206 WDKCYN I H - - - I N M - D K - Y N 1248 Phage- MDWCPRA
[1546] 0.069 1.915 0.129 207 MWHECFY - - - - - - A M - H E - - Y 1249 Phage- MDWCPTD
[1547] 0.363 1.495 0.172 208 MWIVCFA - - - - - T D M - I V - - A 1250 Phage- IDWCPQD
[1548] 0.069 1.416 0.160 209 MWFYCFN I - - - - Q D M - F Y - - N 1251 Phage- MDWCPRD
[1549] 0.076 1.310 0.143 210 MWFECFA - - - - - - D M - F E - - A 1252 Phage- MDWCPRN
[1550] 0.060 1.116 0.093 211 MWTVCFL - - - - - - N M - T V - - L 1253 Phage- MDWCPRA
[1551] 0.073 0.985 0.094 212 MWDKCFF - - - - - - A M - D K - - - 1254 Phage- MNWCPSY
[1552] 0.125 0.854 0.105 213 MWDQCFA - N - - - s Y M - D Q - - A 1255 Phage- MDWCPTY
[1553] 0.086 0.754 0.107 214 MWSECFN - - - - - T Y M - S E - - N 1256 Phage- MDWCPRY
[1554] 0.064 0.687 0.128 215 MWNECFN - - - - - - Y M - N E - - N 1257 Phage- MDWCPMN
[1555] 0.110 0.639 0.137 216 MWYQCFN - - - - - M N M - Y Q - - N 1258 MDWCPW
[1556] Phage- DMWDKCF 0.101 0.586 0.108 217 N - - - - - W D M - D K - - N 1259 Phage- TFGCPTTM
[1557] 0.117 0.181 0.068 218 WNRCFA T F G - - T T M - N R - - A 1260 Phage- NYWCPSS
[1558] 0.295 0.158 0.088 219 MWNRCLH N Y - - - S S M - N R - L H 1261 Phage- FDFCPTTM
[1559] 0.084 0.086 0.081 220 WTYCQH F - F - - T T M - T Y - Q H 1262 Phage- TTWCPTS
[1560] 0.096 0.074 0.072 221 MWLHCFD T T - - - T S M - L H - - D 1263 Phage- MDWCPRD
[1561] 0.075 0.200 0.078 222 QWHNCFN - - - - - - D Q - H N - - N 1264 Phage- MDWCPRD
[1562] 0.066 1.577 0.140 223 RWVDCFF - - - - - - D - - - - - - - 1265
[1563]
[1564] WSGR Docket No. 52426-781.601
[1565] Phage- MDWCPKD
[1566] 0.078 1.091 0.093 224 RWNDCYF - - - - - K D - - N - - Y - 1266 Phage- MDWCPRD
[1567] 0.069 0.392 0.089 225 RWADCFF - - - - - - D - - A - - - - 1267 Phage- MDWCPRD
[1568] 0.218 0.339 0.131 226 RWIDCFN - - - - - - D - - I - - - N 1268 Phage- MDWCPRD
[1569] 0.074 0.102 0.074 227 RWSDCFN - - - - - - D - - S - - - N 1269 Phage- ITWCHVIS
[1570] 0.076 0.193 0.100 228 GLECWN I T - - H V I s G L E - w N 1270 Phage- VPWCQIIS
[1571] 0.076 0.174 0.077 229 GLECLT V P - - Q I I s G L E - L T 1271 Phage- APWCQIIS
[1572] 0.080 0.169 0.078 230 GLECLT A P - - Q I I s G L E - L T 1272 Phage- VPWCLIIS
[1573] 0.455 0.107 0.090 231 GLDCLN V P - - L I I s G L - - L N 1273 Phage- MDWCARF
[1574] 0.948 0.065 0.074 232 VGYGCLD - - - - A - F V G Y G - L D 1274 Phage- MTWCPTSF
[1575] 0.142 0.392 0.405 233 WNRCLD - T - - - T S F - N R - L D 1275 Phage- MDWCPRA
[1576] 0.111 2.668 0.331 234 LWFECFF - - - - - - A L - F E - - - 1276 Phage- MDWCPRY
[1577] 0.063 2.654 0.303 235 LWHECFS - - - - - - Y L - H E - - s 1277 Phage- MDWCPRD
[1578] 0.084 2.639 0.436 236 LWNLCFF - - - - - - D L - N L - - - 1278 Phage- MDWCPSY
[1579] 0.067 2.606 0.447 237 LWHECFF - - - - - s Y L - H E - - - 1279 Phage- MDWCPPY
[1580] 0.539 2.604 0.234 238 LWSECFA - - - - - p Y L - S E - - A 1280 Phage- MDWCPRY
[1581] 0.187 2.603 0.409 239 LWHVCFN - - - - - - Y L - H V - - N 1281 Phage- MDWCPRT
[1582] 0.317 2.601 0.551 240 LWHVCFN - - - - - - T L - H V - - N 1282 Phage- MDWCPRH
[1583] 0.066 2.584 0.374 241 LWHECYS - - - - - - H L - H E - Y S 1283 Phage- MDWCPKH
[1584] 0.098 2.491 0.145 242 LWTECFA - - - - - K H L - T E - - A 1284 Phage- MDWCPRH
[1585] 0.063 2.414 0.167 243 LWYECFN - - - - - - H L - Y E - - N 1285 Phage- MDWCPRY
[1586] 0.071 2.066 0.177 244 LWHECFD - - - - - - Y L - H E - - D 1286 Phage- MDWCPRN
[1587] 0.082 1.397 0.164 245 LWHLCFA - - - - - - N L - H L - - A 1287 Phage- MDWCPKH
[1588] 0.075 1.161 0.092 246 LWNKCFN - - - - - K H L - N K - - N 1288 Phage- MDWCPRF
[1589] 0.073 2.603 0.341 247 MWAECFN - - - - - - F M - A E - - N 1289 Phage- MDWCPRN
[1590] 0.205 1.597 0.524 248 MWHHCFD - - - - - - N M - H H - - D 1290
[1591]
[1592] WSGR Docket No. 52426-781.601
[1593] Phage- MDWCPSD
[1594] 0.191 1.209 0.109 249 MWAHCYN - - - - - S D M - A H - Y N 1291 Phage- MDWCPKV
[1595] 0.136 1.138 0.252 250 MWHYCFA - - - - - K V M - H Y - - A 1292 Phage- MDWCPRF
[1596] 0.092 1.008 0.137 251 MWSECFS - - - - - - F M - S E - - S 1293 Phage- MDWCPRH
[1597] 0.091 0.920 0.165 252 MWINCFA - - - - - - H M - I N - - A 1294 Phage- MVGCATS
[1598] 0.256 0.770 0.746 253 MWNRCLT - V G - A T S M - N R - L T 1295 Phage- MDWCPRY
[1599] 0.078 2.705 0.513 254 LWSECFA - - - - - - Y L - S E - - A 1296 Phage- MDWCPRH
[1600] 0.064 2.649 0.825 255 LWSVCFN - - - - - - H L - S V - - N 1297 Phage- MDWCPFD
[1601] 0.089 2.602 0.651 256 LWHVCYN - - - - - F D L - H V - Y N 1298 Phage- MDWCPRF
[1602] 0.079 2.586 0.351 257 LWHECFN - - - - - - F L - H E - - N 1299 Phage- MDWCPRS
[1603] 0.098 2.412 0.238 258 LWHVCFN - - - - - - S L - H V - - N 1300 Phage- MDWCPRN
[1604] 0.071 1.571 0.112 259 LWHACFN - - - - - - N L - H A - - N 1301 Phage- MDWCPVF
[1605] 0.079 2.661 0.356 260 MWNECFN - - - - - V F M - N E - - N 1302 Phage- MDWCPMF
[1606] 0.102 2.235 1.045 261 MWHECFN - - - - - M F M - H E - - N 1303 Phage- MYWCATS
[1607] 0.248 0.398 0.415 262 MWNRCFV - Y - - A T S M - N R - - V 1304 Phage- MDWCPRH
[1608] 0.074 2.518 0.298 263 MWHECFA - - - - - - H M - H E - - A 1305 Phage- MDWCPRH
[1609] 0.070 2.667 0.636 264 LWHVCFN - - - - - - H L - H V - - N 1306 Phage- MDWCPRF
[1610] 0.270 2.638 0.725 265 MWDLCFA - - - - - - F M - D L - - A 1307 Phage- VTSCPTTM
[1611] 0.396 1.220 0.546 266 WNRCFS V T s - - T T M - N R - - S 1308 Phage- MTLCLSVD
[1612] 0.114 0.632 0.093 267 LVHCWY - T L - L S V D L - H - w Y 1309 Phage- DSFCTWSA
[1613] 0.072 0.130 0.101 269 WQECGR D S F - T W s A - Q E - G R 1310 Phage- MDWCPRD
[1614] 0.118 2.365 0.655 270 FWAFCFF - - - - - - D F - A F - - - 1311 Phage- MDWCPTS
[1615] 0.102 0.087 0.092 271 FWNRCFH - - - - - T S F - N R - - H 1312 Phage- MVWCMSV
[1616] 0.289 0.271 0.284 272 GWAVCLN - V - - M S V G - A V - L N 1313 Phage- IDWCPTAG
[1617] 0.071 0.136 0.075 273 WTYCWF I - - - - T A G - T Y - W 1314 Phage- WVSCLRH
[1618] 0.781 0.723 0.858 274 HWLECFH w V s - L - H H - L E - - H 1315
[1619]
[1620] WSGR Docket No. 52426-781.601
[1621] Phage- MDWCPRD
[1622] 0.172 0.671 0.092 275 HWVDCYS - - - - - - D H - - - - Y s 1316 Phage- IDWCPKIH
[1623] 0.072 0.295 0.082 276 WDLCYF I - - - - K I H - D L - Y - 1317 Phage- MDWCPRS
[1624] 0.080 0.253 0.087 277 HWSECFS - - - - - - S H - S E - - s 1318 Phage- MDWCPRSI
[1625] 0.383 2.548 1.337 278 WYLCFN - - - - - - S I - Y L - - N 1319 Phage- MDWCPRY
[1626] 0.068 2.742 1.141 279 LWAECFN - - - - - - Y L - A E - - N 1320 Phage- MDWCPRY
[1627] 0.073 2.709 0.382 280 LWDYCFA - - - - - - Y L - D Y - - A 1321 Phage- MDWCPRS
[1628] 1.110 2.709 1.774 281 LWFLCFN - - - - - - S L - F L - - N 1322 Phage- MDWCPRD
[1629] 0.060 2.658 0.794 282 LWFACFA - - - - - - D L - F A - - A 1323 Phage- MDWCPRH
[1630] 0.079 2.650 0.393 283 LWNECFN - - - - - - H L - N E - - N 1324 Phage- MDWCPRF
[1631] 2.091 2.643 2.480 284 LWHVCFS - - - - - - F L - H V - - S 1325 Phage- MDWCPRD
[1632] 0.071 2.627 0.889 285 LWAMCFA - - - - - - D L - A M - - A 1326 Phage- MERCPRYL
[1633] 0.164 2.589 0.840 286 WHMCYS - E R - - - Y L - H M - Y S 1327 Phage- MDWCPIA
[1634] 0.073 2.522 0.492 288 LWDFCFA - - - - - I A L - D F - - A 1328 Phage- MDWCPRY
[1635] 0.070 2.513 0.280 289 LWNVCFA - - - - - - Y L - N V - - A 1329 Phage- MDWCPRD
[1636] 0.090 2.505 0.116 290 LWSVCFS - - - - - - D L - S V - - S 1330 Phage- MDWCPRY
[1637] 0.227 2.498 1.137 291 LWHVCFY - - - - - - Y L - H V - - Y 1331 Phage- MDWCPRA
[1638] 0.081 2.492 0.394 292 LWDHCFF - - - - - - A L - D H - - - 1332 Phage- MDWCPRH
[1639] 0.064 2.489 0.171 293 LWFECFN - - - - - - H L - F E - - N 1333 Phage- MDWCPRS
[1640] 0.115 2.488 0.235 294 LWDYCFA - - - - - - S L - D Y - - A 1334 Phage- MDWCPRH
[1641] 0.074 2.482 0.243 297 LWTECFS - - - - - - H L - T E - - S 1335 Phage- MDWCPLY
[1642] 0.094 2.476 0.193 298 LWAECFN - - - - - L Y L - A E - - N 1336 Phage- MDWCPIY
[1643] 0.078 2.453 0.307 299 LWAECFN - - - - - I Y L - A E - - N 1337 Phage- MDWCPRH
[1644] 0.178 2.451 0.479 300 LWFECFF - - - - - - H L - F E - - - 1338 Phage- MDWCPRY
[1645] 0.082 2.450 0.682 301 LWHECFF - - - - - - Y L - H E - - - 1339 Phage- MDWCPRY
[1646] 0.068 2.445 0.310 302 LWHVCFD - - - - - - Y L - H V - - D 1340
[1647]
[1648] WSGR Docket No. 52426-781.601
[1649] Phage- MDWCPRY
[1650] 0.074 2.421 0.329 303 LWTECFS - - - - - - Y L - T E - - s 1341 Phage- MDWCPKF
[1651] 0.311 2.406 0.376 304 LWDECFA - - - - - K F L - D E - - A 1342 Phage- MDWCPRD
[1652] 0.080 2.401 0.174 305 LWTECFS - - - - - - D L - T E - - S 1343 Phage- MDWCPRH
[1653] 0.068 2.394 0.170 306 LWNECFA - - - - - - H L - N E - - A 1344 Phage- MDWCPRY
[1654] 0.179 2.392 0.602 307 LWPVCFH - - - - - - Y L - P V - - H 1345 Phage- MDWCPKS
[1655] 0.395 2.377 0.162 308 LWAECFN - - - - - K S L - A E - - N 1346 Phage- MDWCPMF
[1656] 0.170 2.375 0.591 309 LWHECFN - - - - - M F L - H E - - N 1347 Phage- MDWCPRD
[1657] 0.066 2.374 0.248 310 LWDECFN - - - - - - D L - D E - - N 1348 Phage- MDWCPRD
[1658] 0.069 2.353 0.609 311 LWYQCFN - - - - - - D L - Y Q - - N 1349 Phage- MDWCPRS
[1659] 0.076 2.350 0.209 313 LWNYCFN - - - - - - S L - N Y - - N 1350 Phage- MDWCPIH
[1660] 0.074 2.347 0.157 314 LWNECFN - - - - - I H L - N E - - N 1351 Phage- MDWCPTY
[1661] 0.089 2.324 0.160 315 LWHVCFS - - - - - T Y L - H V - - S 1352 Phage- MDWCPRS
[1662] 0.067 2.316 0.198 316 LWNYCFA - - - - - - S L - N Y - - A 1353 Phage- MDWCPRH
[1663] 0.103 2.297 0.320 317 LWHECFT - - - - - - H L - H E - - T 1354 Phage- MDWCPMF
[1664] 0.132 2.287 0.203 318 LWDECFN - - - - - M F L - D E - - N 1355 Phage- MSWCPRD
[1665] 0.077 2.265 0.319 319 LWHLCFF - s - - - - D L - H L - - - 1356 Phage- MDWCPTY
[1666] 0.120 2.244 0.606 320 LWNECFN - - - - - T Y L - N E - - N 1357 Phage- MDWCPRD
[1667] 0.095 2.221 0.138 321 LWYVCFA - - - - - - D L - Y V - - A 1358 Phage- MDWCPRH
[1668] 0.339 2.214 0.376 322 LWIECFN - - - - - - H L - I E - - N 1359 Phage- MDWCPTY
[1669] 0.085 2.211 0.132 323 LWNVCFA - - - - - T Y L - N V - - A 1360 Phage- MDWCPRH
[1670] 0.216 2.167 0.163 324 LWYECFS - - - - - - H L - Y E - - S 1361 Phage- MDWCPAY
[1671] 0.096 2.166 0.163 325 LWDECFA - - - - - A Y L - D E - - A 1362 Phage- MFWCPITL
[1672] 0.075 2.153 0.143 326 WNECFN - F - - - I T L - N E - - N 1363 Phage- MHWCPRD
[1673] 0.071 2.149 0.150 327 LWHVCFN - H - - - - D L - H V - - N 1364 Phage- MDWCPRA
[1674] 0.323 2.145 0.293 328 LWDHCFN - - - - - - A L - D H - - N 1365
[1675]
[1676] WSGR Docket No. 52426-781.601
[1677] Phage- MDWCPRA
[1678] 0.071 2.140 0.249 329 LWNVCFA - - - - - - A L - N V - - A 1366 Phage- MDWCPRF
[1679] 0.100 2.139 0.309 330 LWDVCFN - - - - - - F L - D V - - N 1367 Phage- MDWCPRH
[1680] 0.098 2.127 0.146 331 LWDECFY - - - - - - H L - D E - - Y 1368 Phage- IDWCPRAL
[1681] 0.269 2.103 0.164 332 WDACLA I - - - - - A L - D A - L A 1369 Phage- MDWCPTD
[1682] 0.078 2.071 0.154 333 LWHECFA - - - - - T D L - H E - - A 1370 Phage- MDWCPRY
[1683] 0.069 2.064 0.164 334 LWDECFS - - - - - - Y L - D E - - S 1371 Phage- MDWCPRF
[1684] 0.146 2.034 0.207 335 LWDYCFA - - - - - - F L - D Y - - A 1372 Phage- MDWCPRD
[1685] 0.139 2.026 0.390 336 LWNWCFN - - - - - - D L - N W - N 1373 Phage- MDWCPKP
[1686] 0.069 2.022 0.152 337 LWHVCFA - - - - - K P L - H V - - A 1374 Phage- MDWCPRF
[1687] 0.143 1.996 0.287 338 LWNECFY - - - - - - F L - N E - - Y 1375 Phage- MDWCPRT
[1688] 0.088 1.992 0.314 339 LWDQCFF - - - - - - T L - D Q - - - 1376 Phage- MSWCPIDL
[1689] 0.072 1.986 0.148 340 WSECFA - s - - - I D L - S E - - A 1377 Phage- MDWCPRH
[1690] 0.084 1.978 0.268 341 LWDECFN - - - - - - H L - D E - - N 1378 Phage- MDWCPRN
[1691] 0.067 1.965 0.175 342 LWHECFA - - - - - - N L - H E - - A 1379 Phage- MDWCPRD
[1692] 0.065 1.932 0.119 343 LWTQCFF - - - - - - D L - T Q - - - 1380 Phage- MDWCPRH
[1693] 0.096 1.914 0.173 344 LWVHCFS - - - - - - H L - - H - - s 1381 Phage- MDFCPRFL
[1694] 0.063 1.908 0.225 345 WHECFN - - F - - - F L - H E - - N 1382 Phage- MDWCPRH
[1695] 0.073 1.826 0.167 346 LWHACFS - - - - - - H L - H A - - S 1383 Phage- MDWCPLF
[1696] 0.116 1.819 0.264 347 LWDQCFN - - - - - L F L - D Q - - N 1384 MAWCPW
[1697] Phage- YLWDECF 0.200 1.810 0.267 348 N - A - - - W Y L - D E - - N 1385 Phage- LDWCPRH
[1698] 0.073 1.780 0.240 349 LWALCFN L - - - - - H L - A L - - N 1386 Phage- MDWCPWF
[1699] 0.158 1.774 0.279 350 LWNECFN - - - - - w F L - N E - - N 1387 Phage- MDWCPMN
[1700] 0.080 1.742 0.160 351 LWHECFA - - - - - M N L - H E - - A 1388 Phage- MDWCPIH
[1701] 0.080 1.734 0.203 352 LWYECFN - - - - - I H L - Y E - - N 1389
[1702]
[1703] WSGR Docket No. 52426-781.601
[1704] Phage- IDWCPLHL
[1705] 0.067 1.693 0.182 353 WHECYH I - - - - L H L - H E - Y H 1390 Phage- MDWCPRY
[1706] 0.083 1.685 0.368 354 LWLECFN - - - - - - Y L - L E - - N 1391 Phage- MDWCPMY
[1707] 0.082 1.652 0.178 356 LWDECFF - - - - - M Y L - D E - - - 1392 Phage- MDWCPRL
[1708] 0.071 1.601 0.109 357 LWHECFN - - - - - - L L - H E - - N 1393 Phage- MDWCPPH
[1709] 0.069 1.449 0.136 358 LWHECFF - - - - - p H L - H E - - - 1394 Phage- MDWCPRP
[1710] 0.063 1.439 0.138 359 LWHECFA - - - - - - P L - H E - - A 1395 Phage- MDWCPMF
[1711] 0.092 1.435 0.193 360 LWHECFS - - - - - M F L - H E - - S 1396 Phage- MHWCPRH
[1712] 0.165 1.430 0.478 361 LWSECFN - H - - - - H L - S E - - N 1397 Phage- MDWCPRIL
[1713] 0.064 1.391 0.174 362 WHECFS - - - - - - I L - H E - - S 1398 Phage- MNWCPMH
[1714] 0.087 1.390 0.140 363 LWAECFN - N - - - M H L - A E - - N 1399 Phage- MDWCPRS
[1715] 0.067 1.387 0.140 364 LWAQCFY - - - - - - S L - A Q - - Y 1400 Phage- MDWCPSY
[1716] 0.079 1.178 0.131 365 LWPVCFN - - - - - s Y L - P V - - N 1401 Phage- MHWCPLY
[1717] 0.153 1.159 0.376 366 LWDECFY - H - - - L Y L - D E - - Y 1402 Phage- MDWCPSF
[1718] 0.063 1.130 0.104 367 LWYECFN - - - - - S F L - Y E - - N 1403 Phage- MSWCPPY
[1719] 0.176 1.104 0.326 368 LWTVCYN - s - - - P Y L - T V - Y N 1404 Phage- MHWCPRD
[1720] 0.072 0.995 0.108 369 LWYECFA - H - - - - D L - Y E - - A 1405 Phage- MTWCPAY
[1721] 0.086 0.985 0.139 370 LWHECFN - T - - - A Y L - H E - - N 1406 Phage- MAWCPRY
[1722] 0.510 0.918 0.216 371 LWAECFF - A - - - - Y L - A E - - - 1407 Phage- MDWCPRY
[1723] 0.095 0.917 0.218 372 LWVDCFA - - - - - - Y L - - - - - A 1408 Phage- MDWCPRIL
[1724] 0.082 0.847 0.113 373 WSDCFN - - - - - - I L - s - - - N 1409 Phage- MAWCPLD
[1725] 0.079 0.770 0.141 374 LWDKCFY - A - - - L D L - D K - - Y 1410 Phage- MNWCPRA
[1726] 0.085 0.759 0.107 375 LWHECFL - N - - - - A L - H E - - L 1411 Phage- MDWCPRH
[1727] 0.109 0.757 0.207 376 LWTYCFH - - - - - - H L - T Y - - H 1412 Phage- MDWCPFD
[1728] 0.087 0.650 0.120 377 LWLECFN - - - - - F D L - L E - - N 1413 Phage- MHWCPLH
[1729] 0.065 0.575 0.083 378 LWNECFA - H - - - L H L - N E - - A 1414
[1730]
[1731] WSGR Docket No. 52426-781.601
[1732] Phage- MDWCPRN
[1733] 0.061 0.538 0.080 379 LWAECFS - - - - - - N L - A E - - s 1415 Phage- MDYCPSY
[1734] 0.065 0.470 0.090 380 LWHECFA - - Y - - s Y L - H E - - A 1416 Phage- MAWCPRIL
[1735] 0.113 0.322 0.129 381 WHQCFN - A - - - - I L - H Q - - N 1417 Phage- ITWCPTSL
[1736] 0.077 0.242 0.089 382 WNRCLV I T - - - T S L - N R - L V 1418 Phage- LAGCQRD
[1737] 0.068 0.229 0.116 383 LATVCVI L A G - Q - D L A T V - V I 1419 Phage- IMWCPTSL
[1738] 0.104 0.161 0.129 384 WNRCVT I M - - - T S L - N R - V T 1420 Phage- ILRCQMNL
[1739] 0.083 0.083 0.077 385 QDECLN I L R - Q M N L Q D E - L N 1421 Phage- NHWCPTT
[1740] 0.293 0.078 0.093 386 LWNRCVA N H - - - T T L - N R - V A 1422 Phage- MDWCPRH
[1741] 0.064 0.066 0.074 387 LWLECFN - - - - - - H L - L E - - N 1423 Phage- MDWCPRF
[1742] 2.200 2.621 2.539 388 MWNFCFF - - - - - - F M - N F - - - 1424 Phage- MDWCPSD
[1743] 0.110 2.621 0.316 389 MWANCFF - - - - - s D M - A N - - - 1425 Phage- IDWCPMH
[1744] 0.078 2.544 0.232 390 MWDFCYN I - - - - M H M - D F - Y N 1426 Phage- MDWCPFD
[1745] 0.063 2.532 0.215 391 MWADCFF - - - - - F D M - A - - - - 1427 Phage- LHWCPTS
[1746] 0.688 2.475 2.456 392 MWTYCYY L H - - - T S M - T Y - Y Y 1428 Phage- MDWCPRD
[1747] 0.069 2.422 0.778 393 MWFECFN - - - - - - D M - F E - - N 1429 Phage- MDWCPRY
[1748] 0.082 2.280 0.377 394 MWSDCFF - - - - - - Y M - S - - - - 1430 Phage- MDWCPKD
[1749] 0.083 2.106 0.457 395 MWAECFN - - - - - K D M - A E - - N 1431 Phage- TDWCPRD
[1750] 0.082 2.106 0.301 396 MWYLCFN T - - - - - D M - Y L - - N 1432 Phage- MDWCPRA
[1751] 0.123 2.106 0.339 397 MWDYCFY - - - - - - A M - D Y - - Y 1433 Phage- MDWCPRN
[1752] 0.095 2.099 0.430 398 MWNFCFF - - - - - - N M - N E - - - 1434 Phage- MDWCPRS
[1753] 0.332 2.019 0.142 399 MWDSCFN - - - - - - S M - D S - - N 1435 Phage- MHWCPTY
[1754] 0.070 1.839 0.161 400 MWSECFA - H - - - T Y M - S E - - A 1436 Phage- MDWCPLD
[1755] 0.085 1.837 0.169 401 MWVLCFA - - - - - L D M - - L - - A 1437 Phage- MDWCPRH
[1756] 0.067 1.815 0.171 402 MWHECFH - - - - - - H M - H E - - H 1438 Phage- MSWCPWD
[1757] 0.069 1.521 0.108 403 MWNECFA - s - - - w D M - N E - - A 1439
[1758]
[1759] WSGR Docket No. 52426-781.601
[1760] Phage- MDWCPRD
[1761] 0.100 1.414 0.179 404 MWTSCFN - - - - - - D M - T S - - N 1440 Phage- MDWCPMS
[1762] 0.102 1.412 0.160 405 MWAFCFD - - - - - M S M - A F - - D 1441 Phage- MNWCPID
[1763] 0.245 1.403 0.175 406 MWTECFN - N - - - I D M - T E - - N 1442 Phage- MNWCPIH
[1764] 0.085 1.373 0.133 407 MWNQCFA - N - - - I H M - N Q - - A 1443 Phage- MFWCPKD
[1765] 0.099 1.258 0.113 408 MWAECFA - F - - - K D M - A E - - A 1444 Phage- LHWCPITM
[1766] 0.229 1.212 0.516 409 WTYCYY L H - - - I T M - T Y - Y Y 1445 Phage- IDWCPRY
[1767] 0.098 1.178 0.164 410 MWHECFF I - - - - - Y M - H E - - - 1446 Phage- MSWCPRF
[1768] 0.081 1.111 0.246 411 MWHECFN - s - - - - F M - H E - - N 1447 Phage- QHWCPRD
[1769] 0.066 1.076 0.149 412 MWNDCYA Q H - - - - D M - N - - Y A 1448 Phage- MDWCPSD
[1770] 0.070 1.075 0.121 413 MWSNCFN - - - - - s D M - S N - - N 1449 Phage- LYWCPRD
[1771] 0.068 1.019 0.157 414 MWAYCYS L Y - - - - D M - A Y - Y S 1450 Phage- MDWCPMY
[1772] 0.099 0.987 0.168 415 MWHKCFH - - - - - M Y M - H K - - H 1451 Phage- MDWCPSN
[1773] 0.072 0.983 0.136 416 MWNECFF - - - - - S N M - N E - - - 1452 Phage- IYWCPTA
[1774] 0.086 0.817 0.073 417 MWNRCSA I Y - - - T A M - N R - s A 1453 Phage- MYWCPKY
[1775] 0.072 0.741 0.099 418 MWSECFA - Y - - - K Y M - S E - - A 1454 Phage- VDWCPAH
[1776] 0.208 0.664 0.085 419 MWNECYN V - - - - A H M - N E - Y N 1455 Phage- MFWCPST
[1777] 0.063 0.464 0.138 420 MWNRCFD - F - - - S T M - N R - - D 1456 Phage- TIFCPSTM
[1778] 0.138 0.262 0.085 421 WNRCWT T I F - - S T M - N R - w T 1457 Phage- MYWCPIN
[1779] 0.122 0.109 0.088 422 MWDYCYA - Y - - - I N M - D Y - Y A 1458 Phage- INLCPTPM
[1780] 0.119 0.103 0.101 423 WNRCWL I N L - - T P M - N R - W L 1459 Phage- ITQCPSTM
[1781] 0.067 0.098 0.108 424 WNRCSV I T Q - - S T M - N R - S V 1460 Phage- MDLCPTA
[1782] 0.063 0.097 0.084 425 MWNRCFY - - L - - T A M - N R - - Y 1461 Phage- MFLCPSA
[1783] 0.069 0.094 0.114 426 MWNRCFY - F L - - S A M - N R - - Y 1462 Phage- VILCPTTM
[1784] 0.100 0.072 0.084 427 WNRCFH V I L - - T T M - N R - - H 1463 Phage- MNWCPST
[1785] 0.067 0.065 0.070 428 MWNRCLT - N - - - S T M - N R - L T 1464
[1786]
[1787] WSGR Docket No. 52426-781.601
[1788] Phage- IHLCHWVP
[1789] 2.516 2.550 2.508 430 WIKCSH I H L - H w V P - I K - s H 1465 Phage- MAWCPAD
[1790] 0.076 1.845 0.456 431 QWHECFN - A - - - A D Q - H E - - N 1466 Phage- IDWCPIIQG
[1791] 0.058 0.368 0.065 432 LPCFA I - - - - I I Q G L P - - A 1467 Phage- MAWCPW
[1792] 0.073 0.071 0.078 433 AQFDECLA - A - - - W A Q F D E - L A 1468 Phage- IVWCPTTQ
[1793] 0.113 0.067 0.083 434 WNRCAT I V - - - T T Q - N R - A T 1469 Phage- MDWCPRD
[1794] 0.157 1.484 0.403 435 RWVDCYA - - - - - - D - - - - - Y A 1470 Phage- MDWCPRD
[1795] 0.063 1.351 0.080 436 RWADCFN - - - - - - D - - A - - - N 1471 Phage- MDWCPVD
[1796] 0.071 1.156 0.315 437 RWADCFN - - - - - V D - - A - - - N 1472 Phage- MDWCPMS
[1797] 0.071 1.000 0.115 438 RWAFCFD - - - - - M S - - A F - - D 1473 Phage- MDWCPRD
[1798] 0.073 0.924 0.096 439 RWDVCFA - - - - - - D - - D V - - A 1474 Phage- MDWCPRD
[1799] 0.106 0.911 0.132 440 RWVDCFN - - - - - - D - - - - - - N 1475 Phage- MDWCPRD
[1800] 0.114 0.899 0.183 441 RWDDCFF - - - - - - D - - D - - - - 1476 Phage- IYWCPIDR
[1801] 0.177 0.867 0.164 442 WNDCYN I Y - - - I D - - N - - Y N 1477 Phage- MDWCPMT
[1802] 0.081 0.671 0.078 443 RWNDCYF - - - - - M T - - N - - Y - 1478 Phage- VNQCTRY
[1803] 0.465 0.566 0.135 444 RWAECLN V N Q - T - Y - - A E - L N 1479 Phage- MDWCPRA
[1804] 0.097 0.497 0.138 445 RWHDCFF - - - - - - A - - H - - - - 1480 Phage- MDWCPRD
[1805] 0.069 0.450 0.077 446 RWDDCFN - - - - - - D - - D - - - N 1481 Phage- MDWCPRD
[1806] 0.073 0.074 0.073 447 RWDVCYY - - - - - - D - - D V - Y Y 1482 Phage- MAWCPW
[1807] 0.104 0.089 0.109 448 ASFDECLA - A - - - w A s F D E - L A 1483 Phage- MVDCPLIS
[1808] 0.246 0.070 0.076 449 FDECLA - V D - - L I s F D E - L A 1484 Phage- EDWCPTD
[1809] 0.100 0.711 0.157 450 VWPYCFS E - - - - T D V - P Y - - S 1485 Phage- MDWCPRF
[1810] 0.246 2.397 0.503 451 WWHECYA - - - - - - F w H E - Y A 1486 MDWCPRD
[1811] Phage- WWHMCF 0.100 2.115 0.243 452 N - - - - - - D w H M - - N 1487 Phage- MDWCPSD
[1812] 0.065 0.707 0.080 453 YWYVCFA - - - - - s D Y - Y V - - A 1488
[1813]
[1814] WSGR Docket No. 52426-781.601
[1815] Table 10. Phage Panning Results of Peptide-87 Library Sequences. (-) indicates the same amino acid position as in Peptide-87 corresponding position.
[1816] Amino add position sequence Phase binding ELISA
[1817] Anti- Anti- CD28 CD28 Fab
[1818] Fab Backgr (SEQ ID signal ound NOs:
[1819] in the signal 2358, SEQ Phage ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 prese 2359) nee of ID NO: signal CD28
[1820] Phage-466
[1821] Y C A G H A W Q Y I N K C L 0.06 0.64 0.07 989 Phage-454
[1822] w s C F Q I P F T C F Y F 0.18 1.44 0.27 977 Phage-455
[1823] w E c L K Y T E A N A C T Y 0.05 1.55 0.07 978 Phage-456
[1824] F M c L P Q N P H P L C F K 0.06 0.84 0.06 979 Phage-457
[1825] P D c Q T I L F K P W c V R 0.05 2.09 0.06 980 Phage-458
[1826] A D T Y F A G M E F 0.07 0.92 0.10 981 Phage-459
[1827] G Q Y P W A F D A M s P 0.05 2.38 0.07 982 Phage-460
[1828] W w D Y K L W V P T Q P 0.11 2.27 0.14 983 Phage-461
[1829] W w D Y R E W V P M T P 0.06 2.30 0.08 984 Phage-462
[1830] E H W s M A V G H A F 0.06 1.77 0.07 985 Phage-463
[1831] s p I N G 0.05 1.49 0.06 986 Phage-464 w w D Y K L W V p M T p 0.11 2.51 0.11 987 Phage-465
[1832] D w W M F E s p G R I 0.06 1.65 0.07 988 Phage-467
[1833] W w Y Y R E w V p M T p 0.06 1.85 0.07 989 Phage-468 w Y C s P s I V R C V L V 0.06 1.51 0.09 990 Phage-469
[1834] p D c H T I L F K P W c V R 0.07 1.00 0.06 991 Phage-470
[1835] w I c D K s G s I M L c R A 0.06 0.91 0.06 992 Phage-471
[1836] s A G s Y A W P Y 0.05 1.49 0.05 993 Phage-472
[1837] D p W L s G F s R P L L c 0.09 1.27 0.07 994 Phage-473
[1838] M s T I Q L W L K c 0.06 2.16 0.09 996 Phage-474
[1839] M P E V 0.07 0.22 0.06 997 Phage-475
[1840] T E E H Y V M 0.05 0.62 0.07 998 Phage-476
[1841] M s H E H w 0.06 0.87 0.07 999 Phage-477
[1842]
[1843] s H E L A E 0.05 0.86 0.06 1000WSGR Docket No. 52426-781.601
[1844] Phage-478
[1845] E s P E L 0.05 1.75 0.06 1019 Phage-479
[1846] E R P E L 0.06 1.27 0.06 1020 Phage-480
[1847] E E G I F W 0.05 2.07 0.06 1021 Phage-481
[1848] E L P E E 0.05 2.06 0.08 1022 Phage-482
[1849] E P E A 0.05 2.15 0.09 1023 Phage-483
[1850] E P E R 0.06 1.63 0.08 1024 Phage-484
[1851] E P E W 0.08 1.63 0.07 1025 Phage-485
[1852] E s Q E N W 0.05 1.41 0.07 1026 Phage-486
[1853] E L P E L G 0.06 1.23 0.08 1027 Phage-487
[1854] E L P E R E 0.06 1.96 0.07 1028 Phage-488
[1855] E L P E L A 0.06 2.34 0.10 1029 Phage-489
[1856] E S Q E L W 0.07 2.36 0.07 1030 Phage-490
[1857] E S s E Q 0.06 2.25 0.10 1031 Phage-491
[1858] H S H L Q V w F 0.06 2.31 0.07 1032 Phage-492
[1859] W s S p P F K Y 0.07 2.06 0.06 1033 Phage-493
[1860] E L p E R 0.08 2.38 0.17 1034 Phage-494
[1861] E L p E L E V 0.07 2.11 0.06 1035 Phage-495
[1862] E L p E Q 0.06 1.90 0.08 1036 Phage-496
[1863] E L p E w 0.09 2.32 0.09 1037 Phage-497
[1864] E p E G 0.10 2.10 0.07 1038 Phage-498 - - D - - s p I - M W - - - 0.08 2.47 0.09 1489 Phage-499 - - E - - - p E - M A - - - 0.07 2.47 0.08 1489 Phage-500 - - D - - L p - - M E - - - 0.06 2.47 0.11 1490 Phage-501 - - - - - - p E - M E - - - 0.06 2.45 0.09 1491 Phage-502 - - D - - s p E - M W - - - 0.07 2.44 0.09
[1865] 1492 Phage-503 - - D - - L p E - M E - - - 0.08 2.44 0.10
[1866] 1493 Phage-504 - - E - - L p - - M W - - - 0.11 2.44 0.17
[1867] 1494 Phage-505 - - D - - L p E - M - - - - 0.06 2.43 0.13
[1868] 1495 Phage-506 - - - - - L p E - M D - - - 0.07 2.42 0.12 1496 Phage-507 - - D - - S A E H M A - - - 0.07 2.41 0.08 1497 Phage-508 - - - - - L P - - M A - - - 0.07 2.41 0.17 1498 Phage-509 - - E - - L P E - M A - - - 0.07 2.41 0.14 1499 Phage-510 - - E - - L P E - M F - - - 0.10 2.40 0.12
[1869] 1500 Phage-511 - - D - - L P - - M A Q - - 0.06 2.40 0.20
[1870] 1501 Phage-512 - - E - - L P - - M Q - - - 0.06 2.39 0.12
[1871]
[1872] 1502WSGR Docket No. 52426-781.601
[1873] Phage-513 - - D - - - p E - M M - - - 0.10 2.39 0.09
[1874] 1503 Phage-514 - - E - - L p E - M W - - - 0.07 2.39 0.08
[1875] 1504 Phage-515 - - E - - - A E - M A - - - 0.07 2.38 0.08
[1876] 1505 Phage-516 - - D - - L P E - L A - - - 0.08 2.38 0.11 1506 Phage-517 - - - - - M P E - M A - - - 0.10 2.38 0.11 1507 Phage-518 - - D - - L P E - M S - - M 0.10 2.38 0.14 1508 Phage-519 - - E - - T A E - M Q - - - 0.08 2.38 0.08 1509 Phage-520 - - M - - - P E - M A - - - 0.11 2.38 0.09
[1877] 1510 Phage-521 - - D - - L P E - M A - - - 0.07 2.37 0.13
[1878] 1511 Phage-522 - - D - - S - E - - G - - - 0.08 2.37 0.07
[1879] 1512 Phage-523 - - D - - L p E - Q E - - - 0.06 2.37 0.10
[1880] 1513 Phage-524 - - - - - L p - - M S - - - 0.06 2.37 0.11 1514 Phage-525 - - D - - L p I - M S Q - - 0.07 2.36 0.12 1515 Phage-526 - - E - - S p E - M A - - - 0.06 2.35 0.07 1516 Phage-527 - - D - - L p E - M S - - - 0.07 2.35 0.14 1517 Phage-528 - - D - - L p - - M A - - - 0.07 2.35 0.15
[1881] 1518 Phage-529 - - Q - - L p M - M A - - - 0.06 2.34 0.08
[1882] 1519 Phage-530 - - D - - L p E - M M - - - 0.07 2.34 0.11
[1883] 1520 Phage-531 - - D - - S p M - - L - - - 0.07 2.34 0.08
[1884] 1521 Phage-532 - - Q - - L p M - M E - - - 0.09 2.34 0.09 1522 Phage-533 - - E - - L p - - M A - - - 0.07 2.34 0.14 1523 Phage-534 - - D - - S p L - M W - - - 0.06 2.34 0.08 1524 Phage-535 - - D - - L p M - M Q - - - 0.06 2.33 0.11 1525 Phage-536 - - D - - L p I - M s - - - 0.07 2.32 0.08
[1885] 1526 Phage-537 - - E - - S - A N L G - - - 0.07 2.32 0.08
[1886] 1527 Phage-538 - - D - - L p E - R E - - F 0.07 2.32 0.07
[1887] 1528 Phage-539 - - E - - L p E - M L - - - 0.06 2.32 0.09
[1888] 1529 Phage-540 - - D - - E p - - M L - - - 0.09 2.32 0.12 1530 Phage-541 - - E - - S p E - M S - - - 0.07 2.31 0.07 1531 Phage-542 - - E - - T M E - M W - - - 0.06 2.31 0.07 1532 Phage-543 - - - - - L P E - M P H - I 0.07 2.31 0.09 1533 Phage-544 - - D - - S P - - - E - - - 0.07 2.31 0.07
[1889] 1534 Phage-545 - - D - - S P E - - L - - - 0.06 2.31 0.09
[1890] 1535 Phage-546 - - D - - L D E - M A - - - 0.07 2.31 0.08
[1891] 1536 Phage-547 - - D - - T L E - M W - - - 0.07 2.31 0.13
[1892] 1537 Phage-548 - - E - - L P L - M W - - - 0.07 2.30 0.07 1538 Phage-549 - - D - - - P E - M A - - - 0.07 2.30 0.09 1539 Phage-550 - - - - - s P E H M W - - - 0.06 2.30 0.06
[1893]
[1894] 1540WSGR Docket No. 52426-781.601
[1895] Phage-551 - - E - - s E E - - S - - - 0.07 2.30 0.08
[1896] 1541 Phage-552 - - D - - L P I - M A - - - 0.07 2.30 0.14
[1897] 1542 Phage-553 - - D - - - P - - M R - - - 0.05 2.30 0.07
[1898] 1543 Phage-554 - - D - - - K E - M W - - - 0.07 2.30 0.07 1544 Phage-555 - - E - - s S E - M L - - - 0.06 2.30 0.07 1545 Phage-556 - - E - - - A E - M E - - - 0.07 2.30 0.11 1546 Phage-557 - - E - - s A - - M S - - - 0.07 2.29 0.07 1547 Phage-558 - - D - - s R E - - A - - - 0.06 2.29 0.08
[1899] 1548 Phage-559 - - D - - L P - - M W - - - 0.07 2.29 0.12
[1900] 1549 Phage-560 - - D - - V P E - M A - - - 0.08 2.29 0.07
[1901] 1550 Phage-561 - - D - - L P M - M M - - - 0.07 2.28 0.14
[1902] 1551 Phage-562 - - Q - - - P E - M A - - - 0.08 2.28 0.10 1552 Phage-563 - - D - - s Q E - M M - - - 0.06 2.28 0.06 1553 Phage-564 - - S - - L p - - M Q - - - 0.06 2.28 0.08 1554 Phage-565 - - D - - S s E - M A - - - 0.07 2.28 0.09 1555 Phage-566 - - D - - - p - - M Q - - - 0.07 2.28 0.11
[1903] 1556 Phage-567 - - E - - L p I - L E - - M 0.06 2.27 0.10
[1904] 1557 Phage-568 - - E - - T p E - M Q - - - 0.07 2.27 0.07
[1905] 1558 Phage-569 - - D - - L p - - M M - - - 0.07 2.27 0.14
[1906] 1559 Phage-570 - - D - - S T E - L w - - - 0.06 2.26 0.06 1560 Phage-571 - - E - - L G I - M Y - - - 0.07 2.26 0.14 1561 Phage-572 - - D - - - A E - M A - - - 0.07 2.26 0.13 1562 Phage-573 - - E - - s Q E - M S - - - 0.07 2.26 0.07 1563 Phage-574 - - D - - L P E - L W - - - 0.07 2.26 0.13
[1907] 1564 Phage-575 - - E - - L P M - M E - - - 0.07 2.25 0.10
[1908] 1565 Phage-576 - - D - - L s E - M E - - - 0.07 2.25 0.08
[1909] 1566 Phage-577 - - E - - S p L - M W - - - 0.06 2.25 0.06
[1910] 1567 Phage-578 - - E - - S p E - M E - - - 0.06 2.24 0.07 1568 Phage-579 - - - - - L p E - M E - - - 0.08 2.24 0.12 1569 Phage-580 - - E - - - - E - M A - - - 0.09 2.24 0.07 1570 Phage-581 - - Q - - L p E - M - - - - 0.06 2.24 0.08 1571 Phage-582 - - D - - S Q E - M A - - - 0.05 2.24 0.08
[1911] 1572 Phage-583 - - Q - - L P I - M E - - - 0.06 2.24 0.09
[1912] 1573 Phage-584 - - D - - L P L - L A - - - 0.05 2.23 0.09
[1913] 1574 Phage-585 - - D - - L P - - M - - - - 0.05 2.23 0.10
[1914] 1575 Phage-586 - - E - - - P M - M w - - - 0.06 2.23 0.08 1576 Phage-587 - - E - - L P E - M Q - - M 0.06 2.23 0.08 1577 Phage-588 - - D - - S A E - M A - - - 0.08 2.23 0.07
[1915]
[1916] 1578WSGR Docket No. 52426-781.601
[1917] Phage-589 - - E - - s P E - M Y - - - 0.06 2.23 0.10
[1918] 1579 Phage-590 - - D - - s M E - M S - - - 0.08 2.22 0.09
[1919] 1580 Phage-591 - - E - - L P M - M D - - - 0.06 2.22 0.07
[1920] 1581 Phage-592 - - D - - R G E - L Q - - - 0.07 2.22 0.09 1582 Phage-593 - - E - - S P - - M w - - - 0.08 2.22 0.12 1583 Phage-594 - - E - - - A E - M T - - - 0.07 2.22 0.08 1584 Phage-595 - - E - - L P - - M K - - - 0.08 2.22 0.10 1585 Phage-596 - - D - - I E E - R A - - - 0.06 2.21 0.07
[1921] 1586 Phage-597 - - E - - - P E - M L - - - 0.06 2.21 0.07
[1922] 1587 Phage-598 - - D - - - P E - M E - - M 0.08 2.21 0.07
[1923] 1588 Phage-599 - - E - - T V E - M A - - - 0.08 2.20 0.08
[1924] 1589 Phage-600 - - D - - K A E - M D - - - 0.07 2.20 0.07 1590 Phage-601 - - D - - - P E - M L - - - 0.05 2.20 0.07 1591 Phage-602 - - D - - - P D - M L - - - 0.05 2.20 0.09 1592 Phage-603 - - D - - L P E - L P - - - 0.07 2.19 0.09 1593 Phage-604 - - D - - M P E - - A - - - 0.07 2.19 0.08
[1925] 1594 Phage-605 - - D - - L P E - L S - - - 0.07 2.19 0.07
[1926] 1595 Phage-606 - - - - - L P E - F L - - - 0.07 2.19 0.08
[1927] 1596 Phage-607 - - D - - S P L - - W - - - 0.07 2.19 0.09
[1928] 1597 Phage-608 - - D - - L P E - M H - - - 0.05 2.19 0.09 1598 Phage-609 - - D - - L P E - - E - - - 0.06 2.19 0.07 1599 Phage-610 - - D - - L P - - K A - - - 0.07 2.19 0.09 1600 Phage-611 - - D - - - V E - M A - - - 0.07 2.18 0.10 1601 Phage-612 - - D - - s I E - R W - - - 0.06 2.18 0.06
[1929] 1602 Phage-613 - - E - - - E E - M Q - - - 0.06 2.18 0.06
[1930] 1603 Phage-614 - - D - - - P E - - Y - - - 0.06 2.18 0.06
[1931] 1604 Phage-615 - - D - - L E E - K Q - - - 0.07 2.18 0.08
[1932] 1605 Phage-616 - - M - - L P - - M Q - - - 0.09 2.18 0.11 1606 Phage-617 - - D - - T Q E - - A - - - 0.05 2.17 0.06 1607 Phage-618 - - D - - T Q E - M A - - - 0.08 2.17 0.07 1608 Phage-619 - - E - - L P V - M W - - - 0.07 2.17 0.09 1609 Phage-620 - - D - - M P E - M W - - - 0.07 2.17 0.09
[1933] 1610 Phage-621 - - - - - S P E - M T - - - 0.05 2.17 0.09
[1934] 1611 Phage-622 - - - - - - P E - - Q - - - 0.06 2.17 0.09
[1935] 1612 Phage-623 - - D - - V A E - R D - - - 0.09 2.17 0.07
[1936] 1613 Phage-624 - - - - - - P E - M Q - - - 0.06 2.16 0.07 1614 Phage-625 - - D - - s N E - M A - - - 0.06 2.16 0.07 1615 Phage-626 - - E - - L P - - L Q - - - 0.07 2.16 0.09
[1937]
[1938] 1616WSGR Docket No. 52426-781.601
[1939] Phage-627 - - D - - V A E - M A - - - 0.15 2.16 0.07
[1940] 1617 Phage-628 - - D - - L P E - M W - - I 0.07 2.15 0.07
[1941] 1618 Phage-629 - - D - - S A E - M W - - - 0.06 2.15 0.08
[1942] 1619 Phage-630 - - D - - S L E - M A - - - 0.05 2.15 0.06 1620 Phage-631 - - E - - L P E - M S - - - 0.06 2.15 0.07 1621 Phage-632 - - - - - L P E - M Q - - - 0.17 2.15 0.09 1622 Phage-633 - - D - - L G I - M w - - - 0.06 2.14 0.08 1623 Phage-634 - - E - - S A E - M A - - - 0.05 2.14 0.06
[1943] 1624 Phage-635 - - D - - S D E - M A - - - 0.06 2.14 0.07
[1944] 1625 Phage-636 - - E - - S L E - - G - - - 0.06 2.14 0.06
[1945] 1626 Phage-637 - - D - - Q P E - M A - - - 0.07 2.14 0.07
[1946] 1627 Phage-638 - - - - - L P E - - S - - - 0.06 2.14 0.08 1628 Phage-639 - - D - - I P I - M S - - - 0.07 2.13 0.08 1629 Phage-640 - - E - - L P - - L A - - - 0.07 2.12 0.10 1630 Phage-641 - - - - - L P L - M E - - - 0.06 2.12 0.06 1631 Phage-642 - - D - - S A E - M M - - - 0.08 2.12 0.08
[1947] 1632 Phage-643 - - E - - L P - - - P - - - 0.07 2.12 0.07
[1948] 1633 Phage-644 - - D - - - P - - M L - - - 0.07 2.12 0.09
[1949] 1634 Phage-645 - - D - - L P V - M A - - - 0.07 2.11 0.09
[1950] 1635 Phage-646 - - M - - S E E - M Q - - - 0.07 2.11 0.07 1636 Phage-647 - - D - - L P E - M H - - - 0.08 2.11 0.11 1637 Phage-648 - - D - - L E E - M A - - - 0.07 2.11 0.09 1638 Phage-649 - - D - - M P E - M L - - - 0.07 2.11 0.09 1639 Phage-650 - - S - - - P I - M A - - - 0.08 2.10 0.07
[1951] 1640 Phage-651 - - - - - T Q E - M S - - - 0.06 2.10 0.05
[1952] 1641 Phage-652 - - E - - S P - - M Q - - - 0.06 2.10 0.06
[1953] 1642 Phage-653 - - D - - V P - - M A - - - 0.08 2.10 0.07
[1954] 1643 Phage-654 - - D - - s A E - M S - - - 0.06 2.10 0.06 1644 Phage-655 - - Q - - L P - - - A - - - 0.06 2.09 0.08 1645 Phage-656 - - - - - L P - - M E - - M 0.06 2.09 0.08 1646 Phage-657 - - - - - L P E H - G - - - 0.05 2.09 0.07 1647 Phage-658 - - E - - T A E - L Q - - - 0.07 2.09 0.10
[1955] 1648 Phage-659 - - - - - S P E - M G - - M 0.07 2.09 0.06
[1956] 1649 Phage-660 - - s - - L P E - M E - - - 0.08 2.09 0.09
[1957] 1650 Phage-661 - - - - - L E I - M Q - - - 0.07 2.09 0.08
[1958] 1651 Phage-662 - - M - - L P - - M E - - - 0.06 2.08 0.08 1652 Phage-663 - - E - - S A E - M W - - - 0.06 2.08 0.09 1653 Phage-664 - - E - - - P E H M A - - - 0.08 2.08 0.10
[1959]
[1960] 1654WSGR Docket No. 52426-781.601
[1961] Phage-665 - - D - - - E - - M E - - - 0.06 2.08 0.07
[1962] 1655 Phage-666 - - E - - s P E - M S H - F 0.06 2.08 0.09
[1963] 1656 Phage-667 - - E - - s M - H M A - - - 0.06 2.07 0.08
[1964] 1657 Phage-668 - - D - - - Q E F M S - - - 0.07 2.07 0.12 1658 Phage-669 - - - - - L P E - - D - - - 0.06 2.07 0.08 1659 Phage-670 - - E - - - P - - - Q - - - 0.06 2.07 0.07 1660 Phage-671 - - D - - E L R - M A - - - 0.07 2.07 0.07 1661 Phage-672 - - D - - L P A - M A - - - 0.07 2.06 0.12
[1965] 1662 Phage-673 - - E - - S D E - M L - - - 0.07 2.06 0.07
[1966] 1663 Phage-674 - - E - - - P E - M M - - I 0.05 2.06 0.06
[1967] 1664 Phage-675 - - E - - - D I - M Q - - - 0.06 2.06 0.07
[1968] 1665 Phage-676 - - E - - s A E - M - - - - 0.06 2.06 0.07 1666 Phage-677 - - D - - - P - - M G - - - 0.08 2.06 0.08 1667 Phage-678 - - E - - L P I - M D - - - 0.07 2.06 0.08 1668 Phage-679 - - D - - - I E - M Q - - - 0.08 2.05 0.07 1669 Phage-680 - - - - - I E E - M w - - - 0.06 2.05 0.06
[1969] 1670 Phage-681 - - Q - - M P E - M D - - - 0.08 2.05 0.07
[1970] 1671 Phage-682 - - D - - - P E - V M - - - 0.08 2.05 0.10
[1971] 1672 Phage-683 - - D - - V G E - M Q - - - 0.10 2.05 0.08
[1972] 1673 Phage-684 - - D - - s A - - M H - - - 0.06 2.05 0.06 1674 Phage-685 - - E - - - P E - M Y - - - 0.05 2.05 0.07 1675 Phage-686 - - D - - L P E - Q M - - - 0.06 2.05 0.08 1676 Phage-687 - - D - - - S E - M M - - - 0.06 2.05 0.06 1677 Phage-688 - - D - - L I E - M E - - - 0.06 2.04 0.06
[1973] 1678 Phage-689 - - E - - - I - - M S - - - 0.06 2.04 0.06
[1974] 1679 Phage-690 - - E - - - P - H M D - - - 0.06 2.04 0.08
[1975] 1680 Phage-691 - - E - - s P - - M S - - - 0.06 2.04 0.07
[1976] 1681 Phage-692 - - D - - F R E - M Q - - - 0.08 2.04 0.06 1682 Phage-693 - - L - - - P - - - Q - - - 0.08 2.04 0.14 1683 Phage-694 - - D - - s S E - M w - - - 0.06 2.03 0.06 1684 Phage-695 - - S - - L P E - M s - - - 0.06 2.03 0.09 1685 Phage-696 - - E - - - P - - - A - - - 0.06 2.03 0.08
[1977] 1686 Phage-697 - - D - - s P M - - G - - - 0.08 2.03 0.07
[1978] 1687 Phage-698 - - - - - L P E - M M - - - 0.05 2.03 0.11
[1979] 1688 Phage-699 - - E - - R P E - M Q - - - 0.06 2.03 0.11
[1980] 1689 Phage-700 - - E - - - R E H M A - - - 0.07 2.02 0.08 1690 Phage-701 - - E - - s P E - M T - - - 0.09 2.02 0.08 1691 Phage-702 - - E - - s I - - M A - - - 0.08 2.02 0.06
[1981]
[1982] 1692WSGR Docket No. 52426-781.601
[1983] Phage-703 - - E - - s L E - M G - - - 0.07 2.02 0.09
[1984] 1693 Phage-704 - - D - - - P E - M E - - - 0.08 2.01 0.09
[1985] 1694 Phage-705 - - D - - M G V - Y W - - - 0.07 2.01 0.09
[1986] 1695 Phage-706 - - D - - E A - - M S - - - 0.08 2.01 0.09
[1987] 1696 Phage-707 - - D - - S H E - M E - - - 0.05 2.01 0.06
[1988] 1697 Phage-708 - - Q - - L P E - M S - - - 0.06 2.01 0.06 1698 Phage-709 - - E - - L S - - M Q - - - 0.11 2.00 0.09
[1989] 1699 Phage-710 - - D - - S P I - M s - - - 0.06 2.00 0.09
[1990] 1700 Phage-711 - - D - - S D - - M w - - - 0.09 2.00 0.11
[1991] 1701 Phage-712 - - D - - L P - - M s - - - 0.07 2.00 0.10
[1992] 1702 Phage-713 - - E - - - A E - M M - - - 0.05 1.99 0.07
[1993] 1703 Phage-714 - - - - - L P M - M H - - - 0.13 1.99 0.18 1704 Phage-715 - - D - - S Q E - - A - - - 0.07 1.99 0.07
[1994] 1705 Phage-716 - - D - - M P - - M S - - - 0.06 1.98 0.08
[1995] 1706 Phage-717 - - V - - L P - - M E - - - 0.06 1.98 0.08 1707 Phage-718 - - D - - L G I - M T - - - 0.06 1.98 0.08
[1996] 1708 Phage-719 - - D - - L - E - M D - - - 0.05 1.97 0.06
[1997] 1709 Phage-720 - - E - - L p M - F L - - M 0.06 1.97 0.06
[1998] 1710 Phage-721 - - D - - L p I - M T Q - - 0.06 1.97 0.08
[1999] 1711 Phage-722 - - E - - L A E - M D - - - 0.07 1.96 0.07 1712 Phage-723 - - D - - L E - - R A - - - 0.06 1.96 0.08
[2000] 1713 Phage-724 - - D - - L P E - L G - - - 0.07 1.96 0.08
[2001] 1714 Phage-725 - - - - - S V E - M A - - - 0.07 1.96 0.08
[2002] 1715 Phage-726 - - D - - S A L - M W - - - 0.11 1.96 0.08
[2003] 1716 Phage-727 - - D - - S S E - M I - - - 0.06 1.95 0.06
[2004] 1717 Phage-728 - - D - - L I E - M Y - - - 0.08 1.95 0.09
[2005] 1718 Phage-729 - - D - - S A E - M Q - - - 0.06 1.95 0.07
[2006] 1719 Phage-730 - - D - - L V E - M s - - - 0.09 1.95 0.08
[2007] 1720 Phage-731 - - E - - L s - - M E - - - 0.06 1.95 0.08 1721 Phage-732 - - D - - S p E H - R - - - 0.08 1.94 0.11
[2008] 1722 Phage-733 - - - - - L E I - M - - - - 0.05 1.94 0.07
[2009] 1723 Phage-734 - - E - - L S E - M A - - - 0.06 1.94 0.20
[2010] 1724 Phage-735 - - E - - L P I - L S - - - 0.07 1.94 0.08
[2011] 1725 Phage-736 - - D - - - s E - M W - - - 0.06 1.94 0.06
[2012] 1726 Phage-737 - - S - - - p E - M A - - - 0.05 1.94 0.06
[2013] 1727 Phage-738 - - E - - R A E - M E - - - 0.06 1.93 0.06
[2014] 1728 Phage-739 - - D - - S P D - - W - - - 0.07 1.93 0.10
[2015] 1729 Phage-740 - - M - - - P E - M E - - - 0.06 1.93 0.07
[2016]
[2017] 1730WSGR Docket No. 52426-781.601
[2018] Phage-741 - - M - - Q p E - M Q - - - 0.08 1.93 0.08
[2019] 1731 Phage-742 - - D - - M p E - M E - - - 0.08 1.93 0.09
[2020] 1732 Phage-743 - - D - - s A E - L A - - - 0.07 1.93 0.08
[2021] 1733 Phage-744 - - D - - s P E - M T - - - 0.06 1.93 0.07
[2022] 1734 Phage-745 - - E - - s M E - M A - - - 0.07 1.92 0.07
[2023] 1735 Phage-746 - - - - - M P E - - D - - - 0.05 1.92 0.06 1736 Phage-747 - - - - - s P E F M E - - - 0.06 1.91 0.06
[2024] 1737 Phage-748 - - D - - L N E - M E - - - 0.05 1.91 0.06
[2025] 1738 Phage-749 - - D - - L K E - Q E - - - 0.07 1.91 0.09
[2026] 1739 Phage-750 - - E - - L A - - M W - - - 0.08 1.91 0.12
[2027] 1740 Phage-751 - - E - - L A V - M Q - - - 0.08 1.91 0.10
[2028] 1741 Phage-752 - - E - - S S E - M E - - - 0.05 1.91 0.06 1742 Phage-753 - - D - - L D I - L A - - - 0.07 1.91 0.08
[2029] 1743 Phage-754 - - E - - S E E - M S - - - 0.06 1.91 0.07
[2030] 1744 Phage-755 - - D - - S Q E - M W - - - 0.06 1.90 0.09 1745 Phage-756 - - D - - - P E - M K - - - 0.05 1.90 0.06
[2031] 1746 Phage-757 - - D - - s K E - M H - - - 0.07 1.90 0.07
[2032] 1747 Phage-758 - - D - - E P - - L E - - - 0.08 1.90 0.08
[2033] 1748 Phage-759 - - D - - - E E - M S - - - 0.05 1.90 0.09
[2034] 1749 Phage-760 - - D - - V E E - L Y - - - 0.05 1.90 0.06 1750 Phage-761 - - - - - L E E - M D - - - 0.05 1.90 0.06
[2035] 1751 Phage-762 - - - - - - P - - M E - - - 0.08 1.90 0.08
[2036] 1752 Phage-763 - - - - - L P - - - A - - - 0.07 1.90 0.09
[2037] 1753 Phage-764 - - D - - L K E - M A - - - 0.05 1.90 0.07
[2038] 1754 Phage-765 - - D - - R P E - M E - - - 0.05 1.90 0.06
[2039] 1755 Phage-766 - - D - - L P E - M G - - - 0.06 1.89 0.11
[2040] 1756 Phage-767 - - E - - L Q E - M E - - - 0.06 1.89 0.10
[2041] 1620 Phage-768 - - E - - I P E - M A - - - 0.06 1.89 0.06
[2042] 1621 Phage-769 - - D - - S P E - M P - - - 0.06 1.89 0.08 1622 Phage-770 - - D - - L A E - M P - - - 0.08 1.89 0.07
[2043] 1623 Phage-771 - - E - - S P E - M W - - - 0.05 1.89 0.09
[2044] 1624 Phage-772 - - D - - I D E - L Q - - - 0.06 1.88 0.06
[2045] 1625 Phage-773 - - E - - V A E - M L - - - 0.05 1.88 0.05
[2046] 1626 Phage-774 - - E - - L S E - M S - - - 0.07 1.88 0.09
[2047] 1627 Phage-775 - - E - - M S E - M A - - - 0.08 1.88 0.11
[2048] 1628 Phage-776 - - D - - S - E - - Q - - - 0.06 1.88 0.07
[2049] 1629 Phage-777 - - E - - S L E - M A - - - 0.07 1.88 0.08
[2050] 1630 Phage-778 - - E - - s Y E - M W - - - 0.06 1.88 0.08
[2051]
[2052] 1631WSGR Docket No. 52426-781.601
[2053] Phage-779 - - E - - L P E - M M - - - 0.06 1.88 0.27
[2054] 1632 Phage-780 - - D - - L P E - M R - - - 0.07 1.88 0.08
[2055] 1633 Phage-781 - - E - - S P L - M S - - - 0.06 1.87 0.09
[2056] 1634 Phage-782 - - E - - S - E - - G - - - 0.08 1.87 0.07
[2057] 1635 Phage-783 - - D - - S A L - M S - - - 0.06 1.87 0.08
[2058] 1636 Phage-784 - - D - - T G V - F Y - - - 0.07 1.87 0.08 1637 Phage-785 - - E - - T S E - M - - - - 0.06 1.87 0.06
[2059] 1638 Phage-786 - - E - - R S E - M A - - - 0.06 1.86 0.06
[2060] 1639 Phage-787 - - D - - L A M - M D - - - 0.05 1.86 0.08
[2061] 1640 Phage-788 - - D - - M P E - L A - - - 0.06 1.86 0.07
[2062] 1641 Phage-789 - - E - - - A E - M S - - - 0.08 1.86 0.07
[2063] 1642 Phage-790 - - - - - s S E - M W - - - 0.08 1.85 0.07 1643 Phage-791 - - D - - s - A - M W - - - 0.11 1.85 0.13
[2064] 1644 Phage-792 - - D - - s A A - - M - - - 0.06 1.84 0.09
[2065] 1645 Phage-793 - - D - - s L - - L G - - - 0.06 1.84 0.09 1646 Phage-794 - - E - - s Q E - M Q - - - 0.05 1.84 0.05
[2066] 1647 Phage-795 - - - - - L P E - L s - - - 0.07 1.84 0.07
[2067] 1648 Phage-796 - - E - - L Q I - M s - - - 0.10 1.84 0.14
[2068] 1649 Phage-797 - - - - - - P E - M F - - M 0.06 1.83 0.06
[2069] 1650 Phage-798 - - E - - R P E - M A - - - 0.06 1.83 0.07 1651 Phage-799 - - E - - L P E - M R - - - 0.05 1.83 0.06
[2070] 1652 Phage-800 - - D - - S P A - M A - - - 0.09 1.83 0.10
[2071] 1653 Phage-801 - - D - - L P M - F A - - M 0.06 1.83 0.06
[2072] 1654 Phage-802 - - D - - S s E - - V - - - 0.08 1.83 0.06
[2073] 1655 Phage-803 - - E - - - A E - M w - - - 0.09 1.83 0.07
[2074] 1656 Phage-804 - - E - - s A E - - F - - - 0.07 1.83 0.05
[2075] 1657 Phage-805 - - E - - s P M - M Q - - M 0.07 1.83 0.06
[2076] 1658 Phage-806 - - D - - s A E - M E - - I 0.06 1.83 0.07
[2077] 1659 Phage-807 - - D - - L P L - M H - - - 0.05 1.82 0.07 1660 Phage-808 - - E - - - P - - L - - - - 0.09 1.82 0.08
[2078] 1661 Phage-809 - - D - - - R E - M T - - - 0.06 1.82 0.06
[2079] 1662 Phage-810 - - D - - T E E - M D - - - 0.07 1.82 0.09
[2080] 1663 Phage-811 - - D - - S S M - M A - - - 0.05 1.82 0.06
[2081] 1664 Phage-812 - - - - - S S E - - W - - - 0.06 1.82 0.06
[2082] 1665 Phage-813 - - E - - S A E F M T - - - 0.06 1.81 0.06
[2083] 1666 Phage-814 - - Q - - S A E - M M - - - 0.06 1.81 0.07
[2084] 1667 Phage-815 - - - - - L P - - M - - - - 0.05 1.81 0.06
[2085] 1668 Phage-816 - - D - - K A E - M E - - - 0.11 1.81 0.09
[2086]
[2087] 1669WSGR Docket No. 52426-781.601
[2088] Phage-817 - - - - - L P M - M A - - - 0.05 1.80 0.08
[2089] 1700 Phage-818 - - D - - T R E - - D - - - 0.06 1.80 0.08
[2090] 1701 Phage-819 - - V - - - P E F M A - - - 0.07 1.80 0.10
[2091] 1702 Phage-820 - - - - - - E - - M A - - - 0.07 1.80 0.08
[2092] 1703 Phage-821 - - D - - L S E - M F - - - 0.05 1.79 0.10
[2093] 1704 Phage-822 - - D - - L G V - M A - - - 0.05 1.79 0.07 1705 Phage-823 - - D - - T S E - - T - - - 0.07 1.79 0.07
[2094] 1706 Phage-824 - - D - - S P E - - A - - - 0.08 1.79 0.23
[2095] 1707 Phage-825 - - D - - L A E - M V - - - 0.08 1.79 0.08
[2096] 1708 Phage-826 - - D - - - P M - M A - - - 0.06 1.79 0.08
[2097] 1709 Phage-827 - - E - - L P A - M Q - - - 0.06 1.78 0.07
[2098] 1710 Phage-828 - - E - - H P - - M A - - - 0.06 1.78 0.09 1711 Phage-829 - - - - - V P E - M A - - - 0.06 1.78 0.07
[2099] 1712 Phage-830 - - D - - s A E - - T - - - 0.06 1.77 0.06
[2100] 1713 Phage-831 - - E - - L D E - M W - - - 0.06 1.77 0.06 1714 Phage-832 - - D - L - S E - M S - - - 0.05 1.77 0.05
[2101] 1715 Phage-833 - - D - - s S E - - A - - - 0.09 1.77 0.07
[2102] 1716 Phage-834 - - E - - s P - - V Q - - - 0.05 1.77 0.06
[2103] 1717 Phage-835 - - E - - s P E - M R - - - 0.07 1.77 0.08
[2104] 1718 Phage-836 - - D - - L D E - M E - - - 0.06 1.76 0.08 1719 Phage-837 - - - - - L P E - M L - - - 0.07 1.76 0.09
[2105] 1720 Phage-838 - - E - - L P I - M S - - - 0.07 1.76 0.09
[2106] 1721 Phage-839 - - V - - L Q E - M E - - - 0.06 1.76 0.06
[2107] 1722 Phage-840 - - D - - S P - - M Q - - - 0.06 1.76 0.07
[2108] 1723 Phage-841 - - D - - I P E - L A - - - 0.05 1.76 0.06
[2109] 1724 Phage-842 - - D - - S Q E - M L - - - 0.05 1.76 0.05
[2110] 1725 Phage-843 - - D - - V E P - L S - - - 0.07 1.76 0.10
[2111] 1726 Phage-844 - - D - - K P - - M E - - - 0.06 1.76 0.08
[2112] 1727 Phage-845 - - D - - I G E - M V - - - 0.06 1.76 0.66 1728 Phage-846 - - E - - L A - - M - - - - 0.08 1.76 0.07
[2113] 1729 Phage-847 - - D - - V Q E - M Q - - - 0.06 1.76 0.07
[2114] 1730 Phage-848 - - H - - L Q E - M A - - - 0.08 1.76 0.07
[2115] 1731 Phage-849 - - D - - S P E - M - - - - 0.06 1.75 0.06
[2116] 1732 Phage-850 - - D - - - P V - M A - - - 0.06 1.75 0.06
[2117] 1733 Phage-851 - - E - - s A E - M L - - - 0.07 1.75 0.07
[2118] 1734 Phage-852 - - D - - H I E - L A - - - 0.07 1.75 0.10
[2119] 1735 Phage-853 - - S - - L P E - M Q - - - 0.06 1.75 0.08
[2120] 1736 Phage-854 - - E - - L P E - M - - - 0.07 1.75 0.07
[2121]
[2122] Q 1737WSGR Docket No. 52426-781.601
[2123] Phage-855 - - D - - s L - - M D - - - 0.06 1.75 0.06
[2124] 1738 Phage-856 - - D - - Y P E - M S - - - 0.07 1.75 0.06
[2125] 1739 Phage-857 - - D - - - S E - M A - - - 0.06 1.75 0.09
[2126] 1740 Phage-858 - - D - - - E K - M Q - - - 0.06 1.74 0.06
[2127] 1741 Phage-859 - - E - - - I E - L A - - - 0.05 1.74 0.07
[2128] 1742 Phage-860 - - E - - s A E - M E - - - 0.06 1.73 0.07 1743 Phage-861 - - S - - s A E - M L - - - 0.07 1.73 0.08
[2129] 1744 Phage-862 - - E - - L P D - M Q - - - 0.06 1.73 0.07
[2130] 1745 Phage-863 - - D - - L E E - M V - - M 0.06 1.73 0.06
[2131] 1746 Phage-864 - - E - - L Q T - M A - - - 0.08 1.73 0.07
[2132] 1747 Phage-865 - - - - - S Q E H - Q - - - 0.07 1.73 0.09
[2133] 1748 Phage-866 - - D - - L P E - - F - - - 0.05 1.73 0.09 1749 Phage-867 - - S - - L P E - M G - - - 0.06 1.73 0.10
[2134] 1750 Phage-868 - - D - - - E E - L W - - - 0.05 1.73 0.06
[2135] 1751 Phage-869 - - - - - s A E - M A - - - 0.05 1.73 0.07 1752 Phage-870 - - D - - s G V - M W - - - 0.08 1.73 0.08
[2136] 1753 Phage-871 - - D - - T Q A - - Q - - - 0.05 1.73 0.06
[2137] 1754 Phage-872 - - D - - - I - - - G - - - 0.06 1.72 0.09
[2138] 1755 Phage-873 - - D - - - A E F M M - - - 0.05 1.72 0.06
[2139] 1756 Phage-874 - - D - - L S E - M A - - - 0.07 1.72 0.08 1757 Phage-875 - - E - - S E M - M K - - - 0.08 1.72 0.07
[2140] 1758 Phage-876 - - D - - L Q I - L W - - - 0.06 1.72 0.07
[2141] 1759 Phage-877 - - Q - - L P V - M E - - - 0.06 1.72 0.06
[2142] 1760 Phage-878 - - D - - - A E - M D - - - 0.05 1.72 0.07
[2143] 1761 Phage-879 - - E - - s V - - M Q - - - 0.06 1.71 0.06
[2144] 1762 Phage-880 - - - - - L P E - L D - - - 0.06 1.71 0.07
[2145] 1763 Phage-881 - - D - - S R E - M V - - - 0.06 1.71 0.06
[2146] 1764 Phage-882 - - D - - L V E - R G - - - 0.06 1.71 0.07
[2147] 1765 Phage-883 - - - - - S A E - M W - - - 0.06 1.71 0.11 1766 Phage-884 - - D - - L Q I - M H - - - 0.07 1.71 0.10
[2148] 1767 Phage-885 - - - - - S M E - M A - - - 0.06 1.71 0.07
[2149] 1768 Phage-886 - - D - - L P E - F L - - - 0.09 1.71 0.11
[2150] 1769 Phage-887 - - D - - S L A - - A - - - 0.05 1.70 0.06
[2151] 1770 Phage-888 - - - - - T Q E - M Y - - - 0.06 1.70 0.05
[2152] 1771 Phage-889 - - E - - - Q E - M S - - - 0.05 1.70 0.08
[2153] 1772 Phage-890 - - E - - L P - - F M - - - 0.06 1.70 0.07
[2154] 1773 Phage-891 - - D - - S - E - M E - - - 0.05 1.70 0.12
[2155] 1774 Phage-892 - - - - - S p L - M L - - - 0.06 1.70 0.10
[2156]
[2157] 1775WSGR Docket No. 52426-781.601
[2158] Phage-893 - - E - - s A E - M Q - - - 0.08 1.70 0.29
[2159] 1776 Phage-894 - - D - - L P V - L E - - - 0.05 1.69 0.06
[2160] 1777 Phage-895 - - - - - L Q E - M Q - - - 0.06 1.69 0.07
[2161] 1778 Phage-896 - - D - - - I E - M A - - - 0.17 1.69 0.08
[2162] 1779 Phage-897 - - E - - K P E - M Q - - - 0.06 1.69 0.06
[2163] 1780 Phage-898 - - D - - - - E - M T - - - 0.10 1.69 0.35 1781 Phage-899 - - E - - s p W - M - - - - 0.06 1.68 0.06
[2164] 1782 Phage-900 - - D - - s p A - - w - - - 0.08 1.68 0.08
[2165] 1783 Phage-901 - - D - - s E - - M s - - - 0.06 1.68 0.07
[2166] 1784 Phage-902 - - D - - - K E - M D - - - 0.08 1.68 0.08
[2167] 1785 Phage-903 - - D - - s T E - M E - - - 0.06 1.68 0.08
[2168] 1786 Phage-904 - - D - - s S L - M H - - - 0.06 1.67 0.07 1787 Phage-905 - - D - - s - - - - S - - - 0.07 1.67 0.05
[2169] 1788 Phage-906 - - E - - - p - - M - - - - 0.08 1.67 0.08
[2170] 1789 Phage-907 - - D - - - p - w M A - - - 0.08 1.67 0.10 1790 Phage-908 - - D - - s R E - M S - - - 0.07 1.67 0.10
[2171] 1791 Phage-909 - - D - - - A E - M A - - V 0.06 1.67 0.07
[2172] 1792 Phage-910 - - E - - - Q E - M - - - - 0.06 1.67 0.06
[2173] 1793 Phage-911 - - E - - - P - - M T - - - 0.06 1.67 0.08
[2174] 1794 Phage-912 - - D - - s A D - M A - - - 0.06 1.67 0.07 1795 Phage-913 - - D - - I G L - L - - - - 0.07 1.66 0.06
[2175] 1796 Phage-914 - - E - - L P M - M I - - - 0.07 1.66 0.09
[2176] 1797 Phage-915 - - E - - L P - - M R p - - 0.06 1.66 0.08
[2177] 1798 Phage-916 - - E - - L S - - M S - - - 0.05 1.66 0.07
[2178] 1799 Phage-917 - - D - - S P E - - G - - - 0.06 1.66 0.07
[2179] 1800 Phage-918 - - - - - L P E F M D - - - 0.06 1.66 0.06
[2180] 1801 Phage-919 - - D - - S R E - M - - - - 0.05 1.66 0.06
[2181] 1802 Phage-920 - - D - - D V E - M A - - - 0.07 1.66 0.07
[2182] 1803 Phage-921 - - D - - S E V - M A - - - 0.07 1.66 0.06 1804 Phage-922 - - D - - S L L - L S - - - 0.07 1.65 0.07
[2183] 1805 Phage-923 - - E - - L A V - M E - - - 0.08 1.65 0.12
[2184] 1806 Phage-924 - - E - - S L M - M W - - - 0.06 1.65 0.08
[2185] 1807 Phage-925 - - - - - - A E - M T - - - 0.06 1.65 0.07
[2186] 1808 Phage-926 - - D - - s V E - M E - - - 0.07 1.65 0.09
[2187] 1809 Phage-927 - - D - - - Q E - R L - - - 0.07 1.65 0.07
[2188] 1810 Phage-928 - - D - - s A E - L L - - - 0.07 1.65 0.07
[2189] 1811 Phage-929 - - D - - G P - - - Q - - - 0.06 1.64 0.07
[2190] 1812 Phage-930 - - E - - I A E - M Q - - - 0.06 1.64 0.13
[2191]
[2192] 1813WSGR Docket No. 52426-781.601
[2193] Phage-931 - - E - - s A - - M H - - - 0.05 1.64 0.06
[2194] 1814 Phage-932 - - E - - T A E H M Q - - - 0.05 1.64 0.05
[2195] 1815 Phage-933 - - - - - V A E - M A - - - 0.06 1.64 0.06
[2196] 1816 Phage-934 - - D - - - T E - M Q - - - 0.05 1.64 0.10
[2197] 1817 Phage-935 - - E - - M - E - M A - - - 0.08 1.64 0.13
[2198] 1818 Phage-936 - - D - - D V E - M S - - - 0.06 1.64 0.05 1819 Phage-937 - - - - - S L E - M Q - - - 0.06 1.63 0.07
[2199] 1820 Phage-938 - - E - - D L I - M w - - - 0.06 1.63 0.06
[2200] 1821 Phage-939 - - - - - - P E - M s - - - 0.05 1.63 0.05
[2201] 1822 Phage-940 - - E - - s S E - M w - - - 0.07 1.63 0.09
[2202] 1823 Phage-941 - - D - - L D V - R A - - - 0.07 1.63 0.09
[2203] 1824 Phage-942 - - E - - L E - - M Q - - - 0.05 1.63 0.06 1825 Phage-943 - - E - - S - V - M A - - - 0.09 1.63 0.07
[2204] 1826 Phage-944 - - D - - S L E - - G - - - 0.06 1.63 0.06
[2205] 1827 Phage-945 - - D - - S E A F M Q - - - 0.07 1.63 0.07 1828 Phage-946 - - - - - L P E - M G - - - 0.05 1.63 0.07
[2206] 1829 Phage-947 - - - - - L A I - M s - - - 0.08 1.63 0.08
[2207] 1830 Phage-948 - - D - - L S E - M s - - - 0.05 1.62 0.06
[2208] 1831 Phage-949 - - E - - V T E - M Q - - - 0.07 1.62 0.08
[2209] 1832 Phage-950 - - D - - - Q E - M D - - - 0.06 1.62 0.08 1833 Phage-951 - - E - - - P - - - M - - - 0.06 1.62 0.06
[2210] 1834 Phage-952 - - D - - E L K - M L - - - 0.05 1.62 0.08
[2211] 1835 Phage-953 - - D - - L L E - K A - - - 0.07 1.62 0.07
[2212] 1836 Phage-954 - - E - - L E E - M A - - - 0.08 1.62 0.07
[2213] 1837 Phage-955 - - D - - S P E - M L - - - 0.07 1.61 0.07
[2214] 1838 Phage-956 - - - - - S P - - M E - - - 0.06 1.61 0.06
[2215] 1839 Phage-957 - - D - - S V K - M A - - - 0.07 1.61 0.06
[2216] 1840 Phage-958 - - S - - L P E - M W - - - 0.07 1.61 0.10
[2217] 1841 Phage-959 - - D - - S V E - K L - - M 0.05 1.61 0.06 1842 Phage-960 - - D - - - Q E - M V - - - 0.05 1.61 0.06
[2218] 1843 Phage-961 - - - - - s p E - M Q - - - 0.06 1.60 0.08
[2219] 1844 Phage-962 - - E - - L p L - M D - - - 0.07 1.60 0.08
[2220] 1845 Phage-963 - - E - - S A A - M Q - - - 0.07 1.60 0.09
[2221] 1846 Phage-964 - - E - - M P E - L Q - - - 0.05 1.60 0.10
[2222] 1847 Phage-965 - - D - - E L - - M A - - - 0.07 1.60 0.08
[2223] 1848 Phage-966 - - D - - R L E - L E - - - 0.06 1.60 0.06
[2224] 1849 Phage-967 - - - - - L D - - - E - - - 0.06 1.60 0.10
[2225] 1850 Phage-968 - - D - - - Q E F - W - - - 0.06 1.60 0.10
[2226]
[2227] 1851WSGR Docket No. 52426-781.601
[2228] Phage-969 - - D - - s E A - M W - - - 0.07 1.59 0.07
[2229] 1852 Phage-970 - - E - - - D E - M W - - - 0.07 1.59 0.06
[2230] 1853 Phage-971 - - E - - s V E - - G - - - 0.06 1.59 0.07
[2231] 1854 Phage-972 - - D - - R V E - M A - - - 0.05 1.58 0.09 1855 Phage-973 - - E - - S - E H M E - - - 0.07 1.58 0.06 1856 Phage-974 - - - - - s s E - - P - - - 0.06 1.58 0.09 1857 Phage-975 - - D - - L p - - L Q - - T 0.07 1.58 0.07 1858 Phage-976 - - D - - - K E - - Q - - - 0.06 1.58 0.06
[2232] 1859 Phage-977 - - E - - L P - - M V - - - 0.07 1.58 0.07
[2233] 1860 Phage-978 - - Q - - - D E - M A - - - 0.07 1.58 0.08
[2234] 1861 Phage-979 - - D - - - E E - L L - - - 0.05 1.57 0.05
[2235] 1862 Phage-980 - - E - - L G I - M T - - - 0.06 1.57 0.08 1863 Phage-981 - - D - - S - - - M W - - I 0.06 1.57 0.09 1864 Phage-982 - - E - - S E E F M S - - - 0.05 1.57 0.08 1865 Phage-983 - - D - - L P M - M K - - - 0.08 1.57 0.10 1866 Phage-984 - - Q - - L P - - V E - - - 0.08 1.57 0.08
[2236] 1867 Phage-985 - - E - - L D M - V W - - - 0.06 1.56 0.08
[2237] 1868 Phage-986 - - D - - S Q E - M A H - - 0.06 1.56 0.07
[2238] 1869 Phage-987 - - D - - S p L - M V - - - 0.05 1.56 0.06
[2239] 1870 Phage-988 - - D - - F L T - M T - - - 0.06 1.56 0.07 1871 Phage-989 - - - - - S E E - M D - - - 0.05 1.55 0.05 1872 Phage-990 - - D - - S E V - M S - - - 0.06 1.55 0.06 1873 Phage-991 - - E - - T L E - M W - - - 0.07 1.55 0.33 1874 Phage-992 - - D - - S Q A H M Q - - - 0.06 1.55 0.08
[2240] 1875 Phage-993 - - - - - D Q - - M E - - - 0.14 1.55 0.23
[2241] 1876 Phage-994 - - D - - L P V - M M - - - 0.06 1.55 0.07
[2242] 1877 Phage-995 - - - - - N A - - M S - - - 0.06 1.55 0.05
[2243] 1878 Phage-996 - - D - - T S E - M T - - - 0.06 1.54 0.06 1879 Phage-997 - - E - - - P V - M F - - - 0.05 1.54 0.08 1880 Phage-998 - - E - - L G - - M E - - - 0.06 1.54 0.08 1881 Phage-999 - - D - - N G V - W W - - I 0.06 1.53 0.07 1882 Phage-1000 - - D - - - P E - L T - - - 0.08 1.53 0.06
[2244] 1883 Phage-1001 - - E - - s I - - M T - - - 0.06 1.53 0.13
[2245] 1884 Phage-1002 - - D - - L Q I - M G - - - 0.05 1.53 0.06
[2246] 1885 Phage-1003 - - D - - S V E - L D - - - 0.05 1.53 0.08
[2247] 1886 Phage-1004 - - D - - - - - - M W - - - 0.09 1.53 0.07 1887 Phage-1005 - - D - - L p E - L A - - - 0.05 1.52 0.06 1888 Phage-1006 - - D - - L A V - M A - - - 0.07 1.52 0.08
[2248]
[2249] 1889WSGR Docket No. 52426-781.601
[2250] Phage-1007 - - - - - L P V - M D - - - 0.09 1.52 0.08
[2251] 1890 Phage-1008 - - E - - S A M - - W - - - 0.09 1.52 0.10
[2252] 1891 Phage-1009 - - - - - L E E - M w - - - 0.07 1.51 0.08
[2253] 1892 Phage-1010 - - D - - S E L - M A - - - 0.06 1.51 0.06
[2254] 1893 Phage-1011 - - D - - S A E - L S - - - 0.07 1.51 0.07
[2255] 1894 Phage-1012 - - E - - M P - - M E - - - 0.06 1.51 0.06 1895 Phage-1013 - - E - - S L M - M A - - - 0.06 1.50 0.06
[2256] 1896 Phage-1014 - - D - - S Q E - M E - - - 0.06 1.50 0.06
[2257] 1897 Phage-1015 - - D - - K A E - M Q - - - 0.09 1.50 0.06
[2258] 1898 Phage-1016 - - D - - S P - - - Q - - - 0.07 1.50 0.07
[2259] 1899 Phage-1017 - - S - - L P - - L E - - - 0.11 1.50 0.31
[2260] 1900 Phage-1018 - - D - - H K E - L L - - - 0.05 1.49 0.06 1901 Phage-1019 - - D - - L A L H M K - - - 0.08 1.49 0.08
[2261] 1902 Phage-1020 - - E - - I M - - M A Q - - 0.06 1.49 0.06
[2262] 1903 Phage-1021 - - D - - L P I - Q A - - - 0.06 1.49 0.10 1904 Phage-1022 - - D - - S E - - - A - - - 0.06 1.49 0.08
[2263] 1905 Phage-1023 - - D - - L P E - - T - - - 0.06 1.49 0.06
[2264] 1906 Phage-1024 - - E - - R P E - M Q - - V 0.06 1.48 0.09
[2265] 1907 Phage-1025 - - - - - T V E N M A - - - 0.07 1.48 0.07
[2266] 1908 Phage-1026 - - E - - V L E - R G - - D 0.07 1.48 0.09 1909 Phage-1027 - - D - - V A E - R H - - - 0.05 1.47 0.06
[2267] 1910 Phage-1028 - - E - - L D - - M T - - - 0.06 1.47 0.08
[2268] 1911 Phage-1029 - - - - - T Q E - - E - - - 0.06 1.47 0.06
[2269] 1912 Phage-1030 - - D - - L A I - - G - - - 0.07 1.47 0.08
[2270] 1913 Phage-1031 - - D - - L E I - M S - - - 0.08 1.46 0.08
[2271] 1914 Phage-1032 - - D - - L L E - M S - - - 0.06 1.46 0.09
[2272] 1915 Phage-1033 - - D - - S L E - M V - - - 0.06 1.46 0.06
[2273] 1916 Phage-1034 - - E - - S L E H - A - - - 0.05 1.46 0.07
[2274] 1917 Phage-1035 - - E - - T P V - M P - - - 0.08 1.46 0.06 1918 Phage-1036 - - Q - - I E P - L A - - - 0.06 1.46 0.05
[2275] 1919 Phage-1037 - - D - - L A I - M W - - - 0.07 1.45 0.09
[2276] 1920 Phage-1038 - - D - - - E E - M A - - - 0.06 1.45 0.06
[2277] 1921 Phage-1039 - - D - - s L - - M S - - - 0.06 1.45 0.06
[2278] 1922 Phage-1040 - - E - - L P - - M T - - I 0.07 1.44 0.08
[2279] 1923 Phage-1041 - - - - - L P - - - Q - - - 0.06 1.44 0.07
[2280] 1924 Phage-1042 - - E - - L A I - Q K - - - 0.06 1.44 0.06
[2281] 1925 Phage-1043 - - E - - - V E - M A - - - 0.05 1.44 0.07
[2282] 1926 Phage-1044 - - E - - L P I - M E - - - 0.10 1.44 0.07
[2283]
[2284] 1927WSGR Docket No. 52426-781.601
[2285] Phage-1045 - - E - - s M E - - Q - - - 0.08 1.44 0.07
[2286] 1928 Phage-1046 - - E - - s Q E - M A - - - 0.05 1.44 0.06
[2287] 1929 Phage-1047 - - D - - L P E - M - Q - - 0.05 1.44 0.07
[2288] 1930 Phage-1048 - - D - - N F - - M E - - - 0.07 1.44 0.06
[2289] 1931 Phage-1049 - - V - - L P - - M Q - - - 0.07 1.43 0.06
[2290] 1932 Phage-1050 - - D - - L P E - - A - - Q 0.06 1.43 0.07 1933 Phage-1051 - - D - - S L E - - E - - - 0.06 1.43 0.06
[2291] 1934 Phage-1052 - - L - - S - P - - H - - Y 0.05 1.43 0.07
[2292] 1935 Phage-1053 - - D - - L D E - M L - - - 0.06 1.43 0.06
[2293] 1936 Phage-1054 - - D - - T P E - M W - - - 0.06 1.43 0.06
[2294] 1937 Phage-1055 - - E - - S Q - - M Q - - - 0.06 1.42 0.08
[2295] 1938 Phage-1056 - - D - - S P A F - Q - - - 0.07 1.42 0.08 1939 Phage-1057 - - D - - S L E - - D - - M 0.07 1.42 0.09
[2296] 1940 Phage-1058 - - Q - - S P N - - T - - F 0.06 1.41 0.06
[2297] 1941 Phage-1059 - - D - - - P E - L G - - - 0.06 1.41 0.06 1942 Phage-1060 - - - - - - E E - L E - - - 0.06 1.41 0.15
[2298] 1943 Phage-1061 - - D - - s H E - M Q - - - 0.06 1.41 0.06
[2299] 1944 Phage-1062 - - - - - s A E - M s - - - 0.06 1.41 0.07
[2300] 1945 Phage-1063 - - D - - L M E - K A - - - 0.06 1.41 0.06
[2301] 1946 Phage-1064 - - E - - S A E - - A - - - 0.07 1.41 0.09 1947 Phage-1065 - - D - - s P E H M G - - - 0.06 1.40 0.09
[2302] 1948 Phage-1066 - - D - - D A R - M E - - - 0.07 1.40 0.06
[2303] 1949 Phage-1067 - - D - - s P E - M Q - - - 0.07 1.40 0.53
[2304] 1950 Phage-1068 - - N - - L P E - M s - - I 0.06 1.40 0.07
[2305] 1951 Phage-1069 - - S - - L P E - M D - - - 0.05 1.39 0.07
[2306] 1952 Phage-1070 - - D - - S L E - M L - - - 0.05 1.39 0.07
[2307] 1953 Phage-1071 - - E - - H P W - V Q - - - 0.07 1.39 0.07
[2308] 1954 Phage-1072 - - D - - N - E - M E - - - 0.05 1.38 0.05
[2309] 1955 Phage-1073 - - D - - - E - - M S - - - 0.07 1.38 0.07 1956 Phage-1074 - - D - L F Q L - M M - - - 0.07 1.38 0.07
[2310] 1957 Phage-1075 - - D - - - P E - - Q - - - 0.07 1.38 0.06
[2311] 1958 Phage-1076 - - E - - L D E - L Q - - - 0.06 1.38 0.07
[2312] 1959 Phage-1077 - - D - - L Q E - M Q - - - 0.06 1.38 0.06
[2313] 1960 Phage-1078 - - D - - Q P - - M s - - - 0.07 1.38 0.09
[2314] 1961 Phage-1079 - - D - - L s E - - G - - - 0.06 1.37 0.06
[2315] 1962 Phage-1080 - - E - - S Q L - M A - - - 0.07 1.37 0.07
[2316] 1963 Phage-1081 - - D - - s E T - L W - - - 0.07 1.37 0.10
[2317] 1964 Phage-1082 - - E - - L P A - M G - - I 0.07 1.37 0.09
[2318]
[2319] 1965WSGR Docket No. 52426-781.601
[2320] Phage-1083 - - E - - L P E - M I - - I 0.06 1.36 0.10
[2321] 1966 Phage-1084 - - - - - T S E - M S - - - 0.06 1.36 0.07
[2322] 1967 Phage-1085 - - D - - M K E - M L - - - 0.05 1.36 0.06
[2323] 1968 Phage-1086 - - D - - V K E - M Y - - - 0.06 1.36 0.06
[2324] 1969 Phage-1087 - - D - - L A L - M W - - - 0.11 1.36 0.17
[2325] 1970 Phage-1088 - - D - - L S I - M T - - - 0.06 1.36 0.07 1971 Phage-1089 - - D - - M V - - M A - - - 0.06 1.36 0.07
[2326] 1972 Phage-1090 - - D - - S E E F M W - - - 0.07 1.35 0.06
[2327] 1973 Phage-1091 - - E - - M E K - M E - - - 0.07 1.35 0.11
[2328] 1974 Phage-1092 - - D - - L P R - M A - - - 0.06 1.35 0.10
[2329] 1975 Phage-1093 - - D - - L P E - M Q - - - 0.09 1.35 0.08
[2330] 1976 Phage-1094 - - D - - L L - - M H - - - 0.10 1.35 0.07 1977 Phage-1095 - - D - - - P L - - Q - - - 0.07 1.34 0.06
[2331] 1978 Phage-1096 - - D - - s K E - M A - - - 0.07 1.34 0.06
[2332] 1979 Phage-1097 - - E - - s P E - M H - - - 0.07 1.34 0.09 1980 Phage-1098 - - D - - s E A - - E - - - 0.08 1.34 0.06
[2333] 1981 Phage-1099 - - - - - V D - - L W - - - 0.07 1.34 0.06
[2334] 1982 Phage- 1100 - - - - - - S E - M A - - - 0.07 1.33 0.08
[2335] 1983 Phage-1101 - - D - - - P - - M R - - - 0.08 1.33 0.08
[2336] 1984 Phage- 1102 - - D - - L P L - M Q - - F 0.06 1.33 0.10 1985 Phage- 1103 - - - - - L P M - M Q - - - 0.06 1.33 0.08
[2337] 1986 Phage- 1104 - - s E - Q I I F - Q - - - 0.07 1.32 0.08
[2338] 1987 Phage-1105 - - E - - L E I - L A - - - 0.06 1.32 0.07
[2339] 1988 Phage-1106 - - D - - T A E F - G - - - 0.06 1.32 0.06
[2340] 1989 Phage- 1107 - - - - - - L E - M G - - - 0.07 1.32 0.06
[2341] 1990 Phage-1108 - - E - - L P E - M I - - - 0.06 1.32 0.06
[2342] 1991 Phage- 1109 - - E - - L P A - M W - - - 0.06 1.31 0.08
[2343] 1992 Phage-1110 - - E - - L P M - M Q - - - 0.07 1.31 0.08
[2344] 1993 Phage-1111 - - D - - I P E - M T - - - 0.06 1.31 0.06 1994 Phage-1112 - - D - - S A E - - A - - - 0.05 1.31 0.05
[2345] 1995 Phage-1113 - - E - - S A V - M S - - - 0.06 1.31 0.06
[2346] 1996 Phage-1114 - - E - - s L E - M M - - V 0.06 1.30 0.07
[2347] 1997 Phage-1115 - - D - - - P - - M A - - I 0.06 1.30 0.06
[2348] 1998 Phage-1116 - - Q - - s V E H M A - - - 0.06 1.30 0.06
[2349] 1999 Phage-1117 - - - - - M P I - M T - - - 0.06 1.30 0.08
[2350] 2000 Phage-1118 - - D - - R A E - M L - - - 0.06 1.29 0.08
[2351] 1756 Phage-1119 - - E - - L V - - M Q - - - 0.06 1.28 0.06
[2352] 1757 Phage- 1120 - - M - - L P I - M E - - - 0.05 1.28 0.05
[2353]
[2354] 1758WSGR Docket No. 52426-781.601
[2355] Phage-1121 - - E - - L p R - M L - - - 0.06 1.28 0.30
[2356] 1759 Phage- 1122 - - D - - L E V - M D - - - 0.13 1.28 0.07
[2357] 1760 Phage- 1123 - - D - - S P A - L Q - - - 0.07 1.28 0.06
[2358] 1761 Phage- 1124 - - E - - S S - w M w - - - 0.06 1.27 0.09
[2359] 1762 Phage-1125 - - E - - F P L - M - - - - 0.06 1.27 0.08
[2360] 1763 Phage-1126 - - E - - S T E - M A - - - 0.08 1.27 0.06 1764 Phage- 1127 - - E - - Q P A - M E - - - 0.05 1.27 0.06
[2361] 1765 Phage-1128 - - D - - - E E - R M - - - 0.05 1.27 0.08
[2362] 1766 Phage- 1129 - - D - - L P V - M T - - - 0.07 1.27 0.07
[2363] 1767 Phage-1130 - - D - - S S V - M L - - - 0.08 1.26 0.06
[2364] 1768 Phage-1131 - - E - - H R I - M Q - - - 0.05 1.26 0.07
[2365] 1769 Phage-1132 - - E - - S E E - M A - - - 0.06 1.26 0.07 1770 Phage-1133 - - E - - M S I - M Q - - - 0.07 1.25 0.07
[2366] 1771 Phage-1134 - - E - - L Q E H M A - - - 0.06 1.25 0.05
[2367] 1772 Phage-1135 - - - - L F E E - M S - - - 0.06 1.25 0.06 1773 Phage-1136 - - E - - L P M - M T - - - 0.05 1.25 0.06
[2368] 1774 Phage-1137 - - D - - S E - - M A - - - 0.06 1.24 0.06
[2369] 1775 Phage-1138 - - E - - T Q E - M Q - - - 0.07 1.24 0.07
[2370] 1776 Phage-1139 - - - - - T A E - M A - - - 0.06 1.24 0.08
[2371] 1777 Phage- 1140 - - E - - L A E - M - - - - 0.06 1.24 0.07 1778 Phage-1141 - - D - - V E E - M T - - - 0.06 1.24 0.07
[2372] 1779 Phage- 1142 - - D - - L E - - M L - - - 0.07 1.24 0.09
[2373] 1780 Phage- 1143 - - E - - I G I - M S - - - 0.07 1.23 0.07
[2374] 1781 Phage- 1144 - - E - - S T E - - Q - - - 0.06 1.23 0.09
[2375] 1782 Phage- 1145 - - D - - S M M - M Q - - - 0.06 1.23 0.06
[2376] 1783 Phage- 1146 - - E - - s A E H M P - - - 0.07 1.23 0.09
[2377] 1784 Phage- 1147 - - V - - Y P E - M E - - - 0.06 1.22 0.07
[2378] 1785 Phage- 1148 - - D - - E A R - M Q - - - 0.09 1.21 0.07
[2379] 1786 Phage- 1149 - - D - - S Q E - M s - - - 0.06 1.21 0.06 1787 Phage-1150 - - H - - L P - - M s - - M 0.07 1.21 0.06
[2380] 1788 Phage-1151 - - - - - L D I - L A - - - 0.06 1.21 0.07
[2381] 1789 Phage-1152 - - - - - - P E - - S - - - 0.08 1.21 0.07
[2382] 1790 Phage-1153 - - D - - s - E - L G - - - 0.05 1.20 0.05
[2383] 1791 Phage-1154 - - E - - - A E - L W - - - 0.05 1.18 0.09
[2384] 1792 Phage-1155 - - D - - R P E - M S - - - 0.05 1.18 0.07
[2385] 1793 Phage-1156 - - E - - M P E - L A - - - 0.06 1.18 0.07
[2386] 1794 Phage-1157 - - E - - - G V - M A - - - 0.06 1.17 0.05
[2387] 1795 Phage-1158 - - E - - s Q T - M W - - - 0.07 1.17 0.08
[2388]
[2389] 1796WSGR Docket No. 52426-781.601
[2390] Phage-1159 - - - - - s s E - - G - - - 0.05 1.17 0.06
[2391] 1797 Phage-1160 - - E - - s Q - - M W - - - 0.05 1.17 0.05
[2392] 1798 Phage-1161 - - D - - L p D - M A - - - 0.06 1.17 0.07
[2393] 1799 Phage-1162 - - E - - - E - - M E - - - 0.07 1.17 0.08
[2394] 1800 Phage-1163 - - E - - L K E - M Q - - - 0.06 1.17 0.07
[2395] 1801 Phage-1164 - - E - - S Y - - M Q - - - 0.06 1.16 0.06 1802 Phage-1165 - - E - - R A E - M s - - - 0.07 1.16 0.09
[2396] 1803 Phage-1166 - - D - - S - I - M V - - - 0.06 1.16 0.06
[2397] 1804 Phage-1167 - - D - - L s V - M s - - - 0.06 1.15 0.07
[2398] 1805 Phage-1168 - - E - - L p - - M s - - - 0.06 1.15 0.09
[2399] 1806 Phage-1169 - - E - - V A E - R A - - - 0.06 1.15 0.09
[2400] 1807 Phage- 1170 - - Q - - L P - - - E - - - 0.06 1.14 0.06 1808 Phage-1171 - - E - - - A A - M G - - - 0.06 1.14 0.08
[2401] 1809 Phage- 1172 - - D - - E Q - - M E - - - 0.06 1.14 0.06
[2402] 1810 Phage- 1173 - - D - - L Q M - M M - - - 0.08 1.14 0.07 1811 Phage- 1174 - - E - - L Y E - M W - - - 0.06 1.13 0.07
[2403] 1812 Phage- 1175 - - V - - S E - - M A - - - 0.07 1.13 0.06
[2404] 1813 Phage-1176 - - D - - E A E - M W - - - 0.09 1.13 0.10
[2405] 1814 Phage- 1177 - - E - - - E - - M K - - - 0.06 1.12 0.07
[2406] 1815 Phage-1178 - - D - - V V E - M S - - - 0.09 1.12 0.08 1816 Phage- 1179 - - - - - L P - - M H - - - 0.06 1.11 0.08
[2407] 1817 Phage- 1180 - - D - - I - p w - E - - - 0.06 1.11 0.11
[2408] 1818 Phage-1181 - - E - - S s L - L E - - - 0.07 1.11 0.08
[2409] 1819 Phage- 1182 - - D - - - M E - M E - - - 0.07 1.11 0.08
[2410] 1820 Phage- 1183 - - E - - L - E - L A - - - 0.06 1.10 0.05
[2411] 1821 Phage- 1184 - - E - - M G E - M L - - - 0.07 1.10 0.06
[2412] 1822 Phage-1185 - - D - - T K E - M W - - - 0.06 1.10 0.06
[2413] 1823 Phage- 1186 - - - - - - E E - M L - - - 0.05 1.09 0.07
[2414] 1824 Phage- 1187 - - E - - s A E - - G - - - 0.07 1.08 0.07 1825 Phage-1188 - - V - - L P E - M L E - M 0.06 1.08 0.07
[2415] 1826 Phage- 1189 - - D - - S F H - M A - - - 0.06 1.08 0.06
[2416] 1827 Phage- 1190 - - E - - S E M - M S - - - 0.06 1.07 0.09
[2417] 1828 Phage-1191 - - D - - - N A - - W - - - 0.06 1.07 0.09
[2418] 1829 Phage- 1192 - - E - - I P M - M L - - M 0.06 1.06 0.09
[2419] 1830 Phage- 1193 - - E - - - Q E - M A - - - 0.07 1.06 0.08
[2420] 1831 Phage- 1194 - - D - - - K V - - W - - - 0.06 1.06 0.08
[2421] 1832 Phage-1195 - - E - - I P A - M A - - - 0.06 1.06 0.08
[2422] 1833 Phage-1196 - - D - - - P I - M Q - - - 0.06 1.06 0.06
[2423]
[2424] 1834WSGR Docket No. 52426-781.601
[2425] Phage- 1197 - - E - - L - E - M K - - - 0.07 1.06 0.07
[2426] 1835 Phage-1198 - - E - - D V - - M Q - - - 0.07 1.06 0.08
[2427] 1836 Phage- 1199 - - E - - S s E - L G - - - 0.05 1.05 0.09
[2428] 1837 Phage-1200 - - D - - L p R - M E - - M 0.06 1.05 0.06
[2429] 1838 Phage-1201 - - D - - S s A - - D - - - 0.09 1.05 0.06
[2430] 1839 Phage-1202 - - E - - L p S - L A - - - 0.06 1.05 0.06 1840 Phage-1203 - - D - - - p E F - R - - - 0.07 1.05 0.07
[2431] 1841 Phage-1204 - - E - - - p - - M S - - - 0.06 1.04 0.08
[2432] 1842 Phage-1205 - - D - - D A R - M T - - - 0.06 1.04 0.09
[2433] 1843 Phage-1206 - - E - - S V E - - L - - - 0.11 1.04 0.06
[2434] 1844 Phage-1207 - - E - - S s A - M R - - - 0.06 1.04 0.06
[2435] 1845 Phage-1208 - - D - - L A E - - Q - - - 0.06 1.04 0.08 1846 Phage-1209 - - - - - S S E - L Q - - - 0.07 1.03 0.09
[2436] 1847 Phage-1210 - - - - - S Q V - M w - - - 0.05 1.02 0.06
[2437] 1848 Phage-1211 - - E - - I E - - M R - - - 0.06 1.01 0.06 1849 Phage-1212 - - F - - - P E - L L - - - 0.08 1.01 0.08
[2438] 1850 Phage-1213 - - E - - L R E - M L - - - 0.06 1.01 0.07
[2439] 1851 Phage-1214 - - E - - S S V - L W - - - 0.05 1.00 0.05
[2440] 1852 Phage-1215 - - E - - S - I - - A - - - 0.05 1.00 0.07
[2441] 1853 Phage-1216 - - D - - L E V - M S - - - 0.06 1.00 0.09 1854 Phage-1217 - - E - - R P E - M A N - - 0.05 1.00 0.06
[2442] 1855 Phage-1218 - - E - - I E P - M Q - - - 0.05 0.99 0.06
[2443] 1856 Phage-1219 - - D - - K P E - M D - - - 0.06 0.99 0.07
[2444] 1857 Phage-1220 - - D - - V G A - M W - - - 0.05 0.99 0.06
[2445] 1858 Phage-1221 - - E - - s A I - - A - - M 0.09 0.98 0.11
[2446] 1859 Phage-1222 - - F - - F P E - M A - - - 0.07 0.98 0.07
[2447] 1860 Phage-1223 - - D - - T G M - - S - - - 0.06 0.98 0.06
[2448] 1861 Phage-1224 - - S - - S - A - - G - - - 0.08 0.98 0.07
[2449] 1862 Phage-1225 - - - - - - A E - M W - - - 0.05 0.97 0.06 1863 Phage-1226 - - Q - - F P - - M A - - - 0.05 0.97 0.07
[2450] 1864 Phage-1227 - - E - - V P E - L V - - - 0.07 0.96 0.06
[2451] 1865 Phage-1228 - - D - - s K E - M s - - - 0.06 0.96 0.07
[2452] 1866 Phage-1229 - - D - - L P E - M L - - - 0.06 0.96 0.09
[2453] 1867 Phage-1230 - - - - - L D V - M S - - - 0.08 0.96 0.09
[2454] 1868 Phage-1231 - - - - - T P E - L D - - - 0.07 0.95 0.06
[2455] 1869 Phage-1232 - - E - - D I R - M M - - - 0.08 0.95 0.08
[2456] 1870 Phage-1233 - - D - - E E R - M A - - - 0.06 0.94 0.06
[2457] 1871 Phage-1234 - - S - - V P E - M E - - - 0.07 0.94 0.06
[2458]
[2459] 1872WSGR Docket No. 52426-781.601
[2460] Phage-1235 - - D - - I P - - V E - - - 0.06 0.94 0.08
[2461] 1873 Phage-1236 - - - - - - E I - M Q - - - 0.05 0.93 0.05
[2462] 1874 Phage-1237 - - E - - - H E - M E - - V 0.06 0.93 0.07
[2463] 1875 Phage-1238 - - D - - H A E - M W - - - 0.05 0.93 0.06 1876 Phage-1239 - - E - - T Q A - L A - - - 0.07 0.93 0.10 1877 Phage-1240 - - - - - S A - - M W - - - 0.05 0.92 0.07 1878 Phage-1241 - - D - - S F E - M A - - - 0.06 0.92 0.06 1879 Phage-1242 - - D - - S A E - L G - - - 0.07 0.92 0.07
[2464] 1880 Phage-1243 - - V - - S P E - - W - - - 0.07 0.92 0.06
[2465] 1881 Phage-1244 - - D - - E L M - M E - - - 0.05 0.92 0.06
[2466] 1882 Phage-1245 - - - - - L E M - M S - - - 0.06 0.91 0.07
[2467] 1883 Phage-1246 - - D - - I K E - M S - - - 0.05 0.91 0.08 1884 Phage-1247 - - D - - L L M - M E - - - 0.05 0.91 0.06 1885 Phage-1248 - - E - - D - M - M E - - - 0.07 0.91 0.07 1886 Phage-1249 - - E - - S Q E - K A - - F 0.07 0.90 0.07 1887 Phage-1250 - - D - - V L M - L A - - - 0.07 0.90 0.09
[2468] 1888 Phage-1251 - - E - - s S A - M A - - - 0.15 0.90 0.07
[2469] 1889 Phage-1252 - - E - - L A A - M Y - - - 0.05 0.89 0.07
[2470] 1890 Phage-1253 - - D - - S T L - M Q - - - 0.07 0.88 0.06
[2471] 1891 Phage-1254 - - D - - T E A - M s - - - 0.07 0.88 0.06 1892 Phage-1255 - - E - - I S E - M G - - - 0.07 0.88 0.05 1893 Phage-1256 - - D - - F T W - M A - - - 0.07 0.87 0.08 1894 Phage-1257 - - D - - I A E - R S - - - 0.11 0.87 0.07 1895 Phage-1258 - - E - - L S E - - G - - - 0.06 0.87 0.06
[2472] 1896 Phage-1259 - - D - - T A - - M W - - - 0.07 0.87 0.07
[2473] 1897 Phage-1260 - - - - - S L - - L G - - Y 0.06 0.86 0.06
[2474] 1898 Phage-1261 - - - - - - A I - M A - - - 0.06 0.85 0.07
[2475] 1899 Phage-1262 - - D - - s M T - M A - - I 0.06 0.84 0.06 1900 Phage-1263 - - D - - K - E - L Q - - - 0.06 0.84 0.06 1901 Phage-1264 - - D - - D p - - - R - - I 0.08 0.83 0.06 1902 Phage-1265 - - E - - L p M - M Q - - M 0.05 0.82 0.07 1903 Phage-1266 - - D - - S G E - M s - - - 0.06 0.82 0.06
[2476] 1904 Phage-1267 - - E - - - R E - M D - - - 0.07 0.80 0.07
[2477] 1905 Phage-1268 - - D - - s M E - M A - - - 0.05 0.80 0.07
[2478] 1906 Phage-1269 - - D - - s P - - L W - - - 0.06 0.80 0.05
[2479] 1907 Phage-1270 - - - - - s A E - - Q - - - 0.08 0.80 0.08 1908 Phage-1271 - - - - - T Q E - M L - - - 0.07 0.78 0.06 1909 Phage-1272 - - Q - - S V - - M A - - - 0.06 0.77 0.06
[2480]
[2481] 1910WSGR Docket No. 52426-781.601
[2482] Phage-1273 - - E - - s S E - M V - - - 0.06 0.77 0.06
[2483] 1911 Phage-1274 - - D - - T G V - K w - - I 0.07 0.76 0.06
[2484] 1912 Phage-1275 - - - - - I G E - M D - - - 0.06 0.75 0.58
[2485] 1913 Phage-1276 - - D - - - G I - V L - - - 0.06 0.75 0.08 1914 Phage-1277 - - D - - N P V - L A - - - 0.05 0.74 0.08 1915 Phage-1278 - - E - - - Q - - M L - - - 0.06 0.74 0.05 1916 Phage-1279 - - - - - s V - - M Y - - - 0.05 0.74 0.06 1917 Phage-1280 - - E - - F G M - M S - - - 0.06 0.73 0.07
[2486] 1918 Phage-1281 - - - - - M P - - M S - - - 0.07 0.72 0.05
[2487] 1919 Phage-1282 - - Q - - - L - - L Q - - - 0.07 0.71 0.08
[2488] 1920 Phage-1283 - - - - - L P - - V s - - - 0.06 0.70 0.06
[2489] 1921 Phage-1284 - - E - - L P w - M s - - - 0.06 0.69 0.09 1922 Phage-1285 - - D - - H L E - - D - - - 0.06 0.69 0.06 1923 Phage-1286 - - D - - L P R F M V - - - 0.05 0.69 0.07 1924 Phage-1287 - - Q - - - P W - M V - - - 0.07 0.69 0.08 1925 Phage-1288 - - E - - M S E - M R - - - 0.07 0.69 0.10
[2490] 1926 Phage-1289 - - V - - L P L - M P N - - 0.09 0.68 0.11
[2491] 1927 Phage-1290 - - D - - E P - - M T - - - 0.07 0.68 0.10
[2492] 1928 Phage-1291 - - E - - L P - - L A - - Y 0.07 0.67 0.08
[2493] 1929 Phage-1292 - - D - - Y G A - - L - - - 0.05 0.67 0.06 1930 Phage-1293 - - E - - - A V - M H - - - 0.14 0.67 0.09 1931 Phage-1294 - - D - - M D A - M S - - - 0.05 0.65 0.06 1932 Phage-1295 - - M - - S A E - M G - - - 0.06 0.64 0.06 1933 Phage-1296 - - D - - - - W - M E - - - 0.05 0.64 0.06
[2494] 1934 Phage-1297 - - D - - - A W - L Q - - - 0.06 0.64 0.07
[2495] 1935 Phage-1298 - - E - - - Q M - M L - - - 0.07 0.64 0.06
[2496] 1936 Phage-1299 - - E - - s R - - M E - - M 0.05 0.63 0.33
[2497] 1937 Phage-1300 - - S - - L P M - M A - - - 0.06 0.62 0.13 1938 Phage-1301 - - E - - L A V H M S - - - 0.06 0.62 0.06 1939 Phage-1302 - - D - - I E M - M S - - M 0.06 0.61 0.06 1940 Phage-1303 - - - - - - L E - M Q - - M 0.07 0.61 0.08 1941 Phage-1304 - - E - - I G D - - A - - - 0.05 0.61 0.36
[2498] 1942 Phage-1305 - - Q - - s E L - M S - - - 0.05 0.60 0.08
[2499] 1943 Phage-1306 - - D - - T P - F R A - - - 0.06 0.59 0.07
[2500] 1944 Phage-1307 - - E - - L Q E - M G - - - 0.05 0.58 0.25
[2501] 1945 Phage-1308 - - D - - V T E - M A - - - 0.06 0.58 0.07 1946 Phage-1309 - - D - - I M P - L D - - - 0.06 0.57 0.05 1947 Phage-1310 - - E - - K K E - M L - - - 0.07 0.56 0.08
[2502]
[2503] 1948WSGR Docket No. 52426-781.601
[2504] Phage-1311 - - E - - V E L - R Q - - - 0.06 0.56 0.06
[2505] 1949 Phage-1312 - - D - - L E T - M Q - - - 0.05 0.53 0.08
[2506] 1950 Phage-1313 - - Q - - L P I - - Q - - - 0.06 0.51 0.07
[2507] 1951 Phage-1314 - - E - - L D E - L Q - - M 0.07 0.51 0.08 1952 Phage-1315 - - - - - T T E - - V - - - 0.06 0.50 0.05 1953 Phage-1316 - - E - - V P - - M G - - - 0.08 0.50 0.08 1954 Phage-1317 - - D - - - A M - M s - - - 0.07 0.50 0.07 1955 Phage-1318 - - E - - L G L - M K - - - 0.06 0.49 0.06
[2508] 1956 Phage-1319 - - - - - - Q E - M R - - - 0.07 0.49 0.07
[2509] 1957 Phage-1320 - - - - - I p - - L - - - - 0.07 0.49 0.07
[2510] 1958 Phage-1321 - - D - - s T E - M w - - - 0.05 0.49 0.06
[2511] 1959 Phage-1322 - - E - - I K D - M T - - - 0.06 0.47 0.08 1960 Phage-1323 - - - - - D A E - M Q - - - 0.07 0.46 0.06 1961 Phage-1324 - - E - - M Q W - M A - - - 0.08 0.45 0.09 1962 Phage-1325 - - E - - - P V - M Q - - - 0.07 0.44 0.08 1963 Phage-1326 - - D - - D E - - L M - - - 0.09 0.44 0.07
[2512] 1964 Phage-1327 - - D - - L P E - M E - - - 0.08 0.43 0.07
[2513] 1965 Phage-1328 - - - - - - s E - L Q - - - 0.05 0.43 0.06
[2514] 1966 Phage-1329 - - D - - s Q I - M s - - - 0.05 0.42 0.06
[2515] 1967 Phage-1330 - - D - - w P G - L w - - - 0.07 0.42 0.06 1968 Phage-1331 - - T - w Q V A - M Q N - F 0.06 0.42 0.06 1969 Phage-1332 - - - - - L D E - M E - - - 0.07 0.40 0.07 1970 Phage-1333 - - D - - T - M - K Q - - - 0.06 0.40 0.08
[2516]
[2517] 1971
[2518] Table 11. Phage Panning Results of Peptide- 92 Library Sequences. (-) indicates the same amino acid position as in Peptide- 92 corresponding position.
[2519] Amino acid position sequence Phage binding ELISA
[2520] Anti- Anti- CD28 CD28
[2521] Fab Backgr Fab (SEQ SEQ 1 1 1 1 1 signal Phage ID 1 2 3 4 5 6 7 8 9 ound ID NOs: ID 0 1 2 3 4 in the signal 2358, NO:
[2522] presen 2359)
[2523] ce of signal
[2524] CD28 Phage-471 s C A A G A S Y A w P Y C L 0.05 1.49 0.05 994 Phage-454 Y w s C F Q I P F T C F Y F 0.18 1.44 0.27 977 Phage-455 W E c L K Y T E - N A C T Y 0.05 1.55 0.07 978 Phage-456 F M c L P Q N P H P L C F K 0.06 0.84 0.06 979 Phage-457 P D c Q T I L F K P W c V R 0.05 2.09 0.06 980 Phage-458 A - D T Y F A G M I N E - F 0.07 0.92 0.10 981
[2525]
[2526] WSGR Docket No. 52426-781.601
[2527] Phage-459 G - Q Y p w A F D A M s - p 0.05 2.38 0.07 982 Phage-460 W - w D Y K L W V P T Q - p 0.11 2.27 0.14 983 Phage-461 W - w D Y R E W V P M T - p 0.06 2.30 0.08 984 Phage-462 E - H W S M W A V G H A - F 0.06 1.77 0.07 985 Phage-463 Y - - G H S P I N I G K - - 0.05 1.49 0.06 986 Phage-464 W - w D Y K L W V P M T - p 0.11 2.51 0.11 987 Phage-465 D - w W M F E s Y P G R - I 0.06 1.65 0.07 988 Phage-466 Y - - G H - W Q Y I N K - - 0.06 0.64 0.07 989 Phage-467 W - w Y Y R E w V P M T - p 0.06 1.85 0.07 990 Phage-468 Y w Y C S P S I V R C V L V 0.06 1.51 0.09 991 Phage-469 P D C H T I L F K P W c V R 0.07 1.00 0.06 992 Phage-470 W I c D K S G S I M L c R A 0.06 0.91 0.06 993 Phage-472 D - p W L S G F S R - L L C 0.09 1.27 0.07 994 Phage-473 Y - - G M s T I Q L w L K C 0.06 2.16 0.09 995 Phage-474 Y - - G H M P Q Y E V K - - 0.07 0.22 0.06 996 Phage-475 Y - - G H T E E H Y V K - M 0.05 0.62 0.07 997 Phage-476 Y - M G H S H E H I w K - - 0.06 0.87 0.07 998 Phage-477 Y - - G H S H E Y L A K - E 0.05 0.86 0.06 999 Phage-1334 T - s - - - T W P - - I - - 0.08 2.00 0.07 1039 Phage- 1335 L - - - - - - W P - - V - - 0.06 2.16 0.08 1040 Phage-1336 T - s - - - - - P - - L - - 0.07 2.38 0.06 1041 Phage-1337 T - - - - - A w P - - Q - - 0.06 2.23 0.08 1042 Phage- 1338 T - s - - - T - T - - K - F 0.06 1.87 0.06 1043 Phage-1339 T - - - - - T w S - - A - F 0.07 2.23 0.07 1044 Phage- 1340 T - - - - - A w G - - L - F 0.08 2.30 0.07 1045 Phage- 1341 L - - - - - T - P - - L - - 0.05 2.39 0.07 1046 Phage- 1342 T - s - - - A - P - - L - - 0.09 2.36 0.08 1047 Phage- 1343 T - s - - - A - S - - A - F 0.07 1.89 0.15 1048 Phage- 1344 L - - - - - T - P - - T - - 0.06 1.71 0.06 1049 Phage- 1345 - - s - - - H - P - - Q - F 0.06 1.16 0.06 1050 Phage- 1346 T - s - - - T - E - - R - - 0.06 1.84 0.06 1051 Phage- 1347 T - s - - - H - P - - I - - 0.06 1.78 0.07 1052 Phage- 1348 - - s - - - A - Y - - W - - 0.09 1.90 0.09 1053 Phage- 1349 T - s - - - T w - - - L - F 0.06 2.31 0.09 1054 Phage-1350 T - - - - - T - L - - T - - 0.06 1.68 0.06 1055 Phage-1351 T - - - - - H - P - - A - - 0.10 1.92 0.07 1056 Phage-1352 L - - - - F T - P - - L - - 0.05 1.73 0.21 1057 Phage-1353 L - K p - V P - K - - T - - 0.06 1.86 0.07 1058 Phage-1354 T - S - - - T w P - - I - - 0.09 2.41 0.11 1972 Phage-1355 L - S - - - M w P - - T - - 0.08 2.39 0.08 1973 Phage-1356 L - s - - - M - S - - T - - 0.07 2.39 0.12 1974 Phage-1357 T - s - - - T w P - - I - - 0.06 2.35 0.08 1975 Phage-1358 T - - - - - M w - - - V - - 0.10 2.32 0.09 1976 Phage-1359 M - s - - - M - K - - L - - 0.05 2.32 0.05 1977 Phage- 1360 T - s - - - T - - - - F - - 0.06 2.31 0.06 1978
[2528]
[2529] WSGR Docket No. 52426-781.601
[2530] Phage- 1361 M - - - - - T - p - - A - - 0.07 2.30 0.06 1979 Phage- 1362 - - - - - - M w p - - V - V 0.07 2.29 0.13 1980 Phage- 1363 T - s - - - - - p - - L - - 0.06 2.29 0.08 1981 Phage- 1364 - - K p - V A N Y - - W - - 0.08 2.29 0.10 1982 Phage-1365 M - S - - - M - S - - L - - 0.10 2.29 0.08 1983 Phage- 1366 L - - - - - T - P - - F - - 0.06 2.28 0.07 1984 Phage- 1367 M - - - - - N - P - - Q - - 0.06 2.28 0.08 1985 Phage-1368 T - s - - - T w S - - M - - 0.07 2.26 0.09 1986 Phage- 1369 L - s - - - M - P - - T - - 0.09 2.25 0.07 1987 Phage- 1370 T - - - - - H - s - - A - F 0.14 2.25 0.07 1988 Phage- 1371 T - - - - - T - p - - S - - 0.06 2.25 0.06 1989 Phage- 1372 R - - - - - - - p - - P - - 0.06 2.25 0.05 1990 Phage- 1373 T - K - - - T - L - - F - - 0.08 2.23 0.08 1991 Phage- 1374 M - - - - F H - P - - A - - 0.06 2.23 0.10 1992 Phage- 1375 T - - - - - N w E - - W - F 0.08 2.22 0.08 1993 Phage- 1376 T - - - - - T - - - - - - V 0.10 2.21 0.09 1994 Phage- 1377 T - - - - - A - p - - L - F 0.12 2.18 0.11 1995 Phage-1378 T - s - - - - N K L s L - - 0.05 2.18 0.06 1996 Phage- 1379 M - s - - - N W P - - L - F 0.06 2.18 0.07 1997 Phage-1380 R - s - - F H - P L s L - - 0.08 2.18 0.06 1998 Phage-1381 N - s - - - T - P - - L - - 0.06 2.17 0.07 1999 Phage-1382 - - - - - - M - S - - T - - 0.08 2.16 0.08 2000 Phage-1383 N - s - - - Q w P - - I - - 0.07 2.15 0.08 2001 Phage-1384 L - - - - - H - P - - Q - - 0.07 2.15 0.07 2002 Phage-1385 T - - - - - H w P - - T - F 0.08 2.15 0.07 2003 Phage-1386 T - s - - - T - T - s K - F 0.05 2.15 0.06 2004 Phage-1387 L - N - - - T - S - - T - - 0.05 2.14 0.06 2005 Phage-1388 T - S - - - T - T - - W - F 0.08 2.14 0.07 2006 Phage-1389 W - K p - - P - K - - P - F 0.05 2.14 0.07 2007 Phage- 1390 T - - - - - M - T - - L - F 0.06 2.14 0.09 2008 Phage- 1391 T - s - - - T w T - - Q - - 0.07 2.14 0.08 2009 Phage- 1392 L - - - - - T - - - - L - - 0.08 2.13 0.07 2010 Phage- 1393 M - - E F F N - p - - L - - 0.07 2.11 0.07 2011 Phage- 1394 T - - - - - T - E - - A - - 0.05 2.09 0.07 2012 Phage-1395 T - s - - - Y - T - - - - F 0.07 2.09 0.08 2013 Phage- 1396 T - - - V F - - G - - E - F 0.06 2.09 0.07 2014 Phage- 1397 - - s - - - M - T - - T - - 0.09 2.09 0.06 2015 Phage-1398 Q - - - - - - - P - - M - - 0.07 2.08 0.08 2016 Phage- 1399 Y - - - - - T - P - - L - - 0.06 2.08 0.08 2017 Phage- 1400 T - - - - - T - - - - E - - 0.05 2.08 0.11 2018 Phage- 1401 T - s E - - T - T - - W - F 0.06 2.05 0.06 2019 Phage- 1402 T - - - - - H - L - - W - M 0.10 2.05 0.08 2020 Phage- 1403 T - s - - - T - V - - Q - F 0.08 2.05 0.07 2021 Phage- 1404 G - - - - - T - P - - s - - 0.06 2.05 0.06 2022 Phage-1405 T - - - - - T - K - - A - - 0.07 2.05 0.09 2023
[2531]
[2532] WSGR Docket No. 52426-781.601
[2533] Phage- 1406 M - s - - - M - p - - T - - 0.06 2.04 0.08 2024 Phage- 1407 T - - - - - - - - - - W - - 0.07 2.03 0.08 2025 Phage-1408 T - s - - - - w - - - W - F 0.07 2.03 0.08 2026 Phage- 1409 T - - - - - M w H - - V - - 0.07 2.03 0.09 2027 Phage-1410 T - s - - F H - E - - R - - 0.05 2.02 0.05 2028 Phage-1411 L - - - - F K - P - - L - - 0.07 2.02 0.07 2029 Phage-1412 L - E E F - D - P - - M - - 0.05 2.01 0.06 2030 Phage-1413 T - - - - - T - S - - M - F 0.06 2.00 0.07 2031 Phage-1414 L - - - - - - - P - - T - - 0.09 2.00 0.10 2032 Phage-1415 H - - - - - H - P - - A - - 0.07 2.00 0.12 2033 Phage-1416 T - - - - - N - P - - - - - 0.07 1.99 0.14 2034 Phage-1417 M - - - - - T - P - - L - - 0.06 1.99 0.07 2035 Phage-1418 T - - - - - T - s - - W - F 0.09 1.99 0.07 2036 Phage-1419 T - - - - - H - T - - E - F 0.07 1.99 0.07 2037 Phage- 1420 - - - - V F - - S - - M - F 0.06 1.99 0.06 2038 Phage- 1421 - - - - - - T - S - - M - - 0.07 1.99 0.09 2039 Phage- 1422 L - - E F F N - P - - L - - 0.06 1.98 0.06 2040 Phage- 1423 Q - s - - - A w P - - F - - 0.07 1.97 0.08 2041 Phage- 1424 M - - - - - H - T - - T - - 0.10 1.97 0.07 2042 Phage-1425 T - s - - - T - E - - W - M 0.06 1.97 0.07 2043 Phage- 1426 M - s - - - N - P - - W - - 0.07 1.97 0.08 2044 Phage- 1427 T - - - - - T - E - - - - F 0.08 1.96 0.06 2045 Phage-1428 W - - - V F - - T - s p - - 0.06 1.96 0.07 2046 Phage- 1429 T - - - - - A - T - - A - F 0.06 1.96 0.06 2047 Phage-1430 T - - - - - T - E - - T - - 0.08 1.96 0.08 2048 Phage- 1431 L - K p - V P N S - - T - - 0.06 1.95 0.06 2049 Phage-1432 T - S - - - H - P - - D - I 0.06 1.95 0.07 2050 Phage-1433 P - - - - - M w P - - V - - 0.05 1.95 0.06 2051 Phage-1434 L - N - - - M - K - - T - - 0.07 1.94 0.06 2052 Phage- 1435 M - S - - - M - P - - L - - 0.07 1.93 0.07 2053 Phage-1436 T - S - - - M w T - - - - F 0.09 1.93 0.08 2054 Phage-1437 T - - - - - Y w T - - A - F 0.09 1.93 0.09 2055 Phage- 1438 T - s - - - G - P - - L - Y 0.07 1.92 0.08 2056 Phage-1439 - - s - - - - L Q L s I - - 0.05 1.92 0.06 2057 Phage- 1440 T - s - - - T W - - - S - F 0.09 1.92 0.10 2058 Phage- 1441 T - s - - - H - V - - M - F 0.07 1.91 0.17 2059 Phage- 1442 T - s - - - T - I - - M - F 0.05 1.90 0.08 2060 Phage- 1443 T - R - - - T - N - - F - - 0.05 1.90 0.07 2061 Phage- 1444 T - s - - - T w P - - I - - 0.07 1.89 0.08 2062 Phage- 1445 T - - - - - - - P - - A - - 0.10 1.89 0.09 2063 Phage- 1446 - - - - V F - F P - s P - - 0.06 1.87 0.08 2064 Phage- 1447 T - s - - F - - S - - A - F 0.05 1.86 0.07 2065 Phage- 1448 T - T - - F - - N - - M - F 0.06 1.85 0.06 2066 Phage- 1449 T - S - - - T - - - - A - Y 0.11 1.84 0.14 2067 Phage-1450 T - S - - - T - s - - Q - - 0.06 1.84 0.07 2068
[2534]
[2535] WSGR Docket No. 52426-781.601
[2536] Phage- 1451 T - s - - - Y - - - - V - - 0.09 1.84 0.08 2069 Phage-1452 L - R - - - M w p - - T - - 0.07 1.83 0.06 2070 Phage-1453 T - S - - - T F H - - Q - F 0.07 1.83 0.08 2071 Phage-1454 T - s - - - H - E - - - - - 0.08 1.82 0.11 2072 Phage- 1455 Q - - - - - - - P - - V - - 0.06 1.82 0.07 2073 Phage-1456 L - K p - V p - Q - - T - F 0.06 1.82 0.05 2074 Phage-1457 T - - - - - M w Q - - V - - 0.06 1.81 0.06 2075 Phage- 1458 P - s - - - T - - - L - - V 0.06 1.81 0.06 2076 Phage-1459 - - - - - - M w p - - V - V 0.05 1.80 0.06 2077 Phage- 1460 - - - - - - A - p - - A - - 0.06 1.80 0.06 2078 Phage- 1461 Y - s - - - Q w p - - I - - 0.09 1.79 0.08 2079 Phage- 1462 T - - - - - - - Q - - L - F 0.07 1.79 0.07 2080 Phage- 1463 - - - - - - - - s - - A - F 0.06 1.79 0.07 2081 Phage- 1464 - - s - - F H - p - - I - - 0.05 1.79 0.07 2082 Phage-1465 L - K p - V P - Q - - T - - 0.06 1.78 0.07 2083 Phage- 1466 M - T - - - L - N - - T - - 0.06 1.78 0.09 2084 Phage- 1467 T - - - - - H - P - - - - - 0.06 1.77 0.05 2085 Phage-1468 W - - E F F N - H - - L - F 0.07 1.77 0.06 2086 Phage- 1469 T - s - - F - L Q L s I - - 0.06 1.77 0.06 2087 Phage- 1470 - - - - - - - - P - - Q - - 0.07 1.77 0.11 2088 Phage- 1471 L - T - - L A - N - - T - - 0.05 1.77 0.05 2089 Phage- 1472 G - - - - - H - P - - F - - 0.06 1.76 0.06 2090 Phage- 1473 T - - - - - V w E - - M - F 0.07 1.76 0.07 2091 Phage- 1474 T - - - - - N - P - - L - - 0.05 1.75 0.08 2092 Phage-1475 M - - - - - M - - - - T - - 0.06 1.75 0.09 2093 Phage- 1476 T - - - - - - F p - - W - - 0.06 1.75 0.06 2094 Phage- 1477 - - - - V F p - p - - P - F 0.05 1.75 0.06 2095 Phage-1478 T - s - - - M - p - - W - V 0.06 1.75 0.08 2096 Phage- 1479 W - - - V F - - s - - L - - 0.05 1.75 0.06 2097 Phage- 1480 G - - - - F H - p - - L - - 0.05 1.74 0.08 2098 Phage- 1481 L - E E F F H - s - - V - - 0.06 1.74 0.06 2099 Phage- 1482 T - - - - - A w p - - H - - 0.05 1.73 0.06 2100 Phage- 1483 Q - - - - - M w T - - A - F 0.06 1.73 0.07 2101 Phage- 1484 M - s - - - T - P - - M - - 0.07 1.73 0.06 2102 Phage-1485 T - - - - - T - P - - S - - 0.06 1.73 0.05 2103 Phage- 1486 T - - - - - V w G - - L - F 0.06 1.73 0.06 2104 Phage- 1487 T - - - - - H - - - - E - F 0.06 1.72 0.06 2105 Phage-1488 R - R - - F - - N - - - - M 0.05 1.72 0.06 2106 Phage- 1489 W - - - - - T w P - - L - I 0.14 1.70 0.17 2107 Phage- 1490 R - - - - V M - D - - V - - 0.07 1.70 0.07 2108 Phage- 1491 T - s - - - H w T - - L - F 0.06 1.69 0.06 2109 Phage- 1492 T - s - - - H F - - - M - F 0.06 1.69 0.07 2110 Phage- 1493 - - - - - - H - V - - F - F 0.07 1.68 0.08 2111 Phage- 1494 T - s - - - T - N - - W - F 0.06 1.68 0.05 2112 Phage-1495 T - s - - - - - P - - V - - 0.06 1.67 0.07 2113
[2537]
[2538] WSGR Docket No. 52426-781.601
[2539] Phage- 1496 W - - - - - M - p - - L - - 0.08 1.67 0.06 2114 Phage- 1497 L - N - - - P - K - - T - - 0.06 1.66 0.07 2115 Phage-1498 L - S - - - M - P - - L - Y 0.06 1.66 0.08 2116 Phage- 1499 T - - - - - M w V - - T - - 0.06 1.66 0.07 2117 Phage- 1500 L - - - - - N - P - - A - - 0.06 1.66 0.07 2118 Phage- 1501 - - - - - - T - T - - M - I 0.07 1.66 0.07 2119 Phage- 1502 - - - - - L - - P - - D - - 0.05 1.65 0.07 2120 Phage- 1503 T - - - - - G w - - - F - F 0.07 1.65 0.09 2121 Phage- 1504 M - s - - - T - p - - - - - 0.06 1.64 0.10 2122 Phage-1505 L - s - - - T - p - - w - M 0.06 1.64 0.06 2123 Phage- 1506 D - w G D - P - p - R V - - 0.06 1.64 0.07 2124 Phage- 1507 W - T - - F - - K L S I - - 0.06 1.63 0.06 2125 Phage-1508 L - S - - - M - Q - - T - - 0.06 1.63 0.06 2126 Phage- 1509 T - S - - - N - E - - W - F 0.06 1.62 0.06 2127 Phage-1510 T - - - - - H - E - - M - Y 0.08 1.61 0.12 2128 Phage-1511 - - s - V F - - - - - T - - 0.05 1.61 0.08 2129 Phage-1512 T - - - - - T w p - - S - - 0.06 1.61 0.08 2130 Phage-1513 T - - - - - H w I - - W - E 0.07 1.61 0.07 2131 Phage-1514 T - - - - - G w Q - - M - F 0.10 1.60 0.11 2132 Phage-1515 - - - - - - T - E - - R - - 0.06 1.60 0.07 2133 Phage-1516 G - - - - - N - P - - L - - 0.06 1.59 0.05 2134 Phage-1517 T - - - - - Y - - - - M - - 0.06 1.59 0.07 2135 Phage-1518 - - - - - - P - p - - E - - 0.06 1.59 0.07 2136 Phage-1519 T - s - - - A - - - - - - - 0.10 1.59 0.07 2137 Phage- 1520 L - - - - - A - p - - M - - 0.06 1.59 0.06 2138 Phage- 1521 - - - - - - T - E - - I - - 0.05 1.59 0.05 2139 Phage- 1522 - - - - - - M w P - - V - V 0.05 1.59 0.07 2140 Phage- 1523 - - - - - - Q - G - - M - - 0.07 1.59 0.05 2141 Phage- 1524 w - - - - - - - P - - W - - 0.06 1.58 0.05 2142 Phage-1525 T - T - V F p - E - - R - - 0.06 1.57 0.07 2143 Phage- 1526 - - - - - - T F H - - M - F 0.07 1.57 0.09 2144 Phage- 1527 T - s - - F - - K - - W - - 0.05 1.57 0.06 2145 Phage-1528 T - - - - - M w T - - E - - 0.07 1.57 0.07 2146 Phage- 1529 T - - - - - T - P - - E - M 0.05 1.57 0.06 2147 Phage-1530 L - - - - F N - P - - L - - 0.05 1.57 0.05 2148 Phage- 1531 M - T - - - T - P - - A - - 0.08 1.56 0.07 2149 Phage-1532 - - S - - - A w P - - W - - 0.09 1.55 0.08 2150 Phage-1533 L - - E - F D - S - - M - - 0.06 1.55 0.08 2151 Phage-1534 T - s - - - T - S - - F - F 0.07 1.55 0.07 2152 Phage- 1535 - - K - - - P - Y - - G - F 0.07 1.54 0.08 2153 Phage-1536 T - S - V F - - T - s N - F 0.05 1.54 0.06 2154 Phage-1537 Q - - - - - M w T - - A - F 0.06 1.54 0.06 2155 Phage- 1538 T - - - - - A w E - - I - F 0.06 1.54 0.06 2156 Phage-1539 T - - - - - M w N - - Q - Y 0.07 1.54 0.07 2157 Phage- 1540 - - s - - - M - P - - M - - 0.06 1.53 0.06 2158
[2540]
[2541] WSGR Docket No. 52426-781.601
[2542] Phage- 1541 T - - - - - - w E - - L - F 0.06 1.52 0.08 2159 Phage- 1542 T - s - - - T - V - - D - F 0.06 1.52 0.09 2160 Phage- 1543 T - E - V F I - s - - F - - 0.09 1.52 0.08 2161 Phage- 1544 L - S - - - M w Q - - T - - 0.05 1.51 0.05 2162 Phage- 1545 L - - E - - D - p - - M - - 0.06 1.51 0.08 2163 Phage- 1546 T - - - - - T w D - - L - F 0.07 1.51 0.06 2164 Phage- 1547 - - - - - - H - K - - V - I 0.06 1.51 0.06 2165 Phage- 1548 I - - - - F I w S - - A - F 0.08 1.51 0.08 2166 Phage- 1549 T - - - - - T - S - - D - F 0.08 1.51 0.06 2167 Phage-1550 Q - - - - - M w T - - V - F 0.09 1.50 0.07 2168 Phage-1551 T - - - - - H - L - - H - - 0.07 1.50 0.12 2169 Phage-1552 P - - - - - M w - - - - - - 0.06 1.49 0.05 2170 Phage-1553 N - s - - - T w p - - M - F 0.08 1.49 0.10 2171 Phage-1554 T - - - - V H F G - - L - F 0.06 1.49 0.07 2172 Phage-1555 T - - - - - T - T - - T - F 0.05 1.48 0.05 2173 Phage-1556 T - - - - - - w E - - A - - 0.05 1.48 0.08 2174 Phage-1557 T - - - - - M - Q - - E - F 0.05 1.48 0.06 2175 Phage-1558 T - - - - - H - T - - T - - 0.06 1.47 0.07 2176 Phage-1559 T - s - - - T - K - - V - - 0.06 1.47 0.06 2177 Phage- 1560 - - s - - - T - E - - - - F 0.06 1.47 0.06 2178 Phage- 1561 T - - - - - N w H - - w - F 0.08 1.46 0.15 2179 Phage- 1562 L - - - - - T - P - - I - - 0.05 1.46 0.08 2180 Phage- 1563 - - s - - - L w K - - V - F 0.06 1.45 0.07 2181 Phage- 1564 T - s - - F - - K - - w - W 0.05 1.45 0.06 2182 Phage-1565 - - s - - - M - Q - - L - F 0.06 1.44 0.09 2183 Phage- 1566 Q - - - - - M w T - - A - F 0.06 1.44 0.06 2184 Phage- 1567 T - s - - - T - M - - A - F 0.09 1.44 0.10 2185 Phage-1568 T - s - - - T - - - - A - F 0.06 1.44 0.08 2186 Phage- 1569 W - G V - M D w R - - E - - 0.06 1.44 0.16 2187 Phage- 1570 T - E D - F H F S - - E - F 0.08 1.44 0.07 2188 Phage- 1571 Q - - - - - M W T - - A - F 0.05 1.42 0.07 2189 Phage- 1572 T - s - - - T - T - - S - F 0.07 1.42 0.06 2190 Phage- 1573 W - D Q F F H - K - - L - - 0.05 1.42 0.07 2191 Phage- 1574 - - - - - - T - V - - M - F 0.06 1.42 0.07 2192 Phage- 1575 T - - - - - H - s - - F - M 0.07 1.42 0.07 2193 Phage- 1576 - - s - - - - L Q L s Q - F 0.06 1.41 0.05 2194 Phage- 1577 R - s F R F I T L A E A - V 0.05 1.41 0.08 2195 Phage-1578 T - s - - - H - P - - I - - 0.06 1.41 0.08 2196 Phage- 1579 T - - - - - Q F - - - L - - 0.06 1.41 0.07 2197 Phage-1580 L - s - - F L F Q - s T - - 0.05 1.41 0.06 2198 Phage-1581 R - - - - F H - s - - N - F 0.05 1.41 0.06 2199 Phage-1582 G - - - - - - - p - - A - - 0.05 1.41 0.06 2200 Phage-1583 P - - - - - M w p - - V - - 0.05 1.41 0.06 2201 Phage-1584 T - s - - - T - s - - A - - 0.05 1.41 0.06 2202 Phage-1585 T - - - - - - w N - - A - E 0.07 1.41 0.07 2203
[2543]
[2544] WSGR Docket No. 52426-781.601
[2545] Phage-1586 L - - - - - H - s - - A - F 0.09 1.41 0.09 2204 Phage-1587 P - s - - V T - - - L - - V 0.05 1.41 0.06 2205 Phage-1588 M - - - - - A w - - - L - - 0.06 1.40 0.07 2206 Phage-1589 T - - - - - - - p - - L - V 0.06 1.40 0.06 2207 Phage- 1590 L - - - - F M - E - - L - F 0.05 1.40 0.06 2208 Phage- 1591 T - s - - - E - T - - L - F 0.07 1.40 0.08 2209 Phage- 1592 - - - - - - A w G - - A - F 0.06 1.39 0.09 2210 Phage- 1593 T - - - - - T w L - - V - - 0.06 1.39 0.08 2211 Phage- 1594 - - s - F F H F H - - A - - 0.08 1.38 0.06 2212 Phage-1595 T - s - - - N W V - - L - - 0.06 1.38 0.07 2213 Phage- 1596 T - s - - - H W V - - - - - 0.07 1.37 0.09 2214 Phage- 1597 - - - - - - T - G - - E - F 0.06 1.36 0.07 2215 Phage-1598 - - - - - - T w - - - A - - 0.06 1.36 0.06 2216 Phage- 1599 L - s - - - M w E - - L - - 0.06 1.36 0.07 2217 Phage- 1600 T - s - - - G - P - - T - - 0.06 1.36 0.06 2218 Phage- 1601 T - s - - - A w T - - L - F 0.05 1.36 0.06 2219 Phage- 1602 T - s - - - A - E - - E - F 0.06 1.36 0.06 2220 Phage- 1603 T - s - - - L w E - - M - F 0.06 1.35 0.06 2221 Phage- 1604 P - - - - - H - T - - T - - 0.07 1.34 0.07 2222 Phage-1605 - - s - - - T - T - - A - - 0.08 1.34 0.07 2223 Phage- 1606 T - s - - - H - S - - K - F 0.06 1.33 0.07 2224 Phage- 1607 - - - - - - H - P - - E - - 0.05 1.32 0.05 2225 Phage-1608 - - - E V F N - V - - F - F 0.07 1.32 0.07 2226 Phage- 1609 T - - - - - A - T - - V - F 0.05 1.32 0.08 2227 Phage-1610 - - - - - - M w E - - K - F 0.07 1.32 0.09 2228 Phage-1611 - - - D - - I w E - - W - F 0.06 1.32 0.07 2229 Phage-1612 T - - - - - T - E - - S - - 0.06 1.32 0.09 2230 Phage-1613 - - s - - - M - T - - T - - 0.08 1.31 0.08 2231 Phage-1614 L - - - - - A w E - - M - F 0.08 1.30 0.06 2232 Phage-1615 Q - s - - - T - - - - F - - 0.07 1.29 0.08 2233 Phage-1616 T - - - - V P - K - - P - - 0.06 1.29 0.06 2234 Phage-1617 - - - - - - T - T - - F - - 0.07 1.29 0.07 2235 Phage-1618 R - - - V F - - T - - P - - 0.06 1.29 0.07 2236 Phage-1619 T - s - - - T - K - - A - F 0.07 1.29 0.05 2237 Phage- 1620 L - - - - - Y - P - - L - F 0.06 1.28 0.06 2238 Phage- 1621 T - T - - F - - K - - T - - 0.08 1.28 0.09 2239 Phage- 1622 N - S - - - T w P - - M - F 0.05 1.27 0.06 2240 Phage- 1623 - - S - - - T - Q - - - - F 0.08 1.26 0.06 2241 Phage- 1624 - - - - - - T - s - - A - - 0.07 1.25 0.07 2242 Phage-1625 N - - - - - M - s - - T - - 0.06 1.25 0.07 2243 Phage- 1626 R - - - - - M w T - - A - F 0.16 1.25 0.06 2244 Phage- 1627 T - - - - - T - M - - V - - 0.05 1.24 0.07 2245 Phage-1628 - - - - - - T w K - - E - - 0.05 1.24 0.07 2246 Phage- 1629 T - - - - - T w L - - W - - 0.06 1.23 0.07 2247 Phage-1630 T - - - - - V w T - - I - F 0.06 1.23 0.05 2248
[2546]
[2547] WSGR Docket No. 52426-781.601
[2548] Phage- 1631 T - - D - - F W Q - - V - - 0.07 1.22 0.07 2249 Phage-1632 T - s - - - - W G - - w - - 0.06 1.22 0.07 2250 Phage-1633 T - s - - - T - S - - - - - 0.06 1.22 0.07 2251 Phage-1634 T - s - - - T - s - - s - F 0.07 1.21 0.09 2252 Phage- 1635 L - - - - - T - p - - D - V 0.06 1.21 0.05 2253 Phage-1636 T - - - - - N w p - - E - - 0.07 1.21 0.08 2254 Phage-1637 L - E E F F H - s - - L - - 0.06 1.21 0.06 2255 Phage- 1638 P - S D - V A - p - - - - V 0.07 1.20 0.06 2256 Phage-1639 - - - - - - H w s - - V - F 0.06 1.20 0.08 2257 Phage- 1640 L - s - - - M - p - - V - - 0.06 1.19 0.08 2258 Phage- 1641 - - s - - - T w - - - Q - F 0.06 1.19 0.08 2259 Phage- 1642 - - s - V F - - R - - K - - 0.05 1.18 0.06 2260 Phage- 1643 - - s - - - G w - - - M - F 0.06 1.16 0.08 2261 Phage- 1644 - - - - - F D - G - - M - - 0.08 1.16 0.06 2262 Phage- 1645 - - - D - F N - V - - L - F 0.06 1.14 0.08 2263 Phage- 1646 T - - - - - N - s - - A - - 0.06 1.14 0.08 2264 Phage- 1647 Q - - - - - T - p - - V - - 0.08 1.13 0.09 2265 Phage- 1648 T - s - - - T - T - - V - F 0.06 1.13 0.06 2266 Phage- 1649 T - s - - - H - E - - K - - 0.09 1.12 0.07 2267 Phage-1650 T - s - - - T - S - - L - F 0.07 1.12 0.09 2268 Phage- 1651 T - - - - - T - S - - S - F 0.06 1.10 0.07 2269 Phage-1652 T - - - - - N - - - - V - - 0.06 1.09 0.13 2270 Phage-1653 T - - - - - H - E - - Q - F 0.06 1.08 0.06 2271 Phage-1654 T - - - - - T - N - - w - F 0.07 1.07 0.07 2272 Phage- 1655 T - - - - - T w T - - T - M 0.06 1.07 0.06 2273 Phage-1656 P - - - - - Q w S - - M - - 0.07 1.07 0.09 2274 Phage-1657 - - - - - s T w - - - A - - 0.05 1.07 0.07 2275 Phage- 1658 - - - - - F H - E - - Q - F 0.05 1.06 0.06 2276 Phage-1659 - - T - - F R I H - - M - F 0.06 1.06 0.12 2277 Phage- 1660 - - - - - - A - - - - W - - 0.06 1.05 0.07 2278 Phage- 1661 M - T - - F - F N - - E - - 0.07 1.05 0.07 2279 Phage- 1662 L - D Q F F H - N - - A - - 0.06 1.04 0.05 2280 Phage- 1663 - - - - V F - F N - - E - F 0.07 1.01 0.07 2281 Phage- 1664 T - s - - - - - S - - - - M 0.07 1.00 0.07 2282 Phage-1665 W - s E V F - - P - - A - - 0.06 0.99 0.06 2283 Phage- 1666 - - T - V F - - - L s P - F 0.05 0.99 0.05 2284 Phage- 1667 L - - - V F A - T - - M - F 0.06 0.98 0.07 2285 Phage-1668 P - - - - - H - V - - V - F 0.07 0.97 0.06 2286 Phage- 1669 T - s - - - T - K - - T - - 0.05 0.97 0.07 2287 Phage- 1670 - - - - - - H w S - - A - - 0.06 0.97 0.06 2288 Phage- 1671 M - - - - - M - N - - L - - 0.07 0.95 0.09 2289 Phage- 1672 - - - - - - - - S - - L - F 0.06 0.95 0.08 2290 Phage- 1673 V - - - - - A - P - - A - - 0.06 0.93 0.07 2291 Phage- 1674 T - s - - - H - P - - M - - 0.07 0.93 0.06 2292 Phage-1675 T - - - - - T w V - - T - F 0.07 0.92 0.07 2293
[2549]
[2550] WSGR Docket No. 52426-781.601
[2551] Phage- 1676 T - s - - - M - N - - E - F 0.08 0.92 0.08 2294 Phage- 1677 T - s - - - M - s - - L - I 0.06 0.91 0.08 2295 Phage-1678 Q - - - - F - - T - - E - Y 0.06 0.90 0.11 2296 Phage- 1679 w - - - F F H - P - - Q - F 0.05 0.87 0.05 2297 Phage- 1680 R - K - - V P - K - - M - - 0.06 0.87 0.06 2298 Phage- 1681 T - - - - - T - E - - s - I 0.07 0.86 0.09 2299 Phage- 1682 T - - - - - K - V - - L - F 0.09 0.85 0.12 2300 Phage- 1683 L - E - - F N - D - - R - - 0.06 0.85 0.07 2301 Phage- 1684 T - - - - - - w D - - F - F 0.07 0.82 0.08 2302 Phage-1685 E - G w E p G Q H - R V - F 0.06 0.82 0.06 2303 Phage- 1686 - - - - - - T - E - - T - - 0.08 0.81 0.07 2304 Phage- 1687 - - - - - - T - K - - A - F 0.05 0.80 0.06 2305 Phage-1688 - - s - - - M w L - - E - F 0.05 0.80 0.06 2306 Phage- 1689 w - s - V F - - Q - - P - F 0.06 0.78 0.06 2307 Phage- 1690 T - s - - - T - K - - M - F 0.06 0.77 0.07 2308 Phage- 1691 T - s - - - T - G - - A - F 0.07 0.76 0.07 2309 Phage- 1692 I - - - - - G w P - - W - - 0.08 0.75 0.10 2310 Phage- 1693 E - s - - - M w G - - A - F 0.06 0.73 0.09 2311 Phage- 1694 T - - - - - T - D - - s - - 0.06 0.71 0.08 2312 Phage-1695 T - - - - - V w Q - - T - F 0.06 0.71 0.06 2313 Phage- 1696 P - s T - 0.06 0.71 0.09 2314 Phage- 1697 T - - - - - Q L E - - W - F 0.09 0.70 0.07 2315 Phage-1698 G - - - - - E - N - - T - - 0.05 0.69 0.64 2316 Phage- 1699 T - - - - - A - T - - H - F 0.09 0.69 0.11 2317 Phage- 1700 T - s - - - Q w E - - A - - 0.06 0.67 0.08 2318 Phage- 1701 W - s - V F - - Q - - V - - 0.07 0.61 0.06 2319 Phage- 1702 s - M - I 0.06 0.59 0.06 2320 Phage- 1703 D - w w D s p - H - R V - - 0.06 0.57 0.07 2321 Phage- 1704 - - - - - - G - G - - Q - - 0.07 0.55 0.13 2322 Phage-1705 - - G G - F H - s - - L - F 0.07 0.55 0.15 2323 Phage- 1706 G - - - - F H - T L s T - - 0.05 0.42 0.05 2324
[2552]
[2553]
[0150] In some embodiments, the peptide mask comprises an amino acid sequence according to: J1-J2-W-C-J3-J4-J5-J6-J7-J8-J9-C-J10-J11, wherein Ji is selected from A, R, N, D, Q, E, G, H, I, L, K, F, P, S, T, W, Y, and V; J2 is selected fromD, P, and Y; J3 is selected fromP and Q; J4 is selected from R, L, and I; J4 is selected from R, L, and I; J5 is selected from D, H, Y, and I; J5 is selected from D, H, Y, and I; Je is selected from L, S, and R; J7 is selected from W and G; Js is selected from V, A, D, H, L, and N; J9 is selected from H, L, E, and D; J10 is selected from F, Y, and L; and Ju is selected from A, N, H, and T. In some embodiments, Ji is selected from A, R, N, D, Q, E, G, H, K, F, P, S, T, W, and Y. In some embodiments, Ji is selected from R, Q, E, H, I, L, K, F, T, W, Y, and V; J2 is D; J3 is P; J3 isP; J4 is R; J5 is D; Je is L; J7 is W; Js is V; J9 is H; J10 is F; and Jn is A. In some embodiments, Ji is selected from R, Q, E, L, K, T, and W; J2 is D; J3 is P; J4 is R; Js is D; Je is L; J7 is W; Js is V; J9 isH; J10 isF; and Ju is A. In some embodiments, Ji is L or I; J2 is D or Y; J3 is P; J4 is R, L, or I; Js isH, Y, or D; Je isL or R; J7 is W; Js is A, D, H, or N; J9 is L, E, or D; J10 isF or Y;WSGR Docket No. 52426-781.601
[2554] and Ju isN or H. In some embodiments, Ji is L or I; J2 is D or Y; J3 is P; J4 is Ror I; J5 isH, Y, or D; Je is L or R; J7 is W; Js is A, D, or N; J9 is L, E, or D; J10 is F or Y; and Ju is N.
[2555]
[0151] In some embodiments, the peptide mask comprises an amino acid sequence according to: Z1-C-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z10-Z11-C-Z12, wherein Zi is selected from Y, H, and A; Z2 is selected from D, E, A, Q, S, V, M, H, L, F, T, W, andN; Z3 is selected from G, E, S, and A; Z4 is selected from H, L, W, and A; Z5 is selected from L, S, A, T, I, V, M, R, E, D, F, H, K, Q, N, Y, W, and G; Z6is selected from P, A, E, Q, S, L, W, G, V, D, K, I, M, R, T, F, H, N, and Y; Z7is selected from E, Q, I, M, V, A, L, R, W, P, D, T, K, S, G, H, and N; Zs is selected from Y, H, F, W, N, Q, and A; Z9 is selected from M, I, L, R, V, K, F, Q, Y, W, and A; Z10 is selected from A, Q, S, W, E, L, G, D, T, M, N, V, H, R, Y, K, P, F, and I; Zu is selected from K, Q, N, H, E, P, and A; and Z12 is selected from L, M, I , F, V, Y, Q, D, T, and A. In some embodiments, Zi is selected from Y and H; Z2 is selected from D, E, A, Q, S, V, M, H, L, F, T, W, and N; Z3 is selected from G, E, and S; Z4 is selected from H, L, and W; Z5 is selected from L, S, A, T, I, V, M, R, E, D, F, H, K, Q, N, Y, W, and G; Z6is selected from P, A, E, Q, S, L, W, G, V, D, K, I, M, R, T, F, H, N, and Y; Z7is selected from E, Q, I, M, V, A, L, R, W, P, D, T, K, S, G, H, and N; Z8is selected from Y, H, F, W, N, and Q; Z9is selected from M, I, L, R, V, K, F, Q, Y, and W; Z10 is selected from A, Q, S, W, E, L, G, D, T, M, N, V, H, R, Y, K, P, F, and I; Zu is selected from K, Q, N, H, E, and P; and Z12 is selected from L, M, I , F, V, Y, Q, D, and T. In some embodiments, Zi is selected from Y and H; Z2 is selected from D, E, A, Q, S, V, M, H, L, F, T, W, and N; Z3 is selected from G, E, and S; Z4 is selected from H, L, and W; Z5 is selected from L, S, A, T, I, V, M, R, E, D, F, H, K, Q, N, Y, W, and G; Z6is selected from P, A, E, Q, S, L, W, G, V, D, K, I, M, R, T, F, H, N, and Y; Z7is selected from E, Q, I, M, V, A, L, R, W, P, D, T, K, S, G, H, and N; Z8is selected from Y, H, F, W, N, and Q; Z9 is selected from M, I, L, R, V, K, F, Q, Y, and W; Z10 is selected from A, Q, S, W, E, L, G, D, T, M, N, V, H, R, Y, K, P, F, and I; Zu is selected from K, Q, N, H, E, and P; and Z12 is selected from L, M, I , F, V, Y, Q, D, and T. In some embodiments, Zi is Y; Z2 is selected from D, E, A, and Q; Z3 is G; Z4 is H; Z5 is selected from L, S, A, T, I, V, and M; Ze is selected from P, A, E, Q, S, L, W, G, V, and D; Z7 is selected from E, Q, I, M, V, A, and L; Z8is selected from Y and H; Z9 is selected from M, I, and L; Z10 is selected from A, Q, S, W, E, L, G, D, T, M, and N; Zu is K; and Z12 is selected from L and M. In some embodiments, Zi is Y; Zi is selected from D, E, and A; Z3 is G; Z4 is H; Z4 is H; Z5 is selected from L, S, A, and T; Z is selected fromP, A, E, Q, S, L, and W; Z7 is selected from E, Q, I, and M; Z8is Y; Z9 is selected from M, I, and L; Z10 is selected from A, Q, S, W, E, L, G, and D; Zu is K; and Z12 is L. In some embodiments, Zi is Y; Z2 is selected from D and E; Z3 is G; Z4 is H; Z5 is selected from L, S, and A; Ze is selected from P, A, E, Q, S, and L; Z7 is selected from E, Q, and I; Z8is Y; Z9 is selected from M, I, and L; Z10 is selected from A, Q, S, W, E, L, G, and D; Zu is K; and Z12 is L.
[2556]
[0152] In some embodiments, the peptide mask comprises the amino acid sequence of SEQ ID NO: 1029. In some embodiments, the peptide mask consists of the amino acid sequence of SEQ ID NO: 1029. In some embodiments, the peptide mask comprises the amino acid sequence of SEQ ID NO: 989. In some embodiments, the peptide mask consists of the amino acid sequence of SEQ ID NO: 989. In some embodiments, the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs:WSGR Docket No. 52426-781.601
[2557] 1019-1038. In some embodiments, the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 1009-1018.
[2558]
[0153] In some embodiments, the peptide mask comprises an amino acid sequence according to: U1-C-U2-U3-U4-U5-U6-U7-U8-U9-U10-U11-C-U12, wherein: Ui is selected from T, S, L, M, W, Q, P, R, G, N, I, Y, D, E, V, H, and A; U2 is selected from A, S, T, K, E, R, G, N, W, and D; U3 is selected from A, E, P, D, G, W, Q, V, and F; U4 is selected from G, V, F, D, E, R, and A; Us is selected from A, F, V, S, L, P, and M; Ue is selected from T, S, H, M, A, N, P, G, Q, D, Y, V, L, I, E, K, F, and R; U7 is selected from Y, W, F, L, N, T, Q, I, and A; Us is selected from P, S, T, A, E, K, Q, N, V, G, H, L, D, Y, I, M, and R; U9 is selected from W, L, and A; U10 is selected from P, S, R, L, E, and A; Un is selected from L, A, T, M, V, W, Y, E, Q, I, F, S, P, K, R, D, H, N, and G; and U12 is selected from L, F, V, M, I, Y, E, W, and A. In some embodiments, Ui is selected from T, S, L, M, W, Q, P, R, G, N, I, Y, D, E, V, and H; U2is selected from A, S, T, K, E, R, G, N, W, and D; U3 is selected from A, E, P, D, G, W, Q, V, and F; U4 is selected from G, V, F, D, E, and R; Us is selected from A, F, V, S, L, P, and M; U6is selected from T, S, H, M, A, N, P, G, Q, D, Y, V, L, I, E, K, F, and R; U7 is selected from Y, W, F, L, N, T, Q, and I; Us is selected from P, S, T, A, E, K, Q, N, V, G, H, L, D, Y, I, M, and R; U9 is selected from W, L, and A; U10 is selected from P, S, R, L, and E; Un is selected from L, A, T, M, V, W, Y, E, Q, I, F, S, P, K, R, D, H, N, and G; and U12 is selected from L, F, V, M, I, Y, E, and W. In some embodiments, Ui is selected from T, S, L, M, and W; U2 is selected from A, S, and T; U3 is selected from A and E; U4 is selected from G, V, and F; Us is selected from A, F, and V; Ue is selected from T, S, H, M, A, and N; U7 is selected from Y, W, and F; Us is selected from P, S, T, A, E, K, Q, N, and V; U9 is selected from W and L; U10 is selected from P and S; Un is selected from L, A, T, M, V, W, Y, E, Q, I, F, and S; and U12 is selected from L, F, V, and M. In some embodiments, Ui is selected from T and S; U2 is selected from A and S; U3 is A; U4 is selected from G and V; Us is selected from A and F; Ue is selected from T, S, and H; U7 is selected from Y and W; Us is selected from P, S, T, and A; U9 is W; U10 is P; Un is selected from L, A, T, M, V, W, and Y; and U12 is selected from L and F.
[2559]
[0154] In some embodiments, the peptide mask comprises the amino acid sequence of SEQ ID NO: 994. In some embodiments, the peptide mask comprises the amino acid sequence of SEQ ID NO: 994. In some embodiments, the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 1001-1008. In some embodiments, the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 1039-1058. In some embodiments, the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 977-2324.
[2560] Linker
[2561]
[0155] In some embodiments, half-life extending molecule is linked to the T-cell engager and is in tandem to the peptide mask.
[2562]
[0156] In some embodiments, the linker has a formula comprising (G2S)n, wherein n is an integer from 1 to 3 (SEQ ID NO: 2365). In some embodiments, the linker has a formula selected from the group consisting of (G2S)n, (GS)n, (GSGGS)n(SEQ ID NO: 2367), (GGGS)n(SEQ ID NO: 2368), (GGGGS)n(SEQ ID NO: 2369), and (GSSGGS)n (SEQ ID NO: 2370), wherein n is an integer of at least 1. In some embodiments, theWSGR Docket No. 52426-781.601
[2563] linker is cleaved by a tumor specific protease thereby exposing the T-cell binding domain to CD3. In some embodiments, the linker is cleaved by a tumor specific protease thereby exposing the T-cell binding domain to CD28. In some embodiments, the tumor specific protease is selected from the group consisting of a matrix metalloprotease (MMP), serine protease, cysteine protease, threonine protease, and aspartic protease. In some embodiments, the matrix metalloprotease comprises MMP2, MMP7, MMP9, MMP13, or MMP14. In some embodiments, the serine protease comprises matriptase (MTSP1), urokinase, or hepsin. In some embodiments, the linker comprises a urokinase cleavable amino acid sequence, a matriptase cleavable amino acid sequence, matrix metalloprotease cleavable amino acid sequence, or a legumain cleavable amino acid sequence.
[2564]
[0157] In some embodiments, the peptide mask comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to any one of the sequences in Table 12. In some embodiments, the peptide mask comprises any one of the amino acid sequences in Table 12. In some embodiments, the linker comprises an amino acid sequence according to SEQ ID NO: 2373. In some embodiments, the linker comprises an amino acid sequence according to any one of SEQ ID NOs: 2371-2402. In some embodiment^ the linker comprises an amino acid sequence of Linker 25 (ISSGLLSGRSDAG) (SEQ ID NO: 2397), Linker 26 (AAGLLAPPGGLSGRSDAG) (SEQ ID NO: 2398), Linker 27 (SPLGLSGRSDAG) (SEQ ID NO: 2399), or Linker 28 (LSGRSDAGSPLGLAG) (SEQ ID NO: 2400), or an amino acid sequence that has 1, 2, or 3 amino acid substitutions, additions, or deletions relative to the amino acid sequence of Linker 25, Linker 26, Linker 27, or Linker 28. In some embodiments, the linker comprises an amino acid sequence of Linker 28 (LSGRSDAGSPLGLAG) (SEQ ID NO: 2400).
[2565] Table 12. Linker Amino Acid Sequences
[2566] Construct Amino Acid Sequence SEQ ID
[2567] Description (N to C) NO:
[2568] Linker 1 GGGGSGGGGSGGGGS 2371
[2569] Linker 2 GGGGS 2372
[2570] Linker 3 GGGGSGGGS 2373
[2571] Cleavable linker GGGGSGGGLSGRSDAGSPLGLAGSGGGS 2374
[2572] Cleavable linker GSSGGSGGLSGRSDAGSPLGLAGSGGGS 2375
[2573] Linker 4 GGGGSLSGRSDNHGSSGT 2376
[2574] Linker 5 GGGGSSGGSGGSGLSGRSDNHGSSGT 2377
[2575] Linker 6 ASGRSDNH 2378
[2576] Linker 7 LAGRSDNH 2379
[2577] Linker 8 ISSGLASGRSDNH 2380
[2578] Linker 9 ISSGLLAGRSDNH 2381
[2579] Linker 10 LSGRSDNH 2382
[2580] Linker 11 ISSGLLSGRSDNP 2383
[2581]
[2582] WSGR Docket No. 52426-781.601
[2583] Linker 12 ISSGLLSGRSDNH 2384
[2584] Linker 13 LSGRSDNHSPLGLAGS 2385
[2585] Linker 14 SPLGLAGSLSGRSDNH 2386
[2586] Linker 15 SPLGLSGRSDNH 2387
[2587] Linker 16 LAGRSDNHSPLGLAGS 2388
[2588] Linker 17 LSGRSDNHVPLSLKMG 2389
[2589] Linker 18 LSGRSDNHVPLSLSMG 2390
[2590] Linker 19 GSSGGSGGSGGSGISSGLLSGRSDNHGSSGT 2391
[2591] Linker 20 GSSGGSGGSGGISSGLLSGRSDNHGGGS 2392
[2592] Linker 21 ASGRSDNH 2393
[2593] Linker 22 LAGRSDNH 2394
[2594] Linker 23 ISSGLASGRSDNH 2395
[2595] Linker 24 LSGRSDAG 2396
[2596] Linker 25 ISSGLLSGRSDAG 2397
[2597] Linker 26 AAGLLAPPGGLSGRSDAG 2398
[2598] Linker 27 SPLGLSGRSDAG 2399
[2599] Linker 28 LSGRSDAGSPLGLAG 2400
[2600] Non-cleavable linker SGGGGSGGASSGAGGS 2401
[2601] Non-cleavable linker GGGGSGGGSGGGGSGGASSGAGGSGGGS 2402
[2602]
[2603] Modified Amino Acids
[2604]
[0158] In some embodiments, the polypeptide or polypeptide complex comprises a modified amino acid, a non-natural amino acid, a modified non-natural amino acid, or a combination thereof. In some embodiment^ the non-natural amino acid comprises a D-amino acid. In some embodiments, the modified amino acid or modified non-natural amino acid comprises a post-translational modification.
[2605] Pharmaceutical Compositions
[2606]
[0159] Disclosed herein are pharmaceutical compositions comprising: (i) the polypeptide or polypeptide complex according to any embodiment disclosed herein, and (ii) a pharmaceutically acceptable excipient.
[2607]
[0160] In some embodiments, the polypeptide or polypeptide complex further comprises a detectable label, a therapeutic agent, or a pharmacokinetic modifying moiety. In some embodiments, the detectable label comprises a fluorescent label, a radiolabel, an enzyme, a nucleic acid probe, or a contrast agent.
[2608]
[0161] For administration to a subject, the polypeptide or polypeptide complex as disclosed herein, may be provided in a pharmaceutical composition together with one or more pharmaceutically acceptable carriers or excipients. The term "pharmaceutically acceptable carrier" includes, but is not limited to, any carrier that does not interfere with the effectiveness of the biological activity of the ingredients and that is not toxic to the patient to whom it is administered. Examples of suitable pharmaceutical carriers are well known in theWSGR Docket No. 52426-781.601
[2609] art and include phosphate buffered saline solutions, water, emulsions, such as oil / water emulsions, various types of wetting agents, sterile solutions etc. Such carriers can be formulated by conventional methods and can be administered to the subject at a suitable dose. Preferably, the compositions are sterile. These compositions may also contain adjuvants such as preservatives, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents.
[2610]
[0162] The pharmaceutical composition may be in any suitable form, depending upon the desired method of administration. It may be provided in unit dosage form, may be provided in a sealed container and may be provided as part of a kit. Such a kit may include instructions for use. It may include a plurality of said unit dosage forms.
[2611]
[0163] The pharmaceutical composition may be adapted for administration by any appropriate route, including a parenteral (e.g., subcutaneous, intramuscular, or intravenous) route. Such compositions may be prepared by any method known in the art of pharmacy, for example by mixing the active ingredient with the carrier(s) or excipient(s) under sterile conditions.
[2612]
[0164] Dosages of the substances of the present disclosure can vary between wide limits, depending upon the disease or disorder to be treated, the age and condition of the individual to be treated, etc. and a physician will ultimately determine appropriate dosages to be used.
[2613] Recombinant Nucleic Acid Molecules
[2614]
[0165] Disclosed herein are recombinant nucleic acid molecules encoding a polypeptide or polypeptide complex of any one of the embodiments disclosed herein.
[2615] Methods
[2616]
[0166] Disclosed herein, in some embodiments, are methods of extending a half-life of a T cell engager disclosed herein. The method can comprise tethering a peptide mask disclosed herein that is in tandem to a half-life extending molecule disclosed herein to the T-cell engager via a linker to generate a modified T-cell engager. In some embodiments, the half-life extending molecule comprises a fragment crystallizable (Fc) domain. In some embodiments, the Fc domain comprises one or more mutations selected from the group consisting of L234A, L235A, N297G, P329G, Y349C, S354C, T366S, T366W, L368A, Y407V, M428G, N434A, H435R, and Y436F mutation according to EU numbering relative to SEQ ID NO: 2335 or a single chain Fc (scFc). The linker can be cleaved when inside atumor microenvironment and the peptide that is in tandem to the half-life extending molecule can be released from the modified T-cell engager to generate a cleaved T-cell engager. In some embodiments, the cleaved T-cell engager does not comprise the half-life extending molecule disclosed herein. In some embodiments, the cleaved T-cell engager does not comprise the peptide mask disclosed herein. In some embodiments, the cleaved T-cell engager does not comprise the half-life extending molecule disclosed herein and the peptide mask disclosed herein. The modified T-cell engager comprising the half-life extending molecule as disclosed herein can exhibit advantages over an unmodified T-cell engager, for example, improved pharmacokinetics, improved pharmacodynamics, enhanced or prolonged half-life, improved solubility, improved or enhanced stability, ease of production,WSGR Docket No. 52426-781.601
[2617] enhanced therapeutic activity, reduced immunogenicity, reduced toxicity, improved potency, improved expression yield, improved purity, improvedin silico immunogenicity, improved activity, and / or improved specificity.
[2618]
[0167] In some embodiments, the modified T-cell engager comprising the half-life extending molecule as disclosed herein has a half-life of at least or about 12 hours, at least or about 24 hours 36 hours, at least or about 48 hours, at least or about 60 hours, at least or about 72 hours, at least or about 84 hours, at least or about 96 hours, at least or about 100 hours, at least or about 108 hours, at least or about 120 hours, at least or about 140 hours, at least or about 160 hours, at least or about 168 hours, at least or about 180 hours, at least or about 200 hours, or more than 200 hours. In some embodiments, the half-life of the modified T-cell engager is in a range of about 12 hours to about 300 hours, about 20 hours to about 280 hours, about 40 hours to about 240 hours, about 60 hours to about 200 hours, about 80 hours to about 140 hours, or about 120 hours to about 170 hours. In some embodiments, the half-life of the modified T-cell engager is in a range of about 120 hours to about 168 hours. In some embodiments, the half-life of the modified T-cell engager is greater than 200 hours. In some embodiments, the half-life of the modified T-cell engager is measured in a mammal. In some embodiments, the half-life of the modified T-cell engager is measured in a primate. In some embodiments, the half-life of the modified T-cell engager is measured in a non-human primate. In some embodiments, the half-life of the modified T-cell engager is measured in a human.
[2619]
[0168] In some embodiments, the modified T-cell engager comprising the half-life extending molecule as disclosed herein has a half-life greater than the unmodified T-cell engager or the cleaved T-cell engager. In some embodiments, the modified T-cell engager comprising the half-life extending molecule as disclosed herein has a half-life of at least or about 1 hour, at least or about 5 hours, at least or about 10 hours, at least or about 15 hours, at least or about 20 hours, at least or about 25 hours, at least or about 30 hours, at least or about 35 hours, at least or about 40 hours, at least or about 50 hours, at least or about 60 hours, at least or about 70 hours, at least or about 80 hours, at least or about 90 hours, or at least or about 100 hours more than the unmodified T-cell engager or the cleaved T-cell engager. In some embodiments, the modified T-cell engager has ahalf-life of at least about 5-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 35-fold, at least about 40-fold, at least about 45-fold, at least about 50-fold, at least about 55-fold, at least about 60-fold, at least about 65-fold, at least about 70-fold, at least about 75-fold, at least about 80-fold, at least about 85-fold, at least about 90-fold, at least about 95-fold, at least about 100-fold greater than the unmodified T-cell engager or the cleaved T-cell engager.
[2620]
[0169] In some embodiments, the modified T-cell engager comprising the half-life extending molecule as disclosed herein has a stability greater than the unmodified T-cell engager or the cleaved T-cell engager. In some embodiments, the stability is measured under stressed conditions (e.g., modified temperature, increased temperature). In some embodiments, the modified T-cell engager comprising the half-life extending molecule as disclosed herein has a stability (e.g., stability under stressed conditions, such as modified temperature, increased temperature) of at least 5-fold, at least about 10-fold, at least about 15-fold,WSGR Docket No. 52426-781.601
[2621] at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 35-fold, at least about 40-fold, at least about 45-fold, at least about 50-fold, at least about 55-fold, at least about 60-fold, at least about 65-fold, at least about 70-fold, at least about 75-fold, at least about 80-fold, at least about 85-fold, at least about 90-fold, at least about 95-fold, at least about 100-fold greater than the unmodified T-cell engager or the cleaved T-cell engager.
[2622]
[0170] In some embodiments, the modified T-cell engager comprising the half-life extending molecule as disclosed herein has a melting temperature stability greater than the unmodified T-cell engager or the cleaved T-cell engager. In some embodiments, the modified T-cell engager comprising the half-life extending molecule as disclosed herein has a melting temperature stability of at least or about 20 degrees centigrade, at least or about 25 degrees centigrade, at least or about 30 degrees centigrade, at least or about 35 degrees centigrade, at least or about 40 degrees centigrade, at least or about 45 degrees centigrade, at least or about 50 degrees centigrade, at least or about 55 degrees centigrade, at least or about 60 degrees centigrade, at least or about 65 degrees centigrade, at least or about 70 degrees centigrade, at least or about 75 degrees centigrade, at least or about 80 degrees centigrade, at least or about 85 degrees centigrade, at least or about 90 degrees centigrade, or at least or about 95 degrees centigrade. In some embodiments, the modified T-cell engager comprising the half-life extending molecule as disclosed herein has a melting temperature stability in a range of about 25 degrees centigrade to about 95 degrees centigrade, about 30 degrees centigrade to about 90 degrees centigrade, 35 degrees centigrade to about 85 degrees centigrade, or 40 degrees centigrade to about 80 degrees centigrade. In some embodiments, the modified T-cell engager comprising the half-life extending molecule as disclosed herein has a melting temperature stability in a range of about 40 degrees centigrade to about 75 degrees centigrade.
[2623]
[0171] In some embodiments, the modified T-cell engager comprising the half-life extending molecule as disclosed herein has a solubility greater than the unmodified T-cell engager or the cleaved T-cell engager. In some embodiments, the modified T-cell engager comprising the half-life extending molecule as disclosed herein has a solubility of at least about 1 mg / ml, at least about 5 mg / ml, at least about 10 mg / ml, at least about 20 mg / ml, at least about 30 mg / ml, at least about 40 mg / ml, at least about 50 mg / ml, at least about 60 mg / ml, at least about 70 mg / ml, at least about 80 mg / ml, at least about 90 mg / ml, at least about 100 mg / ml or greater in a buffer. In some embodiments, the modified T-cell engager has a solubility of at least 5-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 35-fold, at least about 40-fold, at least about 45-fold, at least about 50-fold, at least about 55-fold, at least about 60-fold, at least about 65-fold, at least about 70-fold, at least about 75-fold, at least about 80-fold, at least about 85-fold, at least about 90-fold, at least about 95-fold, at least about 100-fold greater solubility in a buffer than the unmodified T-cell engager or the cleaved T-cell engager. The buffer can be an aqueous buffer. The buffer can be a physiological buffer. The buffer can be a phosphate buffer. The buffer can have a pH from about 4-9. The buffer can have a pH of at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or more. The buffer can have a pH of about 4, about 5, about 6, about 7, about 8, about 9, or more.WSGR Docket No. 52426-781.601
[2624] Production of Antibodies
[2625]
[0172] In some embodiments, the antibodies or antigen binding fragments thereof as described herein are produced using any method known in the art to be useful for the synthesis of polypeptides (e.g. , antibodies), in particular, by chemical synthesis or by recombinant expression, and are preferably produced by recombinant expression techniques.
[2626]
[0173] In some embodiment, the modified T-cell engager comprising the half-life extending molecule as disclosed herein has a greater production yield than the unmodified T-cell engager or the cleaved T-cell engager. In some embodiments, the modified T-cell engager comprising the half-life extending molecule as disclosed herein has a transient production yield of at least or about 10 mg / L, at least or about 20 mg / L, at least or about 30 mg / L, at least or about 40 mg / L, at least or about 50 mg / L, at least or about 60 mg / L, at least or about 70 mg / L, at least or about 80 mg / L, at least or about 90 mg / L, at least or about 100 mg / L, at least or about 200 mg / L, at least or about 300 mg / L, at least or about 400 mg / L, at least or about 500 mg / L, at least or about 600 mg / L, at least or about 700 mg / L, at least or about 800 mg / L, at least or about 900 mg / L, or at least or about 1000 mg / L. In some embodiment, the modified T-cell engager comprising the half-life extending molecule as disclosed herein has a production yield of at least 1-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 35-fold, at least about 40-fold, at least about 45-fold, at least about 50-fold, at least about 55-fold, at least about 60-fold, at least about 65-fold, at least about 70-fold, at least about 75-fold, at least about 80-fold, at least about 85-fold, at least about 90-fold, at least about 95-fold, at least about 100-fold greater than the unmodified T-cell engager or the cleaved T-cell engager.
[2627]
[0174] In some instances, an antibody or its binding fragment thereof is expressed recombinantly, and the nucleic acid encoding the antibody or its binding fragment is assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., 1994, BioTechniques 17:242), which involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligation of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.
[2628]
[0175] Alternatively, a nucleic acid molecule encoding an antibody is optionally generated from a suitable source (e.g., an antibody cDNA library, or cDNA library generated from any tissue or cells expressing the immunoglobulin) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence.
[2629]
[0176] In some instances, an antibody or its binding fragment is optionally generated by immunizing an animal, such as a mouse, to generate polyclonal antibodies or, more preferably, by generating monoclonal antibodies, e.g., as described by Kohler and Milstein (1975, Nature 256:495-497) or, as described by Kozbor et al. (1983, Immunology Today 4:72) or Cole et al. (1985 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Alternatively, a clone encoding at least the Fab portion of the antibody is optionally obtained by screening Fab expression libraries (e.g., as described in Huse et al., 1989, ScienceWSGR Docket No. 52426-781.601
[2630] 246: 1275-1281) for clones of Fab fragments that bind the specific antigen or by screening antibody libraries (See, e.g., Clackson et al., 1991, Nature 352:624; Hane et al., 1997 Proc. Natl. Acad. Sci. USA 94:4937).
[2631]
[0177] In some embodiments, techniques developed for the production of “chimeric antibodies” (Morrison et al., 1984, Proc. Natl. Acad. Sci. 81:851-855; Neuberger et al., 1984, Nature 312:604-608; Takeda et al., 1985, Nature 314:452-454) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity are used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region.
[2632]
[0178] In some embodiments, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,694,778; Bird, 1988, Science 242:423-42; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward et al., 1989, Nature 334:544-54) are adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli are also optionally used (Skerra et al., 1988, Science 242:1038-1041).
[2633]
[0179] In some embodiments, an expression vector comprising the nucleotide sequence of an antibody or the nucleotide sequence of an antibody is transferred to a host cell by conventional techniques (e.g., electroporation, liposomal transfection, and calcium phosphate precipitation), and the transfected cells are then cultured by conventional techniques to produce the antibody. In specific embodiments, the expression of the antibody is regulated by a constitutive, an inducible or a tissue, specific promoter.
[2634]
[0180] In some embodiments, a variety of host-expression vector systems is utilized to express an antibody, or its binding fragment described herein. Such host-expression systems represent vehicles by which the coding sequences of the antibody is produced and subsequently purified, but also represent cells that are, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody or its binding fragment in situ. These include, but are not limited to, microorganisms such as bacteria (e.g., E. coli and B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing an antibody or its binding fragment coding sequences; yeast (e.g., Saccharomyces Pichia) transformed with recombinant yeast expression vectors containing an antibody or its binding fragment coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing an antibody or its binding fragment coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing an antibody or its binding fragment coding sequences; or mammalian cell systems (e.g., COS, CHO, BH, 293, 293T, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g. the adenovirus late promoter; the vaccinia virus 7.5K promoter).WSGR Docket No. 52426-781.601
[2635]
[0181] For long term, high-yield production of recombinant proteins, stable expression is preferred. In some instances, cell lines that stably express an antibody are optionally engineered. Rather than using expression vectors that contain viral origins of replication, host cells are transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, poly adenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells are then allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci that in turn are cloned and expanded into cell lines. This method can advantageously be used to engineer cell lines which express the antibody or its binding fragments.
[2636]
[0182] In some instances, a number of selection systems are used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 192, Proc. Natl. Acad. Sci. USA 48:202), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes are employed in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance are used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, Proc. Natl. Acad. Sci. USA 77:357; O’Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Clinical Pharmacy 12:488-505; WuandWu, 1991, Biotherapy 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596; Mulligan, 1993, Science 260:926-932; and Morgan and Anderson, 1993, Ann. Rev. Biochem. 62:191-217; May 1993, TIB TECH 11(5): 155-215) and hygro, which confers resistance to hygromycin (Santerre et al., 1984, Gene 30: 147). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds., 1993, Current Protocols in Molecular Biology, John Wiley & Sons, NY; Kriegler, 1990, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY; and in Chapters 12 and 13, Dracopoli et al. (eds), 1994, Current Protocols in Human Genetics, John Wiley & Sons, NY.; Colberre-Garapin et al., 1981, J. Mol. Biol. 150:1). In some instances, the expression levels of an antibody are increased by vector amplification (for a review, see Bebbington and Hentschel, the use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol. 3. (Academic Press, New York, 1987)). When a marker in the vector system expressing an antibody is amplifiable, an increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the nucleotide sequence of the antibody, production of the antibody will also increase (Crouse et al., 1983, Mol. Cell Biol. 3:257).
[2637]
[0183] In some instances, any method known in the art for purification of an antibody is used, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.WSGR Docket No. 52426-781.601
[2638] Expression Vectors
[2639]
[0184] Disclosed herein, in some embodiments, are vectors comprising a recombinant nucleic acid molecule encoding a polypeptide or polypeptide complex of any one of the embodiments disclosed herein.
[2640]
[0185] In some embodiments, vectors include any suitable vectors derived from either eukaryotic or prokaryotic sources. In some cases, vectors are obtained from bacteria (e.g. E. coli), insects, yeast (e.g. Pichiapastoris), algae, or mammalian sources. Exemplary bacterial vectors include pACYC177, pASK75, pBAD vector series, pBADM vector series, pET vector series, pETM vector series, pGEX vector series, pHAT, pHAT2, pMal-c2, pMal-p2, pQE vector series, pRSET A, pRSET B, pRSET C, pTrcHis2 series, pZA31-Luc, pZE21-MCS-l, pFLAG ATS, pFLAGCTS, pFLAG MAC, pFLAG Shift-12c, pTAC-MAT-1, pFLAG CTC, or pTAC-MAT-2.
[2641]
[0186] Exemplary insect vectors include pFastBacl, pFastBac DUAL, pFastBac ET, pFastBac HTa, pFastBac HTb, pFastBac HTc, pFastBac M30a, pFastBact M30b, pFastBac, M30c, pVL1392, pVL1393, pVL1393 MIO, pVL1393 Mil, pVL1393 M12, FLAG vectors such as pPolh-FLAGl or pPolh-MAT 2, or MAT vectors such as pPolh-MATl, or pPolh-MAT2.
[2642]
[0187] In some cases, yeast vectors include Gateway® pDEST™ 14 vector, Gateway® pDEST™ 15 vector, Gateway® pDEST™ 17 vector, Gateway® pDEST™ 24 vector, Gateway® pYES-DEST52 vector, pBAD-DEST49 Gateway® destination vector, pAO815 Pichia vector, pFLDl Pichi pastoris vector, pGAPZA,B, & C Pichiapastoris vector, pPIC3.5K Pichia vector, pPIC6 A, B, & C Pichia vector, pPIC9K Pichia vector, pTEFl / Zeo, pYES2 yeast vector, pYES2 / CTyeast vector, pYES2 / NT A, B, & C yeast vector, or pYES3 / CT yeast vector.
[2643]
[0188] Exemplary algae vectors include pChlamy-4 vector or MCS vector.
[2644]
[0189] Examples of mammalian vectors include transient expression vectors or stable expression vectors. Mammalian transient expression vectors may include pRK5, p3xFLAG-CMV 8, pFLAG- My c-CMV 19, pFLAG-Myc-CMV 23, pFLAG-CMV 2, pFLAG-CMV 6a,b,c, pFLAG-CMV 5.1, pFLAG-CMV 5a,b,c, p3xFLAG-CMV 7.1, pFLAG-CMV 20, p3xFLAG-Myc-CMV 24, pCMV-FLAG-MATl, pCMV-FLAG-MAT2, pBICEP-CMV 3, or pBICEP-CMV 4. Mammalian stable expression vector may include pFLAG-CMV 3, p3xFLAG-CMV 9, p3xFLAG-CMV 13, pFLAG-Myc-CMV 21, p3xFLAG-Myc-CMV 25, pFLAG-CMV 4, p3xFLAG-CMV 10, p3xFLAG-CMV 14, pFLAG-Myc-CMV 22, p3xFLAG-My c-CMV 26, pBICEP-CMV 1, or pBICEP-CMV 2.
[2645]
[0190] In some instances, a cell-free system is a mixture of cytoplasmic and / or nuclear components from a cell and is used for in vitro nucleic acid synthesis. In some cases, a cell-free system utilizes either prokaryotic cell components or eukaryotic cell components. Sometimes, a nucleic acid synthesis is obtained in a cell-free system based on for example Drosophila cell, Xenopus egg, or HeLa cells. Exemplary cell-free systems include, but are not limited to, E. coli S30 Extract system, E. coli T7 S30 system, or PURExpress®.
[2646] Host Cells
[2647]
[0191] Disclosed herein, in some embodiments, are host cells comprising an recombinant nucleic acid molecule encoding an polypeptide or polypeptide complex of any one of the embodiments disclosed herein.WSGR Docket No. 52426-781.601
[2648]
[0192] In some embodiments, a host cell includes any suitable cell such as a naturally derived cell or a genetically modified cell. In some instances, a host cell is a production host cell. In some instances, a host cell is a eukaryotic cell. In other instances, a host cell is a prokaryotic cell. In some cases, a eukaryotic cell includes fungi (e.g., yeast cells), animal cell or plant cell. In some cases, a prokaryotic cell is a bacterial cell. Examples of bacterial cell include gram-positive bacteria or gram-negative bacteria. Sometimes the gramnegative bacteria is anaerobic, rod-shaped, or both.
[2649]
[0193] In some instances, gram-positive bacteria include Actinobacteria, Firmicutes or Teneri cutes. In some cases, gram-negative bacteria include Aquificae, Deinococcus-Thermus, Fibrobacteres-Chlorobi / Bacteroidetes (FCB group), Fusobacteria, Gemmatimonadetes, Nitrospirae, Planctomycetes-Verrucomicrobia / Chlamydiae (PVC group), Proteobacteria, Spirochaetes or Synergistetes. Other bacteria can be Acidobacteria, Chloroflexi, Chrysiogenetes, Cyanobacteria, Deferribacteres, Dictyoglomi, Thermodesulfobacteria or Thermotogae. A bacterial cell can be Escherichia coli, Clostridium botulinum, or Coli bacilli.
[2650]
[0194] Exemplary prokaryotic host cells include, but are not limited to, BL21, Maehl™, DH10B™, TOPIO, DH5a, DHIOBac™, OmniMax™, MegaX™, DH12S™, INV110, TOPIOF’, INVaF, TOP10 / P3, ccdB Survival, PIR1, PIR2, Stbl2™, Stbl3™, or StbM™.
[2651]
[0195] In some instances, animal cells include a cell from a vertebrate or from an invertebrate. In some cases, an animal cell includes a cell from a marine invertebrate, fish, insects, amphibian, reptile, or mammal. In some cases, a fungus cell includes a yeast cell, such as brewer’s yeast, baker’s yeast, or wine yeast.
[2652]
[0196] Fungi include ascomycetes such as yeast, mold, filamentous fungi, basidiomycetes, or zygomycetes. In some instances, yeast includes Ascomycota or Basidiomycota. In some cases, Ascomycota includes Saccharomycotina (true yeasts, e.g. Saccharomyces cerevisiae (baker’s yeast)) or Taphrinomycotina (e.g. Schizosaccharomycetes (fission yeasts)). In some cases, Basidiomycota includes Agaricomycotina (e.g. Tremellomycetes) or Puccini omy cotina (e. g. Microbotryomycetes).
[2653]
[0197] Exemplary yeast or filamentous fungi include, for example, the genus: Saccharomyces, Schizosaccharomyces, Candida, Pichia, Hansenula, Kluyveromyces, Zygosaccharomyces, Yarrowia, Trichosporon, Rhodosporidi, Aspergillus, Fusarium, or Trichoderma. Exemplary yeast or filamentous fungi include, for example, the species: Saccharomyces cerevisiae, Schizosaccharomyces pombe, Candida utilis, Candida boidini, Candida albicans, Candida tropicalis, Candida stellatoidea, Candida glabrata, Candida krusei, Candida parapsilosis, Candida guilliermondii, Candida viswanathii, Candida lusitaniae, Rhodotorula mucilaginosa, Pichia metanolica, Pichia angusta, Pichia pastoris, Pichia anomala, Hansenula polymorpha, Kluyveromyces lactis, Zygosaccharomyces rouxii, Yarrowia lipolytica, Trichosporon pullulans, Rhodosporidium toru- Aspergillus niger, Aspergillus nidulans, Aspergillus awamori, Aspergillus oryzae, Trichoderma reesei, Yarrowia lipolytica, Brettanomyces bruxellensis, Candida stellata, Schizosaccharomyces pombe, Torulaspora delbrueckii, Zygosaccharomyces bailii, Cryptococcus neof ormans, Cryptococcus gattii, or Saccharomyces boulardii.WSGR Docket No. 52426-781.601
[2654]
[0198] Exemplary yeast host cells include, but are not limited to, Pichia pastoris yeast strains such as GS115, KM71H, SMD1168, SMD1168H, and X-33; and Saccharomyces cerevisiae yeast strain such as INVScl.
[2655]
[0199] In some instances, additional animal cells include cells obtained from a mollusk, arthropod, annelid or sponge. In some cases, an additional animal cell is a mammalian cell, e.g., from a primate, ape, equine, bovine, porcine, canine, feline or rodent. In some cases, a rodent includes mouse, rat, hamster, gerbil, hamster, chinchilla, fancy rat, or guinea pig.
[2656]
[0200] Exemplary mammalian host cells include, but are not limited to, 293A cell line, 293FT cell line, 293F cells , 293 H cells, CHO DG44 cells, CHO-S cells, CHO-K1 cells, FUT8 KO CHOK1, Expi293F™ cells, Flp-In™ T-REx™ 293 cell line, Flp-In™-293 cell line, Flp-In™-3T3 cell line, Flp-In™-BHK cell line, Flp-In™-CHO cell line, Flp-In™-CV-l cell line, Flp-In™-Jurkat cell line, FreeStyle™ 293-F cells, FreeStyle™ CHO-S cells, GripTite™ 293 MSR cell line, GS-CHO cell line, HepaRG™ cells, T-REx™ Jurkat cell line, Per.C6 cells, T-REx™-293 cell line, T-REx™-CHO cell line, and T-REx™-HeLa cell line.
[2657]
[0201] In some instances, a mammalian host cell is a stable cell line, or a cell line that has incorporated a genetic material of interest into its own genome and has the capability to express the product of the genetic material after many generations of cell division. In some cases, a mammalian host cell is a transient cell line, or a cell line that has not incorporated a genetic material of interest into its own genome and does not have the capability to express the product of the genetic material after many generations of cell division.
[2658]
[0202] Exemplary insect host cells include, but are not limited to, Drosophila S2 cells, Sf9 cells, Sf21 cells, High Five™ cells, and expresSF+® cells. In some instances, plant cells include a cell from algae. Exemplary insect cell lines include, but are not limited to, strains from Chlamydomonas reinhardtii 137c, or Synechococcus elongatus PPC 7942.
[2659] Articles of Manufacture
[2660]
[0203] In another aspect of the disclosure, an article of manufacture containing materials useful for the treatment, prevention and / or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and / or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper that is pierceable by a hypodermic injection needle). At least one active agent in the composition is an isolate polypeptide or polypeptide complex of any embodiment disclosed herein.
[2661] The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises the bispecific antibody of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic orWSGR Docket No. 52426-781.601
[2662] otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.
[2663]
[0204] Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
[2664] EXAMPLES
[2665] Example 1: Improved effects of Half Life Extending Molecule as disclosed herein
[2666]
[0205] This example illustrates the improved technical effects and advantages of modified T cell engager comprising the Half Life Extending Molecule (HLE) as disclosed herein in comparison with an unmodified T cell engagers (for example, a T cell engager that is not tethered to a HLE, a T cell engager that is tethered to a HLE comprising an albumin binder, or a T cell engager that is tethered to a HLE comprising a wild type Fc). For example, a T cell engager that is tethered to a HLE comprising a wildtype Fc can form unwanted dimerization through natural Fc-Fc formation In some embodiments, a modified T cell engager comprising the HLE as disclosed herein can prevent this unwanted dimerization to form, resulting in more functional T cell engagers.
[2667]
[0206] Experiments are carried out to compare one or more of the following properties of the modified T cell engagers of the disclosure: therapeutic activity, stability, immunogenicity, toxicity, potency, specificity, pharmacokinetics (e.g., half-life, stability, clearance), pharmacodynamics, in silico immunogenicity, expression yield, purity, solubility, or another property compared with the unmodified T cell engagers.
[2668] Table 13 provides illustrative sequences of tandem mask and half-life extending molecules that can be tethered to a T cell engager.
[2669]
[0207] The experimental results indicate that the modified T cell engagers comprising Fc (e.g., variant Fc, scFc) as the half-life extending molecule as disclosed herein exhibit enhanced therapeutic activity, improved or enhanced stability, reduced immunogenicity, reduced toxicity, improved potency, improved specificity, improved pharmacokinetics, improved pharmacodynamics, improved in silico immunogenicity, enhanced expression yield, improved purity, enhanced or prolonged half-life, or improved solubility.
[2670] Table 13. Tandem Mask and Half-Life Extending Molecules
[2671] Amino acid Sequences
[2672] Description Chain 1 Chain 2
[2673] Peptide-B DKTHTCPPCPAPEAAGGPSVFLFPPKPK DKTHTCPPCPAPEAAGGPSVFLFPPK (CD3 mask) DTLMISRTPEVTCVVVDVSHEDPEVKF PKDTLMI SRTPEVTCVVVDVSHEDPE + Knob in NWYVDGVEVHNAKTKPREEQYGSTYR VKFNWYVDGVEVHNAKTKPREEQY Hole Fc VVSVLTVLHQDWLNGKEYKCKVSNKA GSTYRVVSVLTVLHQDWLNGKEYK LGAPIEKTISKAKGQPREPQVYTLPPCR CKVSNKALGAPIEKTI SKAKGQPREP DELTKNQVSLWCLVKGFYPSDIAVEWE QVCTLPPSRDELTKNQVSLSCAVKGF SNGQPENNYKTTPPVLDSDGSFFLYSKL YPSDIAVEWESNGQPENNYKTTPPVL TVDKS RWQQGN VF S CS VMHE ALHNHY DSDGSFFLVSKLTVDKSRWQQGNVF TQKSLSLSPGGGGSGGGSGGVYCGPEF SCSVMHEALHNHYTQKSLSLSP (SEQ
[2674]
[2675] DESVGCM (SEQ ID NO: 2403) ID NO: 2337)WSGR Docket No. 52426-781.601
[2676] Peptide-B DKTHTCPPCPAPELLGGPSVFLFPPKPK
[2677] (CD3 mask) DTLMISRTPEVTCVVVDVSHEDPEVKF
[2678] + scFc NWYVDGVEVHNAKTKPCEEQYGSTYR CVSVLTVLHQDWLNGKEYKCKVSNKA LPAPIEKT1SKAKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGGGGSGGGGSGGGGSGGGG S GGGGS GGGGSDKTHTCPPCP APELLG GP S VFLFPPKPKDTLMI SRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTK PCEEQYGSTYRCVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKT1SKAKGQPR EPQVYTLPPSREEMTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGGGGSGG GSGGVYCGPEFDESVGCM (SEQ ID NO:
[2679] 2404)
[2680] Peptide-B EVQLVESGGGLVQPGGSLRLSCAASGS
[2681] (CD3 mask) TFYTAVMGWVRQAPGKGLEWVAAIR
[2682] + AntiWTALTTSYADSVKGRFTISRDGAKTTL
[2683] albumin (HE- YLQMNSLRPEDTAVYYCAARGTLGLFT
[2684] 1) TADSYDYWGQGTLVTVSSGGGGSGGG
[2685] SGGVYCGPEFDESVGCM (SEQ ID NO:
[2686] 2405)
[2687] Peptide-B EVQLVESGGGLVQPGNSLRLSCAASGF
[2688] (CD3 mask) TFS SFGMSWVRQAPGKGLEWVS SISGS
[2689] + AntiGSDTLYADSVKGRFHSRDNAKTTLYL
[2690] albumin (HE- QMNSLRPEDTAVYYCTIGGSLSRS S QGT
[2691] 4) LVTVSSGGGGSGGGSGGVYCGPEFDES
[2692] VGCM (SEQ ID NO: 2406)
[2693] Peptide-41 DKTHTCPPCPAPEAAGGPSVFLFPPKPK DKTHTCPPCPAPEAAGGPSVFLFPPK (CD28 mask) DTLMISRTPEVTCVVVDVSHEDPEVKF PKDTLMI SRTPEVTCVVVDVSHEDPE + Knob in NWYVDGVEVHNAKTKPREEQYGSTYR VKFNWYVDGVEVHNAKTKPREEQY Hole Fc VVSVLTVLHQDWLNGKEYKCKVSNKA GSTYRVVSVLTVLHQDWLNGKEYK LGAPIEKTISKAKGQPREPQVYTLPPCR CKVSNKALGAPIEKTT SKAKGQPREP DELTKNQVSLWCLVKGFYPSDIAVEWE QVCTLPPSRDELTKNQVSLSCAVKGF SNGQPENNYKTTPPVLDSDGSFFLYSKL YPSDIAVEWESNGQPENNYKTTPPVL TVDKS RWQQGN VF S CS VMHE ALHNHY DSDGSFFLVSKLTVDKSRWQQGNVF TQKSLSLSPGGGGSGGGSGGMDWCPR SCSVMHEALHNHYTQKSLSLSP (SEQ DLWVHCFA (SEQ ID NO: 2407) ID NO: 2337)
[2694] Peptide-41 DKTHTCPPCPAPELLGGPSVFLFPPKPK
[2695] (CD28 mask) DTLMISRTPEVTCVVVDVSHEDPEVKF
[2696] + scFc NWYVDGVEVHNAKTKPCEEQYGSTYR CVSVLTVLHQDWLNGKEYKCKVSNKA LPAPIEKTISKAKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGGGGSGGGGSGGGGSGGGG S GGGGS GGGGSDKTHTCPPCP APELLG GP S VFLFPPKPKDTLMI SRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTK
[2697]
[2698] PCEEQYGSTYRCVSVLTVLHQDWLNGWSGR Docket No. 52426-781.601
[2699] KEYKCKVSNKALPAPIEKT1SKAKGQPR EPQWIEPPSREEMTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGGGGSGG GSGGMDWCPRDLWVHCFA (SEQ ID
[2700] NO: 2408)
[2701] Peptide-41 EVQLVESGGGLVQPGGSLRLSCAASGS
[2702] (CD28 mask) TFYTAVMGWVRQAPGKGLEWVAAIR
[2703] + AntiWTALTTSYADSVKGRFTISRDGAKTTL
[2704] albumin (HE- YLQMNSLRPEDTAVYYCAARGTLGLFT
[2705] 1) TADSYDYWGQGTLVTVSSGGGGSGGG
[2706] SGGMDWCPRDLWVHCFA (SEQ ID NO:
[2707] 2409)
[2708] Peptide-41 EVQLVESGGGLVQPGNSLRLSCAASGF
[2709] (CD28 mask) TFS SFGMSWVRQAPGKGLEWVS SISGS
[2710] + AntiGSDTLYADSVKGRFTISRDNAKTTLYL
[2711] albumin (HE- QMNSLRPEDTAVYYCTIGGSLSRS S QGT
[2712] 4) LVTVSSGGGGSGGGSGGMDWCPRDLW
[2713]
[2714] VHCFA (SEQ ID NO: 2410)
[2715] EXEMPLARY EMBODIMENTS
[2716]
[0208] Embodiment 1 : A polypeptide or polypeptide complex comprising:
[2717] a T cell engager comprising an antigen binding domain;
[2718] a peptide mask that binds to the antigen binding domain and impairs binding of the antigen binding domain to an antigen; and
[2719] a half-life extending molecule that is in tandem with the peptide mask, wherein the half-life extending molecule comprises a fragment crystallizable (Fc) domain, wherein the Fc domain comprises one or more mutations or a single chain Fc (scFc).
[2720]
[0209] Embodiment 2: The polypeptide or polypeptide complex of embodiment 1, wherein the Fc domain comprises one or more mutations.
[2721]
[0210] Embodiment 3: The polypeptide or polypeptide complex of embodiment 1 or 2, wherein the one or more mutations are selected from the group consisting of L234A, L235A, N297G, P329G, Y349C, S354C, T366S, T366W, L368A, Y407V, M428G, N434A, H435R, and Y436F mutation according to EU numbering relative to SEQ ID NO: 2335.
[2722]
[0211] Embodiment 4: The polypeptide or polypeptide complex of any one of embodiments 1-3, wherein the Fc domain comprises a first polypeptide and a second polypeptide.
[2723]
[0212] Embodiment 5: The polypeptide or the polypeptide complex of embodiment 4, wherein the first polypeptide comprises one or more mutations selected from the group consisting of L234A, L235A, N297G, P329G, Y349C, T366S, L368A, Y407V, M428G, N434A, H435R, and Y436F, according to EU numbering.WSGR Docket No. 52426-781.601
[2724]
[0213] Embodiment 6: The polypeptide or the polypeptide complex of embodiment 4, wherein the second polypeptide comprises one or more mutations selected from the group consisting of L234A, L235A, N297G, P329G, S354C, and T366W, according to EU numbering.
[2725]
[0214] Embodiment 7: The polypeptide or polypeptide complex of any one of embodiments 1-3, wherein the one or more mutations comprises one or more knob-in-hole (KIH) mutations.
[2726]
[0215] Embodiment 8: The polypeptide or polypeptide complex of embodiment 7, wherein the Fc domain comprises a first polypeptide and a second polypeptide, wherein the first polypeptide of the Fc domain comprises a hole mutation and the second polypeptide of the Fc domain comprises a knob mutation.
[2727]
[0216] Embodiment 9: The polypeptide or polypeptide complex of embodiment 8, wherein the first polypeptide of the Fc domain comprises T366S, L368A, and Y407V mutations according to EU numbering, and the second polypeptide of the Fc domain comprises a T366W mutation according to EU numbering.
[2728]
[0217] Embodiment 10: The polypeptide or polypeptide complex of any one of embodiments 1-9, wherein the Fc domain comprises Fc effector function silencing mutations L234A, L235A, and P329G according to EU numbering.
[2729]
[0218] Embodiment 11 : The polypeptide or polypeptide complex of any one of embodiments 1-10, wherein the Fc domain comprises an engineered disulfide.
[2730]
[0219] Embodiment 12: The polypeptide or polypeptide complex of any one of embodiments 1-11, wherein the Fc domain comprises a Y349C mutation and a S354C mutation according to EU numbering, and wherein the engineered disulfide is formed between two cysteines at the positions of the Y349C mutation and the S354C mutation.
[2731]
[0220] Embodiment 13: The polypeptide or polypeptide complex of any one of embodiments 1-12, wherein the Fc domain comprises a N297G mutation according to EU numbering.
[2732]
[0221] Embodiment 14: The polypeptide or polypeptide complex of any one of embodiments 1-13, wherein the one or more mutations comprise a ProA or ProG mutation.
[2733]
[0222] Embodiment 15: The polypeptide or polypeptide complex of any one of embodiments 1-14, wherein the Fc domain comprises a H435R and / or a Y436F according to EU nu...
Claims
WSGR Docket No. 52426-781.601CLAIMS WHAT IS CLAIMED IS:
1. A polypeptide or polypeptide complex comprising:a T cell engager comprising an antigen binding domain;a peptide mask that binds to the antigen binding domain and impairs binding of the antigen binding domain to an antigen; anda half-life extending molecule that is in tandem with the peptide mask, wherein the half-life extending molecule comprises a fragment crystallizable (Fc) domain, wherein the Fc domain comprises a single chain Fc (scFc) or one or more mutations.2 The polypeptide or polypeptide complex of claim 1, wherein the half-life extending molecule is operatively linked to the peptide mask within a single contiguous polypeptide chain.3 The polypeptide or polypeptide complex of any one of the preceding claims, wherein the one or more mutations comprise a M428G, a N434A, and / or H435R according to EU numbering.4 The polypeptide or polypeptide complex of any one of the preceding claims, wherein the one or more mutations are selected from the group consisting of L234A, L235A, N297G, P329G, Y349C, S354C, T366S, T366W, L368A, Y407V, M428G, N434A, H435R, and Y436F mutation according to EU numbering relative to SEQ ID NO: 2335.5 The polypeptide or polypeptide complex of any one of the preceding claims, wherein the Fc domain comprises a first polypeptide and a second polypeptide.6 The polypeptide or polypeptide complex of any one of the preceding claims, wherein the first polypeptide comprises one or more mutations selected from the group consisting of L234A, L235A, N297G, P329G, Y349C, T366S, L368A, Y407V, M428G, N434A, H435R, and Y436F, according to EU numbering, and / or the second polypeptide comprises one or more mutations selected from the group consisting of L234A, L235A, N297G, P329G, S354C, and T366W, according to EU numbering. 7 The polypeptide or polypeptide complex of any one of the preceding claims, wherein the one or more mutations comprise one or more knob-in-hole (KIH) mutations.8 The polypeptide or polypeptide complex of any one of the preceding claims, wherein the Fc domain comprises a first polypeptide and a second polypeptide, wherein the first polypeptide of the Fc domain comprises a hole mutation and the second polypeptide of the Fc domain comprises a knob mutation.9 The polypeptide or polypeptide complex of any one of the preceding claims, wherein the first polypeptide of the Fc domain comprises T366S, L368A, and Y407V mutations according to EU numbering, and the second polypeptide of the Fc domain comprises a T366W mutation according to EU numbering.10 The polypeptide or polypeptide complex of any one of the preceding claims, wherein the Fc domain comprises Fc effector function silencing mutations comprising L234A, L235A, and P329G mutations according to EU numbering.WSGR Docket No. 52426-781.60111. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the Fc domain comprises an engineered disulfide.
12. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the Fc domain comprises a Y349C mutation and a S354C mutation according to EU numbering, and wherein the engineered disulfide is formed between two cysteines at the positions of the Y349C mutation and the S354C mutation.
13. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the Fc domain comprises aN297G mutation according to EU numbering.
14. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the one or more mutations comprise a ProA or ProG mutation.
15. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the Fc domain comprises a H435R and / or a Y436F mutations according to EU numbering.
16. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the Fc domain comprises a M428G and / or a N434A mutations according to EU numbering.
17. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the Fc domain lacks a C-terminal glycine and a C-terminal lysine.
18. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the Fc domain lacks C-terminal G446 and K447 residues according to EU numbering.
19. The polypeptide or polypeptide complex of any one of the preceding claims, wherein :(i) the Fc domain comprises a scFc comprising an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2337;(ii) the Fc domain comprises a scFc comprising an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2338; or(iii) the Fc domain comprises a scFc comprising an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2339.
20. The polypeptide or polypeptide complex of any one of the preceding claims, wherein half-life extending molecule further comprises a polymer.
21. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the polymer is polyethylene glycol (PEG).
22. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the antigen binding domain comprises a CD3 binding domain.
23. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the CD3 binding domain comprises an anti-CD3 heavy chain variable domain that comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-WSGR Docket No. 52426-781.601CDR2, and the HC-CDR3 comprise amino acid sequences of HC-CDR1 : SEQ ID NO: 2340, HC-CDR2: SEQ ID NO: 2341, and HC-CDR3: SEQ ID NO: 2342 and the second antigen recognizing molecule comprises an anti-CD3 light chain variable domain that comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, and wherein the LC-CDR1, the LC-CDR2, and the LC- CDR3 comprise amino acid sequences ofLC-CDRl: SEQ ID NO: 2343, LC-CDR2: SEQ ID NO: 2344, and LC-CDR3: SEQ ID NO: 2344.
24. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the CD3 binding domain comprises a single chain variable fragment (scFv).
25. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the scFv comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2346.
26. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask is bound to the antigen binding domain through ionic interactions, electrostatic interactions, hydrophobic interactions, Pi-stacking interactions, or H-bonding interactions, or a combination thereof.
27. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask has less than 70% sequence homology to CD3.
28. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises an amino acid sequence according to U1-U2-C- U4-P-U6-U7-U8-U9-U10-U11- U12-C-U14 and U1 is selected from D, Y, F, I, N, V, H, L, A, T, S, and P; U2 is selected from D, Y, L, F, I, N, A, V, H, T, and S; U4 is selected from G and W; U6 is selected from E, D, V, and P; U7 is selected from W, L, F, V, G, M, I, and Y; U8 is selected from E, D, P, and Q; U9 is selected from E, D, Y, V, F, W, P, L, and Q; U10 is selected from S, D, Y, T, I, F, V, N, A, P, L, and H; U11 is selected from I, Y, F, V, L, T, N, S, D, A, andH; U12 is selected from F, D, Y, L, I, V, A, N, T, P, S, G, and H; and U14 is selected from D, Y, N, F, I, P, V, A, T, H, L, M, and S.
29. The polypeptide or polypeptide complex of any one of the preceding claims, wherein U1 is selected from D, Y, F, I, V, and N; U2 is selected from D, Y, L, F, I, and N; U4 is selected from G and W; U6 is selected from E and D; U7 is selected from W, L, F, G, and V; U8 is selected from E and D; U9 is selected from E, D, Y, and V; U10 is selected from S, D, Y, T, and I; U11 is selected from I, Y, F, V, L, and T; U12 is selected from F, D, Y, L, I, V, A, G, and N; and U14 is selected from D, Y, N, F, I, M, and P.
30. The polypeptide or polypeptide complex of any one of the preceding claims, wherein U1 is selected from D, Y, V, and F; U2 is selected from D, Y, L, and F; U4 is selected from G and W; U6 is selected from E and D; U7 is selected from W, L, G, and F; U8 is selected from E and D; U9 is selected from E and D; U10 is selected from S, D, T, and Y; U11 is selected from I, Y, V, L, and F; U12 is selected from F, D, Y, G, A, and L; U14 is selected from D, Y, M, and N.
31. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 1-904, and 2364.WSGR Docket No. 52426-781.60132. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises the amino acid sequence of SEQ ID NO: 4 or a peptide sequence that has 1, 2, or 3 amino acid substitutions, additions, or deletions relative to the amino acid sequence of SEQ ID NO: 4.
33. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the antigen binding domain comprises a CD28 binding domain.
34. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the antigen binding domain comprises an anti-CD28 heavy chain variable domain that comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC- CDR2, and the HC-CDR3 comprise amino acid sequences of HC-CDR1 : SEQ ID NO: 2347, HC-CDR2: SEQ ID NO: 2348, and HC-CDR3: SEQ ID NO: 2349 and the anti-CD28 antibody comprises an anti- CD28 light chain variable domain that comprises complementarity determining regions (CDRs): LC- CDR1, LC-CDR2, and LC-CDR3, and wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 comprise amino acid sequences of LC-CDR1: SEQ ID NO: 2350, LC-CDR2: (KAS), and LC-CDR3: SEQ ID NO: 2351.
35. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the anti-CD28 heavy chain variable domain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2352, and wherein the anti-CD28 light chain variable domain comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2353.
36. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the antigen binding domain comprises a single chain variable fragment (scFv), a single domain antibody, a Fab, a Fab’, or a CrossFab.
37. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the antigen binding domain comprises the scFv, and the scFv comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2354, SEQ ID NO: 2355, SEQ ID NO: 2356, or SEQ ID NO: 2357.
38. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the antigen binding domain comprises the Fab, and the Fab comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2358 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2359.
39. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the antigen binding domain comprises the CrossFab, and wherein:(i) the CrossFab comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2360 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2361; orWSGR Docket No. 52426-781.601(ii) the CrossFab comprises an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2362 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2363.
40. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 904-1058.
41. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises the amino acid sequence of SEQ ID NO: 944 or the amino acid sequence of SEQ ID NO: 973.
42. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises an amino acid sequence according to X1-X2-X3-C-X4-X5-X6-X7-X8-X9-X10-C-X11-X12, wherein Xi is selected from M, I, L, and V; X2 is selected from D, H, N, A, F, S, T, Y, and V; X3 is selected from W, L, and F; X4 is selected from P, A, and L; X5 is selected from R, T, I, M, S, K, L, V, W, F, A, P, and D; Xe is selected from E, D, Y, H, S, F, A, N, T, I, P, and V; X7 is selected from L, M, R, S, Q, and H; Xs is selected from W and Q; X9 is selected from H, N, D, A, S, Y, T, F, V, L, and I; X10 is selected from E, V, L, D, Y, R, Q, H, F, K, A, M, andN; Xu is selected from F, Y, L, W, and V; and X12 is selected from N, A, F, S, Y, H, D, T, and L.
43. The polypeptide or polypeptide complex of any one of the preceding claims, wherein Xi is selected from M, I, and L; X2 is selected from D, H, N, and A; X3 is W; X4 is P; X5 is selected from R, T, I, M, S, and K; Xe is selected from E, D, Y, H, S, and F; X7 is selected from L, M, and R; Xs is W; X9 is selected from H, N, D, A, S, and V; X10 is selected from E, V, L, D, and H; Xi 1 is selected from F, Y, and L; and X12 is selected from N, A, F, S, and Y.
44. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprisesan amino acid sequence according to SEQ ID NO: 912.
45. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises an amino acid sequence according to: J1-J2-W-C-J3-J4-J5-J6-J7-J8-J9-C-J10-J11, wherein:Ji is selected from A, R, N, D, Q, E, G, H, I, L, K, F, P, S, T, W, Y, and V;J2 is selected from D, P, and Y;J3 is selected from P and Q;J4 is selected from R, L, and I;Js is selected from D, H, Y, and I;Je is selected from L, S, and R;J7 is selected from W and G;Js is selected from V, A, D, H, L, and N;J9 is selected from H, L, E, and D;J10 is selected from F, Y, and L; andJn is selected from A, N, H, and T.
46. The polypeptide or polypeptide complex of claim 45, wherein:Ji is selected from A, R, N, D, Q, E, G, H, K, F, P, S, T, W, and Y.WSGR Docket No. 52426-781.60147. The polypeptide or polypeptide complex of claim 45 or 46, wherein:Ji is selected from R, Q, E, H, I, L, K, F, T, W, Y, and V;J2 is D;J3 is P;J4 is R;Js is D;Je is L;his W;J8is V;J9 is H;J10 is F; andJu is A.
48. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises an amino acid sequence according to: Z1-C-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z10-Z11-C-Z12, wherein:Zi is selected from Y, H, and A;Z2is selected from D, E, A, Q, S, V, M, H, L, F, T, W, and N;Z3 is selected from G, E, S, and A;Z4 is selected from H, L, W, and A;Z5is selected from L, S, A, T, I, V, M, R, E, D, F, H, K, Q, N, Y, W, and G;Ze is selected from P, A, E, Q, S, L, W, G, V, D, K, I, M, R, T, F, H, N, and Y;Z7is selected from E, Q, I, M, V, A, L, R, W, P, D, T, K, S, G, H, and N;Z8is selected from Y, H, F, W, N, Q, and A;Z9 is selected from M, I, L, R, V, K, F, Q, Y, W, and A;Z10 is selected from A, Q, S, W, E, L, G, D, T, M, N, V, H, R, Y, K, P, F, and I;Zu is selected from K, Q, N, H, E, P, and A; andZ12 is selected from L, M, I , F, V, Y, Q, D, T, and A.
49. The polypeptide or polypeptide complex of claim 48, wherein:Zi is selected from Y and H;Z2is selected from D, E, A, Q, S, V, M, H, L, F, T, W, and N;Z3 is selected from G, E, and S;Z4 is selected from H, L, and W;Z5is selected from L, S, A, T, I, V, M, R, E, D, F, H, K, Q, N, Y, W, and G;Zs is selected from P, A, E, Q, S, L, W, G, V, D, K, I, M, R, T, F, H, N, and Y;Z7is selected from E, Q, I, M, V, A, L, R, W, P, D, T, K, S, G, H, and N;Z8is selected from Y, H, F, W, N, and Q;Z9 is selected from M, I, L, R, V, K, F, Q, Y, and W;Z10 is selected from A, Q, S, W, E, L, G, D, T, M, N, V, H, R, Y, K, P, F, and I;WSGR Docket No. 52426-781.601Zu is selected from K, Q, N, H, E, and P; andZ12 is selected from L, M, I , F, V, Y, Q, D, and T.
50. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises the amino acid sequence of SEQ ID NO: 1029, the amino acid sequence of SEQ ID NO: 989, or the amino acid sequence of SEQ ID NO: 898.
51. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 1019-1038.
52. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 1009-1018.
53. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises an amino acid sequence according to: U1-C-U2-U3-U4-U5-U6-U7-U8-U9-U10-U11-C-U12, wherein:Ui is selected from T, S, L, M, W, Q, P, R, G, N, I, Y, D, E, V, H, and A;U2 is selected from A, S, T, K, E, R, G, N, W, and D;U3 is selected from A, E, P, D, G, W, Q, V, and F;U4 is selected from G, V, F, D, E, R, and A;Us is selected from A, F, V, S, L, P, and M;U6is selected from T, S, H, M, A, N, P, G, Q, D, Y, V, L, I, E, K, F, and R;U7 is selected from Y, W, F, L, N, T, Q, I, and A;U8is selected from P, S, T, A, E, K, Q, N, V, G, H, L, D, Y, I, M, and R;U9 is selected from W, L, and A;U10 is selected from P, S, R, L, E, and A;Un is selected from L, A, T, M, V, W, Y, E, Q, I, F, S, P, K, R, D, H, N, and G; andU12 is selected from L, F, V, M, I, Y, E, W, and A.
54. The polypeptide or polypeptide complex of claim 53, wherein:Ui is selected from T, S, L, M, W, Q, P, R, G, N, I, Y, D, E, V, and H;U2 is selected from A, S, T, K, E, R, G, N, W, and D;U3 is selected from A, E, P, D, G, W, Q, V, and F;U4 is selected from G, V, F, D, E, and R;Us is selected from A, F, V, S, L, P, and M;U6is selected from T, S, H, M, A, N, P, G, Q, D, Y, V, L, I, E, K, F, and R;U7 is selected from Y, W, F, L, N, T, Q, and I;U8is selected from P, S, T, A, E, K, Q, N, V, G, H, L, D, Y, I, M, and R;U9 is selected from W, L, and A;U10 is selected from P, S, R, L, and E;Un is selected from L, A, T, M, V, W, Y, E, Q, I, F, S, P, K, R, D, H, N, and G; andU12 is selected from L, F, V, M, I, Y, E, and W.WSGR Docket No. 52426-781.60155. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises the amino acid sequence of SEQ ID NO: 994.
56. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 1001-1008.
57. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 1039-1058.
58. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises an amino acid sequence according to any one of SEQ ID NOs: 977-2324.
59. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises a peptide sequence of at least 10 amino acids in length.
60. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises a peptide sequence of at least 10 amino acids in length and no more than 20 amino acids in length.
61. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises a peptide sequence of at least 16 amino acids in length acids.
62. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises a peptide sequence of no more than 40 amino in length.
63. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises at least two cysteine amino acid residues.
64. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the peptide mask comprises a cyclic peptide or a linear peptide.
65. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the half-life extending molecule is linked to a T cell engager via a linker.
66. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the linker is a peptide sequence having at least 5 to no more than 50 amino acids.
67. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the linker is a peptide sequence having at least 10 to no more than 30 amino acids.
68. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the linker is a peptide sequence having at least 10 amino acids.
69. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the linker is a peptide sequence having at least 18 amino acids.
70. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the linker is a peptide sequence having at least 26 amino acids.
71. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the linker has a formula comprising (G2S)n, wherein n is an integer from 1 to 3.WSGR Docket No. 52426-781.60172. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the linker has a formula selected from the group consisting of (G2S)n, (GS)n, (GSGGS)n, (GGGS)n, (GGGGS)n, and (GSSGGS)n, wherein n is an integer of at least 1.
73. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the linker comprises an amino acid sequence according to any one of SEQ ID NOs: 2371-2402.
74. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the linker comprises an amino acid sequence of Linker 25 (ISSGLLSGRSDAG) (SEQ ID NO: 2397), Linker 26 (AAGLLAPPGGLSGRSDAG) (SEQ ID NO: 2398), Linker 27 (SPLGLSGRSDAG) (SEQ ID NO: 2399), or Linker 28 (LSGRSDAGSPLGLAG) (SEQ ID NO: 2400), or an amino acid sequence that has 1, 2, or 3 amino acid substitutions, additions, or deletions relative to the amino acid sequence of Linker 25, Linker 26, Linker 27, or Linker 28.
75. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the polypeptide or polypeptide complex comprises a modified amino acid, a non-natural amino acid, a modified nonnatural amino acid, or a combination thereof.
76. The polypeptide or polypeptide complex of any one of the preceding claims, wherein the modified amino acid or modified non-natural amino acid comprises a post-translational modification.
77. The polypeptide or polypeptide complex of any one of the preceding claims, wherein a linker is bound to N-terminus of the antigen binding domain and / or C-terminus of the antigen binding domain.
78. A method of extending half-life of a T-cell engager comprising tethering a peptide mask that is in tandem to a half-life extending molecule to the T-cell engager via a tinker to generate a modified T-cell engager, wherein the half-life extending molecule comprises a fragment crystaltizable (Fc) domain, wherein the Fc domain comprises a single chain Fc (scFc) or one or more mutations,wherein the tinker is cleaved when inside a tumor microenvironment and the peptide mask that is in tandem to the half-life extending molecule is released from the modified T-cell engager to generate a cleaved T-cell engager, andwherein the modified T-cell engager has a longer half-life in a subject as compared to the unmodified T-cell engager.
79. The method of claim 78, wherein the peptide mask is operatively linked to the half-life extending molecule within a single contiguous polypeptide chain.
80. The method of any one of the preceding claims, wherein the modified T-cell engager has a half-life of at least or about 12 hours, 24 hours 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, 96 hours, 100 hours, 108 hours, 120 hours, 140 hours, 160 hours, 180 hours, 200 hours, or more than 200 hours.
81. The method of any one of the preceding claims, wherein the modified T-cell engager has a half-life of at least or about 1 hour, 5 hours, 10 hours, 15 hours, 20 hours, 25 hours, 30 hours, 35 hours, 40 hours, 50 hours or more than the unmodified T-cell engager.
82. The method of any one of the preceding claims, wherein the one or more mutations comprise a M428G, aN434A, and / or H435R according to EU numbering.WSGR Docket No. 52426-781.60183. The method of any one of the preceding claims, wherein the one or more mutations are selected from the group consisting of L234A, L235A, N297G, P329G, Y349C, S354C, T366S, T366W, L368A, Y407V, M428G, N434A, H435R, and Y436F mutation according to EU numbering relative to SEQ ID NO: 2335.
84. The method of any one of the preceding claims, wherein the one or more mutations comprise one or more knob-in-hole (KIH) mutations.
85. The method of any one of the preceding claims, wherein the Fc domain comprises a first polypeptide and a second polypeptide, wherein the first polypeptide of the Fc domain comprises a hole mutation and the second polypeptide of the Fc domain comprises a knob mutation.
86. The method of any one of the preceding claims, wherein the Fc domain comprises a first polypeptide and a second polypeptide, wherein the first polypeptide of the Fc domain comprises T366S, L368A, and Y407V mutations according to EU numbering, and the second polypeptide of the Fc domain comprises a T366W mutation according to EU numbering.
87. The method of any one of the preceding claims, wherein the Fc domain comprises Fc effector function silencing mutations comprising L234A, L235A, and P329G mutations according to EU numbering.
88. The method of any one of the preceding claims, wherein the Fc domain comprises an engineered disulfide.
89. The method of any one of the preceding claims, wherein the Fc domain comprises a Y349C mutation and a S354C mutation according to EU numbering, and wherein the engineered disulfide is formed between two cysteines at the positions of the Y349C mutation and the S354C mutation.
90. The method of any one of the preceding claims, wherein the Fc domain comprises aN297G mutation according to EU numbering.
91. The method of any one of the preceding claims, wherein the one or more mutations comprise a ProA or ProG mutation.
92. The method of any one of the preceding claims, wherein the Fc domain comprises a H435R and / or a Y436F according to EU numbering.
93. The method of any one of the preceding claims, wherein the Fc domain comprises a M428G and / or a N434A according to EU numbering.
94. The method of any one of the preceding claims, wherein the Fc domain lacks a C-terminal glycine and a C-terminal lysine.
95. The method of any one of the preceding claims, wherein the Fc domain lacks C-terminal G446 and K447 residues according to EU numbering.
96. The method of any one of the preceding claims, wherein :(i) the Fc domain comprises a scFc comprising an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2337;WSGR Docket No. 52426-781.601(ii) the Fc domain comprises a scFc comprising an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2338; or(iii) the Fc domain comprises a scFc comprising an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2336 and an amino acid sequence with at least 80%, 85%, 90%, 95%, 99%, or 100% identity to SEQ ID NO: 2339.
97. The method of any one of the preceding claims, wherein half-life extending molecule further comprises a polymer.
98. The method of any one of the preceding claims, wherein the polymer is polyethylene glycol (PEG).
